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ABSTRACT 
The depletion of muscle and liver glycogen observed during prolonged submaximal 
exercise is associated with fatigue. Resynthesis of glycogen stores during the recovery 
period after exercise is therefore essential for the recovery of endurance exercise capacity. 
In recent years, attention has focussed on the supplementation of protein in addition to 
glucose-polymer during recovery from exercise in an attempt to further increase glycogen 
synthesis. The aims of the frrst and second studies in this thesis were to investigate the 
effect of glucose-polymer and amino acid ingestion, and solely amino acid ingestion upon 
amino acid and carbohydrate metabolism during recovery from glycogen-depleting 
exercise. 
In the first study (Chapter 4), seven well-trained male cyclists completed a bout of 
glycogen-depleting exercise (-90 min) at 70% V02max, then ingested either 1.7 g·glucose·kg 
body Wfl glucose-polymer (6.4% w:v) and 0.3 g·kg body wt·1 L-glutamine (GP + GLN), 
1.7 g·glucose·kg body wt·1 glucose-polymer (6.4% w:v) and an isoenergetic and 
isonitrogenous mixture of L-alanine and L-glycine (GP + ALA & GL Y), or an equivalent 
volume of a placebo solution (CONI and CON2) during a 4 h recovery period. Subjects 
then cycled to volitional fatigue at 70% V02max. Plasma glutamine concentration was 
increased during the recovery period following the ingestion of glucose-polymer and 
glutamine (P < 0.05). An increase was observed in both plasma glucose concentration and 
serum insulin concentration (P < 0.05) following the ingestion of the solutions containing 
glucose-polymer, with a tendency for a greater increase in the GP + GLN condition. 
Furthennore, a there was a tendency for the sum of the phenylalanine and tyrosine 
concentrations to be decreased during the recoveryp~riod, in the .. GP + GLN condition. 
However, cycle time to exhaustion was not sta~istiCally difftri:fu';'!J~tween conditions during 
. '.- .. ~ .~.,', 
the second bout of exercise. 
In the second study (Chapter 5), seve,lI well-trained male cyclists coml'leted a bout of 
glycogen-depleting exercise (-90 min) at 70% V02max, then ingested either 0.3 g·kg body 
wt-I L-glutamine (GLN) or an isoenergetic and isonitrogenous'mix.ture of L-alanine and L· 
glycine (ALA & GLY) dissolved in 31.25 ml'kgbody'wt-I solution during a 4 h recovery 
period. Subjects then cycled to volitional fatigue at 70% V02max. Plasma glutamine 
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concentration was increased during the recovery period following the ingestion of 
glutamine (P < 0.05). Furthermore, plasma glucose concentration was increased during the 
second bout of exercise following the ingestion of glutamine (P < 0.01). However, cycle 
time to exhaustion was not statistically different between conditions during the second bout 
of exercise. 
In the third study (Chapter 6), the hypothesis was tested that oral glutamine or ornithine a-
ketoglutarate would enhance TCA cycle intermediate (TCAI) expansion at the start of 
exercise and hence increase oxidative energy delivery and extend endurance capacity. 
Following a bout of glycogen-depleting exercise (-90 min) and 18 h ofa low-carbohydrate 
diet, seven well-trained male cyclists ingested either 5 ml·kg body wrl placebo solution 
(CON), 0.125 g·kg body wt-l L(+) ornithine a-ketoglutarate dissolved in 5 ml·kg body wt-l 
placebo solution (OKG), or 0.125 g·kg body wt-l L-glutamine dissolved in 5 ml·kg body 
wt-l placebo solution (GLN), I h prior to cycling exercise to exhaustion at 70% V02max. 
Biopsy samples from the vastus lateralis were obtained 1 h post supplement, after 10 min of 
exercise and at exhaustion. Cycle time to exhaustion was not statistically different between 
conditions. Glutamine ingestion increased both plasma and muscle glutamine concentration 
(P < 0.05) compared to the other two conditions. rTCAI (citrate, malate, fumarate, and 
succinate, -85% of total TCAI pool) was not different between conditions 1 h post 
supplement or at exhaustion, but at 10 min exercise rTCAI was greater in the GLN 
condition (499% increase relative to rest) compared to the CON condition (360%; P < 0.05) 
and the OKG condition (394%). Despite this increase in rTCAI at 10 min exercise 
following glutamine ingestion, no sparing of phosphocreatine utilisation or reduction in 
muscle lactate accumulation was observed compared to the other conditions at the same 
time point. The ingestion of glutamine was able to enhance the TCAI pool size at 10 min of 
exercise, but did not delay the onset offatigue. 
The studies in this thesis have been able to demonstrate that the supplementation of amino 
acids during recovery from exercise can modulate metabolism during recovery and exercise 
during a subsequent bout of exercise. However, the supplementation of amino acids to 
increase the total concentration of the TCA cycle intermediates has demostrated that this 
increase may not be as physiologically significant to TCA cycle flux and oxidative energy 
metabolism during exercise as previously thought. 
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CHAPTER 1 
INTRODUCTION 
Prolonged submaximal exercise relies heavily upon the body's stores of both 
carbohydrate and fat to generate energy to fuel muscular work. Moreover, carbohydrate 
is the primary substrate during prolonged submaximal exercise, with muscle glycogen 
being quantitatively the most important energy source at intensities greater than 60% 
V02max (Romijn et al. 1993). Fatigue during prolonged submaximal exercise is 
associated with the depletion of both liver and skeletal muscle glycogen stores 
(Bergstrom et al. 1967; Hultman and Nilsson, 1971). Under normal conditions, the 
glycogen stores in man are relatively small (-100 g in liver and -325 g in skeletal 
muscle), sufficient for -120 min of exercise at 75% V02max• Nutritional strategies to 
increase the glycogen synthesis rate post exercise are essential to achieve complete 
resynthesis of both skeletal muscle and liver glycogen stores and hence restore exercise 
capacity. 
The ability of carbohydrate supplementation to restore glycogen stores post exercise is 
well documented in the literature (Ivy, 1991; Ivy et al. 1988a; Ivy et al. 1988b; Reed et 
al. 1989). More recently however, attention has been directed toward the ingestion of a 
combination of carbohydrate and protein post exercise to enhance muscle glycogen 
restoration (Roy and Tarnopolsky, 1998; Zawadzki et al. 1992; Tarnopolsky et al. 
1997; Carrithers et al. 2000; van Hall et al. 2000a, Jentjens et al. 2001). The 
hypothesis behind this nutritional strategy being that the co-ingestion of carbohydrate 
and protein serves to increase insulin levels to a greater extent than carbohydrate alone, 
thereby increasing glucose uptake and storage in skeletal muscle (Zawadzki et al. 1992; 
Tarnopolsky et al. 1997; Jentjens et al. 2001). However, very little research has 
examined the effect of providing an individual amino acid in combination with 
carbohydrate, or ingested alone post exercise (Varnier et al. 1995; Wagemnakers et al. 
1997; Bowtell et al. 1999, van Hall et al. 2000a). 
Glutamine, a 5e non-essential amino acid, is the most abundant amino acid in both 
plasma and skeletal muscle (with the exception of taurine) (Bergstrom et al. 1974) and 
14 
is synthesised within the tissues of the body, with skeletal muscle (Golden et al. 1982) 
and liver (Hiiussinger, 1989) being the most quantitatively important producers. 
Glutamine is also involved in a variety of metabolic processes in a number of tissues. 
Glutamine has been shown to increase protein synthesis in skeletal muscle (MacLennan 
et al. 1987; MacLennan et al. 1988), to increase both liver and skeletal muscle 
glycogen synthesis (Mouterde et al. 1992; Low et al. 1996; Scislowski et al. 1989; 
Varnier et al. 1995), to be a major precursor for gluconeogenesis (Nurjhan et al. 1995), 
to hold a regulatory role in acid-base balance (Golden et al. 1982), and to be an 
important respiratory fuel for both the gut (Windmueller and Spaeth, 1974) and the 
immnne system (Ardawi and Newsholme, 1983). 
The intravenous administration of glutamine alone after exhaustive exercise has been 
shown to increase muscle glycogen synthesis in human skeletal muscle CV arnier et al. 
1995). Furthermore, the provision of glutamine has been shown to increase liver 
glycogen synthesis in hepatocytes of fasted rats; a situation where it is expected that 
liver glycogen content will be reduced (Mouterde et al. 1992). Therefore, the provision 
of glutamine after prolonged exercise, when both muscle and liver glycogen stores are 
reduced, could conceivably increase both liver and skeletal muscle glycogen synthesis. 
It was hypothesised that this potential increase in glycogen resynthesis, particularly in 
the liver, would allow for a better maintenance of blood glucose concentration in a 
subsequent bout of exercise, thus prolonging endurance capacity, particularly during 
cycling exercise (Coyle et al. 1983). 
The tricarboxylic acid (TCA) cycle provides a link between amino acid metabolism and 
carbohydrate metabolism, since amino acids are important precursors for TCA cycle 
intermediates (TCAl). Furthermore, the relative flux of carbon into and out of the TCA 
cycle will determine the concentration of the TCAl (Lee and Davis, 1979). It is feasible 
that glutamine may be converted to a-ketoglutarate, one of the TCAl, and therefore 
hold an important role in anaplerosis [replenishment of the TCAl] (glutaminase (EC 
3.5.1.2): glutamine + H20 ~ glutamate + NH3; glutamate dehydrogenase (EC 
1.4.1.2): glutamate + NAD+ ~ a-ketoglutarate + NH3 + NADH). It has been suggested 
that an increase in the total concentration of the TCAl may be necessary for increased 
TCA cycle flux and hence oxidative energy production during submaximal exercise 
15 
(Wagenrnakers, 1998b; Sahlin et al. 1990). Therefore, it was hypothesised that the 
supplementation of potential anaplerotic precursors, such as glutamine, may modulate 
oxidative energy delivery and affect the aetiology of fatigue during submaxirnal 
exercise. 
Therefore, the aims of the studies described in this thesis were to examine the role of 
amino acid metabolism both during, and in recovery from, prolonged subrnaximal 
exercise at whole-body and cellular level. In particular, the aim was to determine 
whether the supplementation of glutamine and glucose-polymer, or glutamine alone, 
during recovery from exercise would extend exercise capacity in a subsequent bout of 
exercise. Secondly, to determine whether the supplementation of glutamine prior to 
exercise would reduce the delay in the onset of increased oxidative energy production at 
the start of exercise, and whether this would extend exercise capacity during 
submaximal exercise. 
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CHAPTER 2 
REVIEW OF LITERATURE 
2.1 INTRODUCTION 
The main aim of this chapter is to draw together some of the fmdings from the many 
physiological and metabolic studies conducted over the last few decades, to present a 
framework of our knowledge regarding both carbohydrate metabolism and amino acid 
metabolism during exercise and recovery. 
2.2 PROTEIN 
The body ofa 70 kg man contains about 12 kg of protein (amino acid polymers) and 
200·230 g offree amino acids. Skeletal muscle accounts for 40·45% of total body mass 
and contains approximately 7 kg of protein, primarily in the form of contractile 
(myofibrillar) proteins. About 120 g of the free amino acids are present intracellularly 
in skeletal muscle, while only 5 g of free amino acids are present in the circulation. 
Protein intake typically comprises 10·15% of the total dietary intake in a Western diet 
and this supply of protein is essential to maintain cellular integrity and function, in 
addition to health and reproduction. A continual turnover of protein occurs (breakdown 
+ synthesis), with amino acids being constantly removed from the metabolic pool 
during the synthesis of an array of different functional and structural proteins and 
reappearing in the pool as the result of protein breakdown. 
The contribution of protein to energy expenditure at rest is estimated to be less than 
10% of the body's total energy expenditure (Rennie et aI. 1981; Brooks, 1987). 
However, during exercise, the contribution of protein to energy production has been 
shown to be influenced by carbohydrate availability, with an increase in protein 
catabolism observed in the glycogen·depleted state (Lemon and Mullin, 1980; 
Wagenmakers et al. 1991). Amino acids carmot be stored in the body in a manner 
analogous to carbohydrate and fat, and therefore amino acids in excess of the amount 
required for protein synthesis are oxidised, thus contributing to energy production. 
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During endurance exercise there is a net breakdown of body protein, predominantly in 
the liver and muscle (Rennie et al. 1996a). This is achieved through a decrease in the 
rate of protein synthesis (Rennie et al. 1981) and an increase in the rate of protein 
breakdown (Carraro et al. 1990). In particular, exercise causes a decrease in the rate of 
degradation of contractile proteins and an increase in the rate of degradation of non-
contractile proteins (Dohrn et al. 1987). Post endurance exercise, whole-body 
techniques to determine protein balance have indicated that protein synthesis is 
increased (Rennie et al. 1981; Devlin et al. 1990), which may be linked to an increased 
blood flow post exercise (Biolo et al. 1997; Tipton and Wolfe, 1998). Moreover, the 
administration of exogenous amino acids post exercise increases the rate of protein 
synthesis with a concomitant reduction in the rate of protein breakdown (Biolo et al. 
1997; Borel et al. 1997; Rasmussen et al. 2000). 
2.3 AMINO ACIDS 
Proteins have an important role to play in the formation of body structures and enzymes. 
Proteins are macromolecules consisting of long chains of amino acid subunits, which 
are joined together by peptide bonds. Amino acids exist both in the form of proteins 
and as free amino acids. 
Amino acids consist of an amino group, a carboxyl group, a hydrogen atom and a 
distinctive R group bound to a carbon atom. The basic structure of each of the 20 amino 
acids is identical, except for the structure of the R group, or side chain, which 
determines the specific characteristics of each individual amino acid (Stryer, 1995). 
The exception to this rule is proline that has a secondary amino group and glutamine 
that has both an amino and amide group. 
By convention, the carboxyl carbon is deemed carbon 1 in the amino acid structure, 
with the carbon atom next to carbon 1 being termed the a-carbon or carbon 2 (see Fig. 
2.1a). When the a-carbon has an amino group attached (NH2) it can be classed an 
amino acid. All of the 20 standard amino acids, except for glycine, have four different 
groups arranged tetrahedrally around the a-carbon (see Fig. 2.lb) and thus can exist in 
the D or L configuration. However, D-amino acids rarely occur in nature and are never 
present in proteins. 
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Fig.2.1a 
Fig.2.1b 
General structure of an amino acid (amino and carboxyl groups). 
/"_ ..................... " 
a-carbon H i 0 ) Carboxyl 
(Carbon 2) ~ I III I group 
R _ C -IC _ 0- j 
Amino 
group 
I \.-... ~ ........ j 
(···············N·················_') ~ Carbon I 
iH"- I - H ) i I 
t, ...................... ~ ....................... ../ 
NB: R represents the characteristic side chain. 
General structure of an amino acid (stereoisomers Land D). 
Mjrror plane 
COOH COOH 
NH,. }--{Cr--\. H H 
R R 
!rlmino acid D-amino acid 
NB: R represents the characteristic side chain. 
Amino acids that can be synthesised internally from existing amino acids and other 
substances are termed 'non-essential', whereas those amino acids that cannot be 
synthesised in the body and are required constituents of the diet are tenned 'essential'. 
The free amino acid pool is comprised of those amino acids not incorporated into 
protein; including plasma amino acids and intracellular amino acids in liver and skeletal 
muscle. In contrast to the liver, which is able to oxidise most of the twenty amino acids 
that are present in proteins, human skeletal muscle can oxidise only six amino acids: the 
branched-chain amino acids (leucine, isoleucine, valine), asparagine, aspartate and 
glutamate (glutamate can also be derived through the breakdown). 
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It has been reported that the intracellular concentration of free amino acids is dependent 
upon muscle fibre population, with slow-twitch fibres demonstrating a higher 
concentration of most amino acids. The only amino acids demonstrating higher 
concentrations in fast-twitch fibres were alanine and glycine (Turinsky and Long, 
1990). Although these observations were in rat skeletal muscle, it is feasible that a 
similar pattern should be observed in human skeletal muscle, albeit with a reduction in 
the absolute differences between fibre types, as amino acid concentrations in rat skeletal 
muscle have been reported to be higher than in human skeletal muscle (Bergstrom et al. 
1974) 
A continuous exchange of amino acids between protein and free amino acid pools exists 
in humans, as proteins are constantly being synthesised and simultaneously degraded, a 
process termed 'protein turnover'. Traditionally, the view has been held that the liver is 
the major site of both the catabolism and synthesis of amino acids. However, it has 
been demonstrated that the majority of amino acids in the body are in fact incorporated 
into muscle tissue, and that muscle tissue constitutes the primary site for the degradation 
of amino acids (Goldberg and Chang, 1978). 
2.3.1 AMINO ACID TRANSPORT 
The cellular amino acid requirements for both metabolism and protein synthesis must be 
met by a combination of the biosynthesis of non-essential amino acids and the transport 
of amino acids into the cell. The transport of amino acids is subject to regulation, and 
there are a multiplicity of systems with differing capacities and affmities (characterised 
using the Michaelis-Menton equation; capacity, Vmax; affmity, Km), which complicates 
the study of amino acid transport and regulation. Those transport systems of substantial 
importance are Systems-A, -ASC, -L, and N. 
Alanine and glycine transport 
System-A (A stands for alanine) transports those amino acids with short, polar, or linear 
side chains, in particular alanine and glycine, although many of the other amino acids 
are also in part transported via System-A (Collarini and Oxender, 1987). System-A is a 
high affmity, low-capacity transporter that is sodium-dependent and whose activity is 
markedly reduced at low extracellular pH. Furthermore, System-A is stimulated by 
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insulin in an inward direction and is regulated by the availability of amino acids in the 
extracellular environment, with a substantial up-regulation displayed in the face of low 
alanine concentrations (Rennie, 1996a). Although amongst the first of the amino acid 
transporter systems to be kinetically characterised, the importance of System-A in 
muscle alanine transport may be limited due to its low capacity (Hundal et al. 1989). It 
is possible that a greater proportion of alanine transport between blood and muscle 
occurs via Systems-ASC (alanine; serine; cysteine) and System-L (leucine). System-
ASC is the major sodium-dependent system and is a medium-affmity, medium-capacity 
system, whereas System-L is sodium-independent and is a low-affmity, high-capacity 
system (Collarini and Oxender, 1987). Both systems are unresponsive to insulin in 
skeletal muscle (Rennie, 1996a). 
BCAA and aromatic amino acid transport 
System-L appears to be the primary transporter for the branched-chain and aromatic 
amino acids, but not glutamine to any extent (Collarini and Oxender, 1987). System-L 
transport activity is regulated in response to the availability of System-L amino acids, 
principally leucine, isoleucine, valine, lysine, and phenylalanine. System-L activity is 
unaffected by insulin or any other hormones. None of the amino acids transported by 
this system are electrically charged at a physiological pH, therefore it effectively acts as 
a mechanism to equalise concentrations of its substrates across the sarcolemmal 
membrane. 
Glutamate transport 
Glutamate exchange between blood and tissues generally occurs at a low rate due to the 
relatively low activity of the transporter (Rennie, 1996a). Glutamate transport, and also 
aspartate, most probably occurs via System-XAG (X stands for exchanger) in human 
skeletal muscle. System-XAG is a high-affmity, low-capacity transport system that is 
sodium-independent but W dependent (i.e transporter characteristics are altered in the 
presence oflt). In addition, System-XAG is hormone insensitive. However, the kinetic 
characteristics of System-XAG do not appear to adequately explain the >50 fold 
concentration gradient that is maintained between the muscle and blood (BergstrOm et 
al. 1974), nor how muscle is able to extract glutamate from the blood despite this 
gradient. More work is required in this area before this process is fully understood. 
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Glutamine transport 
In hepatocytes, System-N (nitrogen) is primarily responsible for the uptake of 
glutamine. System-N may be unique to liver cells, as it has not yet been described in 
other cell types, and appears to have the greatest physiological activity, presumably 
because of its medium-range affmity and capacity. System-N is sodium-dependent and 
is subject to regulation by amino acid availability, similar to System-A. The uptake of 
glutamine into hepatocytes is inhibited by histidine and asparagine (Fafournoux et al. 
1983), in addition, facilitated diffusion enables hepatocytes to release glutamine when 
the intracellular concentration is elevated (Fafournoux et al. 1983). Until recently it 
was believed that glutamine metabolising enzymes held an exclusive role in regulating 
glutamine metabolism in the liver (Fafournoux et al. 1983). However, it has since been 
shown that glutamine transport across the plasma membrane may also be a potential 
regulatory site in glutamine metabolism (Haussinger et al. 1985). 
System-Nm (m stands for muscle) is the transporter in muscle analogous to System-N in 
the liver (Hundal et al. 1987). System-Nm is primarily responsible for the transport of 
glutamine. In addition, System-Nm transports asparagine and histidine in skeletal 
muscle, but asparagine and histidine are also substrates for Systems-A and ASC and for 
System-L respectively, and therefore System-Nm has a far lower capacity for these 
amino acids compared to glutamine. System-Nm is a high-capacity, low-affinity, 
sodium-dependent transport system, and this combination of affmity and capacity 
appears to account for the fact that glutamine has the fastest rate of entry into muscle 
relative to other amino acids (Banos et al. 1973). Furthermore, of all the major amino 
acid transport systems, System-Nm appears to be the only system that shows acute 
regulation by insulin (Rennie et al. 1994). Insulin is able to stimulate glutamine 
transport into skeletal muscle and the absence of insulin causes a reduction in the 
intramuscular glutamine pool, due to an increased efilux of glutamine from the muscle 
rather than a decreased influx of glutamine into the muscle (Rennie et al. 1996b). 
The activity of System-Nm is elevated under conditions of stress including, acidosis, 
surgical trauma, sepsis, burns, during corticosteroid treatment, and most probably 
during exercise. The increase in glutamine efilux from skeletal muscle is generally 
linked to an increase in transporter system activity (Babij et al. 1986a; Babij et al. 
1986b; Rennie et al. 1989), rather than an alteration in enzyme activity i.e. glutamine 
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synthetase and glutaminase (Babij et al. 1986a; Hundal et al. 1990). The mechanism 
behind this increase in transporter activity has been linked to the elevation of 
intracellular sodium which may stimulate transporter activity as opposed to increasing 
the carrier affmity for glutamine (Rennie et al. 1986). This mechanism would appear to 
be inherently linked to the observed stoichiometry of glutamine:sodium co-transport 
which has a coupling ratio of 1: 1 (Hundal et al. 1987). Therefore, a decrease in the 
intramuscular glutamine pool may be mediated through an increase in intracellular 
sodium, causing an increase in Na + -dependent glutamine efflux from the muscle 
(Hundal et al. 1987). Factors which influence Na+ transport, mediated either through a 
change in the activity of the Na+-K+ ATPase or by influencing membrane permeability 
to Na+, could alter the flux of glutamine and in turn the intracellular concentration. 
It is conceivable that changes in the plasma concentration of glutamine may modulate 
the size of the intramuscular pool due to the characteristics of glutamine transport in 
human skeletal muscle, with an increase in plasma glutamine concentration leading to 
an increased flux of glutamine into skeletal muscle (Ahmed et al. 1993). Furthermore, 
it has been suggested that glutamine is likely to be the most rapidly exchanging amino 
acid across the muscle membrane at physiological glutamine concentrations due to the 
high capacity of System-Nm (Hundal et al. 1987; Ahmed et al. 1993). Indeed, the 
infusion of glutamine has been observed to increase the intramuscular glutamine pool, 
highlighting the capacity ofSystem-Nm (Varnier et al. 1995). 
The modulation of the intramuscular glutamine pool by System-Nm is further 
demonstrated by the observation that System-Nm displays adaptive regulation, 
suggesting that when glutamine requirements are high and the supply limiting, increased 
synthesis of the transporter protein will occur (Rennie et al. 1994; Tadros et al. 1993). 
Thus, skeletal muscle has the necessary characteristics to be a net exporter of glutamine 
(Rennie et al. 1996b). 
2.3.2 AMINO ACID METABOLISM 
The initial step in the metabolism of amino acids is the removal of the amino group, 
leaving the carbon skeleton of the amino acid. Chemically, the remaining carbon 
skeleton is deemed a keto-acid or oxo-acid. The process of removal of the amino group 
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is termed deamination, resulting in the production of their corresponding keto-acids, and 
generally ammonia. However, most amino acids actually undergo transamination, 
rather than deamination. In this process, the amino group is transferred firstly to the 
catalysing enzyme, leaving the keto-acid, then the enzyme transfers the amino group to 
an acceptor molecule, which is a different keto-acid, thus forming the corresponding 
amino acid. The most common amino group acceptor is a-ketoglutarate resulting in the 
formation of glutamate, thus placing glutamate and a-ketoglutarate in central positions 
in amino acid metabolism. 
The skeletal muscle concentration of the free amino acids aspartate, asparagine and the 
BCAA, derived either through the net breakdown of muscle proteins or via uptake from 
the circulation, is lower than their relative occurrence in muscle proteins, implying that 
they are metabolised in skeletal muscle. Furthermore, some amino acids, such as 
alanine, glutamine and glutamate are present in the free amino acid pool at 
concentrations exceeding those in muscle protein and this reflects the fact that they are 
synthesised in skeletal muscle (Smith and Rennie, 1990). All other amino acids are 
released in proportion to their occurrence in muscle proteins implying that little or no 
metabolism occurs. Indeed, during studies involving exercise, both phenylalanine and 
tyrosine have been used as indicators of protein degradation as they are not subject to 
any intermediate metabolism (Blomstrand and Saltin, 1999). Similarly, 3-
methylhistidine (3-MH) has been used as an indicator of contractile protein degradation, 
as it is a direct by-product of actin and myosin degradation and cannot be subsequently 
metabolised (Elia et al. 1979). However, it has been demonstrated that 3-MH is also 
released during gut proteolysis (i.e. smooth muscle), which questions the use of 3-MH 
appearance as an index of contractile protein degradation (McKeran et al. 1978; Rennie 
and MilIward, 1983). 
The fIrst step in branched-chain amino acid (BCAA) metabolism is the reversible 
BCAA aminotransferase reaction (BCAT; located predominantly in the mitochondria in 
humans, Suryawan et al. 1998) where leucine, isoleucine and valine are converted to 
their respective branched-chain a-keto acids (BCKA) and the amino group acceptor a-
ketoglutarate is converted to glutamate. To complete the oxidation of the BCAAs, the 
BCKAs are degraded in an irreversible oxidative-decarboxylation reaction catalysed by 
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the branched-chain a-keto acid dehydrogenase complex (BCKADH). This reaction is 
suggested to be rate-limiting in BCAA oxidation. This step commits the BCAA carbon 
skeleton to the degradative pathway, therefore the activity of the BCKADH is highly 
regulated through a reversible phosphorylation (inactive )-dephosphorylation (active) 
mechanism (Harper et al. 1984). 
Only 4% of the BCKADH is in the active form in skeletal muscle at rest (Wagemnakers 
et al. 1989), with human skeletal muscle holding a high capacity for BCAA 
transamination (Suryawan et al. 1998). The low activation ofthe BCKADH in human 
skeletal muscle at rest, suggests that the activity of the BCKADH has the potential to 
increase many fold. Indeed, skeletal muscle BCKADH activity has been shown to be 
stimulated by contractile activity, the exogenous provision of BCAA and low muscle 
glycogen content (Kasperek et al. 1985; Wagemnakers et al. 1989; van Hall et al. 
1996b; Jackman et al. 1997; Wagenmakers et al. 1989). Moreover, the activation of 
BCKADH by exercise and BCAA ingestion have been found to be additive, and the 
activation of BCKADH by low muscle glycogen content and BCAA ingestion is via 
different mechanisms (van Hall et al. I 996b). Furthermore, the activation of BCKADH 
by exercise does not lead to an increase in the total enzyme activity in human muscle, 
rather the proportion of the enzyme present in the active state (dephosphorylated) 
increases (Wagenmakers et al. 1989). 
The principal transamination reaction in BCAA metabolism, catalysed by BCAT, has 
been suggested to drain a-ketoglutarate and thus reduce TCA cycle flux which may 
impede the oxidation of glucose and fatty acids (Wagemnakers et al. 1990). More 
specifically, in the case ofleucine, this reaction will put a net carbon drain on the TCA 
cycle, as the carbon skeleton of leucine is oxidised to three acetyl-CoA molecules and 
the aminotransferase step uses a-ketoglutarate as an amino group acceptor. The 
oxidation of both valine and isoleucine do not lead to the net removal of TCA cycle 
intermediates, as valine is oxidised to succinyl-CoA and isoleucine to both succinyl-
CoA and acetyl-CoA. 
The 'draining' effect on a-ketoglutarate by BCAA oxidation is normally counteracted 
by the regeneration of a-ketoglutarate either through the deamination of glutamate via 
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the glutamate dehydrogenase reaction or through transamination of glutamate with 
pyruvate by the alanine aminotransferase reaction (AAT) (Gibala et al. 1997a). 
However, under conditions of low glycogen or in patients with McArdle's disease 
(muscle phosphorylase deficiency), such anaplerotic processes are reduced or do not 
exist (Wagenmakers et al. 1991; Wagenmakers et al. 1990). The reduced availability 
of pyruvate in these situations has been suggested to decrease the anaplerotic capacity 
of the AAT reaction, leading to a decrease in the concentration of the TCA cycle 
intermediates (due to insufficient counterbalance of the carbon-draining effect of the 
BCAA aminotransferase reaction), and reduction in TCA cycle activity (Wagenmakers, 
1998a). Indeed, no increase is observed in arterial or muscle alanine concentration 
during exercise in McArdle's patients (Wagenmakers et al. 1990; Sahlin et al. 1995), 
with only a modest decrease in muscle glutamate concentration during incremental 
exercise (Sahlin et al. 1995) demonstrating a reduced flux through the AA T reaction in 
these patients. 
Under conditions of reduced pyruvate concentration and increased ammonia 
concentration, a situation which exists during the latter stages of prolonged exercise, the 
synthesis of glutamine is favoured (Goldberg and Chang, 1978). Indeed, an increase in 
plasma glutamine concentration has been observed following prolonged submaximal 
exercise (Sahlin et al. 1990). This increase in the presence of glutamine in the plasma 
has been attributed to a large portion of the ammonia produced (through the 
deamination of the BCAA; see section 2.4.3) being bound to glutamate by the action of 
glutamate synthetase, so that the muscle releases large amounts of glutamine and only 
small amounts of ammonia (Eriksson et al. 1985). 
As the muscle becomes depleted of glycogen, such as during prolonged exercise, 
BCKADH activation is increased (van Hall et al. 1996b) and BCAA oxidation is 
accelerated (Rennie et al. 1981), with increasing amounts of the BCAA being extracted 
from the circulation, contributing to the energy required to sustain exercise 
(Wagenmakers et al. 1991; van Hall et al. 1996b; van Hall et al. I 995b). Therefore, it 
has been suggested that the provision of BCAA may serve as an additional, or indeed 
alternative, fuel source during prolonged exercise .. However, the ingestion of a solution 
containing BCAA in addition to glucose-polymer failed to affect cycling performance 
over 100 km in well-trained cyclists, compared to glucose-polymer only (Madsen et al. 
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1996), with similar fmdings being reported during cycling to exhaustion at 70% V02max 
(Galiano et al. 1992), despite elevating plasma BCAA concentrations to -1000 llITlo!.r' 
(normal concentration of plasma BCAA in resting humans is 300-400 Ilmo!.r'). 
2.4 AMMONIA METABOLISM 
Anunonia is produced by skeletal muscle both at rest and during exercise (Lowenstein, 
1972; Mutch and Banister, 1983). The normal resting plasma ammonia concentration is 
less than 50 IlM, but during submaximal exercise to exhaustion the ammonia 
concentration may increase to 250 IlM (Brouns et al. 1990). Ammonia is widely 
deemed to be a toxic by-product of metabolism, however the ammonium ion may 
actually serve to regulate glycolysis to a small extent through the activation of 
phosphofructokinase (PFK) (Lowenstein, 1972; Lowenstein and Goodrnan, 1978; 
Spencer and Katz, 1991a; Lowenstein, 1990). In addition, and somewhat paradoxically, 
ammonia may act as a buffer for lactic acid, thereby helping to maintain pH balance 
(Mutch and Banister, 1983). During exercise, ammonia production is greatly increased 
and is related to the intensity and duration of exercise. However, the pathway(s) by 
which ammonia is produced during exercise has led to much debate in the literature. 
During prolonged submaximal exercise ammonia (NH3)' can be produced through two 
possible avenues in contracting muscle. Firstly, ammonia may be derived from the 
oxidative deamination of glutamate via a reversible reaction catalysed by glutamate 
dehydrogenase (EC 1.4.1.2): 
glutamate + NAD+ ~ a-ketoglutarate + NH3 + NADH 
This reaction is therefore involved in the coupling of amino acid and ammonia 
metabolism. The glutamate dehydrogenase reaction activity appears sufficiently high to 
sustain the ammonia production required for the synthesis of glutamine in resting 
muscle, a reaction catalysed by glutamine synthetase (EC 6.3.1.2; glutamate + ATP + 
NH3 ~ glutamine + ADP + Pi) (Wibom and Hultman, 1990; Wibom et a!. 1992; 
Starritt et al. 1999; Wibom et a!. 1992). Previously however, its has been suggested 
1 In this thesis NH3 represents the sum of both ammonia and the ion, ammonium. 
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that the glutamate dehydrogenase reaction does not contribute significantly to ammonia 
production in exercising muscle, as its activity in the direction of deamination is below 
the observed rates of ammonia production (Lowenstein and Goodman, 1978). 
Furthermore, considering that the reaction is near-equilibrium in nature and that a large 
decrease is observed in glutamate concentration during the early stages of exercise 
(Bergstrom et al. 1985), the ammonia production rate appears to be lower than that 
expected through this pathway, suggesting that ammonia is produced through additional 
pathways. 
Whether or not the glutamate dehydrogenase reaction is capable of sustaining the rate of 
ammonia production during exercise is a contentious issue. More recent evidence 
suggests that the activity of the enzyme is increased with endurance training (Wibom et 
al. 1992). Endurance trained individuals generally experience a lesser increase in 
plasma ammonia during prolonged exercise (Graham et al. 1995). Therefore, it is 
possible in these individuals that the glutamate dehydrogenase reaction may favour 
glutamate formation. This would increase the availability of glutamate (substrate) for 
the glutamine synthetase reaction, which could conceivably increase glutamine 
synthesis and release from muscle (see sections 2.3.2 and 2.6.1 for additional sources of 
glutamate). Although the response of glutamine synthetase to training has not yet been 
studied, an increased release of glutamine from endurance trained muscle has been 
observed suggesting increased activity of this enzyme (Hood and Teljung, 1994). 
Furthermore, as glutamine synthetase is a mitochondrial enzyme, one may expect an 
increase in activity in response to training, in addition to other mitochondrial enzymes. 
The concomitant formation of glutamate through the glutamate dehydrogenase reaction 
and glutamine through the glutamine synthetase reaction would serve to reduce the 
amount of free ammonia present, corresponding to the observation in trained muscle. 
Indeed, if glutamate arises from the amination of a-ketoglutarate via the glutamate 
dehydrogenase reaction, then the synthesis of glutamine, catalysed by glutamine 
synthetase, can be seen as a transporter of two molecules of anunonia. The synthesis of 
both alanine (Graham et al. 1995; MacLean et al. 1994; MacLean et al. 1996; 
Galassetti et al. 1998) and glutamine (Eriksson et al. 1985; Graham et al. 1995; 
MacLean et al. 1994; MacLean et al. 1996; Galassetti et al. 1998) after reaction with 
pyruvate and glutamate respectively, provide a non-toxic mechanism for the removal of 
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amino groups from the muscle, and as such may act as a buffer for ammonia. The 
degree to which both glutamine and alanine are synthesised is largely dependent upon 
the concentration of ammonia within the tissue, with increased levels of ammonia 
favouring glutamine synthesis rather than alanine synthesis (Goldberg and Chang, 
1978). Therefore, when considering muscle ammonia flux it would be imprudent to 
neglect both alanine and glutamine effiux. However, alanine and glutamine synthesis 
and subsequent effiux is unable to prevent the gradual rise in plasma ammonia 
concentration observed during prolonged submaximal exercise. This may be due to the 
competition between intramuscular enzymes, namely transaminases (i.e. alanine 
aminotransferase, aspartate aminotransferase) that exists for pyruvate and glutamate 
during exercise, in addition to the fact that glutamine synthesis is an energy requiring 
process. 
2.4.1 THE PURINE NUCLEOTIDE CYCLE 
Evidence for a second source of ammonia production is demonstrated by the 
observation that extracts of muscle cytosol have been shown to produce ammonia 
(Lowenstein and Goodman, 1978). This suggests that glutamate dehydrogenase, which 
occurs almost exclusively in the mitochondrial matrix (Lindena et al. 1996), cannot be 
solely responsible for ammonia production. This source of ammonia is most likely 
generated via the breakdown of ATP in the purine nucleotide cycle (PNC), proposed by 
Lowenstein (Lowenstein, 1972). The PNC generates ammonia through the deamination 
of AMP to inosine monophosphate (IMP), catalysed by the enzyme AMP deaminase 
(EC 3.5.4.4), producing ammonia as a by-product (Fig. 2.2). The key postive 
modulators of AMP deaminase are thought to be W, AMP, free ADP and Pi (Graham et 
al. 1995). 
The AMP deaminase reaction within the PNC is not reversible under normal 
physiological conditions, therefore a further two reactions exist to convert IMP back to 
AMP (Fig. 2.2). However, ifIMP accumulates and is not reaminated back to AMP, a 
depletion of the adenine nucleotides (AMP, ADP, ATP) will occur. If IMP is 
reaminated, the adenine nucleotide pool is restored. The reactions required to reaminate 
IMP back to AMP are catalysed by adenylosuccinate synthetase and adenylosuccinate 
lyase. These reactions require the amine group from aspartate to proceed, which is 
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derived through transamination with glutamate. It is noteworthy that the reactions of 
the PNC do not act in concert, in other words, AMP deamination does not occur at the 
same time as IMP reamination. Moreover, AMP dearnination occurs during muscle 
contraction, whilst IMP reamination occurs during muscle recovery (Meyer and 
Terjung, 1980). 
H20 
--''';( --
n Adenylosucx:lnate 
~ GOP+P; 
IMP "( ~ 
Aspartate 
+GTP 
Fig.2.2 The purine nucleotide cycle. The reactions are catalysed by a) AMP dearninase; b) 
adenylosuccinate synthetase; c) adenylosuccinate lyase 
The net reaction of the PNC includes the deamination of the a-ammo group of 
aspartate. Therefore, theoretically, the six amino acids oxidised in human skeletal 
muscle (leucine, isoleucine, valine, aspartate, asparagine and glutamate) could also be 
deaminated via the reactions of the PNC, as the a-amino group of these amino acids is 
interchangeable by reversible transamination reactions (Wagenrnakers, 1998a). 
The PNC is also suggested to be involved in nucleotide management. However, if the 
PNC is actually 'cycling' there is no net formation of IMP or removal of AMP, 
suggesting that the PNC does not actually contribute to nucleotide management. In this 
situation, aspartate is deaminated with the formation of ammonia and fumarate by the 
PNC. Therefore, the PNC may not only be responsible for the production of ammonia, 
but may be capable of replenishing TCA intermediates by generating fumarate. The 
generation of fumarate by the PNC in the cytosol may therefore been seen as an 
'anaplerotic' reaction, with fumarate being transported into the mitochondrion 
presumably via a fumarate/malate translocator, which has been shown to exist in rat 
liver and kidney mitochondria (Atlante et al. 1998). It has been suggested that the 
increase in fumarate in rat skeletal muscle observed during exercise can be accounted 
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for by the operation ofthe PNC (Aragon and Lowenstein, 1980). However, in a more 
recent study it was reported that in human skeletal muscle a normal exercise-induced 
increase in fumarate was observed in patients with near total myoadenylate dearninase 
(AMPD) deficiency (AMPD catalyzes the reaction from adenosine monophosphate 
(AMP) ~ inosine monophosphate (IMP) + NH3 within the PNC) (Tarnopolsky et al. 
2001). These results are consistent with the concept that the PNC is not quantitatively 
important in exercise-mediated increase in fumarate. It is however conceivable that 
species difference may exist in the operation of the PNC. 
Whilst not considered as important as the previously discussed pathways for ammonia 
production, there are a number of other pathways by which ammonia may be produced 
in skeletal muscle. Glutaminase (EC 3.5.1.2) catalyses the breakdown of glutamine to 
ammonia: 
glutamine + H20 ~ glutamate + NH3 
Although important in ammonia metabolism in the liver, kidney and gut, the activity of 
this enzyme in skeletal muscle is generally regarded to be low at rest and during 
exercise, although it has not been measured in human skeletal muscle either at rest or 
during exercise. Secondly, adenosine deaminase (EC 3.5.4.4) an enzyme important in 
the control of adenosine concentration may also produce ammonia (adenosine + H20 
~ inosine + NH3). However, as the concentration of adenosine in skeletal muscle is 
very low, suggesting that the quantitative contribution to ammonia production in 
skeletal muscle is most probably negligible. 
Lastly, the deamination of the BCAA also contributes to ammonia production, which is 
discussed in section 2.4.3. 
2.4.2 THE UREA CYCLE 
Armnonia is a universal participant in both amino acid synthesis and degradation. 
However, an accumulation of ammonia above normal physiological concentrations can 
be toxic. Therefore, cells undergoing active amino acid catabolism must be able to 
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excrete ammonia at a rate comparable to the rate of ammonia synthesis. Excess 
ammonia, that is ammonia not involved in the formation of amino acids or the 
biosynthesis of nitrogen compounds, is converted to urea by the urea cycle (Fig. 2.3) in 
the liver. It is then secreted into the bloodstream and extracted by the kidneys for 
excretion in the urine. 
H,O 
~/Arginlne 
-( Urea 
Argininosucdnate Ornithine 
J 
,----------------- --------------------, 
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, ,,' 
Carbamoyl phosphate 
Aspartate Citrulline 
CYTOSOL • MITOCHONDRIAL MATRIX , , , 
,~-------------------------------------,' Fig. 2.3 The urea cycle. Urea is formed by the hydrolysis of arginine. The subsequent reactions of 
the cycle synthesize arginine from ornithine, the other product of the hydrolysis reaction. 
Firstly, ornithine is carbamolyated to citrulline by carbamoyl phosphate. Citrulline then 
condenses with aspartate to form argininosuccinate, which is cleaved to arginine and 
fumarate. 
In the urea cycle ammonia combines with C02 to form carbamoyl phosphate. A series 
of reactions then lead to the formation of urea in liver cells (Fig. 2.3). One of the 
nitrogen atoms of urea is transferred from aspartate, derived from ammonia through the 
transfer to glutamate via the glutamate dehydrogenase reaction and then through 
transamination to aspartate. The second nitrogen atom and carbon atom is from 
carbamoyl phosphate, which is synthesised from C02 (Stryer, 1995). Ornithine, an 
amino acid which is not involved in the synthesis of proteins, acts as the 'carrier' for 
both the nitrogen and carbon atoms. The compartmentation of the urea cycle is such 
that ornithine must be transported into the mitochondrion, and citrulline exported into 
the cytosol for the cycle to proceed. 
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Carbon balance is maintained during cycling by the conversion of the fumarate to 
oxaloacetate in the TCA cycle, and then transaminated to aspartate. This series of 
reactions preserves the carbon skeleton of aspartate in the form of fumarate. The 
synthesis of fumarate therefore links the urea cycle and the TCA cycle, and is also 
analogous to the production of fumarate via the PNC. The net reaction for one turn of 
the urea cycle is: 
CO2 + NH3 + 3ATP + aspartate + 2H20 -7 urea + 2ADP + 2P, + AMP + PP; + fumarate 
The fumarate produced is then hydrated to malate, which is in turn oxidised to 
oxaloacetate. Oxaloacetate then has several possible fates: (1) transamaintion to 
aspartate, (2) conversion to glucose through gluconeogenesis, (3) condensation with 
acetyl CoA to form citrate, or (4) conversion to pyruvate (Stryer, 1995). 
2.4.3 AMMONIA METABOLISM DURING EXERCISE 
At rest, a small uptake of anunonia is observed in skeletal muscle. During exercise 
ammonia is released, the magnitude of which is dependent upon the intensity and 
duration of the exercise. Ammonia production during short, intense exercise is 
primarily due to the net breakdown of adenine nucleotides to IMP and is also related to 
fibre type recruitment, with fast-twitch glycolytic fibres being largely responsible for 
anunonia production due to their significant recruitment during this type of exercise 
(Meyer et al. 1980; Meyer and Terjung, 1979). However, during the fITst 30 minutes of 
prolonged submaximal exercise there is negligible increase in IMP (Sahlin et al. 1990), 
despite an increase in anunonia concentration (van Hall et al. 1995b). 
Therefore, it is questionable whether the PNC contributes significantly to anunonia 
production during prolonged submaximal exercise (refer to section 2.4.1), and 
alternative sources such as BCAA oxidation, may contribute to a greater extent during 
this type of exercise. The fact that ammonia production exceeds the rate of breakdown 
of adenine nucleotides may indicate ammonia production through the deamination of 
amino acids via the PNC, at least during this initial period of submaximal exercise (van 
Hall et al. 1995b). The adequate provision of aspartate through the transamination of 
glutamate, ensures that the PNC may continue to 'cycle' and reaminate IMP to AMP. 
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The a-group of aspartate may be derived from any of the six amino acids which can be 
oxidised within skeletal muscle through reversible transamination reactions involving 
glutamate. However, as an elevation in skeletal muscle aspartate concentration has been 
observed during submaximal exercise, rather than decrease if involved in the PNC it has 
been suggested that PNC cycling may be negligible during exercise of this nature 
(MacLean et al. 1991). This adds to evidence suggesting that the PNC may not actually 
'cycle' under such circumstances (Rennie, 1996a; Tamopolsky et al. 2001). Indeed, 
during submaximal cycling to fatigue, a situation whereby ammonia production should 
be increased (Brouns et al. 1990), no alterations in the key postive modulators of AMP 
deaminase (H., AMP, free ADP and Pi) have been observed, suggesting a greater 
contribution from the amino groups of the BCAA to ammonia production (MacLean 
and Graham, 1993; MacLean et al. 1996; MacLean et al. 1991; van Hall et al. 1995a; 
MacLean and Graham, 1993; van Hall et al. 1995b; MacLeanet al. 1996). 
During prolonged submaximal exercise the oxidation of the branched-chain amino acids 
(BCAA) via transamination and deamination reactions may contribute significantly to 
ammonia production. The first step in the metabolism of the BCAA is the removal of 
the NH3 group by the reversible deamination catalysed by BCAA aminotransferase 
(BCAT). The NH3 group is transferred to a-ketoglutarate, forming glutamate, which is 
then deaminated by glutamate dehydrogenase to produce a-ketoglutarate and NH3. 
Therefore, the transdeamination (transamination and deamination) of the BCAA can 
contribute to ammonia production during exercise. Muscle ammonia levels have been 
reported to be significantly greater during exercise when BCAA are ingested prior to 
exercise. This suggests that the increase in BCAA oxidation results in elevated 
ammonia production, supporting the important contribution of BCAA transdeamination 
to ammonia production (MacLean et al. 1994). 
It has been suggested that a reduction in muscle glycogen content may increase 
ammonia production during prolonged submaximal exercise (Broberg and Sahlin, 1989; 
Broberg and Sahlin, 1988; Wagenmakers et al. 1991). In the glycogen depleted state, 
IMP furrnation is increased during exercise (Spencer and Katz, 1991a; Spencer et al. 
1992) leading to a stoichiometric depletion of the adenine nucleotides (ATP, ADP, 
AMP) and a concomitant production of ammonia via the AMP deaminase reaction. In 
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addition, when muscle glycogen content is reduced during prolonged submaximal 
exercise, an increased uptake of the BCAA into skeletal muscle has been observed, 
presumably suggesting an increased oxidation of these amino acids (Lemon and Mullin, 
1980; Wagenmakers et al. 1991). 
2.4.4 BCAA AND THE CENTRAL FATIGUE HYPOTHESIS 
Little is known about the mechanisms of central fatigue (i.e. fatigue resulting from the 
failure or limitations within the central nervous system). It was suggested in the mid 
1980's that changes in plasma amino acid concentrations could play a role in central 
fatigue by influencing the synthesis and release of neurotransmitters, particularly 5-
hydroxytryptamine (5-RT), in the brain (Newsholme, 1986). 5-RT has been linked to a 
variety of psychological responses including, lethargy, arousal, sleepiness and mood, 
therefore alterations in the concentration of 5-RT in the brain may modulate muscular 
fatigue or perceived exertion during exercise. 
proposed as a potential mediator of 'central 
Blomstrand et al. 1991). 
For these reasons, 5-RT has been 
fatigue' (Blomstrand et al. 1988; 
The rate of 5-RT synthesis is dependent on the supply of its precursor, the amino acid 
tryptophan. The frrst reaction in the synthesis of 5-RT is catalysed by the enzyme 
tryptophan mono-oxygenase, which is considered the rate-limiting reaction in 5-RT 
synthesis (Newsholme and Leech, 1983). Since this enzyme is not saturated with 
substrate, an increase in the supply of tryptophan could theoretically increase the rate of 
5-RT synthesis, implying that the uptake of free tryptophan into the brain is an 
important step in the regulation of 5-RT synthesis. In addition, the rate of 5-RT 
synthesis in the brain is also dependent upon the concentration of tryptophan in the 
blood and also upon the concentration of other large neutral amino acids (LNAA). 
The LNAA transporter is a saturable carrier that transports amino acids across the 
blood-brain barrier, including tryptophan, tyrosine, methionine, phenylalanine and the 
BCAA (leucine, isoleucine and valine). These amino acids compete with tryptophan for 
transport into the brain, with the relative rate of transport into the brain being dependent 
upon the concentration of each amino acid relative to its competitors. Tryptophan is the 
only amino acid that is transported bound to albumin in the plasma (McMenarny and 
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Oncley, 1958). In the resting state, -90% is bound to albumin and -10% is in the free 
form. It has been suggested that the free concentration of tryptophan rather than the 
total concentration governs the rate of entry of tryptophan into the neurons and that free 
tryptophan therefore competes with other LNAA for transport into the brain 
(Blornstrand and NewshoIme, 1996). The plasma concentration of free tryptophan has 
been found to increase during prolonged exercise (Blornstrand et al. 1988), which may 
be related to an increased rate of release of free fatty acids from adipose tissue during 
exercise, causing an increase in the plasma concentration of free fatty acids. The free 
fatty acids are transported bound to albumin in the plasma, like tryptophan, and an 
increase in their concentration decreases the binding of tryptophan to albumin, thereby 
increasing the plasma free tryptophan concentration (McMenamy and OncIey, 1958). 
During the latter stages of prolonged exercise, the mobilisation of free fatty acids is 
increased which may displace the tryptophan bound to albumin, increasing the free 
tryptophan concentration. Concomitantly, an increased uptake ofthe BCAA (the amino 
acids that compete with tryptophan for transport into the brain) from plasma by skeletal 
muscle is observed during this period, which may result in an increase in the plasma 
concentration ratio of free tryptophan:BCAA. As suggested earlier, this may increase 
the rate of tryptophan entry into the brain, which may increase the brain concentration 
of 5-HT. In a study in humans, prolonged exercise caused a decrease in the plasma 
concentration of the BCAA with a concomitant increase in the free tryptophan 
concentration, akin to the proposed hypothesis (Blornstrand et al. 1988). Therefore, 
studies have examined the central fatigue hypothesis by manipulating either the plasma 
BCAA and/or tryptophan concentration. BCAA supplementation has been proposed not 
only to provide an additional fuel source during prolonged submaximal exercise, but 
may also be able to reduce the increase in the plasma concentration ratio of free 
tryptophan to BCAA during prolonged exercise. Through this mechanism, a reduction 
in the uptake of tryptophan into the brain and subsequent increase in brain 
concentrations of the neurotransmitter 5-hydroxytryptamine (5-HT) was proposed. 
One of the fIrst studies aiming to manipulate the plasma BCAA concentration was 
conducted by the research group who proposed the original central fatigue hypothesis. 
Subjects ingested 16 g of a mixture of BCAA in a 5% carbohydrate solution during a 
fIeld-based marathon (Blornstrand et aI. 1991). This dose was able to elevate plasma 
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BCAA levels and thus decrease the plasma free tryptophan:BCAA ratio. Despite this, 
marathon performance was not different compared to the placebo group. However, 
when subjects were divided into fast (:::; 3 h 5 min) and slow runners, a reduction in 
performance time was observed in the slower runners only. It must be noted that some 
criticisms concerning the experimental design of this study have arisen and therefore 
caution should be taken when interpreting the results, particularly considering the 
results oflater studies (van Hall et al. 1995a). Blomstrand et al. (1991) also suggested 
that the slower runners may have depleted their glycogen stores more quickly, therefore 
becoming more susceptible to BCAA provision compared to the fuster runners, as the 
oxidation of the BCAA during exercise appears to be related to glycogen concentration 
in skeletal muscle. An inverse relationship has been found between the activity of the 
branched-chain a-keto acid dehydrogenase complex and skeletal muscle glycogen 
content, suggesting that BCAA oxidation would be increased in the glycogen-depleted 
state (Wagemnakers et aL 1991). However, Varnier et al. tested this hypothesis, by 
infusing BCAA prior to exercise in previously glycogen-depleted subjects, and 
performance during a graded exercise test was not different when compared to a saline 
control (Varnier et al. 1994). 
In a well controlled laboratory-based study, subjects received a 6% sucrose solution 
supplemented with either a low (6 grl) or high (18 grl) concentration of BC AA, or 
tryptophan (1 grl) (van Hall et al. 1995a). Neither the low nor high concentration of 
BCAA affected cycle time to exhaustion at 70% Wmax compared with a placebo trial 
despite an increase in the plasma BCAA concentration. The supplementation of 
tryptophan would be expected to affect performance in a negative manner according to 
the central fatigue hypothesis. In this study, tryptophan supplementation did not affect 
cycle time to exhaustion at 70% Wmax compared to either BCAA supplementation or 
control trials. This was despite an estimated 20-fold increase in free-tryptophan influx 
into the brain. This fmding questions the importance of free Tryp:LNAA for the 
development of central fatigue. 
Therefore, the majority of studies where the plasma concentration ratio of free 
tryptophan to BCAA was altered through either BCAA or tryptophan supplementation 
have failed to demonstrate a positive effect on performance. The results from these 
studies in human subjects would seem to indicate that the manipulation of the plasma 
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concentration ratio of free tryptophan to BCAA is unable to modulate the central fatigue 
mechanism that has been previously observed in rats (Chaouloff et al. 1986). Whether 
this failure in the central fatigue mechanism lies in the transport of amino acids through 
the blood-brain barrier, the conversion of tryptophan to 5-HT, or the proposed effect of 
5-HT on central nervous system function during exercise remains to be elucidated. 
More recently, in the rat, it has been demonstrated that brain ammonia levels increase 
during prolonged exercise, parallel to the increase observed in plasma ammonia 
(Guezennec et al. 1998). In order to detoxify this ammonia, which in itselfmay lead to 
fatigue (Banister and Cameron, 1990), an increase in glutamine synthesis was observed 
(glutamate + NH3 ~ glutamine). It is therefore postulated that an increase in glutamine 
synthesis will decrease both brain glutamate and gamma-amino butyric acid (GABA) 
levels, as glutamate is also the precursor for GABA synthesis. GABA, considered as 
the main inhibitory neurotransmitter, is involved in the regulation of locomotion at 
spinal level (Cazalets et al. 1994). 5-HT release is inhibited by GABA, mediated via 
the pre-synaptic 5-HT receptor, therefore a decrease in brain GABA levels may lead to 
an increase in 5-HT release. Indeed, it has recently been demonstrated that a GABA 
agonist is able to extend endurance time to exhaustion in the rat (AbdelrnaIki et al. 
1997). The supplementation of glutamine may therefore reduce the requirement for 
glutamine synthesis, thus sparing glutamate and maintaining GABA levels in the brain. 
Although an intriguing hypothesis, complimenting the original 'central fatigue' 
hypothesis, until further research is conducted these mechanisms remain speculative, 
especially in humans. 
2.5 AMINO ACID SUPPLEMENTATION POST EXERCISE 
It has been known for more than 30 years that the consumption of carbohydrate during 
recovery from exercise leads to a greater accumulation of muscle glycogen (Bergstrom 
et al. 1967; Hultman, 1967a). More recently however, the consumption of protein in 
addition to carbohydrate during recovery from exhaustive exercise has been 
demonstrated to increase muscle glycogen resynthesis to a greater extent than the 
consumption of carbohydrate alone (Zawadzki et al. 1992). However, the meals 
administered in this study were not isoenergetic, therefore the observed differences may 
be due to additional energy intake rather than the specific properties of protein. 
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In more controlled experiments, the co-ingestion of carbohydrate and protein post-
exercise has been shown to stimulate muscle glycogen resynthesis (Tamopolsky et al. 
1997; Jentjens et al. 2001). It is important to note however, that the rate of muscle 
glycogen synthesis was not greater than the carbohydrate alone condition in these 
experiments. The increase in muscle glycogen storage post-exercise after the co-
ingestion of carbohydrate and protein has been attributed to an increased insulin 
response promoting storage of carbohydrate (Spiller et al. 1987). 
Furthermore, the provision of protein, and more specifically amino acids, in the post-
exercise period may enhance whole-body nitrogen balance and preserve whole-body 
and muscle protein stores (Borel et al. 1997). Therefore, in terms of whole-body 
recovery, the provision of both carbohydrate and amino acids in the post-exercise period 
may be more favourable than the ingestion of carbohydrate alone. In particular, the 
supplementation of a single amino acid has been considered more recently, rather than 
whole protein. Of particular interest in this context is the amino acid glutamine. A 
positive relationship has been observed between protein synthesis and the intramuscular 
glutamine concentration (MacLennan et al. 1987), in addition the intramuscular 
glutamine concentration falls dramatically as a result of starvation, injury, disease and 
after prolonged exercise. During these conditions, glutamine synthetase activity has 
been reported to increase, whereas glutaminase activity was unchanged (Tadros et al. 
1993). Furthermore, an increase in the capacity for glutamine uptake via system Nm 
was observed, suggesting that both system Nm and glutamine synthetase undergo 
adaptive up-regulation in glutamine-deprived muscle cells. Therefore, the 
supplementation of glutamine may preserve intracellular stores and exert an anabolic 
effect. 
2.6 GLUTAMINE 
Glutamine has an elementary composition of carbon (41.09%), hydrogen (6.9%), 
oxygen (32.84%) and nitrogen (19.17%) and has a molecular weight of 146.15. 
Glutamine is a five-carbon amino acid with two amino moieties, an a-amino group, and 
an easily hydrolysed terminal amide group (CSHION203; see Fig. 2.4). Oxidation of one 
molecule of glutamine yields 30 molecules of adenosine triphosphate (ATP), an amount 
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comparable to the 36 molecules of ATP produced from glucose, a six-carbon sugar 
(Lacy and Wilmore, 1990). 
COOH 
I 
H3W - C -H 
I 
CH2 
I 
Fig 2.4 Chemical structure of glutamine. 
Glutamine, although a non-essential amino acid, has been identified as a conditionally 
'essential' amino acid, such that its requirement markedly increases during conditions of 
metabolic stress (Lacy and Wilmore, 1990). Glutamine has a prominent role in the 
maintenance of acid-base balance (Golden et al. 1982), and is an important energy 
source for the cells of the gut (Hartrnann and Plauth, 1989; Souba, 1991; Kight and 
Fleming, 1995; Fleming et al. 1997) and the immune system (Ardawi and Newshohne, 
1983; Newshohne et al. 1989). Skeletal muscle and the small intestine appear to be the 
major sites for glutamine synthesis and uptake, respectively, in humans (Marliss et al. 
1971; Windmueller and Spaeth, 1974). 
Glutamine is the most abundant free amino acid in plasma and skeletal muscle (with the 
exception of taurine) (Bergstrom et al. 1974) and constitutes more than 50% of the free 
intracellular amino acid pool. The concentration of glutamine in human skeletal muscle 
is remarkably high, about 20 mmoVkg wet weight which is approximately 30 times the 
concentration observed in whole blood (0.6 - 0.7 mmol.r1). Glutamine is present in the 
free amino acid pool at a concentration exceeding that in muscle protein, as are alanine 
and glutamate, reflecting the fact that these amino acids are synthesised in muscle. It 
has been estimated that the synthesis rate of glutamine in human skeletal muscle is 
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between 20 and 80 g per day and is higher than that of any other amino acid (Darmaun 
et al. 1986). 
The intramuscular glutamine pool is depleted in response to a variety of situations 
including glucocorticoid treatment (Muhlbacher et al. 1984), severe illness (Rennie et 
al. 1986; Biolo et al. 2000), and prolonged exercise (Rennie et al. 1981). This 
decrease in intramuscular glutamine concentration is also reflected in the plasma 
glutamine concentration, with both surgery (Parry-Billings and Newshoime, 1992) and 
prolonged exercise (Parry-Billings et al. 1987) leading to a decrease in plasma 
glutamine concentration, presumably due to an increased uptake of glutamine by the 
splanchnic bed. 
There is considerable evidence to suggest that a positive correlation exists between 
positive whole-body protein balance and both the size of the intramuscular glutamine 
pool (MacLennan et al. 1987; MacLennan et al. 1988; Jepson et al. 1988) and the 
plasma concentration of glutamine (Watt et al. 1992; Hankard et al. 1998). However, 
this does necessarily suggest a cause and effect relationship. The concentration of 
insulin, a potent anabolic hormone, regulates glutamine transport (see section 2.3.1). A 
reduction in insulin concentration causes a reduction in the intramuscular glutamine 
pool, due to an increased efflux of glutamine from the muscle (Rennie et al. 1996b). 
Therefore, it is feasible that a reduction in intramuscular glutamine concentration and 
protein synthesis may merely reflect a reduction in insulin concentration. However, the 
possibility of a relationship between glutamine concentration and protein turnover rates 
have led to the use of glutamine solutions in both enteral and parental nutrition (Khan et 
al. 1991; Hardy et al. 1992; Hardy et al. 1992; Smith, 1997; Morlion et al. 1998). 
2.6.1 GLUTAMINE METABOLISM 
The catabolism of glutamine occurs via one of two isoforms of glutaminase (Curthoys 
and Watford, 1995), an exclusively mitochondrional enzyme. The liver-type 
glutaminase is expressed only in periportal hepatocytes of the postnatal liver, coupling 
ammonia production and urea synthesis. Kidney-type glutaminase is abundant in 
kidney, brain, intestine and lymphocytes where the resulting armnonia is released 
without further metabolism. 
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The reaction catalysed by glutaminase (EC 3.5.1.2), also referred to glutaminase I, gives 
rise to stoichiometric amounts of glutamate and ammonia The activity of this enzyme 
is termed phosphate-dependent. 
glutamine + H20 ~ glutamate + NH3 
The activity of glutaminase I in human skeletal muscle is still to be quantified. 
Previously, the activity of glutaminase I has been reported to be relatively low in both 
rat skeletal muscle (Ottaway, 1969) and in human skeletal muscle (Swierczynski et aL 
1993). Furthermore, the activity of glutaminase I does not appear to be influenced by 
the concentrations ofits substrate or product (Smith et al. 1984), but may be subject to 
hormonal regulation (Squires et al. 1997). In addition, as glutaminase I is located in 
mitochondria, the transport of glutamine into the mitochondrion may be a point of 
regulation, an area requiring further investigation. 
During acidosis, and possibly other stressful circumstances where pH is lowered, such 
as during exercise, glutaminase I in the kidney demonstrates an increase in activity, 
whereas the enzyme activity in skeletal muscle does not (Swierczynski et al. 1993). 
This response would appear to be inherently linked to the restoration of the acid-base 
balance with the export of glutamine from the muscle, and hence ammonia, leading to 
an increased catabolism in the kidney. Indeed, an increase in the plasma glutamine 
concentration should lead to an increase in renal extraction of glutamine with a 
concomitant increase in flux through the glutaminase I pathway. In the liver, an 
increase in plasma glutamine concentration above physiological levels leads to an 
increase in the activity of glutaminase I and subsequent metabolism of glutamine to 
produce glucose and urea (Curthoys and Watford, 1995). The alterations in hepatic 
glutaminase I activity appear to be mediated by changes in the rate of transcription, 
whereas kidney glutaminase I appears to be regulated at the post-transcriptional level 
(Curthoys and Watford, 1995). 
The action of glutaminase 11 is actually a combination of a number of isozymes, namely 
glutamine aminotransferase and m-amidase. The quantitative importance of these 
reactions in glutamine metabolism is doubtful due to the relatively low concentration of 
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the preferred keto acid substrates (phenylpyruvate and the keto analogues of 
methionine, glycine, serine, cysteine, and asparagine). It has been suggested that 
glutaminase I may be able to support higher rates of glutamine catabolism than 
glutamine aminotransferase and m-amidase in rat skeletal muscle (glutaminase II) 
(Swierczynski et al. 1993). However, the glutaminase I inhibitor 6-diazo-5-oxo-L-
norleucine (DON) does not prevent glutamine catabolism, thereby suggesting that the 
activity of glutamine aminotransferase and co-amidase is in fact greater in rat skeletal 
muscle (Wu et al. 1991). Moreover, it must be recognised that further research is 
required into glutamine catabolism in skeletal muscle, in particular in human skeletal 
muscle, as at present the evidence is limited. 
The catabolism of glutamine via glutaminase I leads to the direct formation of 
glutamate, which can in turn be converted to a-ketoglutarate through the glutamate 
dehydrogenase reaction. The catabolism of glutamine via glutaminase II leads fIrstly to 
the formation of a-ketoglutaramide (glutamine transaminase) and then a-ketoglutarate 
(co-amidase). Irrespective of the glutamine metabolic pathway, the resultant a-
ketoglutarate can conceivably enter the TCA cycle and potentially increase the 
concentration of the TCA cycle intermediates (see section 2.10). 
Glutamine synthetase (EC 6.3.1.2) is responsible for the formation of glutamine from 
glutamate derived from either the action of glutamate dehydrogenase or through 
transamination reactions. It has been demonstrated that in postabsorptive humans, 
BCAA released by proteolysis play a prominent role as a source of a-amino nitrogen 
for glutamine synthesis (Garber et al. 1976a; Garber et al. 1976b; Chang and Goldberg, 
1978; Darmaun and Dechelotte, 1991). The synthesis of glutamine requires glutamate 
to accept a second ammonia moiety in a reaction catalysed by the enzyme glutamine 
synthetase. 
glutamate + NH3 + ATP ~ glutamine + ADP + Pi 
This enzyme is termed a synthetase, rather than a synthase, as the reaction links bond 
formation with the energy released from ATP hydrolysis (Mathews and van Holde, 
1996). 
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Glutamine synthetase is found in most tissues, located in the cytoso~ and although 
skeletal muscle possesses a relatively low activity of this enzyme when expressed per 
gram of tissue, by virtue of its large mass this tissue is the major site of glutamine 
synthesis in the body (Smith and Rennie, 1990). Furthermore, glutamine synthetase 
activity has been reported to be lowest in slow twitch muscle fibres (Falduto et al. 
1992). Although glutamine synthetase activity has been detected in rat kidney extracts 
(Iqbal and Ottaway, 1970), it has not been detected in human kidney (Curthoys and 
Watford, 1995). 
The synthesis of glutamine via the glutamine synthetase reaction is regulated by its 
product (glutamine) and its substrate (glutamate), in addition to glucocorticoids (Smith 
et al. 1984; Max, 1990; Feng et al. 1990). The activity of the enzyme in cultured 
skeletal muscle cells is increased in response to lowered glutamine concentrations and 
increased glutamate concentrations (Smith et al. 1984). Conversely, the enzyme 
activity is lowered in the presence of high glutamine concentrations, however glutamine 
synthetase mRNA levels remain unaltered under such conditions suggesting an 
independent regulation at a post-transcriptional level (Feng et al. 1990; Opara et al. 
1992; Hickson et al. 1996). 
Glucocorticoids have been demonstrated to cause an accelerated release of glutamine 
from skeletal muscle leading to a decrease in intramuscular glutamine levels 
(Muhlbacher et al. 1984). This response would appear to be largely due to an increased 
activity of the glutamine transporter system in skeletal muscle (System Nm; see section 
2.3.1) (Babij et al. 1986a; Babij et al. I 986b). It has previously been reported that 
these alterations in intracellular levels of glutamine were not accompanied by any 
measurable change in the glutamine metabolising enzymes, glutamine synthetase and 
glutaminase (Muhlbacher et al. 1984). More recently however, dexamethasone, a 
potent synthetic glucocorticoid, has been shown to increase glutamine synthetase 
activity, via an increase in glutamine synthetase mRNA level (Max, 1990; Falduto et al. 
1992). This would result in an increased production of glutamine in situations where 
glucocorticoid concentration is increased (Darmaun et al. 1988). Despite 
glucocorticoids increasing the expression of glutamine synthetase, a decrease is 
observed in the intramuscular level of glutamine due to increased glutamine efflux from 
skeletal muscle, as discussed previously. 
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It has been proposed previously that a 'glutamine substrate cycle', involving 
glutaminase I and glutamine synthetase, may exist in skeletal muscle (Parry-Billings 
and Newsholme, 1991). The existence of a 'glutamine substrate cycle' in skeletal 
muscle could conceivably lead to a futile intracellular cycling between glutamine and 
glutamate, with skeletal muscle being responsible for the both the production and 
degradation of glutamine. However, this suggestion has been disputed (Rennie et al. 
1992) as the enzymes involved, glutaminase and glutamine synthetase, are located in 
different cellular compartments [glutamine synthetase is cytosolic, whereas glutaminase 
is mitochondrial] (Kelso et al. 1989). Furthermore, the original proposition by Parry-
Billings et al. seems to have disregarded the contribution that glutaminase II may make 
to glutamine degradation in skeletal muscle. Indeed, Wu et al. (1991) have 
demonstrated that glutamine degradation is not inhibited in rat skeletal muscle in the 
presence of the glutaminase I inhibitor 6-diazo-5-oxo-L-norleucine (DON), suggesting 
that glutaminase II does contribute to glutamine degradation. 
It is feasible however, that a 'glutamine-glutamate cycle' exists between skeletal 
muscle, the liver and the gut (Marliss et al. 1971). The splanchnic bed takes up most of 
the glutamine produced and released by skeletal muscle. Glutamine is then converted to 
glutamate and ammonia by the action of glutaminase 1. However, only about 50% of 
the glutamate produced is available to skeletal muscle, as the splanclmic bed retains 
-50% for metabolism in the gut (Souba, 1991; Windmueller and Spaeth, 1974) and liver 
(Hliussinger, 1989) due to the central role that glutamate plays in a variety of 
transamination and deamination reactions. This may also be complicated by the slow 
mixing of the intracellular and plasma glutamate pools (Darmaun et al. 1986). 
2.6.2 GLUTAMINE SUPPLEMENTATION 
The intravenous administration of glutamine is able to increase both the plasma and 
intramuscular concentrations of glutamine (Watt et al. 1992; Varnier et al. 1995). In 
the postabsorptive state, 54 ± 4 % of enterally delivered [2)5N]glutamine tracer is 
sequestered on the first pass through splanchnic bed (Matthews et al. 1993). More 
recently, using [1,2-13C2]glutamine, it was reported that approximately 58 ± 2 % of an 
enterally delivered tracer is sequestered on the first pass through splanclmic bed (Haisch 
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et al. 2000), suggesting that the uptake of the glutamine tracer is not an artefact of the 
label used. In spite of this substantial extraction and subsequent oxidation by the 
splanchnic bed, the oral delivery of glutamine has been demonstrated to substantially 
increase the systemic glutamine concentration (Dechelotte et al. 1991; Hankard et al. 
1995; Hankard et al. 1998; Darmaun et al. 1994), thus feasibly providing the 
extrasplanchnic tissues with an exogenous supply of glutamine. 
Although it has been demonstrated that the intravenous infusion of glutamine is able to 
increase muscle glutamine concentration (Watt et al. 1992; Varnier et al. 1995), and 
that long-term oral glutamine supplementation is able to increase muscle glutamine 
concentration in rats (Opara et al. 1992), at present no studies have examined whether 
an oral glutamine load is able to transiently elevate muscle glutamine concentration in 
humans. It is feasible however, that an increase in the plasma glutamine concentration 
will augment the rate of uptake of glutamine uptake by the muscle via the lowaffmity, 
high capacity glutamine transporter in skeletal muscle, System Nm (Ahmed et al. 1993) 
(see section 2.3.1). The Michaelis-Menten constant (Km; 0.5-1.5 mM) of glutamine 
transport in human skeletal muscle of near-plasma glutamine concentration (-0.7 mM) 
is suggestive that the influx of glutamine into skeletal muscle is modulated by changes 
in the plasma glutamine concentration (Ahmed et al. 1993). Indeed, skeletal muscle 
accounts for nearly 50% of glutamine uptake from the plasma (Nurjhan et al. 1995; 
Stumvoll et al. 1996). 
Skeletal muscle is primarily responsible for glutamine synthesis (Marliss et al. 1971), 
therefore, due to the transport characteristics of glutamine, it is not surprising that the de 
novo synthesis of glutamine is suppressed in response to exogenous glutamine (Hankard 
et al. 1995), most probably mediated through the modulation of the activity of the 
enzymes involved in glutamine metabolism (Smith et al. 1984; Feng et al. 1990). 
Furthermore, the exogenous provision of glutamine is able to increase both splanchnic 
extraction and oxidation of glutamine indicating a regulatory response to the glutamine 
load, indeed the splanchnic extraction of glutamine increases in a dose-dependent 
manner (Hankard et al. 1995). 
In fasted dogs, the infusion of glutamine inhibits lipolysis, signified by a decrease in 
both glycerol and free fatty acid levels, in the absence of any changes in insulin or 
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glucagon concentration (Cersosimo et al. 1986). Similar fmdings have been reported in 
postabsorptive humans (Dechelotte et al. 1991), suggesting that exogenous provision of 
glutamine exerts an antilipolytic effect. 
2.6.3 GLUTAMINE AND EXERCISE 
There appears to be a lack of consensus within the literature regarding the effects of 
exercise upon plasma glutamine concentration. It has been reported that during 
prolonged submaximal exercise (-60-80% V02max) lasting approximately 90 min, the 
plasma glutamine concentration either remains unchanged or exhibits a moderate 
increase (Eriksson et al. 1985; van Hall et al. 1995b; van Hall et al. 1999; Sahlin et al. 
1990). However, during more prolonged exercise (e.g. marathon), the plasma glutamine 
concentration has been reported to decline (Parry-Billings et al. 1987; Parry-Billings et 
al. 1992). In addition, the efflux of glutamine from skeletal muscle is increased during 
prolonged submaximal exercise (Sahlin et al. 1990; Rennie et al. 1981; van Hall et al. 
1999). During recovery from exercise, plasma glutamine concentration has been 
reported to decline following intermittent high-intensity exercise (Walsh et al. 1998a) 
and steady-state exercise (Rennie et al. 1981). 
Wagenmakers et al. (1991) have suggested that a reduction in muscle glycogen 
concentration or glucose concentration could be responsible for the fall in plasma 
glutamine concentration. Glutamate only contributes a small proportion of the carbon 
required for glutamine synthesis (Wagenmakers et al. 1990), with the production of 
TCA cycle intermediates from muscle glycogen and glucose via carboxylation of 
pyruvate conceivably contributing to the carbon skeletons required for glutamine 
synthesis. Therefore, a reduction in muscle glycogen or glucose concentration may 
result in a reduction in glutamine synthesis in skeletal muscle. Indeed, the consumption 
of a low-carbohydrate diet for 3 days led to a greater decline in plasma glutamine 
concentration during recovery from 60 min of cycling at 70% V02max compared to the 
consumption of a normal diet (Gleeson et al. 1998). Despite this apparent requirement 
for carbohydrate to prevent the decline in plasma glutamine concentration post exercise, 
the consumption of carbohydrate during exercise has been shown to be unable to 
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prevent the decline in plasma glutamine concentration post exercise (van Hall et al. 
1998). 
Exercise may therefore influence the rate of glutamine efflux from skeletal muscle, 
particularly following very prolonged exercise. Metabolism in those tissues and cells 
that are influenced by glutamine may be affected in the recovery period after exercise. 
For example, cells of the immune system require glutamine for both energy provision 
and nucleotide synthesis; therefore a reduction in plasma glutamine concentration may 
impair immune function. Thus skeletal muscle may play an important role in immune 
function (Parry-Billings et al. 1990). 
2.6.4 GLUTAMINE AND IMMUNE FUNCTION 
It has generally been considered that both lymphocytes and macrophages obtain most of 
their energy through the oxidation of glucose. More recently it has been established that 
the rate of glutamine utilisation by these cells is often greater than that of glucose 
(Ardawi and Newsholme, 1983). Glutamine would appear to be necessary for the 
optimal function of cells of the immune system in vitro, with optimal proliferation of 
lymphocytes occurring at a glutamine concentration of between 0.3 and 1.0 mM 
(Ardawi and Newsholme, 1983; Rohde et al. 1995). Indeed, a lowering of the 
glutamine concentration in the medium has been shown to markedly decrease the rate of 
proliferation (Newsholme and Parry-Billings, 1990; Calder, 1994). Therefore, the 
presence of glutamine is required if optimallymphocyte proliferation is to occur. 
However, only -30% of glutamine carbon is completely oxidised within the cells of the 
immune system (Ardawi and Newsholme, 1983), with the partial oxidation of 
glutamine, termed glutaminolysis, contributing to the production of glutamate, 
aspartate, alanine. These by-products are required for the synthesis of purine and 
pyrimidine needed for the formation of DNA and RNA (Newsholme et al. 1989). In 
addition, glutaminolysis also provides precursors for the formation of glucosarnine, 
GTP, and NAD+ (Newsholme et al. 1989). 
There is now considerable evidence to suggest that prolonged, intense exercise is 
associated with adverse effects on the cellular immune system (Pederson et al. 1998). 
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These adverse effects include a lowering of circulating Iymphocyte numbers, a 
reduction in neutrophil function, a decrease in NK cells and a decrease in 
immunoglobulin levels in blood and saliva. In addition, previous studies have indicated 
that a single period of prolonged exercise transiently decreases plasma glutamine 
concentration (Parry-Billings et al. 1987; Parry-Billings et al. 1992). Furthermore, a 
transient decrease in plasma glutamine concentration concomitant with a suppression of 
peripheral Iymphocyte proliferation has been observed in chronically exercised rats 
(Koyama et al. 1998). In humans, a reduction in both plasma glutamine concentration 
and neutrophil function has been observed following very prolonged (-164 min) 
exercise at 55% V02max (Robson et al. 1999). These findings would seem to imply a 
causal relationship between exercise-induced immunosupression and transient 
hypoglutaminaemia post exercise. This relationship may be partly due to the fact that 
exercise places increased demands on muscle and other organs, both in terms of 
provision and requirement, for glutamine post exercise. This may force the immune 
system into 'glutamine debt', thus impairing immune function (pederson et al. 1998). 
For these reasons, the plasma glutamine concentration has been proposed to be a useful 
tool in monitoring overtrained athletes, in whom depressed plasma glutamine levels are 
often observed (Rowbottom et al. 1997; Rowbottom et al. 1996, Kingsbury et al. 
1998). However, the use of plasma glutamine as an indicator of overtraining status has 
recently been deemed insensitive (Bagger et al. 1997). Plasma glutamine concentration 
is influenced by short-term exercise, nutritional status, diet, infection and physical 
trauma, it is important that these factors are considered when using plasma glutamine 
concentration as a marker of overtraining (Walsh et al. 1998b). Nonetheless, it would 
appear that plasma glutamine level or the plasma glutamine to glutamate ratio may 
provide useful markers, and may be more effective when combined with other known 
markers of overtraining. 
Therefore it is feasible that, the provision of glutamine post exercise may aid immune 
function. Based on subjective evidence, the supplementation of glutamine post exercise 
has led to fewer reported incidences of infections in the week following the bout of 
exercise (Castell et al. 1996). Under more controlled conditions, recovery from 
experimentally-induced overtraining may be more rapid with the provision of 
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glutamine, however symptoms of overtraining could not be prevented with glutamine 
supplementation (Bagger et al. 1997). The provision of glutamine has also been shown 
to alter lymphokine-activated killer (LAK) cell activity, but not natural killer (NK) cell 
activity (Rohde et al. 1995), in addition to suppressing tumour growth in tumour-
bearing rats (Shewchuk et al. 1997b). 
It would appear that a degree of circumstantial evidence exists in support of the 
supplementation of glutamine to enhance immune function. However, the purported 
beneficial effects of glutamine supplementation post exercise have not been observed in 
all research studies. 
For example, the supplementation of glutamine post exercise has been shown to have no 
effect upon lymphocyte distribution and was unable to prevent the post exercise decline 
in plasma glutamine concentration (Castell et al. 1997). Lymphocyte metabolism and 
function was not enhanced after the provision of a high-protein diet (2% w/w 
glutamine) to exercise-trained rats for 7 days (Shewchuk et al. 1997a). However, this 
may have been due to the fact that the protocol employed did not induce a transient 
decrease in plasma glutamine concentration post exercise and did not alter plasma 
glutamine concentration following consumption of the high-protein diet. Moreover, 
despite abolishing the post exercise decrease in plasma glutamine concentration, the 
supplementation of glutamine in vivo has been demonstrated to have no effect on the 
post exercise changes in immune function (Rohde et al. 1998). Furthermore, it has 
been suggested that the fall in plasma glutamine concentration does not account for the 
decrease in neutrophil function following prolonged exercise, suggesting there is no 
direct relationship between plasma glutamine concentration and immune function 
(Walsh et aI. 2000). 
Therefore, changes in immune function post exercise may not to be related to a decrease 
in plasma glutamine concentration and may be more related to the level of the 
circulating stress hormones, cortisol and adrenaline, or the cytokines (soluble 
glycoproteins that are produced and mediate communication between and within 
immune and non-immune cells). Indeed, strenuous exercise has been shown to increase 
circulating levels of the cytokine interIeukin (IL )-6 (Rohde et al. 1997), suggesting that 
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exercise induces a strong systemic anti-inflammatory response similar to the response 
seen in trauma (Pederson et al. 1999). 
2.7 ORNITHINE a-KETOGLUTARATE (OKG) 
OKG is a salt formed of two molecules of ornithine and one molecule of a-
ketoglutarate. The pKs ofomithine (10.8) and a-ketoglutarate (1.9 & 1.4) give a pH of 
-7 in aqueous solution over a wide range of OKG concentrations (up to 5 mM) 
(Cynober, 1995), making it possible to provide OKG either enterally or parenterally. 
In recent years, attention has focused on the qualitative improvement of nutritional 
support required in response to catabolic situations, in particular the use of specific 
substrates that play key roles in the control of protein metabolism. The role of the 
amino acid glutamine has already been discussed in this context (see section 2.6), 
additionally, the substrate ornithine a-ketoglutarate (OKG) has been shown to improve 
the nutritional status ofhypercatabolic patients (Vaubourdolle et al. 1987; Le Boucher 
and Cynober, 1997). OKG has received particular attention over recent years due to its 
efficiency in various malnutrition states and its ability to generate anabolic signals, both 
hormonal and metabolic. 
In the extreme catabolic state, for example in bum injury or sepsis, OKG has been 
shown to improve nitrogen balance and decrease hyperphenalaninemia (Cynober et al. 
1987). OKG has also been shown to reduce urinary 3-methylhistidine excretion (Le 
Boucher et al. 1997), demonstrating that OKG can inhibit myofibrillar degradation, and 
counteract the trauma-induced decrease in the intramuscular glutamine pool (Cynober, 
1995; Le Boucher et al. 1997). Furthermore, OKG has been shown to stimulate the 
secretion of both insulin and human growth hormone (hGH), however the effect appears 
to be highly dependent on nutritional and metabolic status (Cynober et al. 1990; 
Cynober et at 1984; Vaubourdolle et al. 1987). 
OKG has been shown to generate glutamine in muscle (Vaubourdolle et al. 1991) and 
the jejunum (Le Boucher et al. 1997). However, the mechanism by which OKG 
increases the muscle glutamine pool is controversial. In particular, the suggestion that 
the a-ketoglutarate moiety is solely responsible for the improvement in glutamine status 
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has been questioned (Hammarqvist et al. 1990; Wernerman et al. 1990), with more 
recent research suggesting an interaction between the ornithine and a-ketoglutarate 
pathways when OKG is provided (Cynober, 1999). 
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Fig 2.5 Ornitbiot and a-ketoglutarate metabolic pathways. Key enzymes are 1) ornithine aminotransferase; 2) ornithine 
carbamoyltransferase; 3) Nitric oxide synthase; 4) arginase; 5) ornithine decarboxylase; 6) transaminases; 7) glutamate 
dehydrogenase; 8) glutamine synthetase; 9) glutaminase. 
Indeed, fIrm evidence of an interaction between ornithine and a-ketoglutarate was 
provided when a group of healthy individuals received either 10 g OKG, 6.4 g ornithine 
or 3.6 g a-ketoglutarate. Only the administration of OKG was able to significantly 
increase arginine and proline plasma levels and glutamine production by the kidney 
(Cynober et al. 1990). The biochernical explanation of the metabolic interaction 
between ornithine and a-ketoglutarate is that these two compounds share a common 
metabolic pathway through which the TCA cycle and the urea cycle are linked (a-
ketoglutarate .... glutamate .... glutamyl-phosphate .... glutamate semialdehyde .... 
ornithine; see Fig. 2.4). In vivo, the main role of ornithine is transamination to 
glutamate. However, as the reactions involved are almost in equilibrium, the 
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administration of both ornithine and a-ketoglutarate as OKG diverts these molecules 
and their direct metabolites toward other pathways generating glutamine, arginine, 
proline, and polyamines, all potent modulators of protein metabolism. 
OKG, through its a-ketoglutarate moiety, has an inherent link with the TeA cycle (see 
Fig 2.5). The positioning of a-ketoglutarate in the TeA cycle, at the beginning of the 
second span of the cycle (see section 2.10), is a point at which carbon could feasibly 
enter the cycle. It has been demonstrated that a-ketoglutarate infusion is able to 
increase the intramuscular a-ketoglutarate content in anaesthetised dogs (Roth et al. 
1991), therefore it is feasible that after being transported into skeletal muscle the a-
ketoglutarate moiety ofOKG could enter the mitochondria and the TeA cycle (refer to 
section 2.12). In skeletal muscle, given the significance of the TeA cycle, this may 
have implications for oxidative energy production, particularly during exercise. 
2.8 GLYCOGEN METABOLISM 
It was demonstrated in a series of experiments in the late 1960's, early seventies 
(Bergstrom et al. 1967; Heimansen et al. 1967; Hultrnan, 1967a, Hultman and 
Nilsson, 1971) that both skeletal muscle glycogen content and liver glycogen content is 
reduced following prolonged exercise. Furthermore, this depletion in glycogen stores 
was associated with fatigue during submaximal exercise (Bergstrom et al. 1967). 
Therefore, the restoration of both muscle and liver glycogen during the recovery period 
after a bout of prolonged exercise is important to the recovery of endurance exercise 
capacity. 
2.8.1 LIVJj:R GLYCOGEN METABOLISM 
The liver is able to release glucose into the circulation, unlike skeletal muscle, due to 
the presence ofthe enzyme glucose-6-phosphatase, which converts glucose-6-phosphate 
(G-6-P) to glucose. Glucose derived from both gluconeogenesis and glycogenolysis in 
the liver is released into the circulation to preserve glucose homeostasis, therefore the 
synthesis and storage of glycogen in the liver is vital. 
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Glucose is extracted from the blood via the hepatic portal vein and is transported into 
liver cells via the faciIitative glucose transporter 2 (GLUT 2). GLUT2 is a low-affinity, 
high capacity transport system, allowing the uninhibited (non-rate limiting) flux of 
glucose into or out of liver cells due to its high Km (-17mM) (Mueckler, 1994; Thorens, 
1996). Therefore, the rate of glucose uptake into the liver via GLUT2 increases in 
parallel with any rise in blood glucose, such as after a meal or when a glucose load is 
delivered. 
The transport of glucose into the liver cell is near-equilibrium, and distinct from other 
tissues, the phosphorylation of glucose to form G-6-P in the liver is catalysed by 
glucokinase which has a very high Km for glucose, between 8 and 12mM (Newsholme 
and Leech, 1983; Wehmeyer et al. 1994). G-6-P has four main fates: glycogen 
synthesis; fatty acid synthesis; the pentose phosphate pathway; or hydrolysis to form 
glucose once more (Newsholme and Leech, 1983). Therefore, if a sufficient increase in 
blood glucose concentration occurs, there will be a concomitant rise in the concentration 
of G-6-P in liver cells, which will reduce glycogenolysis and increase glycogenesis. 
Thus, the synthesis of liver glycogen is dependent on the production of G-6-P, the 
formation of which is proportional to the blood glucose concentration. 
Much debate has occurred over recent years as to whether hepatic glycogen synthesis 
occurs through an 'indirect' pathway, via gluconeogenic processes, or through a 'direct' 
pathway (glucose ~ G-6-P ~ G-I-P ~ UDP glucose ~ glycogen) (Magnusson and 
Shulman, 1991). It is known however, that following a glucose load, hepatic glucose 
production is suppressed and hepatic glycogen synthesis occurs. In postabsorptive 
humans, it has been demonstrated using "c nuclear magnetic resonance spectroscopy 
(NMR), a validated procedure (Gruetter et al. 1994), that -50% of liver glycogen is 
synthesised through the 'direct' pathway following the administration of a glucose load 
and this increases to -70% 4 h after the ingestion of a mixed meal (Magnusson and 
Shulman, 1991; Taylor et al. 1996a; Taylor et al. 1996b). The Km of glucokinase is in 
the order of 8 mM and blood glucose concentration is -6 mM following a glucose load 
(dependent upon the size of glucose load), it is likely therefore that the direct pathway 
contributes to a significant portion of liver glycogen synthesis. In addition, using "c 
NMR, it has been demonstrated that in the fasted state, both hepatic glycogen deposition 
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and glycogen breakdown may occur simultaneously (Magnusson et al. 1994) indicating 
the versatility of liver glycogen metabolism. 
Following prolonged subrnaximal exercise, it has previously been observed that a 
greater proportion of an oral glucose load escapes hepatic retention, thereby allowing 
the repletion of muscle glycogen to take precedence over hepatic glycogen repletion 
(Mrehlum et al. 1978). However, more recent evidence using "c magnetic resonance 
spectroscopy (MRS), has suggested that the role of liver glycogen homeostasis has 
previously been underestimated (Casey et al. 2000). When a relatively small amount of 
glucose was provided post-exercise (l glkg body mass), differences were observed 
between conditions in liver glycogen content, but not muscle glycogen content. These 
fmdings would appear to suggest that the supply of glucose to the liver has priority over 
skeletal muscle when glucose availability is limited. 
2.8.2 SKELETAL MUSCLE GLYCOGEN METABOLISM 
Following prolonged exercise, resulting in muscle glycogen depletion, the degree of 
muscle glycogen resynthesis is largely determined by the availability of glucose to the 
skeletal muscle cell. The transport of glucose into the skeletal muscle cell occurs via 
facilitated diffusion and the glucose transporter in skeletal muscle is expressed in four 
isoforms, glucose transporter 1 (GLUT-I), glucose transporter 3 (GLUT-3) (Stuart et al. 
2000), glucose transporter 4 (GLUT-4) and glucose transporter 5 (GLUT-5). GLUT-l 
is located predominantly on the plasma membrane and appears to be expressed to a 
lesser extent and involved in basal, not insulin or exercise stimulated, glucose transport 
(Douen et al. 1990). GLUT-4, on the other hand is located largely intracellularly in the 
unstimulated state, and its translocation to the plasma membrane from intracellular 
stores is stimulated by insulin and contractile activity (Douen et al. 1990; Cushman et 
al. 1998; Ploug et al. 1987; Ploug and Ralston, 1998). Furthermore, muscle glycogen 
concentration appears to modify GLUT -4 translocation in response to muscle 
contractions, with glycogen depletion causing an increase in GLUT -4 translocation at 
the cell surface (Derave et al. 1999). 
When the concentration of glucose in the systemic circulation is high, and thus readily 
available to skeletal muscle, upon entry into the cell glucose is phosphorylated to G-6-P 
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by the enzyme hexokinase (the first step in the glycolysis or glycogen synthesis 
pathway). The G-6-P has two possible fates in the skeletal muscle cell, either entry into 
the glycolytic pathway, or use for the synthesis of glycogen, the rate-limiting reaction 
catalysed by glycogen synthase. 
Glycogen synthase exists in two forms, an active I-form and an inactive D-form. The 
conversion of glycogen synthase from one form to another is mediated through 
phosphorylation and dephosphorylation reactions, alternating between the D-form and 
the I-form respectively. Phosphorylation, resulting in a decrease in glycogen synthase 
activity, is catalysed by specific kinases; and dephosphorylation, which results in an 
increase in glycogen synthase activity, is catalysed by specific phosphatases (Dent et al. 
1990). Prolonged submaximal exercise which results in a marked degradation of 
muscle glycogen, leads to an increased availability of phosphorylated sites on the 
glycogen synthase enzyme which become available to glycogen synthase phosphatase 
and lead to an increase in glycogen synthase activity (Yan et al. 1992). 
Glycogen synthesis is catalysed by a self-glucosylating protein primer, glycogenin 
(Shearer et al. 2000). Glycogenin autocatalytically generates an oligosaccharide primer 
of 7- i 1 glucosyl units, which serves as a substrate for glycogen synthase, as glycogen 
synthase can only extend an existing glycogen chain. Glycogen synthase and branching 
enzyme then act to catalyse the formation of two physiologically distinct pools of 
glycogen, pro- (pG) and macroglycogen (MG) (Adamo and Graham, 1998a; Adamo et 
al. 1998b). Each glycogen molecule, PG or MG, contains one molecule of glycogenin, 
therefore it has been suggested that glycogenin may be a potential regulator of glycogen 
synthesis in human skeletal muscle (Shearer et al. 2000). Following exhaustive 
submaximal exercise, MG stores are reported to show a greater relative depletion, PG 
being more sensitive to dietary carbohydrate post exercise demonstrating a more rapid 
resynthesis folIowing depletion. However, the supercompensation associated with the 
consumption of high-carbohydrate diet following glycogen-depleting exercise is due to 
greater synthesis of the MG pool (Adamo et al. 1 998b). 
It is evident that the control of glycogen synthesis in skeletal muscle post exercise may 
not rest solely upon the activation of the enzyme glycogen synthase. Consideration 
must also be given to factors including glucose transport/phosphorylation which, using 
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"C NMR., have been shown to control insulin-stimulated glucose disposal (Price et al. 
1994; Iucker et al. 1999; Price et al. 2000). 
Effect of insulin 
The presence of insulin stimulates glycogenesis in skeletal muscle through the 
dephosphorylation and activation of glycogen synthase, the rate-limiting enzyme (Yan 
et al. 1993) (Lawrence and Roach, 1997). An insulin-stimulated protein kinase (GSIG) 
has been shown in vitro to phosphorylate and activate PPl (protein phosphatase-I), 
more specifically PPIG, the glycogen-bound form of PP 1 (Dent et al. 1990). PPIG has 
been shown to be the principal enzyme involved in the regulation of glycogen 
metabolism compared to other forms of PP 1 (Dent et al. 1990). However, the precise 
molecular mechanism by which insulin activates glycogen synthase is still to be 
elucidated. 
The integral role of insulin in glycogen synthesis is demonstrated by the insulin-
mediated activation of both glycogen synthase and GLUT -4 translocation. It is also 
conceivable that glycogen synthase activity and glucose transport may interact to 
control the rate of glycogen resynthesis after glycogen-depleting exercise (Ivy, 1991). 
Indeed, it has recently been suggested that the control of glycogen synthesis by insulin 
in .skeletal muscle is distributed between glucose transport and glycogen synthase 
(Azpiazu et al. 2000). 
Effect of exercise 
The restoration of muscle glycogen after exercise has been demonstrated to occur in a 
bi-phasic pattern (price et al. 1994). Using "c NMR measurements, when muscle 
glycogen content was reduced to <30 mrnol/kg wet weight at the end of exercise, a 
rapid phase of glycogen resynthesis. was identified during the first 30-60 min of 
recovery. This initial rapid phase of glycogen resynthesis was insulin-independent and 
was followed by an insulin-dependent and G-6-P dependent slower second phase. It 
appears that the initial phase of glycogen repletion is more dependent upon the glycogen 
concentration within skeletal muscle. Indeed, it has been demonstrated that glycogen-
depleting exercise itself can activate glycogen synthesis independent of any activation 
by insulin (Wallberg-Henriksson et al. 1988; Price et al. 1994). Furthermore, it has 
been demonstrated that the rate of glycogen resynthesis is dependent upon the absolute 
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glycogen content at the cessation of exercise (Ivy, 1991; Zachwieja et al. 1991) (price 
et al. 2000), with glycogen synthase activity being inversely proportional to the 
glycogen concentration (Yan et al. 1992). Thus, in the glycogen-depleted, post 
exercise state, both skeletal muscle (Yan et al. 1993) and most likely hepatic glycogen 
synthase activity are elevated (Niewoehner and Nuttall, 1995). 
2.9 GLUCONEOGENESIS 
Gluconeogenesis is defmed as the metabolic process by which glucose is formed from 
non-carbohydrate precursors, which include lactate, pyruvate, tricarboxylic acid cycle 
intermediates, the carbon skeletons of most amino acids and glycerol (Newsholme and 
Leech, 1983). In the postabsorptive state, gluconeogenesis plays an integral role in the 
maintenance of blood glucose homeostasis, contributing about one-third of all glucose 
produced by the liver. Gluconeogenesis occurs primarily in the liver (90%), with the 
kidney contributing to a smaller extent (10%). Gluconeogenesis becomes important 
whenever dietary carbohydrate is insufficient to meets demands, for example, during 
fasting or starvation, low-carbohydrate diets, or prolonged exercise. During these . 
situations lipolysis is accelerated, and glycerol, lactate and amino acids become 
quantitatively more responsible for contributing carbon to the glucose pool through 
gluconeogenesis. 
Gluconeogenesis is regulated by the mobilisation and delivery of gluconeogenic 
precursors from peripheral sites, and also hormonally by insulin (inhibition) and 
glucagon (stimulation) (Consoli et al. 1990; Wasserman et al. 1992). In addition, the 
release of cortisol, during prolonged exercise or other conditions of low body 
carbohydrate stores, decreases protein synthesis and increases protein breakdown, 
thereby increasing the availability of amino acids for gluconeogenesis. 
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The production of glucose through gluconeogenesis is via the reversal of the glycolytic 
pathway (Fig. 2.6). Most of the glycolytic reactions are reversible, however, three of 
the reactions are irreversible; the pyruvate kinase reaction, the phosphofructokinase 
(PFK) reaction and the glucokinase reaction. However, to overcome these irreversible 
reactions, additional by-passing reactions exist. A two-stage conversion of pyruvate to 
phosphoenolpyruvate bypasses the pyruvate kinase reaction. This involves the reactions 
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with enzymes pyruvate carboxylase, yielding oxaloacetate, a tricarboxylic acid cycle 
intermediate, and phosphoenolpyruvate carboxylase, yielding phosphoenolpyruvate. 
Fructose 1,6-bisphosphatase converts fructose I ,6-bisphosphate to produce fructose 6-P, 
by-passing the irreversible PFK reaction. Lastly, the enzyme glucose 6-phosphatase, 
not present in muscle cells (see section 2.8.1), converts the glucose 6-phosphate to 
glucose, overcoming the irreversible hexokinase/glucokinase reaction. Within liver 
cells, the first enzyme of gluconeogenesis, pyruvate carboxylase, is located in the 
mitochondrial matrix. The last enzyme, glucose-6-phosphatase is bound to the smooth 
endoplasmic reticulum. The other enzymes ofthe pathway are located in the cytosol. 
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2.9.1 AMINO ACIDS AS GLUCONEOGENIC PRECURSORS 
Previously, the view was held that the most important amino acid gluconeogenic 
precursor was alanine, which led Felig et al. (1970) to introduce the concept of 
'glucose-alanine' cycle. Indeed, alanine has been suggested to be the major 
gluconeogenic substrate during recovery from exhaustive exercise in fasting conditions 
(Favier et al. 1987). More recently however, the incorporation of labelled carbon into 
plasma glucose during the infusion 14C glutamine in postabsorptive subjects has 
demonstrated that glutamine may also be an important gluconeogenic precursor 
(Nwjhan et al. 1995). Although the overall carbon transfer to glucose from glutamine 
and alanine is comparable (Nurjhan et ai. 1995; Stumvoll et al. 1996), glutamine is 
quantitatively more important than alanine in transporting protein-derived carbons 
through plasma and supplying the glucose pool (Nurjhan 'et al. 1995). Indeed, the 
existence of a 'glucose-glutamine' cycle analogous to the 'glucose-alanine' or Cori 
cycles has been proposed (Perriello et al. 1995). However, in contrast to the 'glucose-
alanine' and Cori cycles, the recently proposed 'glucose-glutamine' cycle is able to 
provide a positive transfer of protein-derived new carbon to the glucose pool. 
In postabsorptive humans, 45% of plasma glutamine originates from its direct release 
from tissue protein (Matthews and Campbel~ 1992; Nurjhan et al. 1995), 13% 
originates from plasma glucose (Perriello et al. 1995), with a further 5% coming from 
plasma glutamate (Darmaun et al. 1994; Matthews and Campbell, 1992). The 
remaining glutamine entering the circulation is most probably derived from conversion 
of other amino acids to glutamine in skeletal muscle (Garber et al. 1976c; Chang and 
Goldberg, 1978a; Chang and Goldberg, 1978b; Goldberg and Chang, 1978). 
The infusion of glutamine in postabsorptive subjects, which increased the plasma 
concentration threefold, led to a seven fold increase in the conversion of glutamine into 
plasma glucose (Perriello et al. 1997). The disparity between the increase in the plasma 
concentration of glutamine and the incorporation of glutamine into glucose suggests that 
glutamine may exert a stimulatory and regulatory effect upon gluconeogenesis. This 
stimulatory effect is demonstrated by the fact that physiological increases in plasma 
glutamine have the ability to accelerate both glutamine and alanine conversion to 
glucose (Perriello et al. 1997). In addition, it has previously been shown that an excess 
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of one gluconeogenic substrate may inhibit gluconeogenesis from other gluconeogenic 
precursors, however the role of glutamine as a gluconeogenic precursor was not 
considered (Jahoor et al. 1990). 
Glutamine has been shown to be of greater importance as a gluconeogenic precursor in 
the kidney, with gluconeogenesis from alanine essentially limited to the liver (Stumvoll 
et al. 1998). The difference between the two gluconeogenic organs in substrate 
selection appears to be largely due to differences in enzyme regulation and substrate 
supply. 
2.10 THE TRICARBOXYLIC ACID CYCLE (TCA CYCLE) 
In 1937 Sir Hans Krebs proposed the notion that organic fuels are oxidised through a 
cyclic pathway. This cyclic pathway, the Krebs cycle, was named after its discoverer, 
but subsequently has adopted the titles of the Citric acid cycle, and the Tricarboxylic 
acid (TCA) cycle. 
The primary function of the TCA cycle is to completely oxidise the acetyl group of 
acetyl-CoA producing C02. This occurs with the concomitant reduction of the electron 
carriers, NADH and F ADH2, whose subsequent oxidation in the electron transport chain 
is accompanied by the formation of ATP by oxidative phosphorylation. This accounts 
for approximately two thirds of the ATP formation and oxygen consumption in 
mammals, with the remaining third attributed to the (HJxidation of fats. The pivotal 
step of the TCA cycle involves the condensation of acetyl-CoA (2C) with oxaloacetate 
(4C), to yield citrate (6C) (Figure 2.7). Citrate is then converted to aconitate (6C), and 
then isocitrate (6C), losing one carbon skeleton as C02, forming a-ketoglutarate2 (SC). 
A second carbon skeleton is lost as C02 in the formation of succinyl-CoA (4C). The 
four carbon skeleton forms succinate, fumarate, malate and then oxaloacetate in one 
complete turn of the cycle, where oxaloacetate can again condense with acetyl-CoA to 
begin another turn of the cycle. 
2 a-ketoglutarate is more commonly referred to as 2-oxoglutarate. However, in this thesis, for continuity 
a-ketoglutarate will be used. 
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Fig. 2.7 The tricarboxylic acid (TCA) cycle. This series of reactions is catalysed by the following 
enzymes, as numbered in the diagram (parentheses indicates type of reaction): (j) Citrate synthase 
(condensation); @ Aconitase (dehydration); ® Aconitase (hydration); @ Isocitrate dehydrogenase 
(oxidative carboxylation); ® a-ketoglutarate dehydrogenase complex (oxidative decarboxylation); <ID 
Succinyl CoA synthetase (substrate-Ievel phosphorylation); 0 Succinate dehydrogenase (oxidation); <ID 
Fumarase (hydration); ® Malate dehydrogenase (oxidation). N.B Acetyl-CoA is shown entering the TCA 
cycle at reaction (j) 
The TeA cycle is located within the mitochondrion, however, at least six of the nine 
TeA cycle intermediates (TeAl) are found in both the cytosol and mitochondrion 
(Newsholme and Leech, 1983). Present techniques for the rapid freezing of the muscle 
sample (i.e. inunediately plunging in liquid nitrogen) causes the cell structure to be 
destroyed and thus do not allow resolution of the subcellular compartmentalisation of 
the TeAl. Indeed, at present, it is impossible to attribute the measured concentration of 
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a given TCAl solely to the TCA cycle. The determination of the subcellular 
compartmentalisation of the TCAl is important to further our understanding of TCA 
cycle function. In addition, the concentration of the intermediates cis-Aconitate and 
succinyl-CoA is too low to measure using currently available techniques, and thus no 
values for these intermediates have been quoted in the literature. 
It is noteworthy that the TCA cycle can only oxidise 2C acetyl units. The entry into the 
TCA cycle of carbon skeletons, other than acetyl-CoA, at various points in the cycle 
will merely increase the concentration of the intermediates, unless they are subsequently 
removed from the cycle. 
The oxidation of acetyl groups in the TCA cycle and the oxidation of reduced 
coenzymes in the electron transfer chain are tightly coupled to the phosphorylation of 
ADP to form ATP. Therefore, regulation of the TCA cycle and the electron transfer 
chain is closely linked to the rate of ATP utilisation. In addition the rate of the TCA 
cycle is also controlled by three enzymes catalysing irreversible steps, citrate synthase, 
isocitrate dehydrogenase and a-ketoglutarate dehydrogenase (Figure 2.6), as well as the 
rate at which the reduced coenzyme products of the cycle, NADH and FADH2, are 
oxidised in the respiratory chain. 
The most important factor controlling TCA cycle activity is the mitochondrial ratio of 
NADH to NAD+ (mitochondrial redox state; [NADH]/[NAD+]). This ratio is linked to 
the mitochondrial ATP/ADP ratio and ultimately to the cytosolic phosphorylation 
potential. Indeed, the concentration ofNADH determines the activity of the three non-
eqUilibrium reactions that regulate the activity of the TCA cycle (citrate synthase, 
isocitrate dehydrogenase and a-ketoglutarate dehydrogenase). An increase in the 
NADH concentration, or an increase in the [NADH]I[NAD+] rati03, inhibits these 
enzymes through negative allosteric inhibition. Furthermore, citrate synthase activity is 
regulated by citrate concentration, and both isocitrate dehydrogenase and 0.-
ketoglutarate dehydrogenase are activated by the intramitochondrial Ca2+. 
3 In the case of the two dehydrogenase reactions that regulate TeA cycle activity (isocitrate dehydrogenase and a-ketoglutarate 
dehydrogenase), an increase in the [NADH]I[NADJ ratio would mean a decrease in the concentration ofNAD+, because the total 
concentration ofNADH would be constant. 
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In the rested state, the mitochondrial redox state is highly reduced, such that the NADH 
concentration is high, in addition the rate of ADP entry into the mitochondrion will be 
low. In exercising muscle, the rate of ADP entry into the mitochondrial matrix 
increases and stimulates the rate of electron transfer from NADH to oxygen. This 
increases the rate of oxygen utilisation and the formation ofNAD+, thereby increasing 
the mitochondrial redox state, and concomitantly, the activity of the TCA cycle as 
NAD+ is a substrate for three of the cycle reactions (isocitrate -1- a-ketoglutarate; a-
ketoglutarate -1- succinyl CoA; malate -1- oxaloacetate). 
The TCA cycle has been considered as two physiological pathways: the span from 
acetyl-CoA to a-ketoglutarate and the span from a-ketoglutarate to oxaloacetate 
(Newsholme and Leech, 1983). In skeletal muscle, during sustained exercise, this 
division is only academic, since flux through the two pathways must be identical and 
regulated in a concerted manner. Nonetheless, in the context ofthis thesis this division 
may explain how it is possible for carbon skeletons to feed into the cycle at the level of 
a-ketoglutarate. 
2.11 PYRUVATE DEHYDROGENASE COMPLEX (PDC) 
The link between pyruvate formed through glycolysis (cytosol) and the TCA cycle 
(mitochondrion) is via the pyruvate dehydrogenase enzyme complex (POC). POC is a 
multiple enzyme complex composed of three tightly bound enzyme components 
(pyruvate dehydrogenase, dihydrolipoyl transacetylase, and dihydrolipoyl 
dehydrogenase) and is situated in the inner mitochondrial membrane and catalyses the 
irreversible reaction whereby pyruvate undergoes oxidative decarboxylation to acetyl-
CoA (requiring NAD+ and CoA). Thus POC controls the flux of pyruvate derived 
acetyl-CoA into the TCA cycle. The net reaction catalysed is: 
Pyruvate + CoA + NAD+ -1- acetyl-CoA + CO2 + NADH 
Once acetyl-CoA is formed, the acetyl units have two principal fates in skeletal muscle; 
oxidation to C02 in the TCA cycle, or incorporation into acetylcarnitine. A high rate of 
acetyl group formation by the POC results in the transfer of the acetyl group from CoA 
to carnitine via the carnitine acetyltransferase reaction forming acetylcarnitine, thus 
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maintaining the availability of Co A for TCA cycle function. Therefore, carnitine acts as 
a buffer for the excess acetyl-CoA produced by the POC when the rate of acetyl-CoA 
formation is greater than its rate of entry into the TCA cycle, demonstrated by the large 
increase observed in intramuscular concentration of acetylcarnitine at the onset of 
exercise (Putman et al. 1993; Constantin-Teodosiu et al. 1993; Constant in-Teodosiu et 
al. 1992). 
The phosphorylation state and hence the activity of POC is largely regulated by the 
concerted action of POC kinase and POC phosphatase. Dephosphorylation of POC by 
POC phosphatase produces the active form (pOC.) and this transformation is dependent 
on the simultaneous reduction in activity of POC kinase (Figure 2.8). The in vivo 
regulation of skeletal muscle POC. is believed to be important to the integration of 
carbohydrate and fat oxidation within this tissue (Randle et al. 1963). ~uring 
starvation or carbohydrate deprivation, POC. is lowered when the ratio of acetyl-CoA to 
CoASH increases due to an increased availability and oxidation of fat fuels. This 
reduction in POC. conserves intramuscular and whole-body carbohydrate stores in the 
face of reduced carbohydrate availability (putman et al. 1993). 
PDC. 
(active) 
ATP 
Pi 
PDC kinase 
PDC 
phosphatase 
ADP 
H20 
PDC-P 
(inactive) 
Fig. 2.8 The pyruvate dehydrogenase (PDC) complex. This reaction is regulated by phosphorylation 
and dephosphorylation. ill the dephosphorylated state, PDC is active. However, when a 
phosphate group is transferred from A TP to PDC, the PDC becomes inactive. Phosphorylation 
is catalysed by PDC kinase, whereas the phosphate group is removed by PDC phosphatase. 
At the onset of exercise, a near-complete transformation (-5 fold increase) of POC to 
POCa is observed as acetyl units are delivered to the TCA cycle (Putman et al. 1993; 
Constantin-Teodosiu et al. 1992). This is primarily due to an activation of POC 
phosphatase by a high intramitochondrial concentration of Ca2+ during exercise, whilst 
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PDC kinase activity is inhibited by a high mitochondrial concentration of ADP. 
Conversely, high intramitochondrial [acetyl-CoA]/[CoA], [ATP]/[ADP] and 
[NADH]/[NADi ratios result in PDC kinase activation. The increased ratios reflect an 
abundance of substrate for both the TCA cycle and electron transport chain, 
respectively, thus further decarboxylation of pyruvate by the PDC would be 
superfluous. 
2.12 ANAPLEROTIC PROCESSES IN SKELETAL MUSCLE 
The term "anaplerosis" is derived from the Greek word meaning ''to fill up". In the 
physiological setting and in the context of this thesis, anaplerosis refers to metabolic 
pathways that allow entry of carbon into the TCA cycle, by routes other than the entry 
of carbon as acetyl-CoA via the citrate synthase reaction (Kornberg, 1966). The entry 
of carbon into the TCA cycle increases the total concentration of the TCA cycle 
intermediates (TCAI), and thus expands or "fills up" the TCAI. 
A number of processes could feasibly contribute to anaplerosis during exercise, but their 
physiological significance has been the subject of much debate (Aragon and 
Lowenstein, 1980; Spydevold et al. 1976; Sahlin et al. 1990). The proposed processes 
include the purine nucleotide cycle (PNC), three reactions catalysed by AMP dearninase 
(Eqn 1), adenylosuccinate synthase (Eqn 2) and adenylosuccinate lyase (Eqn 3), 
respectively (see section 2.4.2): 
AMP ~ IMP + NH3 
IMP + aspartate + GTP ~ adenlyosuccinate + GTP + Pi 
adenylosuccinate ~ AMP + fumarate 
(1) 
(2) 
(3) 
One complete turn of the PNC results in the deamination of aspartate, the consumption 
of GTP and the production ofNH3 and fumarate. The fumarate produced may feasibly 
enter into the TCA cycle. 
Other potential anaplerotic reactions are catalysed by glutamate dehydrogenase (GDH; 
Eqn 4), pyruvate carboxylase (PC; Eqn 5), phosphoenolpyruvate carboxykinase 
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(PEPCK, Eqn 6), alanine aminotransferase (AAT; Eqn 7) and malic enzyme (ME; Eqn 
8): 
glutamate + NAD+ ~ a-ketoglutarate + NH3 + NADH 
pyruvate + CO2 + ATP ~ oxaloacetate + ADP + Pi 
phosphoenolpyruvate + C02 + IDP + Pi ~ oxaloacetate + ITP 
glutamate + pyruvate ~ a-ketoglutarate + alanine 
pyruvate + C02 + NAD(P)H ~ malate + NAD(Pt 
(4) 
(5) 
(6) 
(7) 
(8) 
The central role of pyruvate in many of the anaplerotic reactions is highlighted in Figure 
2.9. Indeed, it has been reported that the AAT reaction is the principal mechanism for 
TCAl expansion during the initial period of exercise (Sahlin et al. 1990; Gibala et a1. 
1997a; Spencer et al. 1991b) Furthermore, the AAT reaction is dependent upon the 
availability of both pyruvate and glutamate to proceed. However, if the AAT were the 
principal mechanism for TCAl expansion, one might expect to observe an increase in a-
ketoglutarate, one of the products of the AAT reaction. No such increase has been 
reported during the initial period of exercise when it is purported the AAT reaction is 
most active. On the other hand, an increase is observed in intramuscular alanine 
concentration, the second product of the AAT reaction, together with a decrease in 
glutamate concentration (Gibala et al. 1997a; Sahlin et al. 1990). 
Taken together, these fmdings suggest that the AAT reaction may indeed contribute 
most significantly to anaplerosis during the initial period of exercise. However, the 
anaplerotic carbon derived from the AAT reaction does not appear to accumulate as a-
ketoglutarate. There is a disproportionate increase in the TCAl succinate, malate and 
fumarate during the initial period of exercise (Gibala et al. 1998). As a-ketoglutarate is 
in equilibrium with glutamate via the glutamate dehydrogenase reaction, there is most 
probably a rapid conversion of a-ketoglutarate to these intermediates due to the tight 
regulation of the a-ketoglutarate dehydrogenase complex. Indeed, an increase in a-
ketoglutarate content causes a rapid activation of the a-ketoglutarate dehydrogenase 
complex (Bunik et al. 1991) suggesting a rapid conversion of a.-ketoglutarate to other 
TCAl. Furthermore, any delay in the freezing of the muscle biopsy sample would 
favour the accumulation of the TCAl in the second span of the TCA cycle. 
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Interestingly, the changes observed in muscle TCAI pool size observed following 
pharmacological activation of the PDC with dichloroacetate (DCA) or during exercise, 
have been largely mediated by changes in the intermediates located in the second span 
of the TCA cycle, namely succinate, malate and fumarate and oxaloacetate (Constantin-
Teodosiu et al. 1999; Gibala and Saltin, 1999a; Gibala et al. 1998). Moreover, malate 
appears to undergo the largest increase of any of the measured TCAI during exercise 
(Sahlin et al. 1990; Sahlin et al. 1995; Giba1a et al. 1997a; Gibala et al. 1998; Gibala 
et al. 1997b; Gibala and Saltin, 1999a; Aragon and Lowenstein, 1980). 
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Fig. 2.9 Anaplerotic reactions in human skeletal muscle. Reactions shown catalysed by: <D-® net 
reaction of the PNC; @) glutamate dehydrogenase (GDR); ® pyruvate carboxylase (PC); ® 
phosphoenolpyruvate carboxykinase (PEPCK); ® alanine aminotransferase (AAT); ® and malic enzyme 
(ME); PEP (Phosphoenolpyruvate) reversible reaction to pyruvate catalysed by pyruvate kinase (PK). 
2.13 GLUTAMINE AND GLYCOGEN RESYNTHESIS IN THE LIVER AND 
SKELETAL MUSCLE 
Alterations in the concentration of amino acids in portal blood appear to activate cell 
volume regulatory mechanisms in the liver. The uptake of amino acids in the absorptive 
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state may act as a signal governing the metabolic state of the liver (Haussinger et al. 
1990). In addition, it has been suggested that a similar mechanism involving cell 
volume changes may exist in skeletal muscle in vitro (Parry-Billings et al. 1991). 
Furthermore, a cell volume change, more specifically cell swelling, has been shown to 
be a prerequisite for the amino acid-dependent activation of the hepatic System N 
transporter (Bode and Kilberg, 1991). 
Cell swelling may be regarded as an initial primary signal by which glycogen synthesis 
is activated both in the liver and in skeletal muscle. Glycogen synthesis may be 
modulated by cellular hydration state, both in the liver and skeletal muscle (Lang et al. 
1998). Cell swelling would appear to favour the synthesis of glycogen (anabolic 
signal), whereas cell shrinkage appears to act in the opposite manner (catabolic signal). 
The precise mechanism by which cell volume changes may stimulate glycogen 
synthesis in both liver and skeletal muscle cells remains unclear. However, it has been 
suggested that the cytoskeleton architecture, in particular transmembrane integrins may 
be responsible for transducing the mechanical stimuli (Le. cell swelling) into chemical 
signals which evoke metabolic responses (i.e. glycogen synthesis) (Ingber, 1997; Low 
and Taylor, 1998). 
In hepatocytes, it is likely that cell swelling activates glycogen synthase phosphatase 
and acetyl-CoA carboxylase (Baquet et al. 1990; Baquet et al. 1991b). More 
specifically, swelling appears to activate PI3-kinase (phosphatidylinositol 3-kinase) 
which mediates the swelling induced activation of both glycogen synthase and acetyl-
CoA carboxylase (Low and Taylor, 1995; Krause et al. 1996a; Krause et al. 1996b). 
Furthermore, due to the inherent link between cell swelling and cell pH via Na+/ft 
exchange, which is activated by insulin, glycogen synthesis in hepatocytes may be 
stimulated by acidification, with a concomitant inhibition of glycolysis (Peak et al. 
1992). A further potential mechanism by which glycogen synthesis is mediated is by 
the influx of amino acids causing a decrease in intracellular cr concentration (Meijer et 
al. I 992a). This would allow glycogen synthesis to proceed, as a high concentration of 
cr ions inhibit glycogen synthase phosphatase, thus impairing glycogen synthesis. 
Indeed, it has been demonstrated that cell swelling per se is able to stimulate glycogen 
synthesis both in isolated rat hepatocytes (Baquet et al. 1990; Mouterde et al. 1992) 
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and in rat skeletal muscle cells (Scislowski et al. 1989; Low et al. 1996). The 
provision of glutamine to the perfused rat liver is able to induce liver cell swelling 
(Hliussinger et al. 1990). Upon entry into the in vitro liver cell, glutamine is able to 
stimulate hepatic glycogen synthesis and lipogenesis from glucose and inhibit 
ketogenesis (Katz et al. 1976; Baquet et al. 1990; Baquet et al. 1991a; Meijer et al. 
1992; Peak et al. 1992; Lavoinne et al. 1987; Lavoinne et al. 1996). Furthermore, the 
ability of glutamine to modulate liver glycogen synthesis has also been demonstrated in 
vivo. Niewoehner & Nuttal1 (1996) demonstrated using a rat model, that the oral 
provision of glutamine is able to stimulate liver glycogen synthesis through an 
activation of glycogen synthase, probably mediated via the cell-swelling mechanisms 
discussed previously. 
In humans, the intravenous infusion of glutamine has been shown to promote skeletal 
muscle glycogen resynthesis during recovery from exhaustive exercise compared to the 
infusion of an isonitrogenous and isoenergetic mixture of alanine and glycine (Varnier 
et al. 1995). The proposed mechanism for the increase in muscle glycogen is that 
glutamine may act as a glycogenic precursor or through the activation of skeletal muscle 
glycogen synthase via the mechanisms discussed previously. 
However, more recent work suggests that the supplementation of glutamine in 
combination with glucose post exercise is unable to increase muscle glycogen 
resynthesis to a greater extent than glucose alone (van Hall et al. 2000b). Furthermore, 
glycogen synthase activity was similar in both conditions (Wagenmakers et al. 1997; 
van Hall et al. 2000b). These results are complimentary when compared to those of 
Bowtell et al. (1999) who found that a combination of glutamine and glucose was 
unable to further stimulate post exercise glycogen resynthesis compared to glucose 
alone (Bowtell et al. 1999). Therefore, there appears to be no additive effect on muscle 
glycogen resynthesis When both glutamine and glucose are provided post exercise. It is 
conceivable that the supplementation of a sufficient glucose load (-1.5 g/kg body wt; 
Ivy et al. 1988b) might cause maximal stimulation of glycogen synthase through an 
elevation in insulin concentration, with no further stimulation possible through the 
addition of glutamine. 
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2.14 GLUCOSE TOXICITY AND GLUCOSAMINE- A ROLE FOR 
GLUTAMINE? 
Previous studies have demonstrated a role for the hexosamine biosynthetic pathway in 
glucose regulation of insulin-stimulated glucose transport in adipocytes (Marshall et al. 
1991b). Over-activity of the hexosamine biosynthetic pathway has recently been 
suggested to be one of the possible mechanisms mediating glucose-induced insulin 
resistance or glucose toxicity (McClain and Crook, 1996; Virkamaki et al. 1997). 
Skeletal muscle accounts for the major portion (-75%) of insulin-mediated glucose 
disposal, thus it is important to outline mechanisms that may affect insulin action in this 
tissue. 
Glucose flux though the hexosamine biosynthetic pathway is controlled by its first and 
rate-limiting enzyme, glutamine:fructose-6-phosphate amidotransferase (GFAT) 
(Marshall et al. 1991b; Marshall et al. 1991c). GFAT activity has been shown to be 
present and measurable in human skeletal muscle, but its activity has been found to be 
5-18 fold greater in the liver (Yki-Jarvinen et al. 1996; Nerlich et al. 1998). 
GFAT transfers an amino group from glutamine to fructose-6-phosphate (F-6-P) to 
form glucosamine-6-phosphate (GlcN-6-P) and glutamate (McKnight et al. 1992). The 
fmal products of the hexosamine biosynthetic pathway are uridine diphosphate-N-
acetyl-glucosamine (UDP-GlcNAc) and other nucleotide hexosamines (McClain and 
Crook, 1996). The routing of glucose through the hexosamine biosynthetic pathway 
and the formation of hexosamine products appear to regulate GFAT activity (Traxinger 
and Marshall, 1991). In addition, the products of the hexosamine biosynthetic pathway 
appear to act as negative feedback regulators limiting excessive muscle glycogen 
deposition post exercise by gradually decelerating skeletal muscle glucose uptake 
(McClain and Crook, 1996; Nelson et al. 1997). Indeed, GFAT activity is subject to 
feedback inhibition by the end product of the hexosamine biosynthetic pathway, UDP-
GlcNAc in human skeletal muscle (Yki-Jarvinen et al. 1996). 
Increasing the available fructose-6-phosphate (F-6-P), whilst maintaining the available 
glutamine, has been shown to increase GFAT activity (Nelson et al. 1997). 
Concomitantly, GFAT activity in rats after an overnight fast, as measured by an 
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accumulation ofGIcN-6-P, is decreased by -30% compared to ad libitum fed rats (Buse 
et al. 1996; Nelson et al. 1997). The apparent Km of GFAT for glutamine in several 
mammalian tissues has been reported to be between 0.4 and 1.6 mmo!.r! (Kornfeld, 
1967; Traxinger and Marshall, 1991; Robinson et a!. 1995). The apparent Km ofGFAT 
for F-6-P in muscle being -2.4 mmo!.r! (Robinson et a!. 1995), glucose flux through 
the hexosamine biosynthetic pathway in vivo is therefore highly dependent upon the 
concentration ofF-6-P. 
It is important to recognise that the hexosamine biosynthetic pathway metabolises only 
2-3% of glucose in adipocytes under normal circumstances (Marshall et aI. 1991b). 
The proportion of glucose metabolised via the hexosamine biosynthetic pathway 
appears to be largely determined by GFAT, as this is the rate-limiting enzyme (Marshall 
et a!. 1991a) and accumulation of the hexosamine products seems to parallel GFAT 
activity (Hebert and McClain, 1995). Therefore, it is conceivable that an increase in 
GF AT activity, mediated through a concomitant increase in glucose, glutamine and 
insulin, may increase the flux of glucose through the hexosamine biosynthetic pathway. 
Indeed, absolute flux via the hexosamine biosynthetic pathway was increased in muscle 
in vivo during hyperglycaemia and hyperinsulinemia (Robinson et a!. 1995), as it has 
been observed that both glucose and insulin serve to regulate GF AT activity (Daniels et 
aI. 1996). 
The activity ofGFAT has been reported to be greater in slow twitch muscle fibres (Yld-
Jarvinen et a!. 1997), suggesting that GFAT activity may be greater in endurance 
trained athletes, as they generally have a higher percentage of slow twitch muscle fibres. 
In spite of this finding, GF AT activity has been demonstrated to be unaffected by a 
prolonged bout of exercise, although it may be subject to nutritional regulation post 
exercise (Nelson et al. 1997). Therefore it is feasible that the post exercise 
supplementation of glucose and glutamine, substrates of the GFAT reaction, may be 
expected to increase the activity ofGFAT thus increasing the product of the reaction, 
namely glucosamine. 
Pre-exposure to glucosamine is able to induce insulin resistance in skeletal muscle 
through a reduction in the ability of insulin to increase glucose transport (Robinson et 
a!. 1993). Upon entry into the cell via facilitated diffusion, using the same transport 
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system as glucose, glucosamine is phosphorylated to glucosamine-6-phosphate (GlcN-
6-P) and enters the hexosamine biosynthetic pathway distal to GFAT (Marshall et al. 
1991b; Robinson et al. 1995). 
Glucosamine-induced insulin resistance of glucose transport appears to be restricted to 
those cells expressing the glucose transporter GLUT-4 (i.e. skeletal muscle and 
adipocytes). Glucosamine appears to act by impairing the insulin-induced translocation 
of GLUT -4 from intracellular stores to the plasma membrane. In vitro, the pre-exposure 
or infusion of glucosamine has been shown to cause insulin resistance by impairing 
insulin-induced GLUT-4 translocation in rat skeletal muscle (Robinson et al. 1993; 
Baron et al. 1995). However, glucosamine does not alter basal glucose transport or 
insulin stimulation of GLUT -1 translocation and mitogen-activated protein kinase in 
adipocytes (Heart et al. 2000). 
As GLUT-4 is integral in insulin-stimulated glucose transport, any defect in the 
translocation ofthis glucose transporter will ultimately reduce skeletal muscle glycogen 
synthesis due to a decrease in available G-6-P. The production of glucosamine, via 
GFAT and the hexosamine biosynthetic pathway, has been shown to impair GLUT-4 
translocation from its insulin-sensitive intracellular pool. This decreases glucose uptake 
in to the muscle cell and thus limits skeletal muscle glycogen synthesis. A -60% 
reduction in muscle G-6-P has been observed in glucosamine infused rats, suggesting 
impaired glucose transport (Giaccari et al. 1995). Indeed, the activity of GFAT, 
indicative of flux through the hexosamine biosynthetic pathway, has been shown to be 
inversely related to whole-body glucose disposal rates (Daniels et al. 1996). 
Furthermore the oral provision of glutamine, in addition to 14C labelled glucose, has 
been shown to induce a -40% decrease in skeletal muscle glucose uptake, possibly due 
to increased flux through the hexosamine biosynthetic pathway and increased 
glucosamine production (Sawada et al. 1998). It has been reported that the effects of 
glucosamine are evident -30 min after infusion in rats (Baron et al. 1995), with the 
intrinsic activity of GLUT-4 being reduced within 2 h of glucosamine infusion 
(Hawkins et al. 1999). 
As the hexosamine biosynthetic pathway is able to regulate insulin-stimulated glucose 
transport, one may expect that hexosamine metabolism is also able to regulate glycogen 
74 
synthesis (Giaccari et al. 1995). Indeed, both the over-expression of GFAT or pre-
exposure to glucosamine, have been shown to reduce the ability of insulin to stimulate 
glycogen synthase, mediated via a down-regulation in basal PPl activity, in addition to 
reducing the ability of insulin to stimulate PPl (Crook and McClain, 1996; Robinson et 
al. 1993). 
Hepatic glucose transport IS mediated through the insulin-independent GLUT2 
(Mueckler, 1994; Thorens, 1996), and is therefore not subject to modulation by 
glucosamine production. It has been postulated that the production of glucosamine, 
which may impede glucose uptake in skeletal muscle through the provision of glucose 
and glutamine, may force a compensatory increase in hepatic glucose uptake, leading to 
an increase in liver glycogen synthesis (Bowtell et al. 1999). Indeed, the provision of 
glutamine in addition to glucose-polymer post exercise has been shown to increase 
whole body non-oxidative glucose disposal, in other words whole body carbohydrate 
storage, compared to glucose-polymer alone (Bowtell et al. 1999), with the most likely 
site of increased carbohydrate storage outside of skeletal muscle being the liver. When 
compared with recent fmdings demonstrating that skeletal muscle glycogen synthase 
failed to be activated to a greater extent when combination of glucose and glutamine 
was provided post exercise compared to glucose alone (Wagenmakers et al. 1997), it 
would certainly appear feasible that an increase in liver glycogen may occur in this 
situation. 
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CHAPTER 3 
GENERAL METHODS 
3.1 INTRODUCTION 
The research proposals and all procedures described in this thesis were approved by the 
Ethical Advisory Committee of Loughborough University and were carried out in 
accordance with the 'Code of Practice for Workers having Contact with Body Fluids'. 
Prior to giving written consent to participate in the study, subjects were fully informed 
of the demands that would be placed upon them and also the possible risks and 
discomforts. Subjects were given the opportunity to ask for further information and 
clarification of the tests to be undertaken, in addition subjects were advised that they 
may cease participation in the study at any point, without need for explanation. 
Subjects were also required to complete a medical questionnaire prior to participation in 
the study and provide details of their training background. Subjects with a medical 
condition potentiating an undue personal risk were excluded from the study. In 
addition, as prolonged cycling is extremely demanding, subjects who were fumiliar with 
endurance exercise were accepted as volunteers. All testing was carried out in the 
Department of Physical Education, Sports Science and Recreation Management 
laboratory at Loughborough University, Loughborough, UK 
3.2 DATA COLLECTION 
In all studies, a friction-braked cycle ergometer was used (Monark, Model 824E). 
Resistance was applied by the addition of pre-determined weights to a hanging cradle. 
In order that subjects could assume a position on the ergometer similar to their normal 
cycling position, a seat post that provided both vertical and horizontal adjustment 
(Cranlea & Co, Birmingham, UK) and handlebar stem that allowed multiple adjustment 
(Look Ergostem, Look, France) were fitted. In addition, a racing saddle and racing 
handlebars were fitted to the ergometer. Power output was calculated via an interfuce 
with a BBC microcomputer through high frequency logging of the flywheel angular 
velocity. Through prior calibration of the cycle ergometer, changes in kinetic energy of 
the flywheel were incorporated into the power output calculations, which were recorded 
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every 30 seconds. In addition, flywheel revolutions were recorded through an analogue 
counter (calibrated prior to the commencement of each ride) to enable power output to 
be calculated. The use of a BBC microcomputer enabled a visual display of both power 
output and pedal frequency (revolutions per minute). Furthermore, subjects were 
provided with continual visual feedback of their current pedal frequency via a digital 
display on the ergometer. However, during the cycle to exhaustion rides, subjects were 
unable to see the time elapsed and were never given any indication of this. 
In all studies, heart rates were recorded using a short range radio telemeter (Vantage 
NV, Polar Electro, Finland). Subjects weight was measured using a balance scale 
(Model 3306ABV, Avery Ltd., Birmingham, UK) and their height measured using a 
static measurement scale. 
Expired gas was collected using the Douglas bag technique. During expired air 
collection, subjects wore a nose clip and breathed through a low resistance one-way 
respiratory valve connected to a 200 litre capacity Douglas bag by lightweight smooth 
bore tubing (Falconia Ltd., Manchester, UK). This enabled a closed circuit to be 
formed for the collection of expired air over a given time period. 
The expired gas collections during recovery were for 6 min and those taken during 
exercise were 1 min collections. During recovery, expired air was always collected 
with the subject assuming a seated position and with the subject having rested for -10 
minutes to ensure consistency. In addition, the subject was given the mouthpiece and 
nose-clip -45 seconds prior to expired gas collection to allow the subject to become 
accustomed to the breathing apparatus. This avoided the possibility of hyperventilation 
that may alter the C02 content of expired gas, which in turn could give rise to a spurious 
VC02 value. 
The percentage of oxygen (02) and carbon dioxide (C02) in the dry expired air (silica 
gel was used as a drying agent) was measured using a paramagnetic 02 and infra-red 
C02 analyser (Servomex Model 1400, Crowborough, UK). The O2 analyser operates 
on the basis of the susceptibility of O2 to a paramagnetic gas and provides a digital 
readout to one decimal point. The C~ analyser provides a digital readout to two 
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decimal points. Both analysers were calibrated against nitrogen, a certified reference 
gas (Cryoserve Ltd., Worcester, UK), and atmospheric air prior to each series of expired 
air analyses. The calibration of the analysers was checked at regular time intervals and 
were re-calibrated if necessary. 
After the 02 and the C02 concentrations of the expired gas had been measured, the 
volume of expired gas was measured using a Harvard digital dry gas meter (Harvard 
Apparatus, Edenbridge, UK). The temperature of the expired gas was measured using a 
thermister (Edale Instruments Ltd., Type 2984 Model C) fitted to the inner surface of 
the gas outlet pipe of the dry gas meter. The analogue readout of the thermister was 
calibrated prior to each set of analyses. 
The measured gas concentrations and volume were standardised for temperature, 
atmospheric pressure and water vapour content (STPD). Using the Haldane 
transformation formula, oxygen uptake cV02), carbon dioxide production (VC02), 
minute ventilation (VE) and the respiratory exchange ratio (RER) were then calculated. 
The use of open circuit spirometry allowed for energy expenditure under steady state 
conditions to be estimated using indirect calorimetry. The proportion of energy derived 
from carbohydrate and fat were estimated using the non-protein RER, with the 
carbohydrate and fat oxidation rates determined from measurements ofV02 and VC02 
(Frayn, 1983). 
All experimental tests administered in this thesis were conducted in the laboratory under 
neutral environmental conditions (18-22°C). Ambient conditions in the laboratory were 
carefully monitored throughout the experimental period during all studies, and 
controlled where possible. Wet and dry bulb temperatures were measured using a 
whirling hydrometer (Brannan Thermometers Ltd., Cumberland, UK), operated in close 
proximity to the subject during rest and were subsequently used to calculate relative 
humidity (%) using an appropriate conversion scale. 
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3.3 PRELIMINARY MEASUREMENTS 
Familiarisation 
All subjects who volunteered to take part in the studies described in the thesis were 
familiarised with the laboratory environment and experimental procedures. In all 
studies a series of preliminary tests were conducted prior to the main experimental trial 
to detennine the oxygen cost of submaximal cycling (cycling economy) and maximal 
oxygen uptake (V02max). In addition, a 60 minute familiarisation ride was performed 
prior to the main experimental trial in studies I and 2. During all measurements using 
the cycle ergometer, subjects were required to pedal at 75 revolutions per minute, as this 
was considered to be reflective of the subject groups normal cadence using the 
ergometer. 
Determination of cycling economy 
This test detennined the oxygen cost of cycling over a range of submaximal work-rates 
(V02-work rate). The work rates were selected to each subject's cycling ability and 
corresponded to work rates between 60 - 90% ofthe individual's V02max. This test was 
continuous and involved subjects performing four minute stages at four different work 
rates with the load being increased every stage. Expired air collections were made 
during the last minute of each four minute period and were analysed for oxygen and 
carbon dioxide, to detennine V02 and Ve02 as described previously. In addition, heart 
rate and flywheel revolutions were recorded during the last minute of each stage. By 
applying linear regression to the four values of V02 obtained and their corresponding 
work rate values, individual relationships between V02 and work rate were established 
for each subject. 
Determination of maximum oxygen uptake 
Maximum oxygen uptake (V02max) was detennined using a continuous, incremental test 
to volitional exhaustion. Subjects performed three minute stages with the load being 
increased 0.5 kg at the end of each stage. The starting work rate was based upon the 
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subjects cycling ability and also to ensure a test duration of approximately 10 minutes. 
Expired gas collections were made during minutes 1 min 45 s to 2 min 45 s of each 
stage. Continuous verbal encouragement was given to each subject during the test. A 
fmal collection was taken after subjects had indicated that they could only continue for 
one more minute. From this collection the subjects V02max was determined. Criterion 
for establishing a valid V02max test were, a heart rate approximating an age-predicted 
maximal value and an RER value greater than 1.0. 
Using the data obtained from both the V02-workrate test and the V02max test, the V02 
equating to both 60 and 70% of the subjects V02rnax was determined, which in turn was 
equated to a work rate and subsequently a load corresponding to 60 and 70% V02max. 
Familiarisation ride 
To ensure that the calculated loads for both 60 and 70% V02max were correct and that 
subjects were fully familiarised with prolonged cycling and the procedures that were to 
be used, subjects performed a 60 minute familiarisation prior to the main experimental 
trial in studies 1 and 2. Subjects performed 10 min at 60% V02max and the remaining 
50 min at 70% V02max with expired air collections being made every 10 min. If 
necessary, the load was adjusted accordingly to ensure that the subject was cycling at 
70% of their V02max. 
Glycogen depletion protocol 
In all studies, subjects performed a bout of glycogen depleting exercise. The protocol 
implemented was identical in all studies. Subjects initially performed a 5 min warm-up 
at -60% VD2max. and then undertook a bout of exercise of varying intensity (Fig 3.1), at 
a pedal rate equivalent to -75 rpm. After 30 min of exercise at 70% V02max, subjects 
rested passively for 2 min. The workload was then doubled and they completed 3 x 50 s 
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bursts of activity separated by 2 min rest. This burst of high-intensity activity was 
designed to substantially reduced type 11 fibres of glycogen. 
Finally, they then cycled for a further 45 min at -70% V02max to ensure both a further 
depletion of glycogen in type I fibres and to ensure that blood lactate concentration at 
the end of exercise was low to minimise glycogen resynthesis from lactate during 
recovery. The glycogen depleting exercise was designed to deplete both type I and type 
11 muscle fibres of glycogen as validated by V 011estad et al. (V 011estad et al. 1992). 
Subjects were offered 2 rn1 waterlkg body mass every 15 min during exercise to ensure 
euhydration during the bout of glycogen-depleting exercise. 
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3.4 DIETARY ANALYSIS 
Subjects were required to complete a weighed food intake diary in the 48 hours 
preceding each main trial in all studies. Furthermore, before each of the main trials 
subjects were asked to replicate the food consumed prior to the first main trial. Subjects 
were asked to refrain from consumption of food and beverages from 10 o'clock the 
night prior to the main trial to ensure a 12 h overnight fast. Subjects were offered water 
upon arrival at the laboratory; the volume consumed was monitored and in all cases was 
negligible and insufficient to affect plasma volume and hydration status. Subject's food 
record diaries were analysed for nutritional content, in particular the percentage of 
carbohydrate, fat and protein consumed and their daily energy intake (Comp-Eat 5.0, 
Lifeline Nutritional Services, London). 
In study 3, a low-carbohydrate diet (- 35 % carbohydrate; -55 % fat; -10 % protein; 
-5.9 MJ) was prescribed to subjects, after the glycogen-depleting exercise and before 
the main trial. Each subject had their prescribed diet devised individually using 
computer software (Comp-Eat 5.0, Lifeline Nutritional Services, London). The 
subject's normal diet was recorded for two days and the low-carbohydrate diet was 
based upon this, providing approximately 50 % of their average daily energy intake 
(food was not provided for subjects in this instance). 
3.5 SOLUTIONS 
In all studies in this thesis, a solution was provided either during recovery from exercise 
(studies 1 & 2) or prior to exercise (study 3). The solution contained the assigned 
amino acid(s) or ornithine a-ketoglutarate (study 3) to allow oral consumption. In study 
1, a glucose-polymer solution was provided, in addition to a placebo solution. In 
studies 2 & 3 only a placebo solution was provided. In study 3, the ornithine a-
ketoglutarate provided to the subjects was supplied by Laboratoires Jacques Logeais, 
Paris, France. All solutions provided were artificially sweetened, palatable and 
indistinguishable from the other solutions provided during each study. The composition 
of the solutions used is detailed in Table 3.1 
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Table 3.1 Composition of solutions provided during studies 
(;lucose-JHl~merl Placebo' Placebo' Placebo' 
Carbohydrate (g. 100 mr') 6.4 
- -
-
pH 3.40 3.31 3.42 3.42 
Osmolality (mOsm·kg) 296 75 67 67 
Sodium (mg·1 00 011") 48 51 52 52 
, .. , 
. " Brand name. Lucozade Sport (SnuthKhne Beecham Consumer Healthcare, UK), Soluhon used ID study I, Solunon used m study 
2~"Solution used in study 3. 
3.6 ESTIMATION OF WHOLE BODY REHYDRATION 
Whole body rehydration during the first and second studies of this thesis was estimated 
according to the method ofGonzalez-Alonso et al. (1992). The percentage gain in body 
weight during the recovery period relative to the weight loss during the previous bout of 
exercise provided a suitable index of rehydration. The amount of ingested fluid retained 
within the body after the receovery period equated to the percent rehydration. 
% rehydration = [(BWpre-BWpost) - (BWpre-BW,ec)) 
BWp,e = pre exercise body weight (kg) 
BWpost = post exercise body weight (kg) 
Fluid intake (kg) 
BWrec = post recovery exercise body weight (kg) 
x 100 
3.7 COLLECTION, TREATMENT, STORAGE AND ANALYSIS OF BLOOD 
SAMPLES 
Sample collection 
In all studies, venous blood samples were obtained from an antecubital vein using an 
indwelling cannula (Venflon 2, 18 G, Ohmeda, Sweden) attached to a 10 cm extension 
tube (Connecta, Ohmeda, Sweden) for sampling, which was inserted under local 
anaesthetic (0.5 ml of 1 % w:v lignocaine, Antigen Pharmaceuticals, Ireland). The 
cannula was kept patent by periodic flushing with sterile saline (sodium chloride 
injection, 0.9 % w/v, Steri-Amp, Steripak Ltd., Cheshire, UK). Blood samples were 
taken with the subject adopting a seated position, akin to the position assumed whilst sat 
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on the cycle ergometer. This consistency was also due to the fact that differences have 
been observed in plasma volume depending upon the position of the individual at the 
time of collection and in the preceding time (Hagan et al. 1978; Shirreffs and Maughan, 
1994). In all cases, basal blood samples were obtained after 15 min of passive rest on 
the examination couch. A 12 ml blood sample was taken both at rest and during 
exercise in all studies. During exercise, venous blood samples were taken at regular 
intervals without any interruption to cycling. The exhaustion blood sample was 
obtained during the last minute of exercise. 
Treatment, storage and analysis of blood samples 
In all studies, venous blood was drawn off in untreated plastic syringes (Plastipak, 
Becton Dickinson, Sweden) and dispensed into either lithium-heparinised tubes, EDTA 
tubes or serum (containing no anticoagulant) tubes (Sarstedt, Leicester, UK). The 
venous blood in serum tubes was left to clot for 1 h on ice to obtain serum. 
Plasma NH3 (all studies) and glutamine (study 1) 
1 ml of the venous blood was dispensed into calcium-heparinised flip-top Eppendorf 
tubes (50 units per tube) and centrifuged fur 3 min at 12000 rev. min·! (Eppendort; 
Model 5412). The plasma obtained was snap-frozen in liquid nitrogen before being 
analysed within 48 h for ammonia concentration using a commercially available kit 
(Sigma Diagnostics, Procedure No. 171-UV, see Appendix C). 2 x 1 ml aliquots were 
treated in a similar fashion and the plasma was later stored at -70°C, before being 
analysed at a later date for glutamine concentration (see comparison of methods of 
glutamine measurement, within this chapter). 
Plasma non-esterified fatly acids (NEFA) and glucose4 (studies 1 & 2) 
An aliquot (-3 ml) of the whole venous blood was dispensed into EDTA tubes and 
centrifuged for 15 min at 6000 rev.min·! at approximately 4°C, and the resulting plasma 
was stored at _20°C before being analysed at a later date. This plasma was analysed for 
NEFA; (Wako Chemicals, Osaka, Japan, see Appendix C) and glucose using a 
commercially available kit (Boehringer Mannhein, GmbH) and an automated analyser 
(Cobas Mira Plus, Roche Diagnostic Systems, Basel, Switzerland; see Appendix A). 
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Blood lactate4 (studies 1 & 2) 
Two 20 III aliquots of venous blood were drawn from the tube and immediately 
deproteinised in an Eppendorf containing 200111 perchloric acid (2.5% w:v) prior to 
centrifugation (Eppendort: Model 5412), The supernatant from these samples was 
subsequently analysed for blood lactate via fluorometric analysis (Maughan, 1982). 
Plasma and blood lactate and glucose4 (studies 2 & 3) 
1 rnl of venous blood was presented at an automated glucose and lactate analyser 
(Yellow Springs Instruments (YSI), 2300 STATPLUS, Ohio, USA) for the 
determination, in duplicate, of blood lactate and glucose concentration, After analysis, 
this aliquot of venous blood was then immediately centrifuged for 3 min at 12000 
rev,min,l, The plasma obtained was presented at the YSI automated analyser for the 
determination, in duplicate, of plasma lactate and glucose concentration. 
Serum insulin (all studies) and NEFA (study 3) 
An aliquot (-4 rnl) of the venous blood was dispensed into serum tubes and after 1 h on 
ice, serum was obtained by centrifugation for 15 min at 6000 rev.min'l. The serum was 
stored at -70°C and analysed at a later date for insulin (Radio-immunoassay kit, 
Diagnostic Products Corporation, California, USA; see Appendix E). The serum 
obtained was also analysed for NEFA (study 3; Wako Chemicals, Osaka, Japan, see 
Appendix C). 
Haemoglobin and haematocrit (all studies) 
Two 20 III aliquots of venous blood were drawn from the tube using calibrated micro 
pipettes (Acupette Pipettes, Scientific Industries Ltd.) and mixed with 5.0 rnl of 
Drabkins R~agent (Boehringer Mannhein, GmbH). Haemoglobin concentration was 
photometrically determined using the cyanmethaemoglobin method (Cecil Instruments 
393 Series 2 Digital Grating spectrophotometer). Triplicate 50 III samples of blood 
were drawn from the same sample using heparinised capillary tubes. These samples 
were later micro-centrifuged for 15 minutes at 11,000 rev.min'l (Hawksley Ltd) and 
4 A comparison in the methods of analysis between plasma and blood glucose and lactate was made for 
the samples obtained in study 2. Please refer to Appendix N for the full unpublished paper on this 
comparison. 
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packed cell volume was determined using a sliding haematocrit reader (Hawksley Ltd). 
Percent changes in plasma volume from rest were estimated using the method described 
by Dill & Costill (1974) based upon changes in haemoglobin concentration and packed 
cell volume. 
Plasma amino acids (all studies) 
The remaining whole blood in the tube was immediately centrifuged for 15 minutes at 
3°C at 6,000 rev.min· l (Burkard ~P Koolspin). Plasma obtained was stored at -20°C and 
later analysed for amino acids using high performance liquid chromatography (HPLC) 
using the method of Ou et al. (1996) in the Department of Anatomy and Physiology, 
University of Dundee. 
Comparison 0/ methods 0/ glutamine measurement 
Plasma samples obtained in the fIrst study were analysed for glutamine using an 
enzymatic spectrophotometric procedure (Lund, 1985). Plasma glutamine concentration 
was determined by measuring the glutamate concentration in plasma before and after 
treatment with glutaminase (EC 3.5.1.2), the enzyme responsible for degrading 
glutamine to glutamate. The plasma glutamine concentration was calculated by 
subtracting the untreated glutamate concentration from the glutamate concentration in 
the sample treated with glutaminase. Plasma glutamine concentration was also 
determined using high performance liquid chromatography (Ou et al. 1996). A 
comparison of the two methods revealed that the enzymatic procedure resulted in 
plasma glutamine values ~24% higher than the HPLC method. This disparity between 
the two methods may be due to the instability 0 f glutamine in the acidic or alkaline 
media used in HPLC analysis. The difference between the two methods was similar 
both at low and high glutamine concentrations and therefore the different methods will 
provide qualitatively similar, if quantitatively different values. 
Coefficients o/variation/or blood andplasma assays 
The coefficient of variation (CV) for all blood and plasma assays is shown in Table 3.2 
and was calculated from repeated measurements on the same sample. 
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Table 3.2 Coefficient of variation of blood and plasma assays (n=IO) 
Assay 
Blood lactate (manual') 
Blood glucose (automated2) 
Blood lactate (automated2) 
Plasma glucose (automated') 
Plasma ammonia 
Plasma NEPA' 
SerumNEPA4 
Serum insulin 
Plasma glutamine' 
Coefficient of variation (%) 
2.2% 
1.3% 
2.2% 
2.8% 
6.7% 
2.1% 
2.0% 
6.9% 
4.3% 
JMethod used in study 1; 2Method used in studies 2 & 3 (YSI 2300 STATPLUS analyser); 'Method used in studies 1 & 2 (Cobas 
Mira analyser); "Method used in study 3 (Cobas Mira analyser); NEFA::: non-esterified tatty acids; sEnzyrnatic method used for 
comparative purposes in study 1 only (GP + GLN vs GP + ALA & GLY). 
3.8 COLLECTION, TREATMENT, STORAGE AND ANALYSIS OF 
MUSCLE SAMPLES 
Collection of muscle samples 
Muscle samples were obtained from the vastus lateralis by a percutaneous needle biopsy 
technique (Bergstrom, 1975) with suction applied. The skin and fascia over the anterior 
aspect of one thigh was anaesthetised (2-3 ml of 1 % w:v lignocaine, Antigen 
Pharmaceuticals, Ireland) and small incisions (-I cm) were made in skin and 
subcutaneous layer of fascia to allow extraction of muscle samples using a biopsy 
needle. 
Human vastus lateralis is comprised of 52% (range 36-71%) type I, 36% (range 23-
57%) type IIa, and 10% (range 0-35%) type lIb fibres (Schantz et al. 1983), and 
therefore a biopsy sample represents a mixture of these fibre types. Furthermore, vastus 
lateralis has been shown to be actively involved during cycling exercise (Essen, 1978), 
making this muscle an appropriate site for sampling. 
Treatment and storage of muscle samples 
In order to measure the concentration of metabolic intermediates in a tissue at the time 
point of sampling, the metabolic reactions must be inhibited very rapidly. Therefore, 
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the biopsy needle containing the muscle sample was immersed into liquid nitrogen 
within 1-2 s after removal from the leg. The samples were then quickly removed from 
the biopsy needle, placed into screw-top Eppendorfs (with pierced tops), and kept in 
liquid nitrogen for 24-48 h until they were freeze-dried. 
Each sample was freeze-dried for 12-18 h using a freeze-drier (Edwards Modulyo, 
Crawley, UK) and stored at -70 'c in an anhydrous state. This procedure allows long-
term storage of the samples with reactions inhibited. Furthermore, in this state it is 
easier to remove fat, blood contaminants and connective tissue from the muscle sample. 
Fat was removed from the freeze-dried muscle by washing the sample twice with 1 ml 
petroleum ether (30-40°C). Each time the sample was mixed and centrifuged before 
removing the ether. Finally, the tube was left open in a fume cupboard to allow 
evaporation of ether until the sample was completely dry. At a later date, the freeze-
dried muscle was dissected free of visible connective tissue and blood, and then 
powdered using an agate pestle and mortar at 18-23°C. The powdered muscle sample 
was then weighed using an electrical balance accurate to five decimal places (Mettler-
Toledo AG245, Switzerland), placed in a screw-top Eppendort; centrifuged (22,000 x g, 
1 min) to ensure all the fibres collected at the apex of the Eppendorfand stored at -70°C 
until later analysis. 
Extraction procedure for measurement of mixed muscle metabolites 
Samples were extracted according to the method of Harris et al. (1974). 0.5 M ice-cold 
perchloric acid (HCI04; PCA) containing ImM ethylendiamine tetra-acetic sodium salt 
(EDTA), was added to each sample for 10 min [volume added (1-11) = weight of muscle 
powder / 12.5; round up volume to nearest 50 1-11]. This procedure rapidly inactivates 
and precipitates protein. Each sample was gently vortexed at 30 s intervals, and kept on 
ice in the time intervals, for a total of 10 min «10 min results in a significantly lower 
release of ATP compared to 10 and 20 min periods; Harris et al., 1974). The vortexing 
was vigorous enough to free the fibres from the apex of the Eppendorf. Each sample 
was then centrifuged (22,000 x g, 1 min; 3-4°C) to ensure the sample collected at the 
apex of the Eppendorf. A known volume of the resulting supernatant (i.e. extract) was 
removed, recorded, and stored in flip-top Eppendorfs. The supernatant was neutralised 
89 
with 2.2 M potassium bicarbonate (KHC03) liberating C02 and producing a white salt 
[volume added in III = volume of extract in 111/4]. The samples were then centrifuged 
(22,000 x g, I min; 3-4°C), the supernatant was removed, and placed in screw-top 
Eppendorfs and kept on ice. To ensure that the neutralisation step was complete, the pH 
of the extract was checked using Litmus paper to ensure a pH measurement of7.0. The 
samples were then stored at -80°C until later analysis. 
Measurement of muscle metabolites 
Prior to each assay the muscle extracts were taken from storage at -80°C and defrosted 
rapidly by immersing the samples in hot water, then vortexed to ensure homogeneity of 
the extract. The muscle extracts were assayed for the different metabolites using 
modifications of the methods described by Harris et al. (1974), Lowry & Passonneau 
(1972) and Lnnd (1985). Adenosine triphosphate (ATP), phosphocreatine (PCr) and 
creatine (Cr) were assayed spectrophotmetrically (Beckman DU 650). Lactate, 
pyruvate, citrate, succinate, malate, fumarate, glutamate and glutamine were assayed 
flurometrically (Hitachi F2000). All assays were based on enzyme catalysed reactions. 
Detailed methods for all muscle assays performed are presented in the Appendix (F-M). 
Buffers, co-factors (Grade-I) and enzymes were obtained as standard commercial items 
from either Boehringer Mannheim or Sigma Chemicals. All reagents were prepared 
with double-distilled water and kept at 4°C. Standards were prepared using Grade-I 
chemicals on the day of analysis or were from pre-prepared frozen stock (-20°C). 
Calculations for muscle parameters 
ATP, phosphocreatine (PCr) and creatine (Cr) concentrations were determined 
spectrophotometrically using the method of Harris et al. (1974 & 1983). The contents 
of these metabolites were measured indirectly from changes in the absorbance of 
NADH and NADPH. Both the oxidised and reduced forms of these nucleotides absorb 
visible light at 260 nm, but only the reduced form absorbs visible light at 340 nm. The 
formation of ATP, PCr and Cr do not directly involve this interconversion (Le. there is 
no spectral change), but may be assayed using the concept of 'coupled reactions'. In 
such reactions, the complete utilisation of the metabolite is coupled to a reaction 
utilising the NAD+/NADH or NADP+/NADPH systems by means of common 
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intermediates (see individual assays). Metabolite concentration can then be calculated 
from the recorded changes in absorbance according to the Beer- Lambert law: 
C=MI(&xd) 
A = absorbance 
c = concentration (ofmetabolite, mmol kg-1 dm) 
& = molar extinction coefficient (IM NADH &340nm = 6.22 cm2'Jlmor1) 
d = light path (cms) 
The calculation of metabolite concentration for assays using fluorometric methods, was 
based upon the inter-conversion of the coenzymes NAD+/NADH or NADP+/NADPH 
respectively. The calculation was dependent upon the generation of a standard curve, 
which was always linear (r = 0.98 to r = 1.00), and metabolite concentrations were 
calculated using the resulting standard regression equation (see individual assays). 
Blanks (double-distilled water), standards, dilution factors and extraction factors were 
taken into consideration where necessary. In addition, changes in muscle metabolites 
were normalised to the mean total creatine (TCr) content for each subject (sum of 
phosphocreatine concentration ([PCr]) and creatine concentration ([Cr]) (118.0 ± 1.9 
mmoVg dry wt)) to correct for variability in solid non-muscle constituents between 
biopsies (with the exception of lactate). The TCr content did not change significantly 
between conditions or over time (P >0.05) in study 3. 
Coefficients o/variation/or assays 
The coefficients of variation (CV) for all muscle assays are shown in Table 3.3 and was 
calculated from repeated measurements on the same extract (CV = (standard deviation / 
mean) x 100). All muscle metabolite concentrations were determined in dry weight to 
avoid changes in concentration due to water shift during exercise. 
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Table 3.3 Coefficient of variation of muscle metabolite assays (n=10) 
Assay Coefficient of 
variation (%) 
ATP 1.5% 
PCr 2.3% 
Cr 2.9% 
Pyruvate 9.6% 
Lactate 3.6% 
Citrate 3.2% 
Malate 3.1 % 
Fumarate 8.7% 
Succinate 6.0% 
Glutamine 5.3 % 
Glutamate 4.9% 
ATP = adenosine triphosphate; PCr = phosphocreatine; Cr = creatine 
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CHAPTER 4 
EFFECT OF GLUCOSE-POLYMER AND GLUTAMINE 
SUPPLEMENTATION DURING RECOVERY ON EXERCISE METABOLISM 
IN A SUBSEQUENT BOUT OF EXERCISE 
4.1 INTRODUCTION 
Glycogen is a branched-chain polysaccharide containing glucose residues and is stored 
primarily in the liver and skeletal muscle. Glycogen stored in the liver is used primarily 
to maintain blood glucose levels. In contrast, the role of glycogen stored in skeletal 
muscle is to provide a source of energy during muscular contraction, in particular during 
moderate to intense exercise. Fatigue during prolonged submaximal exercise is 
associated with the depletion of muscle glycogen stores (Bergstrom et aI. 1967). 
Furthermore, a reduction in liver glycogen concentration (Hultman and Nilsson, 1971) 
with a concomitant reduction in blood glucose concentration has been suggested as a 
possible cause of fatigue (Coyle et al. 1983). Therefore, the resynthesis of glycogen, 
both liver and skeletal muscle, during the recovery period after exercise is important to 
the recovery of endurance exercise capacity (Casey et aI. 2000). 
It is known that the consumption of carbohydrate during recovery from exercise leads to 
a greater accumulation of both muscle and liver glycogen (Hultman, 1967a; Casey et aI. 
2000). More recently however, research has focussed upon the supplementation of both 
carbohydrate and protein during recovery from exercise (Zawadzki et aI. 1992; Roy 
and Tarnopolsky, 1998; Carrithers et aI. 2000; Jentjens et aI. 2001). It has been 
demonstrated that a combination of carbohydrate and protein can stimulate muscle 
glycogen resynthesis to a greater extent than placebo (TarnopoIsky et al. 1997; van 
Hall et al. 2000a). Furthermore, it has been demonstrated consistently that the addition 
of protein to a carbohydrate solution consumed during recovery from exercise is able to 
increase insulin concentration to a greater extent than when carbohydrate alone is 
consumed (SpiIIer et al. 1987; Tarnopolsky et al. 1997; van Hall et al. 2000; Jentjens 
et aI. 2001). It has been clearly demonstrated that insulin modulates glycogen 
metabolism by activating glycogen synthase, the enzyme involved in glycogen 
synthesis, and also by increasing the skeletal muscle cell permeability to glucose, 
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thereby increasing muscle glucose uptake (Ivy and Kuo, 1998). However, the co-
ingestion of carbohydrate and protein post exercise appears to be unable to increase 
muscle glycogen synthesis to a greater extent than carbohydrate alone, when sufficient 
carbohydrate is provided (Tarnopolsky et al. 1997; van Hall et al. 2000a; Jentjens et 
al. 2001). 
During exercise a net loss of body protein is observed due to an increase in whole-body 
protein breakdown and a decrease in whole-body protein synthesis (Rennie et al. 1981). 
However, during recovery from exercise an anabolic response is elicited due to an 
increase in whole-body protein synthesis (Rennie et al. 1981). Essential amino acids 
appear to be the primary stimulators of muscle protein synthesis (Rasmussen et al. 
2000; Svanberg et al. 1996), rather than non-essential amino acids (Smith et al. 1998), 
with insulin playing a less significant role in muscle protein synthesis than previously 
thought (Gautsch et al. 1998; Long et al. 2000). Therefore, the ingestion of essential 
amino acids with carbohydrate postexercise may prove the optimal combination to 
promote skeletal muscle anabolism post exercise. 
The provision of the non-essential amino acid glutamine, which is considered 
'conditionally essential' (Lacy and WiImore, 1990), has been shown to stimulate 
glycogen synthesis both in skeletal muscle myotubes (Low et al. 1996) and in rat liver 
cells (Lavoinne et al. 1987; Mouterde et al. 1992). The mechanism has been attributed 
to the activation of glycogen synthase via cell swelling induced by increased uptake of 
this amino acid (Baquet et al. 1990; Low et al. 1996). An increase in the plasma 
concentration of glutamine, either through oral provision or intravenous administration, 
will lead to an increase in intramuscular glutamine concentration (Vamier et al. 1995) 
due to the rapid uptake of glutamine into skeletal muscle via System Nm (Ahmed et al. 
1993). Indeed, it has been demonstrated that the intravenous infusion of glutamine after 
exhaustive exercise promoted a greater degree of muscle glycogen resynthesis than the 
infusion of an isoenergetic and isonitrogenous mixture of alanine and glycine (Vamier 
et al. 1995). In addition, the oral provision of glutamine after exhaustive exercise is 
able to increase muscle glycogen resynthesis, however a combination of glutamine and 
glucose-polymer was unable to increase muscle glycogen resynthesis to a greater extent 
than glucose-polymer alone (Bowtell et al. 1999). Van Hall et al. (2000b) recently 
confirmed this rmding and demonstrated that the co-ingestion of glucose-polymer and 
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glutamine after exhaustive exercise does not further increase the activation of glycogen 
synthase, and thus 'the rate of muscle glycogen resynthesis, compared to glucose-
polymer alone. 
However, the ingestion of glutamine and glucose-polymer after exhaustive exercise 
appears to promote whole-body carbohydrate storage to a greater extent than glucose-
polymer alone. The most likely site of increased carbohydrate storage being the liver 
(Bowtell et al. 1999). This response has been attributed to an increase in flux through 
the hexosamine pathway, due to an increase in the intracellular concentration of both 
glucose and glutamine, resulting in the formation of glucosamine (Crook et a1. 1995). 
Glucosamine induces insulin resistance by causing an impairment of GLUT-4 
translocation from an insulin-sensitive intracellular pool to the sarcolemmal membrane 
(Baron et al. 1995), in addition to decreasing the insulin sensitivity of glycogen 
synthase (Crook et al. 1995). Therefore, glucose uptake into skeletal muscle is 
reduced, reducing skeletal muscle glycogen synthesis through a lesser activation of 
glycogen synthase and reduced availability of glucose to fonn glycogen. However, the 
uptake of glucose in the liver is via GLUT -2, so hepatic glucose uptake is not impaired. 
It was hypothesised that the supplementation of both glucose-polymer and glutamine 
'post exercise, would promote hepatic glycogen resynthesis, but that muscle glycogen 
resynthesis would not be different compared to the supplementation of glucose-polymer 
alone. However, the addition of glutamine may promote increased skeletal muscle and 
whole body anabolism during recovery from exercise. 
Fatigue during prolonged rurming is not associated with a decline in blood glucose 
concentration (Tsintzas et al. 1995; Williams et al. 1990). However, fatigue during 
prolonged cycling appears to be associated to a decline in blood glucose concentration 
(Coyle et al. 1983; Derman et al. 1996), possibly linked to the increased glucose 
uptake by skeletal muscle observed during cycling (Richter et al. 1988; Richter, 1996). 
Therefore, if liver glycogen content can be increased to a greater extent during recovery 
from exercise after the consumption of glucose-polymer and glutamine, blood glucose 
concentration may be better maintained in a subsequent bout of exercise, which could 
conceivably delay the onset offatigue. 
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The aims of this study were to investigate the effect of oral glutamine and glucose-
polymer supplementation compared to alanine and glycine plus glucose-polymer 
supplementation during recovery from exhaustive exercise and to determine the effect 
upon endurance capacity in a subsequent bout of exercise. 
4.2 METHODS 
Subjects. Seven well-trained, healthy male subjects participated in this study. Their 
mean (± SEM) age, height, body mass and V02max were 24.0 ± 1.6 y, 180.4 ± 1.8 cm, 
78.7 ± 1.6 kg and 4.83 ± O.13l.min·\ (61.5 ± 2.0 m1.kg·\.min·\ respectively. 
Preliminary tests. Subjects reported to the laboratory approximately I week before the 
experiment and undertook two preliminary tests in order to determine: (i) the oxygen 
cost of submaximal cycling, and (ii) maximal oxygen uptake c\r02max). The protocols 
of these tests have been described elsewhere (see Chapter 3). Subjects were fully 
familiarised with the experimental procedures to be used during the experimental trials. 
Protocol of the study. Subjects were instructed to consume their habitual diet and 
refrain from exercise or strenuous physical activity for 48 h prior to each experiment. 
On arrival at the laboratory on the morning of the experiment, the overnight fasted 
subject rested in a supine position and a cannula was inserted into an antecubital vein 
and a resting blood sample was obtained. The experimental procedure utilised in this 
study was a standard 'recovery protocol' similar to a protocol adopted previously in the 
literature (Fallowfield and Williams, 1997), consisting of two bouts of exercise 
separated by a 4 h passive recovery period. 
Subjects performed a bout of glycogen depleting exercise (EX!), as described 
previously (Chapter 3). EXI was immediately followed by a 4 h passive recovery 
period, during which they consumed one of the assigned solutions. They then 
immediately cycled to exhaustion at -70% V02rnax (EX2) (Fig. 4.1) during which 
subjects were offered no fluid. 
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The two bouts of exercise (EXI and EX2) were separated by a 4 h controlled recovery 
during which the subjects remained within the laboratory and their activity levels were 
minimal. After completion of EX I subjects were rested for -10 min before their post 
exercise nude bodyweight was measured. Any excess sweat on the subject's skin was 
towelled off prior to their weight being recorded. 
Subjects undertook four trials during which they received one of three different drinks 
during the 4 h recovery period. On two occasions subjects consumed 31.25 ml'kg-l 
body wt of an artificially sweetened placebo (CONI) and (CON2) (SmithKIine 
Beecharn Consumer Healthcare, Gloucestershire, UK), during the experimental trials 
subjects consumed either 1.7 g glucose·kg body wt- l (6.4 % w:v glucose-polymer) and 
0.3 g·kg body wt- l L-glutamine (Sigma-Aldrich Chemicals, Dorset, UK) (GP + GLN) 
(Smithkline Beecham Consumer Healthcare, Gloucestershire, UK), or 1.7 g glucose-kg 
body wt-I (6.4 % w:v glucose-polymer) and an isoenergetic and isonitrogenous mixture 
ofL-alanine (0.1829 g'kg body wt-I ) and L-glycine (0.1543 g'kg body wt-I ) (GP + ALA 
& GL Y) (Sigma-Aldrich Chemicals, Dorset, UK). 
Subjects received 780 mI of solution in the fITst drink with the remaining solution being 
divided into 5 equal aliquots. In the glucose-polymer conditions (GP + ALA & GL Y 
and GP + GLN), the frrst drink was fonnulated to supply 50 g of carbohydrate. 
Subjects consumed the first of the six drinks after 30 min of recovery, after the fITst 
expired air collection, and then every 30 min thereafter. The last drink was 
administered at the 3 h point during recovery (1 h before exercise) to minimise the 
possibility of gastro-intestinal stress in the forthcoming exercise bout. Urine voided 
during the recovery period was collected and a cumulative volume recorded. 
Prior to EX2, after voiding the bladder of urine, subject's post-recovery nude body 
weight was recorded in order to calculate rehydration status. Subjects then completed a 
5 minute warm up at 60% Y02max, prior to commencing EX2. During EX2, subjects 
were instructed to cycle to volitional exhaustion at a workrate equivalent to -70% 
Y02max, in order to determine their endurance capacity in terms of cycle time to 
exhaustion. Subjects were given no indication of the time completed during EX2. In 
order to ensure the reproducibility of cycle time to exhaustion, the point of exhaustion 
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was defmed as the inability to maintain the required power output, despite strong verbal 
encouragement. Subjects indicated when they could only continue for one more minute, 
at which point the fmal expired air collection and blood sample was taken. 
Expired air collections were taken prior to the commencement of EX I, then at 30 min, 
60 min and 80 min during EXl. During recovery, collections were taken at 30 min 
intervals, with a collection being taken every 10 min and at exhaustion during EX2 (Fig. 
4.1). Venous blood samples were taken prior to EXI and after 30 miD, 60 min and at 
cessation ofEXl. During recovery, samples were taken at 60, 75, 90,105,120,180 and 
240 min, with a subsequent sample being taken at exhaustion during EX2 (Fig. 4.1). 
Dry bulb temperatures within the laboratory during the main experimental trial were 
19.9 ± 0.3 QC, 20.5 ± 0.4 QC, 20.7 ± 0.5 °c and 20.0 ± 0.2 °c for CONI, CON2, GP + 
GLN and GP + ALA & GL Y conditions respectively. Relative humidity within the 
laboratory during the main experimental trial was 52.7 ± 1.9 %, 49.6 ± 4.0 %, 49.6 ± 2.2 
% and 49.9 ± 2.3 % for CONI, CON2, GP + GLN and GP + ALA & GL Y conditions 
respectively. No statistical difference was observed in the relative humidity 
measurements between trials. 
Analysis. Expired air samples were collected and analysed as previously described 
(Chapter 3). Venous blood samples were analysed for blood lactate and plasma glucose 
concentration, plasma ammonia, NEF A and amino acid concentration, serum insulin 
concentration, and haemoglobin concentration and haematocrit values (Chapter 3). 
Percentage changes in plasma volume were calculated as previously described (see 
Chapter 3). 
Pre-exercise energy intake. The energy intake of the subject's habitual diet during the 
48 h prior to the main trial are presented in Table 4.1. No differences were observed 
between conditions in the pre-exercise diet. 
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Table 4.1 Energy content and percentage of the primary dietary nutrients of the pre-
exercise diet for all conditions (mean ± SEM). Data presented is mean of 2 
days diet 
CONI CON2 GP+ALA&GLY GP+GLN 
Energy (MJ/day) 12.9±0.6 13.6 ± 0.9 13.2 ± 0.7 13.1±0.9 
Carbohydrate (%) 57.8 ±3.O 59.7 ±2.5 58.5 ± 3.9 59.0 ± 3.1 
Fat (%) 28.9 ±3.2 26.6 ± 3.7 28.5 ±4.2 27.1 ± 3.4 
Protein (%) 13.7 ± 1.3 13.6 ±0.9 13.1 ± 1.1 13.9 ± 1.5 
4.3 REPRODUCIBILITY OF PROTOCOL 
The reproducibility of endurance capacity has previously been reported to be poor, with 
cycle time to exhaustion varying by as much as 26.6 % over five trials (Jeukendrup et 
al. 1996). During this study, subjects undertook four main experimental trials that were 
separated by at least ten days. 
In order to assess the reproducibility of the protocol and the physiological 
measurements, subjects undertook two placebo trials. This also allowed the efficacy 
and sensitivity of using cycle time to exhaustion as tool for measuring any improvement 
in endurance capacity to be assessed. The first trial that subjects completed was always 
a placebo trial, and the order in which subjects completed the remaining three 
conditions (CON, GP + GLN, GP + ALA & GL Y) was allocated by systematic rotation 
using a double-blind design. 
In summary, the control trials not only provided a benchmark with which to compare 
the experimental trials, but also acted as a means of assessing the reproducibility of the 
protocol. It would have been desirable to include more than two trials to gain a better 
assessment of reproducibility. However, it was felt that the demands of completing 
more than four trials in total would have been too great and may have reduced subject 
compliance. 
Subjects were asked to cycle to volitional exhaustion, with the cessation of exercise 
determined .by the sllbject. However, if the subject failed to maintain the required 
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power output despite strong verbal encouragement on more than five occasions, then the 
test was terminated. 
Statistical analysis. The data were analysed by two-way analysis of variance (ANOVA) 
for repeated measures (time X condition). Cycle time to exhaustion data were analysed 
by one-way ANOV A. When the ANOVA resulted in a significant Fratio, Fisher's post 
hoc test was used to locate differences between means. Statistical significance was 
accepted at the 5% level (P <0.05). Results are presented as means ± SEM. 
A "Limits of Agreement" analysis was used to assess the reproducibility of cycle time 
to exhaustion, illustrated using a Bland and Altman plot (Bland and Altman, 1986; see 
Fig 4.2) 
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4.4 RESULTS 
Cardiorespiratory data. Pulmonary oxygen uptake CV02), expired minute ventilation 
(data not shown) and %V02max were all increased during exercise (P < 0.05), however 
there were no differences between conditions (Table 4.2). Power output was not 
different between conditions in either EXl (CONI: 238 ± 4; CON2: 239 ± 5; GP + 
ALA & GLY: 236 ± 4; GP + GLN: 234 ± 2, watts) or EX2 (CONI: 236 ± 4; CON2: 
228 ± 7; GP + ALA & GL Y: 220 ± 10; GP + GLN: 227 ± 11, watts). 
Heart rate increased during both bouts of exercise (Table 4.2). The average heart rate 
during EXl was 147 ± 3 b.min·1, 152 ± 4 b.min-I, 147 ± 3 b.min-1 and 149 ± 3 b.min-1 in 
the CONI, CON2, GP + ALA & GL Y and GP + GLN conditions respectively, however 
there were no differences between conditions. The average heart rate during exercise 
EX2 was 169 ± 2 b.min-I, 167 ± 1 b.min-I, 154 ± 1 b.min-1 and 161 ± 1 b.min-1 in the 
CONI, CON2, GP + ALA & GL Y and GP + GLN conditions respectively. Heart rate 
was significantly higher (P < 0.05) in the control conditions compared to the glucose-
polymer conditions during EX2. 
Endurance capacity. Cycle time to exhaustion tended to be longer during the glucose-
polymer conditions relative to the control conditions (CONI: 37.3 ± 2.0; CON2: 33.8 ± 
1.8; GP + ALA & GL Y: 40.6 ± 5.8; GP + GLN: 41.8 ± 6.2, min), but the differences 
did not attain statistical significance. The percentage difference in cycle time to 
exhaustion between conditions is presented in Table 4.3. 
No difference was observed between the two placebo conditions both in terms of 
physiological responses throughout the experimental period and endurance capacity 
(CONI: 37.3 ± 2.0; CON2: 33.8 ± 1.8 min). In addition, based on individual times, a 
-21% variation (range: 2.3% - 72.1%) was observed between the two conditions in 
cycle time to exhaustion. 
In the present study, the reproducibility of endurance capacity, in terms of the calculated 
95% limits of agreement are 3.5 ± 17.0 min (Fig 4.2). Therefore, a given subject's 
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endurance capacity in a second cycle to exhaustion should lie between -13.5 to + 20.5 
min of their first cycle to exhaustion. It is evident in Fig 4.2 that the data is skewed by 
two subjects (signified by triangular data points). Considering the small number of 
subjects in the present study, the effect of individual data has a greater bearing on the 
group data. If the same calculations are applied to 5 subjects (signified by square data 
points), the calculated 95% limits of agreement, expressed with bias become -1.3 ± 5.4 
min, equating to a second cycle to exhaustion of between - 6.7 to + 4.1 min relative to 
the first cycle to exhaustion (see later in chapter for full discussion). 
Plasma glucose and blood lactate concentration. Plasma glucose concentration was not 
different between conditions in EXI (Fig. 4.3). During recovery, the plasma glucose 
concentration increased (P < 0.05) in both conditions where glucose-polymer was 
ingested (GP + ALA & GL Y and GP + GLN), whilst the concentration in the control 
trials remained at a value similar to that at the end of EXI. Plasma glucose 
concentration increased more rapidly in the GP + GLN condition and was higher (P < 
0.05) than the GP + ALA & GL Y condition at 60 and 75 min of recovery. Plasma 
glucose concentration in the GP + GLN condition tended to be elevated above the GP + 
ALA & GL Y condition for the first three hours of the recovery period. The peak in 
plasma glucose concentration was observed at 60 min of recovery in both glucose-
polymer conditions, 30 min after the ingestion of the flfst drink. The area under the 
plasma glucose curve (AUC) during the recovery period had a tendency to be greater in 
the GP + GLN condition during the second hour of the recovery period (CONI: 5.2 ± 
0.2; CON2: 5.2 ± 0.2; GP + ALA & GL Y: 6.3 ± 0.6; GP + GLN: 7.0 ± 0.4, all mmol.h· 
I). Plasma glucose concentration was significantly higher (P < 0.05) in the GP + GLN 
condition than the control conditions until 180 min of recovery. In the GP + ALA & 
GL Y condition, the concentration was significantly higher (P < 0.05) than the control 
conditions at 60, 75 and 90 min of recovery. At the end of the recovery period, plasma 
glucose concentration was not different between conditions. During EX2, plasma 
glucose concentration increased from the value at the end of the recovery period in the 
GP + GLN condition, but decreased in all other conditions (CONI: -3.8 ± 9.7; CON2: -
5.7 ± 5.4; GP + ALA & GL Y: -8.8 ± 7.8; GP + GLN: +12.3 ± 12.4, all %). The 
percentage change in the GP + GLN condition was significantly different (P < 0.05) to 
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the GP + ALA & GL Y condition. However, no difference between conditions was 
observed in plasma glucose concentration at exhaustion. 
Blood lactate concentration increased (P < 0.05) to a similar extent during EXI and 
EX2 in all conditions (Fig 4.4). During recovery, the area under the blood lactate 
concentration curve (AVC) was higher (P < 0.01) in the GP + GLN condition compared 
to all other conditions. In addition, the AVC during recovery in the GP + ALA & GL Y 
condition was higher (P < 0.05) compared to the control conditions (AVC: CONI: 4.9 ± 
0.5; CON2: 5.6 ± 0.7; GP + ALA & GLY: 6.6 ± 0.8; GP + GLN: 8.0 ± 0.7, mmoI.r1·4 
h). 
Carbohydrate and/at oxidation rates. During recovery, the respiratory exchange ratio 
was higher (P < 0.05) in the glucose-polymer conditions compared to the control 
condition (Table 4.3), however no differences were observed between conditions in 
either bout of exercise, although an increase was observed relative to baseline in all 
conditions (P < 0.05). The rate of carbohydrate oxidation and fat oxidation increased 
during exercise (P < 0.05). During EX2, total fat oxidation had a tendency to be lower 
in the glucose-polymer conditions compared to control conditions (CONI: 26.0 ± 3.4; 
CON2: 22.3 ± 2.3; GP + ALA & GLY: 21.5 ± 3.0; GP + GLN: 21.8 ± 4.4, g), and total 
carbohydrate oxidation had a tendency to be higher (CONI: 90.5 ± 9.4; CON2: 83.2 ± 
9.7; GP + ALA & GLY: 102.8 ± 16.2; GP + GLN: 111.3 ± 15.4, g) in the glucose-
polymer conditions compared to the control conditions. 
Carbohydrate and fat oxidation rates were not different between conditions during EXI. 
Throughout the recovery period, although no statistically significant differences were 
noted between conditions, fat oxidation was higher during the control conditions 
(CONI: 0.084 ± 0.004; CON2: 0.085 ± 0.005; GP + ALA & GL Y: 0.056 ± 0.009; GP + 
GLN: 0.047 ± 0.008 g.min·1) and carbohydrate oxidation was lower (CONI: 0.129 ± 
0.012; CON2: 0.140 ± 0.014; GP + ALA & GLY: 0.201 ± 0.019; GP + GLN: 0.218 ± 
0.022 g.min·1) compared to the glucose-polymer conditions. 
During EX2, carbohydrate oxidation rate was greater (P < 0.05) in the GP + GLN 
condition after 10 min of exercise compared to the control conditions (CONI: 2.31 ± 
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0.14; CON2: 2.31 ± 0.16; GP + ALA & GLY: 2.63 ± 0.15; GP + GLN: 3.02 ± 0.21 
g.min· I ), an observation not evident in the GP + ALA & GL Y condition. At exhaustion, 
the carbohydrate oxidation rates were similar between conditions. Fat oxidation rates 
were greater (P < 0.05) at 10 and 20 min and at exhaustion during EX2 in the control 
conditions compared to the glucose-polymer conditions. 
Total grams of carbohydrate oxidised during the recovery period and EX2 was 
significantly greater (P < 0.05) in the GP + GLN condition compared to the control 
conditions (CONI: 125 ± 9; CON2: 123 ± 13; GP + ALA & GLY: 153 ± 25; GP + 
GLN: 165 ± 25 g), an observation not apparent in the GP + ALA & GL Y condition. 
Serum insulin and plasma NEFA concentration. Serum insulin concentration was not 
different between conditions during EXl (Fig. 4.5). During recovery, serum insulin 
concentration increased in both glucose-polymer conditions and reached a peak 
concentration after 60 min of recovery (30 min after ingestion of the first drink). Serum 
insulin concentration remained elevated in the glucose-polymer conditions compared to 
the control conditions until ISO min of recovery (P < 0.01). There was a tendency for 
the serum insulin concentration to be higher in the GP + GLN condition (57.5 ± 6.1 
IlIU.ml·l) compared to the GP + ALA & GL Y condition (50.2 ± 7.4 IlIU.ml·l) in the 
first hour after ingestion of the drink, however this difference was not statistically 
significant. Serum insulin concentration in the control conditions remained at a level 
similar to basal throughout recovery. During EX2, serum insulin concentration 
decreased in all conditions, with no difference observed between conditions. 
Plasma NEF A concentration was not different between conditions during EXl (Fig. 
4.6). During recovery, plasma NEF A concentration increased in the control conditions 
and was higher compared to the glucose-polymer conditions (P < 0.05). Plasma NEFA 
concentration decreased in the glucose-polymer conditions, but not to a value 
significantly lower than basal. There was a tendency for the plasma NEF A 
concentration to be lower in the GP + GLN condition compared to the GP + ALA & 
GL Y condition during the recovery period. During EX2, plasma NEF A concentration 
increased in all conditions with a greater increase (P < 0.05) in the glucose-polymer 
conditions (CONI: +167 ± 2S; CON2: +147 ± 14; GP + ALA & GLY: +S52 ± 154; GP 
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+ GLN: 828 ± 283, all %). There was no difference in the plasma NEFA concentration 
between conditions during EX2. 
Plasma ammonia and amino acid concentration. Plasma ammonia concentration 
increased relative to basal value (P < 0.05) to a similar extent during EXl in all 
conditions (CONI: +647 ± 85; CON2: +658 ± 89; GP + ALA & GL Y: +619 ± 85; GP + 
GLN: 619 ± 83, all %), reaching a peak concentration at the 60 min time point in all 
conditions (Fig. 4.7). No difference was observed between conditions during EXl. 
During recovery, there was a tendency for plasma ammonia concentration to be elevated 
above basal levels in all conditions, with no differences observed between conditions. 
During EX2, the increase in plasma ammonia concentration was greater in the control 
conditions (CONI: +709 ± 227; CON2: +755 ± 208; GP + ALA & GLY: +353 ± 112; 
GP + GLN: 336 ± 71, all %), however no difference was observed between conditions. 
During the recovery period, after glucose-polymer and glutamine ingestion, plasma 
glutamine concentration was significantly greater (P < 0.05) than the other three 
conditions for the fITst 90 min of recovery, and remained elevated above the control 
conditions until 180 min of recovery (Fig. 4.8). During the recovery period, after 
glucose-polymer and alanine and glycine ingestion, plasma alanine and glycine 
concentrations were significantly elevated (P <0.01) compared to the other three 
conditions (Table 4.5). In addition, plasma serine concentration was significantly 
elevated (P <0.01) during the recovery period after glucose-polymer and alanine and 
glycine ingestion (Table 4.5). 
Total plasma BCAA concentration decreased by 8 % during EXl in all conditions, 
parallel to the -6-fold increase in plasma ammonia concentration (Table 4.5). After 
consumption of the drink, plasma BCAA concentration was lower in the glucose-
polymer conditions relative to the control conditions during the recovery period (4-h 
time point: CONI: 385.3 ± 19.0: CON2: 383.7 ± 30.6; GP + ALA & GLY: 198.6 ± 
14.2; GP + GLN: 172.7 ± 18.0 J!M, P < 0.05), with a tendency for the plasma BCAA 
concentration to be lower in the GP & GLN condition compared to the GP + ALA & 
GL Y condition (P = 0.08). At exhaustion, plasma BCAA concentration decreased in 
the control conditions relative to the concentration at the end of the recovery period 
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compared to the two glucose-polymer conditions (CONI: -6.3 ± 7.8; CON2: -8.0 ± 2.0; 
GP + ALA & GLY: +31.8 ± 8.7; GP+ GLN: +67.1 ±21.4, all %; P< 0.001). 
There was a tendency for both plasma phenylalanine (area under the curve (AUC): 
CONI: 64.7 ± 3.4: CON2: 65.5 ± 3.1; GP + ALA & GLY: 59.6 ± 6.8; GP + GLN: 47.5 
± 3.8, all mM.h·l ) and tyrosine (AVC: CONI: 70.3 ± 4.1: CON2: 72.2 ± 2.8; GP + ALA 
& GLY: 64.1 ± 6.8; GP + GLN: 58.0 ± 6.8, all mM.h· l ) concentration to be lower 
during the recovery period in the GP & GLN condition compared to the other three 
conditions. Indeed, the sum of plasma phenylalanine and tyrosine concentrations (Fig. 
4.9) was significantly lower in the GP + GLN condition from 90 min recovery until 
exhaustion (compared to CONI), from 60 min recovery until exhaustion (CON2) and at 
60, 90 and 180 min of recovery in the GP + ALA & GL Y condition (all P < 0.05). 
However, the sum of plasma phenylalanine and tyrosine concentrations was 
significantly lower (P < 0.05) in the GP + ALA & GL Y condition than the control 
conditions at 240 min of recovery and at exhaustion only. 
The sum of the essential amino acids (His, Iso, Leu, Lys, Met, Phe, Thr, Try & Val) was 
significantly lower (P < 0.05) during the recovery period in the GP + GLN condition 
compared to the other three conditions (Fig. 4.10). The sum of the non-essential amino 
acids (Ala, Arg, Asp, Asn, Glu, GIn, Gly, Ser & Tyr), sum of the non-metabolisable 
amino acids (Thr, Met, Phe, Lys, Gly & Tyr) and the sum of all amino acids were 
significantly higher (P < 0.01) during the recovery period in the GP + ALA & GL Y 
condition compared to the other three conditions. 
From 75 min of recovery, the free tryptophan:BCAA ratio was significantly higher in 
the GP + GLN condition (P < 0.05) compared to the other three conditions (Table 4.5). 
At exhaustion, the free tryptophan:BCAA ratio was significantly higher (P < 0.005) 
compared to the other three conditions in the GP + GLN condition (CONI: 0.13 ± 0.02: 
CON2: 0.12 ± 0.01; GP + ALA & GLY: 0.09 ± 0.01; GP +GLN: 0.17 ± 0.01) 
Rehydration, urine output data and plasma volume. The extent of rehydration during 
the recovery period was not different between conditions (CONI: 105.4 ± 7.6; CON2: -
94.6 ± 12.3; GP + ALA & GLY: 99.7 ± 7.9; GP + GLN: 104.2 ± 7.3, all %; see Chapter 
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3 for calculation). Total urine output during the recovery period was not different 
between conditions (CONI: 2274 ± 262; CON2: 2170 ± 191; GP + ALA & GLY: 1997 
± 209; GP + GLN: 2225 ± 246, ail ml). Plasma volume changes were not different 
between conditions during EXl. During recovery there was a tendency for plasma 
volume to be greater in the glucose-polymer conditions. No difference was observed in 
plasma volume at exhaustion between conditions (data not shown). 
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Table 4.2 Oxygen uptake (V02), %V02max, heart rate (HR), respiratory 
exchange ratio (RER), carbohydrate oxidation rate (CHO Ox) and fat oxidation 
rate (Fat Ox) at rest and during first bout of exercise period in the control, GP + 
ALA & GL Y and GP + GLN conditions. 
EXI 
Condition Basal 30min 60min 85min 
Vo,(l.min') CONI 0.22 ±0.03 3.39 ± 0.10' 323 ±O.14' 3.3S±0.IS' 
CON2 0.23 ±0.02 3.30 ± O.OS' 3.19±O.10' 3.24±0.14' 
GP+ALA &GLY 0.22 ±o.ol 3.27± 0.14' 3.1HO.17' 3.18±0.IS' 
GP+GLN 0.21 ±o.ol 3.2H 0.12' 3.08±0.ll' 3.IS ± 0.13' 
O/OV021111X CONI 4.6±0.6 70.1 ±0.9' 66.8± I.S' 69.2± 1.6' 
CON2 4.7±0.S 6S.4 ± 1.1' 66.0± I.S' 66.9 ± 1.6' 
GP+ALA&GLY 4.7 ±0.3 67.6 ±2.5' 6S.2± 2.9' 6S.S ± 3.4' 
GP+GLN 4.4±0.2 67.H 1.6' 63.S ± 12' 6S.7± 1.6' 
HR (b.min-') CONI 138±S IS6 ± S' IS6±6' 
CON2 144±7 160 H' 160 ± S' 
GP+ALA&GLY 141±S ISH 6' 158 ±6f 
GP+GLN 142±S IS4± ,. IS7± 7' 
RER CONI 0.S7±0.03 0.92± 0.01' 0.90 ±O.OI' 0.91 ±O.OI· 
CON2 0.92 ± 0.02 0.92 ±o.ol 0.90 ± 0.01 0.91 ±o.ol 
GP+ALA&GLY 0.S6 ± 0.02 0.92 ± 0.01' O.SS ± 0.01 0.S9 ± 0.01 
GP+GLN 0.91 ±0.02 0.92±0.01 0.S9 ± 0.01 0.S9 ±0.01 
CHO Ox (g.min-') CONI 0.16 ± 0.04 2.91 ±0.09' 2.SH 0.16' 2.79 ±0.27' 
CON2 0.20 ±0.03 2.91 ± O.IS' 2.S4± 0.13' 2.66 ±021' 
GP+ALA&GLY O.l4± 0.02 2.84±0.27' 22H021' 2.44 ±0.26' 
GP+GLN O.l7± 0.02 2.S0±0.IS' 2.31 ± 0.16' 2.40 ±O.17' 
Fat Ox (g·min-I ) CONI O.OS ±0.01 0.49 ± 0.02' O.S7± O.OS' 0.S2 ±O.OS' 
CON2 O.OH 0.01 0.4S±0.OS' O.SS ±O.OS' 0.52 ±O.OS' 
GP+ALA&GLY 0.0S±0.01 0.46 ±0.06' 0.66 ±0.04' 0.S8±0.04' 
GP + GLN 0.03 ±0.01 OA7±O.04* 0.S9 ± 0.02' 0.60 ±O.OS' 
Values are means ± SEM for 7 subjects . • p < O.OS vs. basal value, # P < 0.05 vs. 30 min (EXl). N.B. Heart rate was not 
measured at rest 
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Table 4.2 (cont'd) Oxygen uptake (V02), %V02max. heart rate (HR), respiratory exchange ratio (RER), carbohydrate oxidation rate 
(CHO Ox) and fat oxidation rate (Fat Ox) during the recovery period in the control, GP + ALA & GL Y and GP + GLN conditions. 
RECOVERY 
Condition 30min 60min 90min 120 min 150 min 180 min 210 min 240 min 
VO, (I.min·') CONI 0.30 ± 0.03 0.29 ± 0.02 0.28±0.03 0.26 ±0.02 0.29 ± 0.03 0.26 ± 0.03 0.26 ± 0.02 0.2S±0.03 
CON2 0.27±0.02 0.30 ± 0.03 0.29 ± 0.03 0.30 ±0.04 0.28±0.03 0.29 ± 0.03 0.28 ± 0.03 0.27 ±0.03 
GP+ALA&GLY 0.28 ± 0.02 0.29 ± 0.02 0.29 ± 0.02 0.2S±0.04 0.29 ±0.03 0.27±0.02 0.28 ± 0.01 0.27±0.02 
GP+GLN 0.24±0.02 0.31 ± 0.03 0.28 ± 0.02 0.27±0.03 0.29 ±0.03 0.27±0.03 0.28±0.03 0.26±0.03 
%Y011IIIIl( CONI 6.1 ± 0.6 6.0±0.4 5.8 ±O.S 5.4 ±0.4 5.9 ± 0.6 S.S±0.5 S.4±0.4 5.2 ± 0.6 
CON2 5.6 ± 0.5 6.2±0.6 6.0 ±0.7 6.2 ±0.8 S.9±0.6 5.9 ± 0.6 S.8±0.6 S.S±0.6 
GP+ALA&GLY 5.8 ± 0.4 6.1±0.S 6.1±0.4 5.1 ± 0.8 6.2±0.S S.S±0.4 S.7±0.3 S.S±0.4 
GP+GLN S.O±O.4 6.4±0.S 5.8 ±O.S 5.6 ± 0.5 6.0 ± 0.6 55 ± 0.5 S.7±O.S 5.3 ± 0.5 
HR (b.min·') CONI 
CON2 
GP+ALA&GLY 
GP+GLN 
RER CONI 0.80±0.03 0.87±0.02 0.81 ± 0.02 0.82± 0.01 0.84±0.01 0.84±0.01 0.8S±0.02 0.79±0.03 
CON2 0.79 ±0.02· 0.87±0.02 0.84± 0.01' 0.82± 0.01' 0.83 ± 0.02' 0.87±0.01 0.8S± 0.02' 0.82±0.0I' 
GP+ALA&GLY 0.79 ±0.03' 0.8HO.02 0.91 ± 0.02"" 0.89 ± 0.02" 0.90±0.01" 0.92± 0.01" 0.92± 0.01'" 0.90±0.Q1"· 
GP+GLN 0.79±0.0I' 0.87±0.02 0.92 ± 0.02" 0.93±0.02" 0.93 ±0.01" 0.94±0.02" 0.9HO.02" 0.92±0.04" 
CHO Ox (g·min') CONI O.l2±0.04 0.19 ±0.03 0.09± 0.03 O.l2±0.02 0.1S±0.03 O.l4± 0.01 O.lHO.02 0.08 ±0.03 
CON2 0.08±0.02 0.19 ±0.02 O.l5± 0.02 O.l2± 0.01 0.12± 0.02 0.19 ± 0.03 O.lS±0.02 O.l2±0.02 
GP+ALA &GLY 0.09 ±0.04 O.lS±0.03 0.24± 0.03 0.19± 0.04 0.23±0.02 0.23±0.02 0.2S±0.03 0.22±0.02 
GP + GLN 0,08±0.01 0.20 ± 0.03 0.23±0.03 0.2H 0.03 0,26 ±0.03 0,26 ± 0.03 0,26 ±0,02 0,21±0.02 
Fat Ox (g.mioo1 ) CONI 0.10 ± 0.02 0.07± 0.01 0.1O±0.02 0.08± 0.01 0.08±0.01 0.08± 0.01 0.07± 0.01 0,09±0.02 
CON2 0.10 ± 0,02 0.07± 0.01 0.08±0.01 0.10 ± 0,02 0,09 ±0.02 0,06 ± 0,01 0.08± 0.02 0.08±0,02 
GP+ALA&GLY 0.10 ± 0.02 0.08± 0.01 0.0S±0.01 0.04±0.01 0.0S±0.01 O.OHO.OI 0.04±0.01 O.OH 0.01 
GP + GLN 0.09 ± 0,01 0.07±0.01 O.OHO.OI O,OHO.OI O.OH 0.01 0.03±0.01 0.03±0.01 0.OHO.02 
Values are means ± SEM for 7 subjects. *different to basal value (P < 0.05); -different to CONI (P < 0.05); bdifferent to CON2 (P < 0.05). N.B. Heart rate was not measured at rest. 
Table 4,2 (cont'd) Oxygen uptake (\T02), %V02max, heart rate (HR), respiratory 
exchange ratio (RER), carbohydrate oxidation rate (CHO Ox) and fat oxidation 
rate (Fat Ox) during the second bout of exercise in the contro~ GP + ALA & 
GL Y and GP + GLN conditions. 
EX2 
Condition lOmin 20min Exh 
Vo, (I.min·') CONI 3.S4±O.l7' 3.60 ±0.08' 3.31± 0.09' 
CON2 3.47±0.17' 3.20 ±0.04' 3.14±0.19' 
GP+ALA &GLY 3.11 ±O.l4' 3.16 ± 0.20' 2.98 ± 0.23' 
GP+GLN 3.19±0.II' 3.19±O.l9' 2.99± 0.18' 
%V011lllll< CONI 71.9±0.I' 69.7±2.S' 66.5± 1.4' 
CON2 68.2± I.S' 66.3± 1.6' 64.8± 2.6' 
GP+ALA &GLY 64.4 ±2.3' 65.3 ± 3.6· 61.4 ± 3.8' 
GP+GLN 66.0 ± 1.1' 66.3± 1.6' 61.7±2.6' 
HR (b. min") CONI 165±S 170±S 172±S 
CON2 165±S 169±4 169±S 
GP+ALA &GLY IS3±S" ISS±6" 154 ± 7B.b 
GP+GLN IS9 ± S .. 163±6'-' 162±7'" 
RER CONI 0.87± 0.01 0.88 ± 0.01 0.87± 0.02 
CON2 0.88± 0.01 0.87±0.02 0.88 ± 0.02 
GP+ALA &GLY 0.91 ±O.oJ' 0.91±0.0I' 0.88±0.02 
GP+GLN 0.94±0.01'-' 0.92 ± 0.01 0.89± 0.01 
CHO Ox (g.min·') CONI 2.31 ± 0.14' 2.S4±O.l4' 2.39 ±0.38' 
CON2 2.31 ±0.16' 2.09 ±0.23' 2.37±0.48' 
GP+ALA&GLY 2.63± O.IS' 2.66 ± 0.26' 2.20±0.4I' 
GP+GLN 3.02 ±0.2I' 2.74± 0.27' 2.22±0.3I' 
Fat Ox (g.rnin· l ) CONI 0.78±0.06' 0.75±0.03' 0.75±O.lO' 
CON2 0.69 ± 0.06' 0.74± 0.08' 0.67±0.09' 
GP+ALA &GLY 0.47 ± 0.02",a,b 0.48 ± 0.02",o,b 0.58 ± O.OS· ... b 
GP+GLN 0.35 ± O.O,'.II.b 0.47± O.07'A' 0.58 ± 0.0'· ... ." 
Values are means ± SEM for 7 subjects. ·different to basal value (P < 0.05); 'different 
to CONI (P < 0.05); bdifferent to CON2 (P < 0.05). 
Table 4,3 Percentage difference in endurance capacity between conditions (mean ± SEM). 
CONI CON2 GP+ALA&GLY GP+GLN 
CONI -7.1 ± S.O 9.6 ± 16.4 12.S ± IS.! 
CON2 22.3 ± IS.O 23.6 ± 16.3 
GP+ALA & GLY 5.4 ± 10.4 
GP+GLN 
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Table 4.4 Plasma amino acid concentrations at rest and during the first bout of exercise 
during the control, GP + ALA & GL Y and GP + GLN conditions 
EXI 
Condition Basal 30min 60min 85min 
Alanine CONI 375 ± 32 483± 47' 465±30 395±36 
CON2 367 ± 52 458± 19' 489±73" 439± 67 
GP+ALA&GLY 345 ±25 506±34" 511 ± 59" 460 ± 34-
GP+GLN 368±45 S67±68'" 602 ± 74·'"a,b,c 564 ± 77"aJ>,c 
Glutamate CONI 37±5 33±3 34±4 41±6 
CON2 41 ±7 31 ±2 36±4 43±6 
GP+ALA &GLY 37±3 36± I 38±4 45±3 
GP+GLN 41±2 35 ±3 31±S 40±4 
Valine CONI 187±9 190 ± IS 177±S 168±9 
CON2 172±4 185± 14 173±4 167± 10 
GP+ALA&GLY 178±8 177±9 165± 17 17S±8 
GP+GLN 172±9 181 ± 13 164±6 167±9 
Isoleucine CONI 61±S 62±S 55±5 54±6 
CON2 58±2 61±3 S5±1 S2±3 
GP+ALA&GLY 60±3 60±4 53±3 SI±2 
GP+GLN 52±2 S5±3 49±2 48± I 
Leucine CONI 107±6 109± 8 93±8 88±7' 
CON2 100±2 III± 10 97±2 89±4 
GP+ALA &GLY 103 ±4 93±6" 83±7' 85±3' 
GP+GLN 90±3' 96±S 86±2 8Si3 
Tyrosine CONI S5±5 65±5' 67±S· 65±6+ 
CON2 55 ±7 63±5 65±3· 60±4 
GP+ALA &GLY 48±4 S4± 7" 63±6' 59±8' 
GP+GLN 48±S 54 ± Sa,b 54 ± 61l,b,c 57±6· 
Phenylalanine CONI 43 ±2 47±4 46±3 46±4 
CON2 44±S 47±3 48±2 47±4 
GP+ALA&GLY 42±3 44±3 48±7 50±6+ 
GP + GLN 36 ± 3l1.C 41±4 40±3'" 42±3c 
Tryptophan CONI 4S±2 46± 5 44±4 43±6 
CON2 39±3 4S±S 44±S 44±4 
GP+ALA&GLY 36±41 35 ±4a,h,d 38±S 41 ±6 
GP+GLN 43 +3 45±4 43±3 44±4 
Values are means ± SEM for 7 subjects. expressed ID J.lmoVL NHJ• ammoma. different to basal 
value (P< 0.05), ... differentto basal value (P < 0.01), 'different to CONI (P < 0.05), bdifferent to 
CON2 (P < 0.05), . 'different to GP + ALA & GLY (P < 0.05), 'different!o GP + GLN (P < 0.05) 
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Table 4.4 (cont'd) Plasma amino acid concentrations during recovery and the second bout of exercise during the control, GP + ALA & GLY and GP + GLN conditions 
RECOVERY EXl 
Condition 60min 75 min 90 min 10S min 120 min 180 min 240 min Exh 
Alanine CONI 260 ± 3'" 30H 3S 271± 33 269 ± 30' 234 ±29" 223±2S" 320 ± 27 37H 41 
CON2 31H38 301 ± 22 31H 37 26S± 18' 260 ± 34" 20H 19' 267±25" 339 ± SI 
GP+ALA &GLY 602 ± 3S",a,b,d 627 ± 61··"'b.d 611 ± 49·· .. b.d 621 ±56"'M 647 ± st°a,b.d 684 ±42°'s,b,ll S41 ±66· .... ' 381 ±3S 
GP+GLN 39H 42' 396 HS'" 378 H4' 341 HI 3SH 37" 31S±37" 27S± 35' 376 ±43 
Glutamate CONI 27±S 27±3 29H 25±3' 2H4' 27±4 3S±3 48±S" 
CON2 31±4 30±2 30±4" 26 ±3u 32±S 30 ±S 4H 10 SH 12' 
GP+ALA &GLY 39±41 43±9'" 3H3 3H2' 35 ±21 39 ± S' 38±4 39±S' 
GP+GLN 42±41 40±2' 41 ±3a.b 29±3 3H3 3S±4 31±3' 39±4' 
Valine CONI 149 ± 13" 161 ± 11' 156 ± 14" IS8 ± 12' 155 ± 12" 163± 14' 192± 9 183 ± 14 
CON2 168± IS 163± 9 17S ± 17 ISO ±7 170±17 IS8 ± 18 19H 12 176 ± 12 
GP+ALA &GLY 16H 8 166 ± 18 147± 8'" 145 ± 6" 136 ± 11'" 120± 10 ..... 116 ± 10''0' 137 ± 13"a,b 
GP+GLN 14S±7~ 141 H'''' 127 ± ,,·a.b 118±9°°a,b,c 113 ± 6"a,b,t: 102 ± 11'''' 101 ± 10· ... 143± 7· ... • 
Isoleucine CONI 45 ± 3" 47±3°' 47±3" 43 ±4" SO ± 3" S7±4 73 ± 40 • 68 ±8 
CON2 SHS 53±6 SH7 48H' S6 ±6 60± 11 74 ±9" 68±S" 
GP+ALA&GLY 4Hz' 4H2'" 43±2" 39±2" 38 ±2 ..... 31 ttOu 33 ± 2"a,b 47 ± 3"s,b 
GP + GLN 40±3~ 38 ± 2'" 33 ± 3"a.h,c 30 ± 3"a,b 28 ± 3"a,b,c 24 ± 3"a,b 27 ± 3"'s,b 46±1a.b 
Leucine CONI 72 ±,." 79±6" 78±8" 73 ± ," 86 ± 7" 100±9 120±i 107± 10 
CON2 91±8 87±7 84±9' 81 ±6' 97± 10 9S± 14 116±11' 107±8 
GP+ALA&GLY 78 ± 3" 69 ±2°'"b 63 ± 3"a,b 59±4" 55 ± S"a,b 45 ± S"a,b 50 ± S··a.b 78± 10"0.' 
GP+GLN 73±4~ 66 ±4°'" 57 ± S"a,b 52 ± S .... a,b 47 ± 4··a.b 39 ± S··a.b 44 ± S"a,b 80±S'" 
Tyrosine CONI 47±5 S3±3 48± 3 SH2 48±4 41 ± 5" SS±7 67±6' 
CON2 S7±3' 5H2 S1±3 48± I SH3 43 t4' SH4 56± S' 
GP+ALA&GLY S3±7 4S±4 S1±S 48±S 44 ±6 37±S' 33 ± 4"a.b 46± 4a.b 
GP+GLN 47± 3' 48±4 4H7 43 is' 37±4Oa.b 31 ± S"a,b 32 ± SO'1Ib 42 ± 4a,b 
Phenylalanine CONI 41±2 4H3 4H2 46± 3 4H3 46H SS ± 5'· 61 ± 7" 
CON2 4S±2 49±4 46H 43±2 43 ±2 4HS SI H 54± 5" 
GP + ALA & GLY 46±6 43±S 4H4 41 ±48 40±4' 38±6 38 ± 6a,b 41 H' 
GP+GLN 3S ±2b,e 36 ± 2s,b 33 ± 48,b,e 33 ± 3a.b.e 32 ± 2a,b,e 30±3a.b,e 32 ±4a,b 41±4a.b 
Tryptophan CONI 34±6" 33 ± 4" 3HS" 33 ±4" 33 ± 4" 3S ±4'" 39±3 44±5 
CON2 40±4 36±3 37±4 3H2 36 ±2 31±4' 40±3 40±4 
GP+ALA&GLY 41±6 40±S 3S±S 36±S 33±S 31± S 2S ± 4· .. ·b.d 24±4'"a,b,d 
GP+GLN 38±3 40±2 36±4 37±3 34±3" 29± 3" 32 ± 4"a.b 4S± I 
, . Values are means ± SEM for 7 subjects, expressed In j..lmoVI. NH). ammoma. different to basal value (P < 0.05), dIfferent to basal value (P < 0.01), dtfferent to CONt (P < 
0.05). 'different to CON2 (P< 0.05) •. 'different to GP+ ALA & GLY(P <O.OS), 'different to GP+ GLN (P< O.OS) 
Table 4.4 (cont'd) Plasma amino acid concentrations at rest and during the first bout of exercise during 
the control, GP + ALA & GL Y and GP + GLN conditions 
EXI 
Condition Basal 30min 60min 85min 
Lysine CONI 109±9 142± 12' 126 ± 16 132± 16 
CON2 108± 10 139 ± 13 122 ± 14 122± 13 
GP+ALA&GLY 89± 13 III ±22 115±27 101±17 
GP+GLN 106± 10 126 ± 17 113 ± 14 113± 14 
Ornithine CONI 43±2 49±3 40±4 38±3 
CON2 46±4 44±3 39±3 43±4 
GP+ALA &GLY 49±7 43±6 43±9 48±7' 
GP+GLN 49±4 43±5 45±4 42±3 
Methionine CONI 23±2 25±3 24±3 24±2 
CON2 23± I 25±2 25±2 24±3 
GP+ALA&GLY 23±2 24±2 25±2 23±2 
GP + GLN 25± I 28±2 28±2' 29±2a.b,e 
Threonine CONI 119±8 109±7 112±9 102± 10 
CON2 115±9 113±9 114±12 106±12 
GP+ALA &GLY 114± 10 120± ID 110± 10 115± ID 
GP+GLN 102± 8 III ±9 105±7 106 ± 10 
Glycine CONI 244±32 230±17 199 ± 12 205±28 
CON2 206 ± 14 223± 14 230 ±24 202 ± 13 
GP+ALA&GLY 242±33 256± 37 230 ±27 233±36 
GP + GLN 249±43 268 ± 40 245±41 251 ±45 
Histidine CONI 45±7 46±5 42±5 41 ±4 
CON2 47±8 41±4 51 ± 8 49±9 
GP+ALA&GLY 48±9 44±9 48±8 45±6 
GP + GLN 39±4 44±5 48±2 49±5 
Aspartate CONI 10± I 8±1 9±1 9±1 
CON2 9±1 9±1 IO± I 1O±2 
GP+ALA&GLY 11± I 11 ± la 12±2' 12 ± I' 
GP+GLN 11 ± I 11 ± I' 12± I' 12± I,ll 
Asparagine CONI 43±5 37±2 33± I 33±3' 
CON2 37±4 38±3 37±3 35±3 
GP+ALA&GLY 36±3 38±3 33±3 35±4 
GP+GLN 34±2 37±2 34±2 35±3 
Serine CONI 123±5 124±9 127± 10 118±9 
CON2 115±6 112± IS 122 ± 12 116 ± ID 
GP+ALA&GLY 118 ±6 122±8 112±9 124±8 
GP+GLN 119±5 128±8 114±6 117± 8 
Arginine CONI 90±4 91±7 89±6 81 ±7 
CON2 83±5 95±S- 91±7 84±7 
GP+ ALA & GLY 79±7R 86±8 81 ± 10 86± 10 
GP+GLN 72±4'" 84±6·~ 77± 6 .. 1> 82±8 
.. Values are means ± SEM for 7 subjects. expressed In Ilmolll. NH1• anunoma. different to 
basal value (P< 0.05), ··different to basal value (P < 0.01), 'differentto CONI (P < 0.05). 
bdiffcrent to CON2 (P < O.OS) •. <=different to GP+ ALA & OL Y (P < 0.05), ddiffcrent to GP 
+ GLN (P < 0.05) 
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Table 4.4 (cont'd) Plasma amino acid concentrations during recovery and the second bout of exercise during the control, GP + ALA & GL Y and GP + GLN conditions 
RECOVERY EX2 
Condition 60min 7S min 90min 105 min 120 min 180 min 240min Exh 
Lysine CONI lIH 21 10H 13 10H 12 10H 11 113±16 114± 12 118± 19 136± 18 
CON2 1I4± 12 101 ± 16 98± 17 IOH 12 101± IS 98± 19 1I7± 18 IIH 20 
GP+ALA&GLY 94± 12 86± 10 8H9 76±7 76 ± 10' 6H 10" 56 ± ,'a,b 58±2'" 
GP+GLN 79 ± 3a,b 78±6 70±9' 71 ± So .. 66 ± 7",a)J 61 ± S"a.b 65± to'A' 74±8'" 
Ornithine CONI 36±4 36±2" 3H3' 3H2' 31±S 39±3 39±2 3H3 
CON2 41±3 34± l u 3H3' 3H2' 38±3' 35± I" 37±3' 31 ± 3"" 
GP+ALA&GLY 49± ,.' 50 ± 9a,b,d 46±7" 41 ±7' 43±8 39 ± 8' 34±4" 39±9''"b 
GP+GLN 42±4' 42±4" 40 ± 5'·, 43±4 40 ± 4" 41 ± 3' 40±S' 38±3" 
Methionine CONI 19 ± 3' 20± I 19 ± I' 18 ± I' 18 ± I" 19 ± 2' 22±3 24±3 
CON2 20± 3 20±2 19 ±2 17± I' 18 ±t 17±2" 21 ±2 22±2 
GP+ALA &GLY 21 ± I 19 ± I' 19 ± I' 20± I 21 ±3 21 ± 3' 19±4' 22±4 
GP+GLN 23±2' 2H2 20±2' 20±2' 18 ± I" 16 ± l"~ IS± l"a,b,c 20± I' 
Threonine CONI 86±7' 88 ±S" 87±8' 85 ±6' 82 ± 7" 81±7' 1I0±8 103±9 
CON2 97±7 91±8 96±8 85 ±6' 92±6' 91 ± 7' 101± 10 100± 10 
GP + ALA &GLY 136 ± IS· ...... 158±20"lI,b,d 133± I"" 136 ± 17'AbA 134 ± 16 ... ·' 129± ISa.b,d 106± 13' 114± 27' 
GP + GLN 89±6 90±6 84±7 74 ± S·· 7H" 72 ± ," 64 ± "ou 74 ± S"S,b 
Glycine CONI 163 ± 20" 165 ± 16" 161±21" 156 ± 14" IS6± 17" 162± 16" 191 ± 21 199 ± 21 
CON2 174 ± 11 181 ± 17 181 ± 18 ISH 10 163± 11 154 ±9 182± 24 190 ± 26 
GP+ALA &GLY 554 ± sf·a•M 659 ± 78''''''' 670 ± 66"a,b,d 617 ±4S"a.b,d 757 ± 77"aM 894 ±69 ..... ' 714± IOI .... b.d 423 ± 4S·'a.b,d 
GP+GLN 186 ±24' 183± 26' 170 ± 25" 159±17" 157± 16" 151± 14" 149± 13" 177±28" 
Histidine CONI 31 ±6' 41±3 34±4 40±3 36±S 31±S 54± 11 S7±8 
CON2 3HS 36±4 3H2 31±S 37±5 37±6 S2±9 47±8 
GP+ALA&GLY 41 ± 8 43±8 42±8 38±8 3H7 32±6' 42±8 34±S' 
GP+GLN 36± 3 36±2 34±S 38±2 21±2 24±4' 27 ±4a,b·~ 36±41 
Aspartate CONI 1± I 8 ± I 7 ± I' 8 ± I 6 ± I' 7 ± I' 9±1 11 ±2 
CON2 9±1 1O± I 9±1 8± I 9 ± 1- 9±1 11 ± I IH I' 
GP+ALA&GLY 11± I' 11 ± I' 14 ± 2"a.b 13 ±2a.b 12±2" 12 ± Ia.b 12± I 10±2 
GP+GLN 13 ± I'" 14±1'a.b 14 ± 2',a·b 11 ± I'" 12±2" 13±2a,b 10 ± I IH I 
Asparagine CONI 27 ± 3" 29±2" 28 ± 3" 28 ± 2" 27 ± 2" 30t 2" 35±3 3S±3 
CON2 32±3' 33±3 32±3' 28 ± 1" 32 ± 3" 32±3' 37±3 37±3 
GP+ALA&GLY 40± 2a,b.d 41 ±3'a.b.d 38 ± 2a.b.d 39 ± 2a.b,d 39 ± 3a.b,d 39±2a.b.d 34±2' 27 ± 3"a.b 
GP + GLN 29±2' 29±2' 28 ±2" 2S ±2" 26 ± 2Ot\) 26± 2"b 24 ± 2"a.b 27 ±2"a,b 
Serine CONI 96±7" 92±6" 94±8" B8±S" 87±8" 97± 8" 118 ± 10 114±7 
CON2 99± 9 97±7 92±8' 81 ± So, 93±8' 91± 8' 104±9 III ±9 
GP+ ALA & GLY 126±9 ... ·' ISS ±23· ... b.d 131 ± 8a,b,d 128± 14 ...... 143± 10· ..... 161 ± 12 ...... 158 ± 14'''''' 131 ± 13M 
GP+GLN 95±S' 93 ±6" 87±6" 76 ± S·· 78±S" 80±6" 77 ± 7t .a.b 91 ±4"a.b 
Arginine CONI 69±S" 7S±6" 68± 7" 71 ± 6" 67±S" 70tS" 82± 12 79±7 
CON2 79±5 80± 5 7S±S 68±S" 68±5" 67t6" 74±8 76±7 
GP+ALA&GLY 76±9 7S±9 69±8 71±9 67±6' 66±9' 64 ± 7"· 64 ± 9""" 
GP+GLN 68±4' 70±6 66±7 S9 ± 3' .. d 60±6' 61±7 SS ± 6·· .. b 61 ± S· .. b 
.. Values are means t SEM for 7 subjects, expressed ID J.l.molll. NHh ammonia. different to basal value (P < 0.05). dlfferent to basal value (P < 0.01), different to CONI (P < 
0.05), 'different to CON2 (P < 0.05), . 'different to GP + ALA & GLY (P < 0.05), 'different to GP + GLN (P < 0.05) 
Table 4,5 
Tryp:BCAA 
n-mAA 
BCAA 
AAA 
EAA 
NEAA 
Tot. AA 
Summed plasma amino acid concentrations at rest and during the 
first bout of exercise during the control, GP + ALA & GL Y and GP 
+ GLN conditions 
EXI 
Condition Basal 30min 60min 85min 
CONI O.l3± 0.01 O.l3±O,02 0.14± 0.01 O.l4±0.02 
CON2 O.I2±D.OI 0.13±0.01 O.l4± 0.02 0.14± 0.01' 
GP+ ALA & GLY O.ll± 0.02 0.11 ±O.OI' 0.13 ± 0.01 0.13 ± 0.02' 
GP+GLN O.l4± 0.01' 0.14±0.01' 0.14±0.01 O.l5± 0.01 
CONI 593±43 618± 17 574± 34 57H 51 
CON2 550±32 611 ± 13 604±29 560±28 
GP+ALA&GLY 559 ±40 609±53 591± 51 581± 46 
GP + GLN 565±49 627±33 585±40 598± 58 
CONI 355± 18 361 ± 28 325± 17 311 ± 21' 
CON2 330±7 357±27 32H6 307± 16 
GP+ALA&GLY 341 ±9 330 ± 16 302±26 311 ±9 
GP+GLN 31H 13 332±20 299±7 300 ± 10 
CONI 144±7 158 ± 10 157± 12 154± 13 
CON2 138 ± 14 155± 10 157± 7' 151 ± 10 
GP+ALA&GLY 126± 8 133 ± 13" 149 ± 15' 150 ± 15' 
GP+GLN 126±8 140 ± 14 131± 9a.b 143± 12 
CONI 738±36 776±42 720±45 700±47 
CON2 706±28 768 ±41 728 ± 22 699 ± 33 
GP+ALA&GLY 664±28 709± 36 685±67 686±21 
GP + GLN 781±40 726±32 676± 8 683± 33 
CONI 1500±68 1590 ± 77 1559 ± 51 1463± 110 
CON2 1396±77 1574±56 1630± 121' 1520 ± 120 
GP+ALA&GLY 1398±72 1644±99' 1580± 125 1565± 120 
GP + GLN 1425± 91 1727± 133'" 1702 ± 132" 1705± 160··· 
CONI 2281 ± 97 2415± 104 2318±86 2200 ± 149 
CON2 2147± 104 2387± 88 2396 ± 139 2262± 152 
GP+ALA&GLY 2140 ± 76 2395± 128 2309 ± 197 2299 ± 134 
GP+GLN 2138± 110 2496± 151' 2423± 189' 2431 ± 189' 
Values are means ± SEM for 7 subjects, expressed in J-lmolll. n-m AA, sum of non-metabolised amino 
acids (Thr, Met, Phe, Lys, Gly & Tyr); BeM sum of branched-chain amino acids (Len, Iso. Vat); 
AAA. sum of aromatic amino acids (Try, Tyr & Phe); EAA, sum of essential amino acids (His. Iso, 
Leo, Lys, Met, Phe, Thr, Try, & VaI); NEAA. sum of non -essential amino acids (Ala, Arg, Asp, Asn, 
Glu, Gin ,Gly. Ser, & Tyr); Tot. AA. sum orall amino acids. 
"different to basal value (P < 0.05). ··different to basal value (P < 0.01), adifferent to CONI (P < O.OS), 
bdifferent to CON2 (P < 0.05), . Cdifferent to GP + ALA & GL Y (P < 0,051 ddifferent to GP + GLN (P 
<0.05 
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Table 4.5 (cont'd) Summed plasma amino acid concentrations during recovery and the second bout of exercise during the control, GP + ALA & GL Y and GP + GLN 
conditions 
RECOVERY EX2 
Condition 60min 75 min 90min lOS min 120 min 180 min 240min Exh 
Tryp:BCAA CONI 0.13 ± 0.02 O.l2± 0.02 0.12± 0.02 O.l2± 0.01 O.l2± 0.02 0.11 ± 0.01 0.10 ± 0.01 O.l3±0.02 
CON2 O.l3± 0.01 O.l2±O.OI 0.12±0.01 O.l3± 0.01 0.11 ± 0.01 O.lO±O.OI 0.11 ±0.01 0.12 ± 0.01 
GP+ALA&GLY 0.14 ± 0.02" 0.14±0.02·~ O.l4±O.OZo, 0.15 ± O.OZ"a,b O.lH 0.02'''' 0.16 ± 0.02'''' O.l2± 0.02 0.09 ± 0.01" 
GP+GLN O.lHO.OI O.l6±0.01·A' 0.16 ± 0.01""'" 0.19 ± om· ... ·' 0.18 ± O,Ol"a,b,c O.l8±o.ol·'" 0.18 ± 0.01""" O.l7±O.OI· .... 
n-mAA CONI 467 ±46°' 471 ±29°' 467 ± 36" 463±26" 460±40" 470± 31" 552±49 590 ± 54 
CON2 507± 19 500 ± 16 493±26 450 ± 13' 476 ± 19 446±31' 524± 54 536 ± 64 
GP+ALA&GLY 903 ± 66· ... b.d 1010 ± 93°'"a,b,d 1000 ± 76'''''' 997 ± 64°'a,b,d 1073±92· ...... 1186 ± 84"'" 965 ± 113°'a,b,d 70U 56· ..... 
GP + GLN 459 ±29' 457± 28' 421 ± 35" 400±23" 38H23'" 359±21'~ 356 ± 32O°a.b 427 ± 41·· .. b 
BCAA CONI 266±23" 287±20" 282±24" 274± 16" 291 ±20" 320 ± 25 38H 19 357± 29 
CON2 311 ±27' 303± 20 31U30 280 ± 15' 322±32 313±41 384±31' 351 ± 25 
GP+ALA&GLY 288 ± 10' 278 ± 16" 253± 11" 242 ± 10" 229± It°a.b 195 ± 16"a.b 199 ± 14· ... • 262 ± 2S"a,b 
GP+GLN 258± 11'" 24H 9· ... • 217 ± 14O'"a,b 201±17'''' 189± 12· ... • 166 ± lS"a,b 173 ± lS
u
a,b 269 ± 12'" 
AAA CONI 122± 12' 130±8 12H7 l3U5 123 ± 9' 122± 10' 149 ± 12" 172 ± 13 
CON2 142± 8' 137±6 l3H 10 12H3 131 ±7 119 ± 12 143 ± 9" 150± 13' 
GP+ALA&GLY 139 ± 13 128 ± 10 128 ± 11 12H 11 117± 12' 109 ± 12" 96 ± 10· ... ' 1I1±6" 
GP+GLN 120 ± 7" 123±8 113± 15' 113± 10 103± 8" 89 ± 10'" 9H12'" 123± 11" 
EAA CONI 589 ± 50" 61H 38" 602±42" 604± 30" 614±40" 657±44 784±47 782± 57 
CON2 663± 37' 642± 17 64H 39' 598± 14' 656 ± 36 631±62 764±61 728 ± 63 
GP + ALA &GLY 667±30 66H48 609 ± 29 588 ± 37' 568±46" 514±47''''' 484 ± 3S··a,b 551 ± 30· ... • 
GP+GLN 559±21 .... 546 ± 18~" 494 ± 36"a.b,c 475 ± 31· ... b,c 440 ± 2S"a,b,c 397 ± 3S· ... b,c 406 ±43· ... • 559 ± 29· ... 
NEAA CONI 1171±95" 1237± 79" 1186 HO" 1162±72" 1I07±76" 1149± 54" 1373± 117 1393± 77 
CON2 1314± 84 1314±62 1311±83 1157± 39' 1216 ± 82 1159 ± 60' 1322± 97 1402± 129 
GP+ALA &GLY 2053 ± 134· ..... 2209 ± 191 .. • .. 2143 ± 136'~·,·, 2167 ± 135· ..... 2291 ± 167· ...... 2495 ± 136 .. ...,·' 2108 ± 204 ..... • 1580 ± 116' 
GP + GLN ISOS±96" IS09± 104" 1443± lOO' l302± 85 1327±74' 1303 ±SS 1147± 81'~ 1324± 87 
Tot. AA CONI 179S± 141" 1888 ± 113" 1823± 132" 1801 ± 98" 17S8± 114" 1844± 91" 2196± IS4 2212± 128 
CON2 2019±119 1989 ± 75 199U 119 1790 ±46" 1910 ± 115 182H 121' 2123± 149 2162± 192 
GP+ALA&GLY 2769± 147 ..... 2924±215· ..... 2798± 149· ...... 2796 ± 164 ..... • 2903± 202""" 3049± 174 ..... • 2627± 234· ...... 2170 ± 128 
GP+GLN 2106± 106' 2098± 109 1977± 109 1819±101' 1807± 88' 1741 ± 103" 1593 ± 12S
u
a,b 1921 ± liS' 
Values are means ± SEM for 7 subjects, expressed in Ilmoll1. n-m AA, sum of non-metabolised amino acids (Thr, Met, Phe, Lys, Gly & Tyr); BCAA, sum of branched-chain amino acids (Leu, 
Iso, Vat); AAA, sum ofaromatic amino acids (Try, Tyr & Phe): EAA, sum of essential amino acids (His, Iso, Leu, Lys, Met, Phe, Thr, Try, & Val); NEAA, sum of non~sential amino acids 
(Ala, Arg, Asp, Asn, Glu, Gin ,Gly, Ser, & Tyr); Tot. AA, sum of all amino acids. 
-different to basal value (P < O.05), "different to basal value (P < O.Ot), ·different to CaNt (P < 0.05), bdifferent to CON2 (P < 0.05), . cdifferent to GP + ALA & GLY (P< 0.05), ddifferent to GP 
+ GLN (P < 0.05) 
Fig. 4.2 Bland·Altman plot showing mean difference in endurance capacity between CONI and 
CON2 conditions. 
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Fig. 4.3 Plasma glucose concentration during the experimental period in the control, GP + ALA & 
GL Y and GP + GLN conditions. Values are means ± SEM for 7 subjects. 
~ 9 
-o-CONI 
*tae 
-..., 
-0 __ CON2 
El 8 El 
---l>-GP + ALA & GLY ~
" ........ GP+GLN 0 7 .~ 
@ 6 
" 8
" 
5 
'" 8 
~ 4 
'" +-EXl-,,~ RECOVERY El;g 3 
~ 
-a 0 0 .,.. 0 on 0 .,.. 0 
[(j r<l '" 
00 
'" 
..... 0"> 0 
'" - -~ 
Time (min) 
• = significantly different to basal in GP + GLN condition (P < 0.05) 
t = significantly different to basal in GP + ALA & GL Y condition (P < 0.05) 
a = significantly different to control in glucose-polymer conditions (P < 0.05) 
b = significantly different to control in GP + GLN condition (P < 0.05) 
*t 
• EX2 
0 0 ~ 00 .... 
- '" 
~ 
c = significantly different to GP + ALA & GL Y condition in GP + GLN conditioo (P < 0.05) 
118 
Fig. 4.4 Blood lactate concentration during the experimental period in the control, GP + ALA & GL Y 
and GP + GLN conditions. Values are means ± SEM for 7 subjects. 
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Fig. 4.5 Serum insulin concentration during the experimental period in the control, GP + ALA & GL Y 
and GP + GLN conditions. Values are means ± SEM for 7 subjects. 
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Fig. 4.6 Plasma NEFA concentration during the experimental period in the control, GP + ALA & 
GL Y and GP + GLN conditions. Values are means ± SEM for 7 subjects. 
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Fig. 4.7 Plasma ammonia concentration during the experimental period in the control, GP + ALA & 
GL Y and GP + GLN conditions. Values are means ± SEM for 7 subjects. 
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Fig. 4.8 Plasma glutamine concentration during the experimental period in the control, GP + ALA & 
GLYand GP + GLN conditions. Values are means ± SEM for 7 subjects. 
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Fig. 4.9 Sum of plasma phenylalanine and tyrosine concentration during the experimental period in the 
control, GP + ALA & GLY and GP + GLN conditions. Values are means ± SEM for 7 
subjects. 
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Fig. 4.10 Sum of plasma essential amino acid concentration during the experimental period in the control, GP + ALA & GL Y and GP + GLN conditions. Values are means 
± SEM for 7 subjects. 
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4.5 DISCUSSION 
The main fmding of this study was that the supplementation of glucose-polymer and 
glutamine during recovery from exhaustive exercise did not extend endurance capacity 
in a subsequent bout of exercise compared to placebo and glucose-polymer and alanine 
& glycine. 
Glutamine is transported across the intestinal brush border by both sodium-dependent 
and -independent systems (Taylor et al. 1989). Due to this co-transport, and previous 
work that has demonstrated that the addition of glutamine to oral rehydration solutions 
increases sodium absorption and therefore bulk water flow (Rhoads et al. 1991; van 
Loon et al. 1996), it has been suggested that the ingestion of glutamine may promote a 
more rapid intestinal absorption in the gut. However, despite implementing a more 
frequent sampling period in the second hour of recovery, the peak in plasma glucose 
concentration occurred 30 min after consumption of both of the glucose-polymer 
containing drinks. However, both the peak plasma glucose concentration and the area 
under the plasma glucose curve had a tendency to be greater during the second hour of 
recovery in the GP + GLN condition compared to the GP + ALA & GL Y condition, 
despite receiving the same glucose-polymer dose. Indeed, the proportion of the area 
under the plasma glucose curve during the recovery period was greater (P < 0.05) in the 
GP + GLN condition during the second hour of recovery (CONI: 33%; CON2: 33%; 
GP + ALA & GL Y: 35%; GP + GLN: 37%). Therefore, the time course for the 
appearance of glucose in the systemic circulation appears to have been greater in the GP 
+ GLN condition, suggestive that the addition of glutamine may have increased the rate 
of intestinal absorption. However, it must be recognised that the plasma concentration 
merely reflects the balance between entry and removal of glucose into or out of the 
systemic circulation. 
The ingestion of glutamine with the glucose-polymer solution was able to elevate the 
plasma glutamine concentration by -30 % (relative to the baseline concentration). 
Therefore, in spite of the reported -50 % extraction and substantial oxidation of 
enterally delivered glutamine by the splanchnic bed, in addition to a reduction in 
glutamine de novo synthesis (Matthews et al. 1993; Hankard et al. 1995; Haisch et al. 
2000), the oral glutamine load used in the present study was sufficient to increase 
123 
glutamine concentration in the systemic circulation. Furthermore, it has been reported 
that the plasma concentration of glutamine decreases by up to 25% following prolonged 
submaximal exercise (van Hall et a!. 1998), therefore it appears that the glutamine dose 
provided in the present study was able to counteract any post exercise reduction in 
plasma glutamine concentration. However, a reduction in plasma glutamine 
concentration was still evident in the control conditions, where neither glutamine nor 
glucose-polymer was provided. Furthermore, although the supplementation of glucose-
polymer during exercise has been shown to be able to counteract the post exercise 
decrease in plasma glutamine concentration (van Hall et a!. 1998), it is feasible that the 
supplementation of glucose-polymer post exercise may also serve to maintain plasma 
glutamine concentration by providing carbon skeletons for glutamine synthesis via the 
carboxylation of pyruvate (Wagenmakers et al. 1991). 
It has been reported that the intravenous administration of glutamine is able to increase 
plasma glutamine concentration by ~ 70 %, which caused intramuscular glutamine 
concentration to increase by ~ 16 % (Varnier et al. 1995). In the present study, the oral 
provision of glutamine and glucose-polymer was able to increase plasma glutamine 
concentration by ~34 %, therefore theoretically increasing intramuscular glutamine 
concentration by ~8 %. Furthermore, hepatic glycogen synthase activation and 
glycogen synthesis is increased in rats orally fed glutamine (Niewoehner and Nuttal~ 
1996). Therefore, an increase in plasma glutamine of the order observed in the present 
study should be sufficient to increase both muscle and liver glutamine concentration, 
and therefore modulate metabolism in these tissues. 
The non-essential amino acids alanine and glycine were supplemented to provide an 
isoenergetic and isonitrogenous comparative condition. It has been demonstrated that 
alanine is able to mimic some of the properties of glutamine, for example, alanine is 
both synthesised and exported by skeletal muscle (Chang and Goldberg, 1978c) and is 
an important gluconeogenic precursor, predominantly in the liver (Sturnvo 11 et aL 
1998). Glycine, on the other hand, is deemed metabolically inert within skeletal 
muscle, however this amino acid is able to interact with metabolism in other tissues, in 
particular the liver. 
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During prolonged submaximal exercise with normal glycogen levels, both plasma 
alanine and glutamine concentration appear to increase during the first 30 min and then 
gradually return to resting values when exercise is continued for 90 min (van Hall et al. 
I 995b). Concomitant to this observation, a gradual reduction in the release of both 
alanine and glutamine from the muscle during prolonged submaximal exercise has been· 
observed (van Hall et al. 1999). Indeed, a similar pattern was observed in the present 
study with an initial increase observed in both plasma alanine and glutamine 
concentration during the fIrst bout of exercise (with normal glycogen levels), which 
then decreased towards the end of exercise (-90 min). 
During the second bout of exercise, plasma alanine concentration again increased in all 
conditions, except when alanine had been supplemented during the recovery period, 
suggesting a suppression of alanine de novo synthesis in this condition. However, 
plasma glutamine concentration did not demonstrate the expected increase in any 
condition during the second bout of exercise. Tbis may be attributable to a reduction in 
muscle glycogen levels in the control conditions (van Hall et al. 1998), and a 
suppression of glutamine de novo synthesis following glutamine supplementation in the 
GP + GLN condition. It is interesting to note, that relative to the baseline concentration, 
no decrease in plasma glutamine concentration occurred during the recovery period in 
the GP + ALA & GL Y condition. Although not statistically significant, the plasma 
concentration of glutamine in the GP + ALA & GL Y condition was elevated above the 
control conditions during the second hour of the recovery period, suggesting that some 
degree of synthesis or reduction in splanchnic bed uptake of glutamine occurred. A 
suppression of hepatic gluconeogenesis will have occurred following the provision of 
glucose-polymer, resulting in a reduction in the uptake of hepatic gluconeogenic 
precursors such as alanine. Therefore, a portion of the -76 % increase in plasma 
alanine concentration observed in the present study, following alanine supplementation, 
may be attributable to a reduction in the hepatic uptake of alanine. Furthermore, it is 
feasible that the provision of alanine in the GP + ALA & GL Y condition may have 
promoted the synthesis of glutamine during the recovery period (Dechelotte et al. 
1991), through a reversal of the alanine aminotransferase reaction, producing glutamate 
that can combine with anunonia to produce glutamine via the glutamine synthetase 
reaction. Furthermore, this notion is also supported by the tendency for a lower plasma 
anunonia concentration during recovery in the GP + ALA + GL Y condition. 
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There seems to be a general agreement that during prolonged exercise skeletal muscle 
protein synthesis is reduced (Dohm et al. 1982; Rennie et al. 1981). Similarly, skeletal 
muscle protein breakdown is decreased, but is increased immediately after prolonged 
exercise (Carraro et al. 1990; Dohm et al. 1987). Neither phenylalanine or tyrosine are 
metabolised in skeletal muscle, therefore release of these amino acids into the plasma 
may be deemed indicative of muscle protein breakdown and these amino acids have 
been used as indicators of muscle protein breakdown in the literature (Blomstrand and 
Saltin, 1999; van Hall et al. 1999). However, it is important to consider the possibility 
that tissues other than skeletal muscle may play a role in exercise-induced proteolysis. 
It has been demonstrated that exercise-induced proteolysis also occurs in the splanchnic 
bed of postabsorptive humans (Felig and Wahren, 1971), with the contribution of the 
splanchnic bed (liver and gut) estimated to be -40% of the whole body proteolysis 
during exercise (Wasserman et al. 1991; Williarns et al. 1996; Halseth et al. 1998). 
However, it was outside the scope of the present study to directly determine protein· 
turnover in the different organs or tissues of the body. 
During the recovery period the plasma phenylalanine and tyrosine concentrations were 
significantly lower in the GP + GLN condition compared to both the control conditions 
and the GP + ALA & GL Y condition. It has previously been demonstrated that 
glutamine inhibited protein breakdown in perfused rat skeletal muscle (MacLennan et 
al. 1988) and the present data lend support to this observation. Insulin has been 
suggested to play a major role in the stimulation of skeletal muscle protein synthesis 
(Newman et al. 1994; Millward, 1990; Kimball et al. 1994; Biolo et al. 1995), and 
also in the attenuation of skeletal muscle protein breakdown (Barrett and Gelfand, 1989; 
Svanberg et al. 1996). The concentration of insulin was increased after the provision of 
glucose-polymer in both glucose-polymer conditions, therefore it is possible to attribute 
a portion of the reduction in plasma phenylalanine and tyrosine concentration to the 
increased insulin concentration due to the provision of glucose-polymer i.e. insulin-
induced hypoaminoacidemia (Barrett and Ge1fand, 1989). However, a greater reduction 
in phenylalanine concentration and in the sum of phenylalanine and tyrosine 
concentration was observed in the GP + GLN condition compared to the GP + ALA & 
GL Y condition, therefore the addition of glutamine appears to have exerted an 
additional inhibitory effect on protein breakdown, most probably in skeletal muscle 
(MacLennan et al. 1988). Furthermore, the increase in the summed plasma 
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concentration of those amino acids that cannot be metabolised in skeletal muscle, and 
hence are more indicative of muscle protein breakdown, was smaller in the GP + GLN 
condition than in the control conditions towards the end of the recovery period and 
during the second bout of exercise (a similar finding is observed compared with the GP 
+ALA & GL Y condition when glycine is excluded). Taken together, these results 
suggest that the combination of both glucose-polymer (which increased insulin 
concentration) and glutamine (which possibly inhibited muscle protein breakdown) may 
have promoted a more positive protein balance during the recovery period. 
The increase in plasma essential amino acid concentration in the last hour of the 
recovery period and during the second bout of exercise was greater during the control 
conditions than the glucose-polymer conditions, reinforcing the notion of increased 
protein loss in the control conditions. This notion is further supported by the greater 
increase in the sum of phenylalanine and tyrosine concentrations in the control 
conditions, compared to the glucose-polymer conditions in the last hour of the recovery 
period and during the second bout of exercise. 
The ingestion of glucose in addition to amino acids caused a marked hyperglycemia and 
hyperinsulinemia in both the GP + GLN and GP + ALA & GL Y conditions. The 
elevation in plasma glucose concentration reached a peak in both conditions 30 min 
after the ingestion of the first drink. Although there was no difference in the amount of 
glucose ingested between the GP + GLN and GP + ALA & GL Y conditions, the peak in 
plasma glucose concentration, and indeed the plasma glucose concentration throughout 
recovery, was greater in the GP + GLN condition. This was mirrored by the serum 
insulin response during the first 90 min of recovery, which tended to be higher in the 
GP + GLN condition compared to the GP + ALA & GL Y condition. It has been 
suggested that the consumption of protein may enhance the insulin response (Spiller et 
al. 1987), and indeed that the ingestion of individual amino acids may also augment the 
insulin response (Bertrand et al. 1995). Furthermore, the ingestion of protein in 
combination with carbohydrate has been shown to augment the insulin response (Spiller 
et al. 1987; Tamopolskyet al. 1997; van Hall et al. 2000a; Jentjens et al. 2001). It is 
noteworthy, that despite the augmentation of the insulin response following the 
ingestion of protein in combination with carbohydrate after exercise, no further increase 
in muscle glycogen synthesis was observed (van Hall et al. 2000a; Jentjens et al. 
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2001). The results of the present study make it difficult to differentiate whether the 
additional insulin response in the GP + GLN condition is due to the higher glucose 
concentration or due to the amino acid itself. However, the latter would appear more 
likely if recent research is considered (van Hall et al. 2000b). 
The plasma NEFA concentration decreased rapidly during recovery, from its elevated 
concentration at the end of the first exercise bout, in the glucose-polymer conditions. 
Conversely, an increase in plasma NEF A concentration during recovery was observed 
in the control conditions. The decrease in plasma NEF A concentration in the glucose-
polymer conditions during recovery is most probably due to the inhibition of lipolysis 
by insulin, as the increase in serum insulin concentration was parallel to a decrease in 
plasma NEFA concentration. It must be recognised that the concentration of NE FA in 
plasma only represents a balance between the rate of mobilisation by lipolysis in 
adipose tissue and their oxidation by skeletal muscle, a measurement of plasma glycerol 
concentration would provide a better index of the rate of fatty acid mobilisation as 
glycerol is released from adipose tissue during lipolysis and is neither phosphorylated 
nor recycled. However, although plasma glycerol concentrations were not determined 
in the present study, the increase in plasma NEFA concentration during the placebo 
conditions, in the absence of any increase in serum insulin concentration, would suggest 
that the suppression of lipolysis mediated by insulin is indeed responsible for the 
decrease in plasma NEF A concentration. 
There was a tendency for the plasma NEF A concentration to be suppressed to a greater 
extent during the GP + GLN condition compared to the GP + ALA & GL Y condition. 
This added suppression is most likely due to the increased serum insulin response 
observed during the GP + GLN condition, but may be partly due to the reported 
inhibitory effect that an elevation in plasma glutamine concentration has upon lipolysis 
(Cersosimo et al. 1986; Dechelotte et al. 1991). However, during the second bout of 
exercise, the more rapid increase in the plasma NEF A concentration in the glucose-
polymer conditions is presumably attributable to the rapid decline in insulin 
concentration over this time period. 
During prolonged submaximal exercise, the oxidation of BCAA is increased, and 
ammonia is produced in skeletal muscle via a series of transamination and deamination 
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reactions. The greater increase in plasma ammonia concentration in the control 
conditions in the second bout of exercise compared to the glucose-polymer conditions is 
most probably related to the muscle glycogen content at the end of the 4 h recovery 
period. After the fIrst bout of exercise, both muscle and liver glycogen stores will be 
reduced (Vollestad et al. 1992). In addition, it is expected that there will be a negligible 
increase in the muscle glycogen resynthesis rate during the recovery period in the 
control conditions (Ivy et al. 1988b), and therefore it is expected that muscle glycogen 
content will remain substantially reduced in the control conditions at the end of the 4 h 
recovery period. Furthermore, it is expected that despite the provision of glucose-
polymer in the glucose-polymer conditions, glycogen concentration will be reduced 
compared to normal levels after only 4 h recovery. 
The exercise-induced activation of the branched-chain a-keto acid dehydrogenase 
complex (BCKADH) is enhanced in the glycogen-depleted state (Wagenmakers et al. 
1991), with leucine oxidation being suppressed by oral glucose supplementation 
(Bowtell et al. 2000). Therefore, one may expect greater BCAA oxidation and hence 
ammonia production in the second bout of exercise in those conditions where muscle 
glycogen content is lower. Indeed, in the control conditions, where it is expected that 
glycogen concentration will have been substantially depleted, a decrease was observed 
in plasma BCAA concentration, whereas an increase was observed in both the glucose-
polymer conditions. This may suggest an increased BCAA extraction and oxidation by 
skeletal muscle during the second bout of exercise in the control conditions. 
The subjective sensations of fatigue that accompany prolonged exercise are generally 
considered a result of the events occurring in the exercising muscles or cardiovascular 
system. There is also evidence to suggest that the signals that arise in the periphery are 
modulated by events occurring within the central nervous system; generally referred to 
the 'central fatigue'. One hypothesis proposes that an increased concentration of the 
brain neurotransmitter serotonin (5-hydroxytryptamine; 5-HT) is associated with the 
onset of fatigue. 5-HT has been linked to a variety of psychological responses including 
lethargy, arousal, sleepiness and mood, therefore alterations in the concentration of 5-
HT in the brain may modulate muscular fatigue or perceived exertion during exercise. 
Amino acids do not readily enter across the blood-brain barrier and are transported by 
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means of a carrier or transporter. The large neutral amino acid (LNAA) transporter is a 
saturable carrier that transports six amino acids across the blood-brain barrier: 
tryptophan, tyrosine, phenylalanine and the BCAA (leucine, isoleucine and valine). Of 
particular importance in this context, is the fact that the apparent affmity of the LNAA 
transporter, and therefore the relative rate of transport into the brain of each individual 
amino acid, is dependent upon the concentration of each amino acid relative to its 
competitors. Therefore, a change in the plasma concentration ratio of free 
tryptophan:BCAA may increase the rate of tryptophan entry into the brain. This ratio 
could conceivably increase during prolonged exercise due to an increased uptake to the 
BCAA by skeletal muscle with a concomitant mobilisation of free fatty acids which can 
displace the tryptophan bound to albumin (McMenamy and Oncley, 1958) thereby 
increasing the free tryptophan concentration. This would lead to an increase in the free 
tryptophan:BCAA ratio which would conceivably lead to an increased entry of 
tryptophan into the brain. Tryptophan is a precursor for the synthesis of 5-HT. 
This putative indicator of central fatigue, the plasma tryptophan:BCAA ratio 
(Blomstrand et al. 1997), was significantly greater in the GP + GLN condition at 
exhaustion in the second bout of exercise. Whether or not this increase in the plasma 
tryptophan:BCAA ratio contributed to an earlier onset of fatigue is unclear and the 
mechanism behind the increase in the tryptophan:BCAA ratio in the GP + GLN 
condition is unclear (although largely related to the greater increase in tryptophan 
concentration). However, recent evidence would suggest that the central fatigue 
hypothesis is a rather tenuous one, as under controlled laboratory conditions, no benefit 
has been gained from supplementing BCAA during exercise (Varnier et al. 1994; van 
Hall et al. 1995a; Verger et al. 1994; see Review of Literature section 2.4.4 for fuller 
discussion). 
During the recovery period, the initial increase in plasma glucose concentration was 
greater in the GP + GLN condition compared to the GP + ALA & GL Y condition and 
control conditions. There are several possible reasons for this; 1) a decrease in skeletal 
muscle glucose uptake, 2) an increase in hepatic glucose export, 3) an increase in renal 
gluconeogenesis (Stumvoll et al. 1998). It is expected that muscle glucose uptake will 
be increased in previously exercised muscle after glucose ingestion (Richter, 1996) due 
to an increase in GLUT -4 translocation. However, the addition of glutamine to the 
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glucose-polymer solution may have induced a synergistic effect, increasing the 
production of glucosamine, a product of glucose metabolism via the hexosamine 
biosynthetic pathway (Marshall et al. 1991b). In rat skeletal muscle, glucosamine has 
been shown to induce insulin resistance by causing an impairment of the translocation 
of GLUT-4 from an insulin-sensitive intracellular pool to the sarcolemmal membrane 
(Baron et al. 1995). The amination of fructose-6-phosphate to form glucosarnine-6-
phosphate catalysed by glutamine-fructose-6-phosphate arnidotransferase (GFAT), with 
glutamine acting as the arnido group donor, is the rate-limiting step in the hexosamine 
biosynthetic pathway (Buse et al. 1995; Marshall et al. 1991b; Marshall et al. 1991c; 
Crook et al. 1995; McClain and Crook, 1996). An increase in intracellular glucose and 
glutamine concentration, induced through the ingestion of the glucose-polymer and 
glutamine drink, may have increased flux through this rate-limiting step leading to 
increased production of glucosarnine. An impairment of GLUT -4 translocation in 
skeletal muscle would serve to reduce skeletal muscle glucose uptake, which in turn 
may limit muscle glycogen synthesis despite any insulin-induced activation of glycogen 
synthase. Indeed, recent in vitro work has demonstrated that the addition of glutamine 
to rat skeletal muscle incubated with 14C labelled glucose was able to reduce muscle 
glucose uptake (Sawada et al. 1998), suggesting that the provision of a combination of 
glucose and glutamine may indeed modulate skeletal muscle glucose uptake differently 
than when provided individually. It is unlikely that hepatic glucose output was 
increased during the recovery period after exercise when depleted hepatic glycogen 
stores are at least partially replenished, particularly as systemic glucose availability was 
increased by oral glucose. Finally, although an increase in gluconeogenesis provides a 
possible explanation for the increase in plasma glucose concentration during the 
recovery period in the GP + GLN condition, this is unlikely as the supplementation of 
glucose-polymer is likely to suppress gluconeogenesis. 
Glutamine has previously been shown to be an effective substrate for hepatic glycogen 
synthesis in 72 h fasted rats (Mouterde et al. 1992), when hepatic glycogen 
concentration is substantially reduced, a situation that could also occur after prolonged 
exercise (Hultman and Nilsson, 1971). In heptocytes, the inward transport of glutamine 
(via hepatic system N), due to an increase in the systemic concentration, causes an 
intracellular accumulation of glutamine, particularly due the Na+-coupled transport 
process (Haussinger et al. 1990). This increase in substrate flux across the cell 
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membrane, due to an increase in substrate concentration, will modify cellular osmolality 
and result in an increase in cell volume (i.e. cell swelling) (Lang et al. 1998). 
Therefore, both hepatocyte swelling and an increase in hepatic glutamate concentration 
(Meijer et al. 1992) may stimulate hepatic glycogen synthesis via a stimulation of 
glycogen synthase phosphatase leading to an activation of hepatic glycogen synthase 
(Lavoinne et al. 1987). This may be independent or additive to any cell swelling and 
glycogen synthesis mediated by insulin (Haussinger et al. 1994). It has been suggested 
that the cytoskeleton architecture, in particular transmembrane integrins, may be 
responsible for transducing the mechanical stimuli (i.e. cell swelling) into chemical 
signals, which evoke metabolic responses (i.e. glycogen synthesis) (Ingber, 1997). 
Furthermore, liver glucose uptake occurs via the non-insulin dependent transporter 
GLUT-2, which is not affected by glucosamine in the same manner as the skeletal 
muscle GLUT-4 transporter. Therefore, it is expected that liver glycogen synthesis will 
be increased in the GP + GLN condition, not only due to an increase in the hepatic 
glutamine concentration, but also due to an augmented liver glucose uptake due to a 
reduction in muscle glucose uptake. Indeed, it has recently been reported that the 
ingestion of glucose-polymer and glutamine promotes the storage of carbohydrate 
outside of skeletal muscle, the most feasible site being the liver (Bowtell et al. 1999). 
Therefore, the effect of consuming glutamine and glucose-polymer during recovery 
from exercise has the potential to increase glycogen synthesis in both the liver and 
skeletal muscle. Further 'indirect' support for this hypothesis is gained from the 
observation that carbohydrate oxidation rates after 10 min of the second bout of exercise 
were greater in the GP + GLN condition compared to the control conditions, suggesting 
increased carbohydrate storage, a phenomenon not observed in the GP + ALA & GL Y 
condition. Unfortunately, in order to elucidate whether the addition of glutamine to the 
glucose-polymer caused a greater increase in liver glycogen storage during the recovery 
period, liver biopsies, J3C labelling or proton NMR would be required. At present it is 
impossible to directly confirm or refute this hypothesis. 
The higher blood lactate concentration during recovery in the GP + GLN condition may 
also lend support to increased hepatic glucose metabolism via an increased flux through 
the 'indirect pathway' of glycogen synthesis (Magnusson and Shulman, 1991). Glucose 
may be passed through the liver to the peripheral tissue ( e.g. muscle) where it is 
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converted to lactate, which is then transported back to the liver to serve as a 
gluconeogenic substrate (Wehrneyer et al. 1994). The G-6-P generated by 
gluconeogenesis can be used to regenerate glycogen stores in the liver. Presumably, the 
higher blood lactate concentration observed in the GP + GLN condition reflects the 
conversion of glucose to lactate in the peripheral tissues. However, if consideration is 
given to glucosamine-induced reduction in muscle glucose uptake, then the contribution 
that skeletal muscle may make to the conversion of glucose to lactate in muscle may be 
limited. 
It is also interesting to note that in the fmal hour of recovery there is a rapid drop off in 
both plasma glucose and glutamine concentration in the GP + GLN condition. 
Intuitively, one would expect a drop off in both plasma glucose and glutamine 
concentration during this period since the glucose-polymer and glutamine were not 
consumed in the fmal hour of recovery. However, ouly a 26 % decrease was observed 
in the plasma glucose concentration in the last hour of recovery in the GP + ALA & 
GL Y condition, whereas a 48% decrease in plasma glucose concentration was observed 
in the GP + GLN condition during the same period. The coincidence of a decrease in 
plasma glutamine concentration and an exaggerated decrease in plasma glucose 
concentration in the GP + GLN condition may be due to a compensatory increase in the 
rate of glucose uptake by the muscle or a decrease in the hepatic export of glucose. The 
former being the more likely explanation if flux through the hexosamine biosynthetic 
pathway is reduced during this period, due to a reduction in glutamine concentration and 
thus available amido donor. It has been reported that the effects of glucosamine are 
evident -30 min after infusion in rats (Baron et al. 1995), with the intrinsic activity of 
GLUT-4 being reduced within 2 h of glucosamine infusion (Hawkins et al. 1999). In 
the present study, a slightly longer time course would be expected for activation of 
GFAT and glucosamine production after the ingestion of glucose-polymer and 
glutamine, to allow for the uptake of both substrates into the muscle cell and form 
glucosamine via flux through the hexosamine biosynthetic pathway. However, it is 
quite feasible for the effects of glucosamine to be prevalent during the second half of 
the recovery period and during the second bout of exercise. 
Furthermore, it is quite feasible that an increased extraction of glucose and conversion 
to glycogen by the liver during the recovery period in the GP + GLN condition, gave 
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rise to an increase in hepatic glycogenolysis and export of glucose during the second 
bout of exercise. In addition, although the time course of the effects of glucosamine in 
human skeletal muscle are unclear, it is conceivable that during the second bout of 
exercise there may have been prevailing effects of glucosamine resulting in impaired 
glucose uptake into skeletal muscle, which jointly may account for the higher plasma 
glucose levels observed during this period in the GP + GLN condition. 
In both the glucose-polymer conditions, where glucose-polymer was ingested during the 
4 h recovery period, no difference was observed in cycle time to exhaustion compared 
to the control conditions. The ingestion of 1.0 g CHO body mass·2 hot during 4 h of 
recovery in comparison with a placebo solution has previously been shown to improve 
endurance running capacity in a subsequent bout of exercise (Fallowfield et al. 1995). 
The failure to observe a difference in endurance cycling capacity between the control 
and glucose-polymer conditions in the present study compared to this study may be 
related to the carbohydrate dose, the mode of exercise, or the sensitivity of endurance 
capacity to detect difference between conditions. 
Reproducibility of protocol 
It has been argued that the use of a correlation technique to assess the difference 
between two methods is inappropriate and can be misleading (Bland and Altman, 1986). 
Instead, a 'limits of agreement' approach provides a more qualitative method of 
assessing the difference between two methods. The calculated 95% limits of agreement 
of the present data are 3.5 ± 17.0 min, suggesting that a given subject's cycle time to 
exhaustion in another cycle to exhaustion should lie within -13.5 and +20.5 min of the 
flfst cycle to exhaustion. This range is not acceptable if one is attempting to assess the 
efficacy of a supplement where it is expected that only small changes in cycle time to 
exhaustion will be observed. 
Although the present data do not display heteroscedasticity (i.e. the greater the cycle 
time to exhaustion the larger the difference between cycle times to exhaustion), it is 
apparent that the data is skewed by two subjects (signified by triangular data points; Fig. 
4.1). Indeed, if these two subjects are removed, the variation in cycle time to 
exhaustion is reduced to 7.2 ± 2.7% (range: 2.3 - 16.5%). Given the small sample 
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number in the present study, the effect of individual data has a significant bearing on the 
group data. If the same 'limits of agreement' calculations are applied to five subjects 
(signified by square data points; Fig. 4.1), the 95% limits of agreement become -1.3 ± 
5.4 min, equating to a second cycle time to exhaustion of between ---6.7 and +4.1 min, 
relative to the first cycle time to exhaustion. These limits of agreement appear more 
acceptable in the present context, however small improvements in endurance capacity 
may not be detectable, suggesting that cycle time to exhaustion may not be sufficiently 
sensitive. 
Previously, a large degree of individual variability has been associated with cycle time 
to exhaustion (Jeukendrup et al. 1996; McLellan et al. 1995) which may negate any 
true differences in endurance capacity. Therefore, it may be argued that endurance 
capacity is not a sensitive enough measure to detect any beneficial effect that may have 
been gained from the supplementation of both glucose-polymer and glutamine. In this 
context, the present study was able to demonstrate that that in terms of physiological 
measurements, no difference was observed between the two placebo conditions. 
However, this is does not necessariIy infer true reproducibility (Bland and Altman, 
1986). 
Many investigators assume that the reproducibility of cycling time to volitional fatigue 
is satisfactory, and the use of time to volitional fatigue as an index of the efficacy of a 
particular intervention is widespread (Coyle et al. 1983; Casey et al. 2000; Collomp et 
al. 2000; Morrison et al. 2000). In the present study, with regard to cycle time to 
exhaustion, 5 of the 7 subjects demonstrated good reproducibility, or low variability, 
with test-retest variability of -7% of their first cycle to exhaustion. In the 2 subjects 
who demonstrated poor reproducibility, or high variability, their test-retest variability 
was -56%. Using a limits of agreement approach to assess reproducibility (Bland and 
Altman, 1986), based on the 5 subjects demonstrating good reproducibility, it was 
estimated that their second cycle to exhaustion would be between - 6.7 to + 4.1 min of 
their first cycle to exhaustion. It may be argued that an increase in the number of 
subjects may help elucidate whether cycle time to exhaustion is indeed an appropriate 
index. However, despite the data being skewed by these two subjects the mean within-
subject test-retest variability was -21% (2.3% -72.1%). Previously, the reproducibility 
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of submaximal cycling time to exhaustion in trained cyclists has been reported to be 
poor, with the coefficient of variation for five rides to exhaustion ranging from 17.4% to 
39.5% (mean 26.6%) in one study (Jeukendrup et al. 1996), and from 2.8 to 31.4% in 
another (McLellan et al. 1995). Therefore, the results of the present study are 
comparable, if not better than previous research. 
In conclusion, the results from this study suggest that that the consumption of glutamine 
in combination with glucose-polymer during recovery from exhaustive exercise was 
effective in maintaining plasma glucose levels in a subsequent bout of exercise, which 
may be attributable to an increase in liver glycogen resynthesis. In addition, the results 
suggest that skeletal muscle protein breakdown was reduced post exercise following 
glucose-polymer and glutamine supplementation during recovery from exercise. 
However, the observed effects of glucose-polymer and glutamine supplementation did 
not extend endurance cycling capacity in a subsequent bout of exercise. 
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CHAPTERS 
EFFECT OF GLUTAMINE SUPPLEMENTATION DURING 
RECOVERY ON EXERCISE METABOLISM IN A SUBSEQUENT BOUT OF 
EXERCISE 
5.1 INTRODUCTION 
There is strong evidence from in vitro work, that insulin stimulates protein synthesis. 
However, this anabolic effect has been difficult to reproduce in vivo (Gelfand and 
Barrett, 1987). Previous experiments have demonstrated that plasma amino acid 
concentrations also have a role in the stimulation of amino acid accretion as protein in 
peripheral tissues (Lundholm et al. 1987). Furthermore, the addition of insulin to an 
amino acid mixture was unable to further increase skeletal muscle protein synthesis in 
rats (Mosoni et al. 1993). Therefore, amino acid availability may represent an 
important factor in protein balance, with several possible mechanisms to explain both 
the stimulation of skeletal muscle protein synthesis and decreased protein breakdown in 
humans (Garlick and Grant, 1988; Borel et a!. 1997; McNulty et a!. 1993). In 
particular, certain amino acids are able to stimulate protein synthesis and decrease 
protein breakdown in skeletal muscle by mechanisms that are not related to their role as 
components of protein structures (Svanberg et al. 1996). 
In this context, the non-essential amino acid glutamine, the most abundant free amino 
acid in the body, appears to have a role in the regulation of protein metabolism. 
Considerable evidence suggests that a positive correlation exists between positive 
whole-body protein balance and both the size of the intramuscular glutamine pool 
(MacLennan et a!. 1987; MacLennan et al. 1988; Jepson et al. 1988) and plasma 
glutamine concentration (Watt et al. 1992; Hankard et a!. 1998). The existence of a 
relationship between glutamine levels and protein turnover rates has led to the use of 
glutamine in both enteral and parenteral nutrition (Khan et al. 1991; Hardy et al. 1992; 
Smith, 1997; Morlion et al. 1998) to promote positive protein balance. It has been 
suggested that glutamine becomes a conditionally 'essential' amino acid in critical 
illness (Hall et al. 1996; Lacy and Wilmore, 1990). Therefore, the fIrst aim of this 
study was to investigate whether the supplementation of glutamine post exercise exerts 
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a controlling influence on whole-body protein balance, assessed indirectly via plasma 
amino acid concentration changes. 
Glutamine has also been shown to be an important gluconeogenic precursor (Nurjhan et 
al. 1995), with the proposal that a 'glucose-glutamine' cycle analogous to the 'glucose-
alanine' cycle exists in humans (Perriello et al. 1995). Glutamine infusion in 
postabsorptive humans led to a seven-fold increase in the conversion of glutamine into 
plasma glucose, demonstrating the significance of glutamine as a gluconeogenic 
precursor (Perriello et al. 1997). Therefore, in situations where the availability of 
glucose is reduced, such as in the post exercise state, the availability of gluconeogenic 
precursors such as glutamine, or indeed alanine, may allow for a better maintenance of 
glucose levels. Therefore, the post exercise provision of glutamine and alanine may 
provide the necessary substrate for the kidneys and liver, respectively (Stumvoll et al. 
1998), to generate glucose in order to maintain homeostasis. 
The provision of glutamine has been shown to stimulate glycogen synthesis both in 
skeletal muscle myotubes (Low et al. 1996), in rat skeletal muscle (Scislowski et al. 
1989), and in rat liver cells (Lavoinne et al. 1987; Mouterde et al. 1992). The 
mechanism is thought to be the activation of glycogen synthase via cell swelling 
induced by increased uptake ofthis amino acid (8aquet et al. 1990; Low et al. 1996). 
More specifically, it has been suggested that the cytoskeleton architecture, in particular 
transmembrane integrins may be responsible for transducing the mechanical stimuli (i.e. 
cell swelling) into chemical signals which evoke metabolic responses (Le. glycogen 
synthesis) (Ingber, 1997; Low and Taylor, 1998). 
An increase in the plasma concentration of glutamine, either through oral provision or 
intravenous administration, will lead to an increase in intramuscular glutamine 
concentration due to the rapid uptake of glutamine into skeletal muscle via System Nm 
(Varnier et al. 1995). Indeed, it has been demonstrated that the intravenous infusion of 
glutamine after exhaustive exercise is able to increase skeletal muscle glutamine 
content, resulting in a greater degree of muscle glycogen resynthesis than an infusion of 
an isoenergetic and isonitrogenous mixture of alanine and glycine (Varnier et al. 1995). 
It was suggested that the increase in skeletal muscle glycogen content was mediated via 
glycogenic mechanisms rather than glucogenic mechanisms as no increase in skeletal 
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muscle glycogen content was observed following infusion of glycine and glucogenic 
alanine. 
An increase in both liver and skeletal muscle glycogen synthesis, either directly via 
glycogenic processes, or indirectly through gluconeogenesis, would result in a better 
maintenance of blood glucose concentration and a supply of readily available fuel for 
exercise. Indeed, an increase in systemic glucose circulation has been reported to delay 
the onset of fatigue during prolonged cycling exercise (Coyle et al. 1983). 
Furthermore, the rate of glucose utilisation is reported to be increased during cycling 
exercise compared to running exercise (Derman et al. 1996), due to a greater glucose 
utilisation of the smaller active muscle mass involved in cycling (Richter et al. 1988). 
These findings would suggest that systemic glucose concentration may play an 
important role in the aetiology offatigue during prolonged cycling exercise. Therefore, 
the second aim of this study was to determine whether the supplementation of glutamine 
during recovery form prolonged exercise could extend endurance capacity in a 
subsequent bout of cycling exercise. 
Plasma glutamine concentration has been shown to decline following prolonged 
submaxirnal exercise (Parry-Billings et al. 1987), reducing the availability of glutamine 
to tissues that utilise this substrate e.g. liver, kidneys, gut and cells of the immune 
system. Glutamine synthesis and effiux in skeletal muscle is increased in catabo lic 
situations (Muhlbacher et al. 1984; Babij et al. 1986a; Babij et al. 1986b), reducing 
the availability of glutamine to take part in glycogenic processes within skeletal muscle 
itself. Therefore, the supplementation of glutamine during recovery from exercise 
should provide an exogenous source of the substrate, thus allowing these tissues and 
cells to function normally. 
Furthermore, the provision of an individual amino acid, glutamate, the deamination 
product of glutamine, .has been shown to enhance the insulin response (Bertrand et al. 
1995), which could conceivably increase skeletal muscle protein synthesis (Newman et 
al. 1994). In addition, given the important role that insulin plays in governing skeletal 
muscle glycogen synthesis, the supplementation of glutamine may prove anabolic in the 
post exercise state not only in terms of protein metabolism, but also in terms of 
glycogen metabolism. 
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The use of glutamine is common within the clinical setting, both in parenteral and 
enteral nutrition. More recently, within the sports setting glutamine has been used by 
athletes in an attempt to boost the immune system post exercise. However, the use of 
glutamine for it's glycogenic and gluconeogenic properties post exercise has rarely been 
advocated and has only been assessed in a few studies (Varnier et al. 1995; Bowtell, 
1997; Bowtell et al. 1999; van Hall et al. 2000b). 
Inherently linked to the previous study (Chapter 4), the underlying aim of the present 
study was to gain an understanding of the potential anabolic properties of glutamine 
alone. In the previous study, a combination of glucose-polymer and glutamine was 
ingested, both of which promote positive protein balance (Roy et al. 1997) and 
glycogen synthesis (Varnier et al. 1995). Therefore, the purpose of this second study 
was to allow us to delineate the effects of glutamine ingestion alone from any possible 
synergistic effects that may occur from ingesting glutamine in combination with 
glucose-polymer. 
5.2 METHODS 
Subjects. Seven well-trained, healthy male subjects participated in this study. Their 
mean (± SEM) age, height, body mass and V02max were 26.4 ± 2.2 y, 180.5 ± 1.7 cm, 
77.4 ± 2.1 kg and 4.66 ± 0.18l.min-1 (60.4 ± 2.6 ml.kg-1.min-1), respectively. 
Preliminary tests. Subjects reported to the laboratory approximately 1 week before the 
experiment and undertook two preliminary tests in order to determine: (i) the oxygen 
cost of submaximal cycling, and (ii) maximal oxygen uptake (V02max). The protocols 
for these tests have been described elsewhere (see Chapter 3). Subjects were fully 
familiarised with the experimental procedures used during the experimental conditions. 
Protocol of the study. Subjects were instructed to consume their habitual diet and 
refrain from exercise or strenuous physical activity for 48 h prior to each experiment. 
On arrival at the laboratory on the morning of the experiment, the overnight fasted 
subject rested in a supine position and a carmula was inserted into an antecubital vein 
and a resting blood sample was obtained. The experimental procedure utilised in this 
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study was a standard 'recovery protocol' similar to a protocol adopted previously in the 
literature (Fallowfield and Williams, 1997) and in the previous study, consisting oftwo 
bouts of exercise separated by a 4 h passive recovery period (Fig. 5.l). 
Subjects performed a bout of glycogen depleting exercise (EX!), as described 
previously (Chapter 3), which was immediately followed by a 4 h passive recovery 
period, during which they consumed one of the assigned solutions allocated by 
systematic rotation in a double-blind fashion. They then immediately undertook a cycle 
to exhaustion at -70% V02max (EX2) (Fig. 5.l) during which subjects were offered no 
fluid. 
Expired air collections were taken prior to the commencement of EX I, then at 30 min, 
60 min and 80 min during EX1. During recovery, collections were taken at 30 min 
intervals, with a collection being taken every 10 min and at exhaustion during EX2 (Fig. 
5.1). Venous blood samples were than taken after 30 min, 60 min and at cessation of 
EX1. During recovery, samples were taken at 60, 75, 90, 105, 120, 180 and 240 min, 
with a subsequent sample being taken at exhaustion during EX2 (Fig. 5.1). 
The two bouts of exercise (EXI and EX2) were separated by a 4 h controlled recovery 
during which the subjects remained within the laboratory and their activity levels were 
minimal. After completion of EXI subjects were rested for -10 min before their post 
exercise nude bodyweight was measured. Any excess sweat on the subjects skin was 
towelled off prior to their weight being recorded. 
Subjects received one of two drinks during the 4 h recovery period; they consumed 
either 0.3 g'kg-1 body wt L-glutarnine (Sigma-Aldrich Chemicals, Dorset, UK) (GLN) 
dissolved in 31.25 rnI'kg-1 body wt solution or an isoenergetic and isonitrogenous 
mixture of L-alanine and L-glycine (ALA & GL Y) (Sigma-Aldrich Chemicals, Dorset, 
UK) dissolved in 31.25 rnI·kg-1 body wt solution. Subjects received 780 rnl of solution 
in the first drink with the remaining solution being divided into 5 equal aliquots. 
SUbjects consumed the flfst of the six drinks after 30 min of recovery, after the first 
expired air collection, and then every 30 min thereafter. The last drink was 
administered at the 3 h point during recovery to minimise the possibility of gastro-
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intestinal stress in the forthcoming exercise bout. Urine voided during the recovery 
period was collected and a cumulative volume recorded. 
Prior to EX2, subjects post-recovery nude body weight was recorded in order to 
calculate rehydration status. Subjects then completed a 5 minute warm up at 60% 
Y02max, prior to commencing EX2. During EX2, subjects were instructed to cycle to 
volitional exhaustion at a workrate equivalent to -70% Y02max, in order to determine 
their endurance capacity in terms of cycle time to exhaustion. Subjects were given no 
indication of the time completed during EX2. Exhaustion was determined using the 
defmition described previously (Chapter 4, page 96). Subjects indicated when they 
could only continue for one more minute, at which point the fmal expired air collection 
and blood sample was taken. 
Dry bulb temperatures within the laboratory during the main experimental trial were 
21.1 ± 0.2 °C and 20.1 ± 0.2 °C for the GLN and ALA & GLY conditions respectively. 
Relative humidity within the laboratory during the main experimental trial was 55.4 ± 
0.6 % and 55.8 ± 0.7 % for the GLN and ALA & GL Y conditions respectively. No 
statistical difference was observed in relative humidity between conditions. 
Analysis. Expired air samples were collected and analysed as previously described 
(Chapter 3). Venous blood samples were analysed for blood lactate and glucose 
concentration (using an automated analyser; YSI 2300 ST ATPLUS, see Chapter 3), 
plasma ammonia and amino acid concentration, serum insulin and NEF A 
concentrations, and haemoglobin concentration and haematocrit values, as previously 
described (Chapter 3). Percentage changes in plasma volume were calculated as 
previously described (see Chapter 3). 
Pre-exercise energy intake. The energy intake of subjects during the 48 h prior to the 
main trial are presented in Table 5.1. No statistical differences were observed between 
conditions in the pre-exercise diet. 
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Table 5.1 Energy content and percentage of the primary dietary nutrients of the pre-exercise diet 
for both conditions (mean ± SEM). 
ALA & GLY GLN 
Energy (M.J/day) 12.8 ± 0.9 13.2±0.9 
Carbohydrate (%) 54.0± 3.6 52.0 ± 5.0 
Fat(%) 30.4 ± 3.7 33.8 ±4.3 
Protein (%) 14.7± 1.2 14.0 ± 0.9 
NB. Data presented is mean of2 days diet 
Statistical analysis. The data were analysed by two-way analysis of variance (ANOVA) 
for repeated measures (time X condition). Cycle time to exhaustion data were analysed 
using a paired Hest. When the ANOV A resulted in a significant F ratio, Fisher's post 
hoc test was used to locate differences between means. Statistical significance was 
accepted at the 5% level (P <0.05). Results are presented as means ± SEM. 
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5.3 RESULTS 
Cardiorespiratory and exercise performance. Pulmonary oxygen uptake (V02), expired 
minute ventilation (data not shown), carbohydrate oxidation and fat oxidation were all 
increased during exercise (P < 0.05), but there were no differences between conditions 
(Table 5.4). Mean power output was not different between conditions in either EXl 
(ALA & GLY: 232 ± 1; GLN: 229 ± 2, watts) or EX2 (ALA & GLY: 226 ± 5; GLN: 
225 ± 4, watts). 
Heart rate increased during both bouts of exercise, however there were no differences 
between conditions (Table 5.2). The average heart rate during EXl was 152 ± 4 b·min·1 
and 150 ± 4 b·min·1 in the ALA & GL Yand GLN conditions respectively. The average 
heart rate during exercise EX2 was 167 ± 2 b·min-1, and 165 ± 2 b·min-1 in the ALA & 
GL Y and GLN conditions respectively. 
Cycle time to exhaustion was 38.4 ± 4.3 min and 35.0 ± 1.6 min in the ALA & GL Y 
and GLN conditions respectively. Cycle time to exhaustion was not significantly 
different between conditions_ 
Plasma glucose and lactate data. Plasma glucose concentration decreased during EXl 
in both conditions and was significantly lower (P < 0.05) than basal after 60 min of EX 1 
in the ALA & GL Y condition (Fig. 5.2)_ During the recovery period no difference was 
observed in plasma glucose concentration between conditions. During EX2, plasma 
glucose concentration decreased in both conditions, with the decline much greater in the 
ALA & GLY condition (-16.8 %) compared to the GLN condition (-3.0 %) relative to 
the concentration at the end of the recovery period, this difference being significantly 
different between conditions (P < 0.01). 
In both conditions, plasma lactate concentration increased to a similar extent (P < 0.05) 
during both bouts of exercise (EX! and EX2), but there were no differences between 
conditions (Fig. 5.3). There was a tendency for plasma lactate concentration to be 
higher during the recovery period in the ALA & GL Y condition, however no difference 
was observed between conditions. 
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Serum insulin and plasma NEFA data. A similar decrease was observed in serum 
insulin concentration (P < 0.05) during exercise in both conditions (Fig. 5.4). During 
recovery, serum insulin concentration increased sharply in both conditions, with the 
peak in serum insulin concentration occurring after 75 min of recovery in both 
conditions and being greater in the ALA & OLY condition (P < 0.01). No statistically 
significant difference was observed between conditions during the recovery period at 
any other time point during the recovery period. However, the area under the serum 
insulin curve during the recovery period was greater (P < 0.05) in the ALA & OL Y 
condition than the OLN condition (ALA & OL Y: 1357 ± 103; OLN: 1162 ± 86, 
IlIV.ml.4 h-I ). 
Plasma NEFA concentration initially decreased during EXI and then increased sharply 
at the end of EXI in both conditions (Fig 5.5). During recovery plasma NEFA 
concentration demonstrated a slight increase over the 4 h period in both conditions, with 
the concentration in the OLN condition at the end of the recovery period being 
significantly greater (P < 0.05) than the basal value. However, no significant 
differences were observed between conditions during the recovery period in plasma 
NEF A concentration. During EX2, plasma NEF A concentration increased to a similar 
extent in both conditions. 
Plasma ammonia and amino acid data. Plasma anunonia concentration increased (P < 
0.05) to a similar extent (ALA & OL Y: +579 ± 72 %; OLN: +574 ± 91 %) during EXI 
in both conditions, with no difference were observed between conditions (Fig. 5.6). 
During recovery, plasma anunonia concentration remained slightly elevated above basal 
levels in both conditions. During EX2, the increase in plasma anunonia concentration 
was slightly higher in the OLN condition (ALA & OL Y: +478 ± 88 %; OLN: +526 ± 
146 %), however no statistically significant difference was observed between 
conditions. 
After glutamine ingestion, plasma glutamine concentration in the OLN condition was 
elevated significantly (P < 0.05) compared to the ALA & OL Y condition throughout the 
recovery period (Fig. 5.7). In addition, after glutamine ingestion, plasma glutamate 
(Fig. 5.8) and plasma aspartate concentration (Table 5.3) increased significantly (P < 
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0.05) during the recovery period compared to the ALA & GL Y condition. Plasma 
methionine (Table 5.3) concentration was significantly lower (P < 0.05) during the 
second hour of the recovery period after glutamine ingestion. 
Plasma phenylalanine concentration had a tendency to be higher and plasma tyrosine 
concentration a tendency to be lower during the recovery period after glutamine 
ingestion (Table 5.3). In the second bout of exercise, no difference was observed in the 
plasma phenylalanine concentration, whereas plasma tyrosine concentration was lower 
(P < 0.05) in the GLN condition compared to the ALA & GL Y condition. 
Plasma alanine (Fig. 5.9) and glycine (Fig. 5.10) concentrations increased significantly 
(P < 0.01) after the ingestion of the alanine and glycine solution compared to the GLN 
condition, and plasma glycine concentration remained elevated in the second bout of 
exercise. In addition, the plasma concentration of serine and threonine was significantly 
increased (P < 0.01) during the recovery period after the ingestion of alanine and 
glycine (Table 5.3). 
During the recovery period and during the second bout of exercise, the sum of plasma 
BCAA was greater (P < 0.05) following GLN ingestion (Fig. 5.11). However, no 
statistical difference was observed during this time in the sum of the essential plasma 
amino acids (Fig. 5.8). 
The plasma tryptophan:BCAA ratio was not different between conditions during the 
experimental period (Table 5.4). The sum of the non-metabolised plasma amino acids 
(Thr, Met, Phe, Lys, Gly, & Tyr), the sum of the non-essential plasma amino acids (Ala, 
Arg, Asp, Asn, Glu, Gin, Gly, Ser, & Tyr) and the sum of all amino acids were higher at 
all time points during the recovery period in the ALA & GL Y condition (P < 0.05) 
(Table 5.4). 
Carbohydrate and Jat oxidation rates. During EX1, respiratory exchange ratio, 
carbohydrate oxidation rate and fat oxidation rate increased in both conditions relative 
to the basal value (Table 5.2). During the flfst 30 min of recovery, the carbohydrate 
oxidation rate decreased and the fat oxidation increased in both conditions relative to 
the basal value. The respiratory exchange ratio was decreased relative to the basal value 
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in both conditions throughout the recovery period. However, no statistically significant 
differences were observed in respiratory exchange ratio, carbohydrate oxidation rate and 
fat oxidation rate during EXl and the recovery period between conditions. 
During the second bout of exercise, there was a tendency for carbohydrate oxidation to 
be greater and fat oxidation to be lower in the ALA & GL Y condition in the initial 
period of exercise (Table 5.2). However, no statistically significant differences were 
observed in respiratory exchange ratio, carbohydrate oxidation rate and fat oxidation 
rate during the second bout of exercise. 
Rehydration, plasma volume and urine output data. Rehydration during the recovery 
period was not different between conditions (ALA & GL Y: 94.5 ± 6.1 %; GLN: 99.3 ± 
6.0 %; see Chapter 3 for calculation). Plasma volume decreased during both bouts of 
exercise and increased during the recovery period, however there was no difference 
between conditions (data not shown). Total urine output during the recovery period was 
not different between conditions (ALA & GLY: 2261 ± 154 ml; GLN: 2022 ± 172 ml). 
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Table 5.2 Oxygen uptake (V02), %V02max, heart rate (HR), respiratory exchange ratio 
(RER), carbohydrate oxidation rate (CHO Ox) and fat oxidation rate (Fat Ox) at rest and 
during the frrst exercise bout in the ALA & GL Y and GLN conditions. 
EXI 
Condition Basal 30min 60min 8Smin 
VO, (I.min") ALA & GLY 0.30 ±0.02 3.39 ±0.I3· 3.40±0.I3· 3.47 ± O.lS· 
GLN 0.32 ±0.01 3.36 ±0.16· 3.37 ± 0.14· 3.40 ± O.lS· 
%Vo,~ ALA & GLY 6.6±0.S 72.7±0.8· 73.0 ± 1.2· 74.4 ± 1.6· 
GLN 6.9±0.3 72.0 ± 1.4· 72.S ± \.5. 72.9 ± 1.2· 
HR (b.min") ALA&GLY 139±6 IS9 ±6t 162±7t 
GLN 14S ±S IS7±6t 161 ±6t 
RER ALA&GLY 0.88 ±om 0.93 ±0.01" 0.92±0.02· 0.92 ± 0.02* 
GLN 0.88 ±om 0.93 ±0.01· 0.92±0.01* 0.92±0.01· 
CRO Ox (g.min") ALA & GLY 0.21 ±0.03 3.06 ±0.30* 3.00 ±0.36· 3.10±0.38· 
GLN 0.22±0.02 3.06 ±0.28· 2.99±0.24· 2.96±0.21· 
Fat Ox (g·min") ALA&GLY 0.06±0.01 0.43 ±0.08· 0.46 ±O.IO" O.4S ± 0.10" 
GLN 0.07±0.01 0.41 ± 0.07" O.4S ±0.06* 0.47 ±0.06* 
Values are means ± SE for 7 subjects. • P < O.OS vs. basal value; t P < O.OS vs. 30 min (EXI) 
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Table 5.2 (cont'd) Oxygen uptake (V02), %V02max, heart rate (HR), respiratory exchange ratio (RER), carbohydrate oxidation rate (CHO 
Ox) and fat oxidation rate (Fat Ox) during the recovery period in the ALA & GL Y and GLN conditions. 
RECOVERY 
Condition 30min 60min 90min 120 min 150min 180 min 210 min 240min 
VO, (l.min·l) ALA&GLY 0.36 ±0.01 0.37±0.02 0.39 ±0.02 0.37±0.02 0.36±0.02 0.35 ±0.02 0.35±0.01 0.34 ± 0.01 
GLN 0.37 ±0.01 0.39 ± 0.02 0.39 ± 0.02 0.37±0.02 0.36 ±0.02 0.36 ±0.01 0.36±0.02 0.35±0.02 
%YO'mox ALA & GLY 7.9 ±0.6 8.1 ± 0.6 8.5±0.6 7.9 ± 0.4 7.9±0.5 7.6±0.5 7.6 ± 0.4 7.4 ± 0.4 
GLN 7.9 ±0.4 8.4 ± 0.5 8.4 ± 0.6 7.9 ± 0.4 7.9 ± 0.4 7.7±0.6 7.8 ± 0.4 7.4 ± 0.4 
HR (b.min·1) ALA&GLY 
GLN 
RER ALA&GLY 0.73 ±0.02· 0.82 ±0.02· 0.82 ±0.02· 0.81 ±0.02· 0.79±0.02· 0.81 ±0.02· 0.80 ± om· 0.76±0.01· 
GLN 0.73 ±0.01· 0.85 ± 0.01· 0.82 ± 0.02· 0.79 ±0.01· 0.8l±0.01· 0.82 ±0.02· 0.81 ± 0.02· 0.75 ±0.02· 
CRO Ox (g.min·1) ALA&GLY 0.03 ±0.02 0.17±0.04 0.17±0.03 0.14 ±0.04 0.11 ±0.03 0.14 ±0.02 0.13±0.02 0.06 ± 0.01 
GLN 0.03 ±0.02 0.22±0.02 0.16 ± 0.02 0.11 ±0.02 0.14±0.02 0.16±0.03 0.15 ± 0.02 0.05±0.03 
Fat Ox (g.min·1) ALA & GLY O.l7±O.OI O.l2± 0.01 0.J2±0.02 0.13 ±0.02 O.l4±O.OI 0.J2± 0.01 0.12±0.01 0.15 ±0.01 
GLN 0.17 ±0.01 0.10 ± 0.01 O.l3±0.02 0.14 ±0.02 0.13±0.02 0.11 ± 0.01 0.12 ±0.02 0.15±0.02 
Values are means ± SE for 7 subjects. • P < 0.05 vs. basal value. 
Table 5.2 (cont'd) Oxygen uptake (VOz), %VOZmax, heart rate (HR), 
respiratory exchange ratio (RER), carbohydrate oxidation rate (CHO Ox) 
and fat oxidation rate (Fat Ox) during the second bout of exercise in the 
ALA & GL Y and GLN conditions. 
EX2 
Condition 10min 20min Exh 
VO, (I.min·') ALA & GLY 3.44 ±0.13· 3.46 ±0.\3* 3.42 ± 0.11· 
GLN 3.38 ±0.14· 3.50 ± 0.18· 3.34±0.18· 
%VO'nw< ALA&GLY 73.9 ± 1.\. 74.5 ± 1.\. 73.6 ± 1.7· 
GLN 72.5 ± 1.4· 75.0 ± 1.8· 71.8±3.1* 
HR (b.min·') ALA&GLY 16S ±6 168 ±6t 170 ± st 
GLN 16S ±6 167±7 170 ±6t 
RER ALA&GLY 0.91 ±0.01 0.91 ±0.02 0.90 ± 0.02 
GLN 0.90 ±0.01 0.90 ± 0.02 0.91 ±0.02 
CHO Ox (g.min·') ALA&GLY 2.91 ±0.27· 2.91 ±O.3S* 2.71 ±O.3S* 
GLN 2.61 ±0.22* 2.76 ±0.29* 2.80 ±OAO· 
Fat Ox (g. min") ALA&GLY 0.S2 ±0.07* 0.S3 ±0.09· 0.59 ±O.lI· 
GLN 0.61 ±0.07* 0.61 ±0.08· 0.S2 ±O.lI* 
Values are means ± SE for 7 subjects. • P < O.OS vs. basal value. 
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Table 5.3. Plasma amino acid concentrations at rest and during exercise in the ALA & GLY and GLN conditions. 
EXI RECOVERY EXl 
Condition Basal 30min 60min 85min 60min 7Smin 90min 105 min 120 min 180 min 240 min Exh 
Valine ALA&GLY 193± 11 187±8 173± 13' 171± 11' 143 ± 13" 164 ± 13" 153 ±12" 156 ± 9" 139±11" 136 ± 4" 144± 8" 171± 11' 
GLN 215 ± 13' 220 ± 12' 210±16' 20St 13' 183 ± 12"· 178± 14" 167 ± 9" 155 ± S" 165 ± 10"· 162± 9" 174± 11" 192±17' 
Isoleucine ALA & GLY S4±3 S4±3 49±S 47±4' 37 ± 4" 41±4" 39±4" 40±4" 35 ± 4" 37± 3'" 39±3" S2±4 
GLN 63±3' 6S±41 60±S' 58±r so ± 3"· 48 ± 3"· 45 ± 2" 43 ± I" 46 ± 3"· 48 ± 2'" SH2" 60±S· 
Leucine ALA & GLY 104 ±4 102±6 9H9 91±8 70±9" 8H9" 77i9" 78 ± s'· 68±9" 68±S" 71 ±S·· 97±7 
GLN 113±8 119±9' 11H 10' 108± 7' 95±7" 91 ± 7'" 85 ±6" 78 ±4" 84± 6"· 86 ± 4"· 94 ± ,"a 109 ± 10 
Tyrosine ALA&GLY 48±2 SO±4 SS ±S SS±6 44±6 46± 3 4H3 45 ±2 40±3 36± 4 34±3' 44±4 
GLN 38 ±41 34±61 33 is· 3S ± S· 30±41 28±3' 30±S 30±S' 27±4 2S± 3 2H2 27±r 
Phenylalanine ALA&GLY 41 ± I 40±2 4H3 4H3 33 ± 5" 38±3 36±3 37±3 33 ± 3" 33 ±3" 34±3' 4S±3 
GLN 42 ±2 46±2c 47±3' 47 ± I" 42 ±21 41 ±2 39±2 37±2 39±21 41 ± I' 4H2' 49±2" 
Tryptophan ALA&GLY 28 ±S 33±4 34±4' 34±4 29± 3 27±4 26±3 24±3 24±3 24±4 2H4 3H4 
GLN 41 ± 3a 45±41 46±3' 45±21 38 ±2' 37±3' 3S±2' 29 ± 2" 32 ± 3"1 32 ± I"· 32±2'" 3S±2' 
Lysine ALA&GLY 127 ±7 I1St 10 120 ± IS 118 ± 14 92 ± 17" 109 ± 13 IOH 17' J04± 13 86 ± 14"· 78 ±9" 8H 12" 98 ± 11' 
GLN 117± 14 \3S ± 14 127± 10 1l4±6 1l2±9 IOU8 110 ± 12 89 ± 10' 85 ± S" 88 ±t 88±9' 94±9 
Ornithine ALA&GLY 58 ±3 S4±3 SH4 49±4' 41 ±6" 44±2! 46±6'0 S1±S 43 ± 6" 38 ±6'" 4S± 5" 43 ± 5" 
GLN 39 ±Sa 42±S' 39±4a 36 ± 3' 36±4 34±3a 35 ±3a 3HS' 30±3' 30±3' 30 ± 2'a 30±3' 
Methionine ALA&GLY 26 ± I 29± I 28 ±2 27±2 22±3' 2S±2 23±2 24± I 21 ± I" 20 ± 1" 21 ±2" 2S±2 
GLN 2S± I 28±2 28±2 29 ± I' 23 ± I 21 ± lOa 19 ± I"· 20± 1·· .. 20 ± 1" 18 ± I" 19 ± I" 2H I 
Threonine ALA&GLY 118±9 120±8 117±9 llH 11 14J± 8'~ 151 ±7'~ 140 ± 9'" 135± 9'" 114± 8' 108± 9' 98 ± 5" b 89 ± 7"' 
GLN 114±5 119±7 115±8 114±6 97±6" 94±7" 88±7" 87±7" 86 ± 5"" 79±6" 80 ± 6" 91 ± 7" 
Glycine ALA&GLY 213 ± 16 224±22 208 ± 25 201±28 66S± 103'" 841 ± 106'" 733± S7'~ 669 ± 62'~ 578 ± 52'" S3S±S2'~ 4SHSI'~ 328±36" 
GLN 243± 34 261 ± 33 240 ± 31 231 ±26 176 ± 19 16S± IS 154 ± 18 ISI±14' 144± 11' 134 ± 12' 149± IS' 177± 14 
Histidine ALA&GLY S7±4 SHS S9±8 SH6 45±7" S4±6 5H7 S1±S 45±7' 44 ±4' 41 ± 6" 49±4 
GLN SH3 63 ±4 S8±3 S8±2 61 ± 2' SH2 S7±2 49± 3 SH3 55 ± 1· S1±2 S6±3 
Aspartate ALA&GLY 14 ± I IH2 14± I 14± I 16 ± I' 16 ± I 1St I 14± I IH I 13 ± I IH I 14 ± I 
GLN 14± I IS±! IS ±1 IS±1 23±t"a 24 ± I"· 22±1" a 19±1'··. 20± 1 ... • 18 ± I"· 16± l' IS ±! 
Asparagine ALA&GLY 36 ±2 36± I 3S±2 34±2 40±2" 42± 1" 39±2 37±2 33± I 3H2' 31 ± I" 30i2" 
GLN 35± I 3H2 34± I 3H I 30±1"· 29 ± l"a 27± 1'" 27 ± t'·· 27±1"· 26± 10 •• 28 ± I·" 30 ± 1"" 
Serine ALA&GLY 123±5 13St 11 120±7 116±6 141±S'" 158 ± 9°"tl 160±lt'b ISH 11'" 144±9'" l50± IS"'\) ISO± 10'" 138±8 
GLN 115 ± 10 112 ± IS' 108±9 106±9 8H7" 79±6" 78 ±6" 7St6" 74±5" 69±5'· 79±S" 96 ± 10~ 
Arginine ALA&GLY 80±4 8S±4 8HS 8HS 77±6 76±4 69± 5" 69± 5" 62±4" 60±4" 61 ±4" 61 ± 7"' 
GLN 80±5 87±4 8S±S 81±4 79±5 76±4 73±7 70±4' 68±4" 61 ± S" 66±7" 73 ±61 
, . .. 
. '.' 
.. Values are means ± SD for 7 subjects, expressed In Jlmolll. different to basal value (P < 0.05), different to basal value (P < 0.01), different to ALA & GL Y condltJon (P < 0.05), different to GLN condition (P < 
0.01). 
Table 5.4. Summed plasma amino acid concentrations at rest and during exercise in the ALA & GLY and GLN conditions. 
EXI RECOVERY EX2 
Condition Basal 30min 60min 85min 60min 7Smin 90min 105 min 120min 180 min 240 min Exh 
Tryp:BCAA ALA&GLY 0.08 ±0.02 0.10 ± 0.01 O.ll±O.OI' 0.11 ±O.OI' 0.12± 0.02" 0.09 ±0.01 0.10 ± 0.01 0.09 ± 0.01 0.10 ± 0.01 0.10 ± 0.01 0.09 ± 0.01 0.1O±0.01 
GLN O.1l±O.OI' 0.11 ±0.01 0.12± 0.01 O.l2± 0.01 0.12± 0.01 0.12 ±O.OI' 0.12± 0.01' 0.11 ± 0.01 O.ll±O.OI 0.11 ± 0.01 0.1O±0.01 0.1O±0.01 
n-mAA ALA&GLY 578 ± 19 578 ± 3I 570 ±46 556 ± 50 997± 112'~ 1213± 119'~ 1078 ± 80'" 1014± 7S'''' 872±66'~ 810 ± 68'" 723 ±68'~ 629 ±46' 
GLN 572±46 623 ±43 591 ± 44 571 ±29 479± 25 451±20' 441 ± 29' 403±29" 402±11" 386 ±24" 403±21" 461±23' 
AAA ALA&GLY 117±6 124 ±6 131±10 131 ±9 101 ± 14 107± 10 lOB 8 106 ±7 97±8 89± 9 91 ± 10 121 ± 8' 
GLN 114±6 124 ± 10 126±9 128±6 110±4 I06±S IOB7 96± 8 99± 7 98 ±4 98 ± 6 III ±4 
NEAA ALA & GLY 1348 ± 29 1584 ± 59" 1582± 95~ 1527± 97' 2117± 189'" 2468 ±206"" 220B 90'''' 2161 ± 102'" 1846 ± 70'~ 1759 ± 120'~ 1576 ± 93'" 1534± 83 
GLN 1469 ± 80 1837 ± 82~·8 1893± Ill'" 1762± 67'" 1644± 36 1640 ±48 IS07± 88 1419 ± SO 1381±45 1263± 58 1233± 74' 1448 ± 72 
Tot. AA ALA&GLY 2160 ± 32 2370 ± 75' 2348± 144 2272 ± 137 2767± 223'~ 3204± 238'" 2900 ± 149'~ 2860 ± 119'" 2454 ± 105" 2392 ± 152' 217S ± 131' 2234± 107 
GLN 2289±104 2717±91'" 2737± 142'" 2575 ±69°·· 2381 ±S4 2338±72 2188 ± 108 2038 ± 56 2022 ±47 1903± 76' 1897± 95' 2187± liS 
Values are means ± SE for 7 subjects, expressed in j.l.moill. n-m M sum of non-metabolised amino acids (Thr, Met, Phe, Lys, Gly & Tyr); ~ sum of aromatic amino acids (Try, Tyr & Ph 
acids (Ala, Arg, Asp, Aso. Glu, Gin ,Gly, Ser, & Tyr); Tot. M sum ofal1 amino acids. "different to basal value (P < 0.05), ··different to basal value (P < 0.01), 'different to ALA & GLY con 
e); NEAA, sum of non -essential amino 
dition (P < 0.05), bdifferent to GLN 
condition (P < 0.01). 
BCAA, sum of branched-chain amino acids (Leu, Iso, Va)) and EM sum of essential amino acids (His, Iso, Lell, Lys, Met, Phe, Thr, Try, & Val) are shown in Fig. !U 1 & 5.12 respectively. 
Fig. 5.2 Plasma glucose concentration during the experimental period in the ALA & GL Y and GLN 
conditions. Values are means ± SEM for 7 subjects. 
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Fig. 5.3 Plasma lactate concentration during the experimental period in the CON, OKG and GLN 
conditions. Values are means ± SEM for 7 subjects. 
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Fig. 5.4 Serum insulin concentration during the experimental period in the ALA & GL Y and GLN 
conditions. Values are means ± SEM for 7 subjects. 
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Fig. 5.5 Plasma NEFA concentration during the experimental period in the ALA & GL Y and GLN 
conditions. Values are means ± SEM for 7 subjects. 
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Fig. 5.6 Plasma ammonia concentration during the experimental period in the ALA & GL Y and GLN 
conditions. Values are means ± SEM for 7 subjects. 
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Fig. 5.7 Plasma glutamine concentration during the experimental period in the ALA & GLY and GLN 
conditions. Values are means ± SEM for 7 subjects. 
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Fig. 5.8 Plasma glutamate concentration during the experimental period in the ALA & GL Y and GLN 
conditions. Values are means ± SEM for 7 subjects. 
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Fig. 5.9 Plasma alanine concentration during the experimental period in the ALA & GL Y and GLN 
conditions. Values are means ± SEM for 7 subjects. 
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Fig.5.10 Plasma glycine concentration during the experimental period in the ALA & GLY and GLN 
conditions. Values are means ± SEM for 7 subjects. 
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Fig.5.11 Sum of plasma branched-chain amino acids (BCAA) during the experimental period in the 
ALA & GLY and GLN conditions. Values are means ± SEM for 7 subjects. 
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Fig. 5.12 Sum of essential plasma amino acids during the experimental period in the ALA & GL Y and 
GLN conditions. Values are means ± SEM for 7 subjects. 
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5.3 DISCUSSION 
The main finding from the present study was that no difference was observed in cycle 
time to exhaustion between conditions in the second bout of exercise, despite a better 
maintenance of plasma glucose concentration during the second bout of exercise after 
the ingestion of glutamine during the recovery period. 
The ingestion of glutamine in the recovery period was able to elevate plasma glutamine 
concentration at peak concentration by 64 ± 8 % relative to the basal value (ALA & 
GL Y condition: 18 ± 6 %). This elevation in systemic glutamine concentration 
occurred despite the expected sequestration of approximately 55 % ofthe oral glutamine 
load by the splanchnic bed (Matthews et al. 1993; Haisch et al. 2000). It has been 
demonstrated that the intravenous infusion of glutamine is able to increase plasma 
glutamine concentration by -70 % which resulted in a -16 % increase in intramuscular 
glutamine concentration (Varnier et al. 1995). Therefore the increase in plasma 
glutamine concentration of -65 % following oral glutamine ingestion in the present 
study is expected to have increased glutamine concentration in many tissues. Although 
not measured in this study, it is probable that the increase in plasma glutamine 
concentration will have increased glutamine concentration particularly in the liver, 
kidneys and skeletal muscle (Nurjhan et al. 1995; Stumvoll et al. 1996; Stumvoll et al. 
1998). 
In addition to the elevation in plasma glutamine concentration, the ingestion of 
glutamine increased the plasma glutamate concentration by 56 ± 14 %, relative to the 
basal value (ALA & GL Y condition: 25 ± 8 %). This increase in plasma glutamate 
concentration is presumably due to glutamine-glutamate cycling, between the liver, 
kidneys, and skeletal muscle (Stumvoll et al. 1998). 
It has been suggested that in normal postabasorptive humans 40-60 % of plasma 
glutamine disappearance is due to oxidation (Nurjhan et al. 1995; Perriello et al. 1997; 
Stumvoll et al. 1996), 10-20 % to gluconeogenesis (Nurjhan et al. 1995; Perriello et al. 
1997; Stumvoll et al. 1996) and most of the remainder (-15 %) to protein synthesis 
(Perriello et al. 1997). However, it is feasible that the provision of exogenous 
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glutamine may alter the contribution of glutamine to these processes, for example 
increasing both gluconeogenesis (Nurjhan et al 1995) and skeletal muscle protein 
synthesis (MacLennan et al. 1988). Indeed, glutamine has been shown to increase liver 
glycogen synthesis in 72 h fasted rats, i.e., when glycogen is depleted (Mouterde et a1. 
1992). This scenario could also occur after a bout a prolonged submaximal exercise, 
when both skeletal muscle and liver glycogen levels has been shown to be considerably 
reduced (Casey et at. 2000). Therefore, it is conceivable that the better maintenance of 
plasma glucose concentration observed during the second bout of exercise in the GLN 
condition is indicative of an increased hepatic glycogen storage during the recovery 
period. This may be due to the provision of exogenous glutamine causing a more rapid 
increase in liver glycogen stores compared with intramuscular stores post exercise, as a 
larger proportion of glutamine is extracted on first pass by the splanchnic bed 
(Matthews et al. 1993; Haisch et at. 2000). 
Therefore, during the second bout of exercise, the better maintenance of plasma glucose 
level is most probably related to an increased hepatic glucose output, although a 
reduction in skeletal muscle glucose uptake cannot be ruled out. When the results of the 
present study are compared to the previous study, it is feasible that a better maintenance 
of plasma glucose concentration is observed in both studies during the second bout of 
exercise following the ingestion of glutamine (glucose-polymer and glutamine in the 
previous study) during the recovery period. It is therefore conceivable that at least part 
of the maintenance in plasma glucose concentration observed in the second bout of 
exercise is attributable to glutamine ingestion during the recovery period, demonstrating 
the purported glucogenic or glycogenic properties of glutamine. 
Despite a better maintenance of plasma glucose concentration in the second bout of 
exercise after the ingestion of glutamine in the recovery period, cycle time to exhaustion 
was not different between conditions. It has been reported that blood glucose 
concentration is an important factor in the aetiology of fatigue, particularly during 
cycling (Coyle et at. 1983; Derman et at. 1996). One may therefore have expected 
cycle time to exhaustion in the second bout of exercise to be greater after the ingestion 
of glutamine in the recovery period, but this was not observed. It appears that at least 
with the protocol employed in the present study, blood glucose concentration was not 
the crucial limiting factor in the aetiology of fatigue in the second bout of exercise. 
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Other factors including muscle glycogen concentration, may dictate cycle time to 
exhaustion during the second bout of exercise employed in the present protocol. 
Recently, van Hall et al. demonstrated that a combination of glucose-polymer and 
glutamine solution consumed after exhaustive exercise does not increase skeletal muscle 
glycogen resynthesis, or activate glycogen synthase to a greater extent than glucose-
polymer alone (van Hall et al. 2000a). However, no comparison was made with a 
glutamine only condition, therefore any effect that the ingestion of glutamine may have 
on skeletal muscle glycogen resynthesis, such as the increase demonstrated by Vamier 
and colleagues (Vamier et al. 1995), may have been masked by the co-ingestion of 
glucose-polymer. Indeed, the dose of glucose-polymer used by van Hall et al. (0.8 
g'kg-1) was sufficient to maximally stimulate glycogen synthase and achieve the 
maximal rate of muscle glycogen resynthesis (Ivy, 1988b). It would have been 
intriguing to have included a condition in which glutamine was ingested alone or in 
combination with a lower dose of glucose-polymer to examine the possible synergistic 
effects of glutamine and glucose-polymer supplementation during recovery from 
exercise. 
During the determination of the plasma amino acid concentrations in the present study, 
problems were experienced with the autoinjector during the HPLC analysis. In 
particular the amino acids alanine, tyrosine, isoleucine, leucine and ornithine were 
affected. The basal concentration and the concentration during the first bout of exercise 
are significantly different between conditions, a period where no differences in the 
treatment of the subjects occurred, hence no statistical differences in the physiological 
measurements were expected. Therefore, the data obtained and subsequent discussion 
of the results for these particular amino acids must be treated with caution. 
Despite problems with the determination of alanine concentration, the ingestion of 
alanine and glycine during recovery from exercise resulted in a significant increase in 
the concentration of both of these amino acids relative to the GLN condition during the 
recovery period. Plasma glycine concentration increased by -300 % (at peak 
concentration; 45 min after ingestion) relative to basal concentration after alanine and 
glycine ingestion, with plasma glycine concentration falling by -30 % at the same time 
point following glutamine ingestion. Plasma alanine concentration increased by -100 
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% (at peak concentration; 45 min after ingestion) relative to basal concentration after 
alanine and glycine ingestion, with a plasma alanine concentration falling by -10 % at 
the same time point following glutamine ingestion. 
Following alanine and glycine supplementation, the area under the serum insulin curve 
was greater during the recovery period, suggesting an increase insulin response 
following the ingestion of these amino acids. Therefore, it would appear that either one 
or both of these amino acids has a greater insulinogenic effect than glutamine. Indeed, 
it has previously been reported in sheep that the intravenous infusion of both glycine 
and alanine individually increase the area under the plasma insulin curve to a greater 
extent than glutamine, with glycine invoking the greatest response (Kuhara et al. 1991). 
In addition, the infusion of these two amino acids also produced a greater glucagon 
response, suggesting that alanine and glycine ingestion individually may promote the 
secretion of both insulin and glucagon. 
During the recovery period, there was a tendency for plasma tyrosine concentration to 
be reduced, conversely, there was a tendency for plasma phenylalanine concentration to 
be higher after glutamine ingestion. This is somewhat paradoxical as tyrosine is 
synthesised almost exclusively from phenylalanine via the phenylalanine hydroxylase 
reaction. Therefore, any increase in phenylalanine concentration should be reflected by 
an increase in tyrosine concentration, however in the present study this does not appear 
to be the case. This may be explained by a rapid increase in the rate of flux through the 
phenylalanine hydroxylase reaction following glutamine ingestion resulting in the rapid 
disappearance of tyrosine and the appearance of phenylalanine in plasma. However, in 
light of the potential problems experienced with the determination of tyrosine, these 
results should treated with caution. 
Both the sum of the non-essential plasma amino acids and the total amino acids were 
significantly higher during the recovery period in the ALA & GL Y condition compared 
to the GLN condition. This difference is primarily due to the ingestion of the amino 
acid glycine, which is not metabolised in skeletal muscle and therefore remains present 
in the plasma for a prolonged period of time. Linked to the high prevailing plasma 
concentration of glycine is the synthesis of other amino acids. For example, serine is 
synthesised from glycine via the serine transhydroxymethylase reaction, and although 
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this reaction proceeds more often in the direction of glycine synthesis from serine, the 
ingestion and high plasma concentration of the non-metabolisable amino acid glycine 
appears to have forced the reaction towards serine production. Furthermore, it is 
feasible that the increase in glycine concentration explains the increase in threonine 
concentration, as the high concentration of glycine presumably forced the threonine 
aldolase reaction in the direction of threonine synthesis. However, glycine combines 
with acetaldehyde in this reaction, which in high concentrations is toxic, suggesting that 
this pathway of biosynthesis less likely. In this respect, the increase in threonine 
concentration is difficult to explain. 
Plasma asparagine concentration was also elevated during the recovery period following 
the ingestion of the alanine and glycine. This amino acid is synthesised primarily from 
aspartate via the asparagine synthetase reaction. However, no concomitant increase in 
plasma aspartate concentration was observed after the ingestion of the alanine and 
glycine, leaving the mechanism for the increase in asparagine concentration unresolved. 
There was however, an increase in plasma aspartate concentration during the recovery 
period following the ingestion of glutamine. Aspartate is primarily derived from 
asparagine in the asparaginase reaction, however it is also possible for aspartate to be 
synthesised via the aspartate aminotransferase reaction (aspartate + a-ketoglutarate ~ 
oxaloacetate + glutamate). In the present study, the ingestion of glutamine increased the 
plasma concentration of both glutamine and glutamate, thereby providing readily 
available substrate for the aspartate aminotransferase reaction. Concurrently, the influx 
of glutamine derived carbons (glutamine ~ glutamate ~ a-ketoglutarate) into the TCA 
cycle may have increased the availability of oxaloacetate. An increase in the 
availability of the substrates oxaloacetate and glutamate may therefore have increased 
flux through the aspartate aminotransferase reaction in the direction of aspartate 
formation. 
Indeed, in isolated intestinal mucosal cells, glutamine carbon has been shown to be 
incorporated into aspartate (Fleming et al. 1997). The most likely pathway by which 
glutamine carbon could be incorporated into aspartate would be via efflux of 
intermediates from the TCA cycle. Therefore, if this mechanism is to explain the 
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increase in aspartate concentration following glutamine ingestion, this fmding provides 
indirect evidence that carbon derived from glutamine can enter the TCA cycle and be 
removed at various points to be used in the biosynthesis of a variety of metabolites 
including glutamate, lactate, alanine, aspartate, citrulline, C02, pro line, succinate, and 
ornithine (Fleming et al. 1997). Furthermore, the availability of glutamine appears to 
influence the rate of entry of glutamine carbons into the TCA cycle (see Chapter 6). 
Increasing the entry of glutamine into the TCA cycle in intestinal epithelial cells 
resulted in a decreased fractional oxidation of glutamine and an increased incorporation 
into synthetic products such as aspartate, lactate, alanine and succinate (Quan et al. 
1998). 
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CHAPTER 6 
EFFECT OF GLUTAMINE AND ORNITHINE a-
KETOGLUTARATE SUPPLEMENTATION PRIOR TO 
EXERCISE ON TCA CYCLE INTERMEDIATE POOL SIZE AND OXIDATIVE 
ENERGY DELIVERY 
6.1 INTRODUCTION 
The tricarboxylic acid (TCA) cycle is the central site for interaction between 
carbohydrate, fat and amino acid metabolism in human skeletal muscle both at rest and 
during exercise. Acetyl units derived from glycolysis, the ~-oxidation offats and amino 
acid metabolism are oxidised during their passage through the TCA cycle. There is a 
nine-fold increase in the total content of the TCA cycle intermediates (TCAl) during the 
transition from rest to exercise at 75% V02max (Sahlin et al. 1990). However, it is not 
clear whether this expansion is of any functional significance to oxidative energy 
production. It has been suggested that the increase in the total content of the TCA cycle 
intermediates may be necessary for optimal oxidative energy production during intense 
muscular contraction (Sahlin et al. 1990; Lee and Davis, 1979). The alternative view is 
that this expansion of the TCAl pool may merely reflect the increase in pyruvate 
availability resulting from the mismatch between the rate of pyruvate formation, due to 
the increase in glycolysis at the onset of exercise, and the rate of oxidation of acetyl 
units in the TCA cycle (Constantin-Teodosiu et al. 1999; Gibala et al. 1998). 
It has also been suggested that a decrease in the total content of TCAl may reduce flux 
through the TCA cycle and the capacity to provide energy via oxidative metabolism 
(Sahlin et al. 1990). Therefore, it is expected that at fatigue the total content of the 
TCAl would be reduced, indeed, this is the case during prolonged submaximal exercise 
(Sahlin et al. 1990; Gibala et al. 1997b). However, this evidence is not sufficient to 
suggest a direct relationship between the total content of the TCAl and fatigue during 
prolonged submaxirnal exercise. 
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The TCAl pool size is determined by balance between the flux of carbon into and out of 
the TCA cycle (Lee and Davis, 1979). The increase in TCAl at the onset of exercise is 
thought to be primarily due to an increase in the rate of anaplerosis [replenishment of 
TCAl), attributable largely to an increase in flux through the alanine aminotransferase 
reaction (glutamate + pyruvate ++ a-ketoglutarate + alanine) (Gibala et al. 1997a; 
Sahlin et al. 1990; Spencer et al. 1991 b), with carbon entering the TCA cycle at the 
level of a-ketoglutarate. The significance of this 'anaplerotic' reaction is highlighted by 
the increase in muscle alanine and decrease in muscle glutamate content at the onset of 
moderate intensity exercise (Gibala et al. I 997a). One way in which to examine the 
functional significance ofthe TCAl pool size would be to attempt to further increase the 
expansion of the TCAl at the onset of exercise through nutritional intervention and 
examine the effect upon metabolism. 
The content of the TCAl may also be affected by changes in muscle amino acid 
metabolism, as many of the TCA cycle intermediates take part in ancillary reactions 
involving amino acids. During conditions in which glycogen availability is limited, for 
example at the latter stages of prolonged exercise, branched-chain ketoacid 
dehydrogenase activity is increased (Wagenmakers et al. 1991), increasing BCAA 
oxidation. The first step in branched-chain amino acid (BCAA; leucine, isoleucine, 
valine) pathway is a reversible transamination reaction in which a-ketoglutarate acts as 
an amino group acceptor, forming glutamate and a branched-chain ketoacid. Therefore, 
an increase in BCAA oxidation may result in an increased rate of a-ketoglutarate 
'drainage' from the TCA cycle (Wagenmakers et al. 1991; Wagenrnakers et al. 1990). 
The implications of the removal of a-ketoglutarate from the TCA cycle are minimal as 
this 'drainage' is normally counteracted by the regeneration of this intermediate by the 
alanine aminotransferase reaction. However, during the latter stages of prolonged 
exercise when pyruvate availability for the alanine aminotransferase reaction is reduced, 
due to decreased glycogen or blood glucose, and anunonia levels are increased, the 
formation of glutamine is favoured (Goldberg and Chang, 1978). In this scenario, it has 
been suggested that the content of a-ketoglutarate may decrease, due to a net export of 
a-ketoglutarate as glutamine from the muscle. This may lead to a reduction in TCA 
cycle flux and the rate of oxidative energy production, which may have implications for 
the development of fatigue. This hypothesis was recently tested by supplementing 
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BCAA in the glycogen depleted state in an attempt to increase BCAA oxidation and 
reduce the muscle a-ketoglutarate content (Gibala et al. 1999b). The reduction in 
muscle a-ketoglutarate content was negligible, however only 15 min of moderate 
intensity exercise was performed; the scenario at fatigue may be different. We 
hypothesised that the provision of a nutritional supplement that could increase the 
muscle content of a-ketoglutarate may delay the fatigue process during prolonged 
exercise, particularly when glycogen levels are low. 
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CO2 /CD \® 
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Fig 6.1 Proposed entry of carbon into TeA cycle. (j) Conversion of glutamine to glutamate via the 
action of glutaminase or glutamine transaminase; ~ Conversion of glutamate to a-ketoglutarate through 
the action of glutamate dehydrogenase; ® Alternate conversion of glutamine to a-ketoglutaramate via the 
action of glutamine transaminase; @) Alternate conversion of a-ketoglutaramate to a-ketoglutarate 
through the action of ro-amidase; ~ Proposed entry of a-ketoglutarate moiety of ornithine a-ketoglutarate 
(OKG). 
It is feasible that carbon from the amino acid glutamine could enter the TCA cycle at the 
level of a-ketoglutarate (see Fig 6.1). Indeed, this has been demonstrated in intestinal 
epithelial cells (Quan et al. 1998), and should occur in skeletal muscle since all of the 
enzymes (glutaminase [EC 3.5.1.2], glutamine transaminase [EC 2.6.1.15], glutamate 
dehydrogenase [EC 1.4.1.2], ro-amidase [EC 3.5.1.3]) required to catalyse the 
conversion of glutamine to a-ketoglutarate are present (Wu et al. 1991; Rennie et al. 
1992; Wibom et al. 1992; Swierczynski et al. 1993). Given the purported anabolic 
properties of glutamine (Lacy and Wilmore, 1990; MacLennan et al. 1988), the 
supplementation of this amino acid could also conceivably modulate liver, skeletal 
muscle and whole-body metabolism. 
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A more direct approach to provide carbon at the level of a-ketoglutarate would be to 
provide the substrate a-ketoglutarate itself (see Fig 6.1). Ornithine a-ketoglutarate 
(OKG) (a salt formed of two molecules of ornithine and one molecule of a-
ketoglutarate) is a precursor of glutamine, arginine, proline, and polyamines, all of 
which have potent roles in the control of protein metabolism (for review see Le Boucher 
and Cynober, 1998). Furthermore, OKG administration has been shown to restore the 
intramuscular glutamine pool (Hanunarqvist et al. 1990; Le, Boucher et al. 1997). 
Glutamine synthesis is increased after OKG administration as ornithine and a-
ketoglutarate share a common metabolic pathway in which all the steps depend upon 
enzyme reactions at equilibrium or uncontrolled unenzymatic reactions (see section 2.4, 
Chapter 2). This means that ornithine and a-ketoglutarate metabolism divert to other 
pathways when the common pathway is saturated, resulting in glutamine formation 
(Cynober, 1999). Therefore, in addition to modulating TCA cycle metabolism by 
providing the TCAl a-ketoglutarate, the ingestion of OKG may also promote protein 
retention. 
The aims of the present study were therefore twofold. Firstly, to determine whether, 
under conditions of low glycogen availability, the consumption of glutamine or OKG 
influenced the TCAl pool size at rest and during exercise. Secondly, if successful, to 
investigate the effect of this expansion upon energy metabolism and exercise capacity in 
human skeletal muscle. 
6.2 METHODS 
Subjects. Seven healthy well-trained male subjects participated in this study. Their 
mean (± SEM) age, height, body mass and V02max were 24.1 ± 1.2 y, 180.2 ± 2.0 cm, 
80.0 ± 1.6 kg and 4.99 ± 0.15I.min-1 (62.5 ± 1.8 ml.kg-1.min-1), respectively. 
Preliminary tests. Subjects reported to the laboratory approximately I week before the 
experiment and undertook two preliminary tests in order to determine: (i) the oxygen 
cost of submaximal cycling, and (ii) maximal oxygen uptake (V02max). The protocols 
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for these tests have been described elsewhere (see Chapter 3). Subjects were fully 
familiarised with the experimental procedures used during the experimental trials. 
Protocol of the study. Subjects were instructed to consume their habitual diet and 
refrain from exercise or strenuous physical activity for 48 h prior to each experiment. 
On the afternoon before the experiment, subjects performed a bout of glycogen-
depleting exercise, as described previously (Chapter 3). Prior to, and immediately after 
this bout of exercise, a finger prick capillary blood sample was obtained from each 
subject to determine both blood lactate and glucose concentrations (YSI 2300 
STATPLUS lactate and glucose analyser) to ensure that blood lactate concentration 
was sufficiently reduced to prevent gluconeogenesis and glycogen resynthesis from 
lactate during recovery. Subjects then consumed a diet low in carbohydrate over the 
next -18 h (see Chapter 3). 
All food consumed after the glycogen-depleting exercise bout was prescribed for each 
subject and was identical before all trials for a given subject, providing 35 ± 2% 
carbohydrate, 56 ± 2% fat, and 11 ± 2% protein, -6.0 MJ (Compeat 5.0 Diet Analysis 
Software, Carlston Bengston Consultants Ltd, USA), to ensure that muscle glycogen 
stores were reduced prior to the main exercise trial. 
On arrival at the laboratory on the morning of the experiment, the overnight fasted 
subject rested in a supine position and a cannula was inserted into an anti-cubital vein 
and a resting blood sample was obtained. Subjects then consumed one of three 
solutions, in a double-blind manner, 5 ml'kg,l body wt of an artificially sweetened 
placebo (CON), 0.125 g'kg,l body wt L(+)ornithine a-ketoglutarate (Laboratories 
Jacques Logeais, Paris, France) dissolved in 5 ml'kg'l body wt of the artificially 
sweetened placebo (OKG), or 0.125 g'kg,l body wt L-glutamine (Sigma-Aldrich 
Chemicals, Dorset, UK) dissolved in 5 ml'kg,l body wt of the artificially sweetened 
placebo (GLN). The solutions were allocated by systematic rotation. After 
consumption of the assigned solution, subjects rested for 60 min, then immediately 
cycled at 70% V02max until volitional exhaustion. Exhaustion was determined using the 
defmition as described previously (Chapter 4, page 96). 
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Approximately 15 min before exercise, the skin and fascia over the anterior aspect of 
one thigh was anaesthetised (Lignocaine, 1 % w:v, Antigen Pharmaceuticals, Ireland) 
and three small incisions were made to allow extraction of needle biopsy samples from 
the vastus lateralis muscle (Bergstrom, 1975). Needle biopsy samples were obtained 
immediately prior to exercise (60 min after consumption of the assigned solution), after 
10 min of exercise and at exhaustion (see Chapter 3 for description of method). During 
the 1 h rest period, after consumption of the assigned solution, venous blood samples 
were taken every 20 min. During exercise, venous blood samples were taken at 10 min, 
and then every 15 min thereafter and at exhaustion. Expired air samples were collected, 
by Douglas bag for 6 min at rest, 20 and 40 min after consumption of the solution, and 
for 1 min every 15 min during exercise and at exhaustion. 
Dry bulb temperature and relative humidity within the laboratory during the glycogen 
depleting exercise and the main experimental trial are presented in Table 6.1. No 
significant differences were observed in temperature and relative humidity between 
conditions. 
Table 6.1 
Condition 
CON 
OKG 
GLN 
Dry bulb temperature (DBT) and relative humidity (RH) during the 
glycogen depleting exercise and the main experimental trial. 
Glycogen depletion Main trial 
DBT("C) RH(%) DBT ("C) RH(%) 
21.4 ± 0.1 56.6±2.8 20.8 ±0.2 54.0±2.6 
21.5 ± 0.4 55.1 ±3.5 20.6±0.6 52.6 ± 1.8 
21.2 ± 0.4 55.8 ±2.4 20.5 ±0.6 54.1 ± 1.8 
Analysis. Expired air samples were collected and analysed as previously described 
(Chapter 3). Venous blood samples were analysed for whole blood lactate and glucose 
concentration, haemoglobin concentration and haematocrit values, plasma ammonia and 
amino acid concentration, serum insulin and NEF A concentrations, as previously 
described (Chapter 3). Percentage changes in plasma volume were calculated as 
previously described (see Chapter 3). 
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Muscle biopsy samples were immediately immersed in liquid nitrogen, removed from 
the needle and stored in liquid nitrogen until freeze-dried and stored at -70°C. At a later 
date the freeze-dried muscle sample was dissected free of visible blood and connective 
tissue, powdered and washed twice with petroleum ether to remove any fat (see Chapter 
3 for full description). Muscle metabolites (ATP, PCr, Cr, lactate, pyruvate, citrate, 
succinate, malate, fumarate, glutamine and glutamate) were extracted (see Chapter 3 for 
full description) and determined enzymaticaIly (see Appendix for each procedure). 
Pre-exercise energy intake. The energy intake of subjects during the 48 h prior to the 
glycogen depletion protocol of the main trial are presented in Table 6.2. No differences 
were observed between conditions in the pre-exercise diet. 
Table 6.2 Energy content and percentage of the primary dietary nutrients 
of the pre-exercise diet for all conditions (mean ± SEM). Data 
presented is mean of2 days diet. 
CON OKG GLN 
Energy (MJ/day) 12.0 ± 1.7 11.9 ± 1.8 12.0 ± 1.7 
Carbohydrate (%) 65.3 ± 3.1 64.9±3.2 64.9±3.2 
Fat(%) 22.3 ±3.9 22.7±3.9 22.8±3.9 
Protein (%) 12.5 ± 0.6 12.5 ± 0.6 12.5 ± 0.6 
Statistical analysis. The data were analysed by two-way analysis of variance (ANOVA) 
for repeated measures (time X condition). Cycle time to exhaustion data were analysed 
by one-way ANOVA. When the ANOVA resulted in a significant F ratio, Fisher's post 
hoc test was used to locate differences between means. Statistical significance was 
accepted at the 5% level (P <0.05). Results are presented as means ± SEM. 
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Fig. 6.2 Schematic illustration of the main experimental trial 
6.3 RESULTS 
No differences were observed between conditions in any of the measured physiological 
variables during the glycogen depleting exercise including blood lactate and glucose 
concentrations. 
Cardiorespiratory and exercise capacity data. Heart rate, pulmonary oxygen uptake, 
respiratory exchange ratio and expired minute ventilation (data not shown) showed 
main effects for time (P < 0.05); however, there were no significant differences between 
conditions (Table 6.3 & 6.3). The average heart rate during the glycogen-depleting 
exercise was 158 ± 2 b.min·\ 162 ± 2 b.min·\ and 157 ± 2 b.min·\ in the CON, OKG 
and GLN conditions respectively. The average heart rate during exercise in the main 
experimental trial was 169 ± 3 b.min·\, 172 ± 3 b.min·\ and 171 ± 4 b.min-\ in the CON, 
OKG and GLN conditions respectively. 
Cycle times to exhaustion were 77.5 ± 6.9 min, 63.7 ± 5.4 min and 84.4 ± 9.3 min in the 
CON, OKG and GLN conditions respectively. Cycle time to exhaustion was not 
significantly different between conditions. 
Blood glucose and lactate concentration. Blood lactate concentration was not different 
during the 1 h rest period after the consumption of the assigned solution. Blood lactate 
concentration increased during exercise (P < 0.05), but there were no differences 
between conditions, despite a tendency for a higher concentration in the OKG condition 
during exercise (Fig. 6.3). 
Blood glucose concentration was not different between conditions in the 1 h after 
ingestion of the assigned solution (Fig. 6.4). Blood glucose concentration increased 
slightly in all conditions during exercise, with a tendency for a higher concentration in 
the OKG condition throughout exercise and at exhaustion (Fig. 6.4). 
Serum insulin and NEFA concentration. The serum concentration of insulin increased 
(P < 0.05) during the 1 h after consumption of the OKG and GLN solution compared to 
the CON condition (Fig. 6.5), with the concentration in the OKG condition still elevated 
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above the CON condition immediately prior to exercise (P < 0.05). During exercise, the 
serum insulin concentration decreased in all conditions, with no differences observed 
between conditions. 
Serum NEF A concentration increased steadily during the I h after consumption of the 
solution in the CON condition compared to the basal value (Fig. 6.6). In contrast, a 
decrease was observed from basal values in the OKG and GLN conditions. During 
exercise, the serum NEF A concentration steadily increased in all conditions until 
exhaustion, with no differences between conditions observed. 
Plasma ammonia and amino acid concentration. Plasma anunonia concentration was 
not different between conditions at any time point. At exhaustion, plasma ammonia 
concentration was significantly elevated (P < 0.01) in all conditions (Table 6.5). 
The plasma concentration of both glutamine (Fig 6.7) and glutamate (Fig 6.S) was 
increased 1 h after consumption of the supplement in the GLN condition, compared to 
both the CON and OKG conditions (P < 0.05). Furthermore, the plasma concentration 
of glutamine remained elevated at 10 min of exercise in the GLN condition, compared 
to both the CON and OKG conditions (both P < 0.05). Plasma ornithine concentration 
was higher 1 h after ingestion of the supplement in the OKG condition (Fig. 6.9) and 
remained elevated throughout exercise in the OKG condition compared to both the 
CON and OKG conditions (both P < 0.05). Plasma alanine concentration significantly 
increased (P < 0.05) in all conditions during exercise relative to the basal value (Fig. 
6.10). In addition, plasma alanine concentration was significantly higher in the GLN 
and OKG conditions compared to the CON condition 1 h after the consumption of the 
supplements and at 10 min of exercise. Plasma aspartate concentration increased 
significantly (P < 0.05) in the GLN condition 1 h after the consumption of the solution, 
compared to both the CON and OKG conditions (Table 6.5). Plasma arginine 
concentration was significantly elevated at 10 min of exercise in the OKG condition 
compared to the CON condition (P < 0.05). 
No differences were observed over time or between conditions in the sum of the plasma 
branched chain amino acids (Iso, Vat, & Leu). No differences were observed in the sum 
of the plasma concentration of the essential amino acids (His, Iso, Leu, Lys, Met, Phe, 
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Tbr, Try, & Val) between conditions at any time point (Table 6.6). The sum of the 
plasma concentration of the non-essential amino acids (Ala, Arg, Asp, Asn, Glu, Gin, 
Gly, Ser, & Tyr) was significantly higher (P < 0.05) in the GLN condition compared to 
the CON condition 1 h after ingestion of the solution. In addition, the sum of the 
plasma concentration of the non-essential amino acids increased at exhaustion in all 
conditions, with no differences observed between conditions (Fig. 6.11). The sum of 
the plasma concentration of the aromatic amino acids (Try, Tyr & Phe) was 
significantly higher (P < 0.05) in the OKG condition I h after consumption of the 
solution and at 10 min exercise (Fig. 6.12). Total plasma amino acid concentration was 
significantly lower (P < 0.05) in the CON condition 1 h after consumption of the 
solution and at 10 min exercise (Table 6.6). 
Muscle amino acid content. The intramuscular content of glutamine pre exercise was 
significantly higher (P < 0.05) after GLN supplementation (Table 6.7), compared with 
the CON and OKG conditions. Muscle glutamine content was not different between 
conditions at 10 min of exercise or at exhaustion. Intramuscular glutamate content 
decreased by -60 % in all conditions after 10 min of exercise (P < 0.05) relative to the 
pre exercise value and was unchanged at exhaustion (Table 6.7). No difference was 
observed between conditions in muscle glutamate content at any time point. 
TeAl content. The total content of the four measured TCAl (LTCAl; citrate, succinate, 
malate, and fumarate) was not different between conditions at rest (Fig. 6.13). The 
L;TCAl at 10 min of exercise was greater than at rest in all conditions (P < 0.05), and 
was higher in the GLN condition (4.90 ± 0.61 mmol/kg dry wt) compared to the control 
condition (3.74 ± 0.38 mmol/kg dry wt, P < 0.05) and the OKG condition (3.85 ± 0.28 
mmol/kg dry wt) (Fig. 6.13). The L;TCAl decreased in all conditions at exhaustion, 
with no difference observed between conditions (CON: 3.16 ± 0.49; OKG: 3.49 ± 0.75; 
GLN: 3.41 ± 0.53, mmol/kg dry wt). The decrease in the LTCAl at exhaustion was 
greatest in the GLN condition with the value at exhaustion being significantly lower 
than at 10 min of exercise (Fig. 1). The total content of the TCAl pre exercise was 
comprised of malate (-22%), succinate (-23%), citrate (-52%) and fumarate (-3%). At 
10 min of exercise, the total content of the TCAl was comprised of malate (-42%), 
succinate (-31%), citrate (-22%) and fumarate (-5%). At exhaustion, the total content 
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of the TCAl was comprised of malate (-34%), succinate (-33%), citrate (-29%) and 
fumarate (-4%). There were no differences in any of the individual TCAl between 
conditions (Table 6.8). 
Intramuscular metabolite content. No differences were observed in ATP content over 
time or between conditions. PCr content had declined to a similar extent after 10 min of 
exercise in all conditions (CON: from 89.5 ± 2.9 mmollkg dm by 26 ± 6 %; OKG: from 
93.5 ± 1.7 mmollkg dm by 19 ± 7 %; GLN: from 88.2 ± 3.7 mmollkg dm by 21 ± 6 %, 
Table 6.9). At exhaustion, there was a slight tendency for a further decrease in all 
conditions in PCr content relative to the 10 min value, however no difference was 
observed between conditions. Intramuscular lactate content was not different between 
conditions either pre exercise, at 10 min of exercise or at exhaustion (Table 6.9). 
Intramuscular pyruvate content increased in all conditions during flIst 10 min of 
exercise (CON: from 0.37 ± 0.06 mmollkg dm by 70 ± 39 %; OKG: from 0.31 ± 0.06 
mmollkg dm by 134 ± 96 %; GLN: from 0.32 ± 0.05 mmollkg dm by 171 ± 99 %, 
Table. 6.9). Pyruvate content continued to increase in the CON condition such that the 
content at exhaustion was significantly different (P < 0.05) to the pre exercise value. 
No differences were observed between conditions at any time point. 
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Table 6.3 Oxygen uptake (VO,), % Vo,,,,,,,, heart rate (HR), respiratory exchange 
ratio (RER), carbohydrate oxidation rate (CRO Ox) and fat oxidation rate (Fat Ox) 
during the glycogen depleting exercise in the CON, OKG and GLN conditions. 
Exercise 
Condition 30min 60min 85min 
CON 3.62±0.12 3.58 ±0.14 3.62±O.l6 
~O, (I.min·') OKG 3.67±0.12 3.65 ±O.l5 3.81 ±O.l9 
GLN 3.53 ±O.lO 3.77 ±O.l5 3.61 ± 0.11 
CON 73.6 ± 1.8 72.7 ± 1.4 73.4±2.1 
%~O,,,,,,,, OKG 74.6 ±0.8 74.1 ± 1.6 77.2±2.4 
GLN 71.7 ± 0.7 76.7 ±2.2 73.5 ± 1.2 
HR (b.min·') CON 155±4 160±6 161 ±5* 
OKG 159±5 163 ±7 165 ±5* 
GLN 154 ±3 159 ±5 160 ± 5' 
RER CON 0.95±0.01 0.93 ±0.01 0.92 ±0.01* 
OKG 0.96 ±0.01 0.95 ±0.01 0.94 ±0.01* 
GLN 0.95±0.01 0.93 ±0.02 0.92 ±0.02* 
CRO Ox (g·min·') CON 3.45 ±0.11 3.46±0.12 3.38 ±0.\3 
OKG 3.71 ±0.20 3.47±0.22 3.41 ±0.30 
GLN 3.53 ±O.l5 3.46±0.19 3.30±0.22 
Fat Ox (g.min·') CON 0.32 ±0.09 0.48±0.07 0.47 ±0.08* 
OKG 0.35±0.05 0.37±0.09 0.47 ±0.08* 
GLN 0.36 ± 0.07 0.44 +0.06 0.45 ±0.11* 
Values are means ± SEM for 7 subjects . 
• p < 0.05 vs. 30 min 
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Table 6.4 Oxygen uptake, % YO,,,,,,,,, heart rate (HR), respiratory exchange ratio (RER), carbohydrate oxidation rate (CHO Ox) and filt oxidation rate (Fat Ox) during 
the main experimental trial in the CON, OKG and GLN conditions. 
Rest Exercise 
Condition Basal -40min -20min 15min 30min 45min 60min Exh 
CON 0.34±0.02 0.34 ±0.01 0.36 ±0.02 3.73± 0.16 3.89 ±O.15 3.77 ±0.18 3.91 ± 0.14 3.71 ±0.24 
VO, (I.min-') OKG 0.33 ± 0.01 0.32 ±0.01 0.35 ±0.01 3.73± 0.15 3.74 ± 0.15 3.76 ±O.18 3.78 ± 0.23 3.64 ±0.21 
GLN 0.33±0.01 0.36 ±0.01 0.36 ± 0.01 3.72 ± 0.14 3.71 ± 0.13 3.73 ±O.l5 3.52 ± 0.14 3.62 ±O.l9 
CON 6.8 ± 0.4 6.9 ± 0.2 7.2 ± 0.4 75.7 ± 1.6 79.4 ± 3.5 76.5± 1.7 78.2 ±2.8t 75.1±3.4 
%YO,,,,,,,, OKG 6.7± 0.2 6.6 ± 0.3 7.2 ± 0.4 75.7 ± 1.7 76.0 ±2.0 76.3 ±2.1 74.8 ±2.3 73.8 ±3.0 
GLN 6.7±0.3 7.2 ±0.2 7.4 ± 0.2 75.5 ±2.0 75.4 ± 1.5 75.8 ± 1.7 71.9 ± 1.3 73.3 ±2.3 
HR (b.min·') CON 158 ±6 166 ±6" 171 ±6 176±6 177±6 
OKG 162 ±5 171 ± 5" 175 ±5 179±7 179 ±6 
GLN 157±4 167 ±4" 171 ±4 174 ±5 177 ±5 
RER CON 0.78 ±0.02 0.81 ± 0.02 0.80±0.01 0.89±0.01 0.88 ± 0.01 0.90 ±0.03 0.91 ±0.01 0.89 ±0.02 
OKG 0.79 ±0.02 0.80±0.02 0.80 ± 0.02 0.90±0.01 0.91±0.02 0.90 ±0.01 0.90 ±0.02 0.90 ±0.02 
GLN 0.77 ±0.02 0.80±0.02 0.80 ± 0.01 0.89 ±0.01 0.89 ±0.01 0.88 ±0.01 0.89 ±0.Q3 0.91 ±0.02 
CHO Ox (g'min-') CON 0.09±0.03 0.13 ±0.03 0.13 ±0.02 2.72 ± 0.22 2.71 ±O.18 2.96 ±0.51 3.29 ±0.39 2.93 ±0.46 
OKG 0.10±0.03 0.12 ±0.03 0.13 ±0.02 3.01 ± 0.26 3.09 ± 0.28 2.99 ±0.34 3.02 ±0.52 3.01 ±0.47 
GLN 0.09±0.02 0.12 ±0.03 O.14±0.02 2.74 ± 0.19 2.80 ± 0.11 2.62 ± 0.19 2.65 ±O.18 3.13 ± 0.48 
Fat Ox (g'min-') CON 0.13 ±o.o2 0.11 ± 0.01 0.13 ±0.02 0.74 ± 0.08 0.83 ±0.07' 0.87±0.06 0.67±0.07 0.65 ±0.09 
OKG 0.11 ±0.02 0.11 ±0.02 0.12 ±0.01 0.69 ± 0.08 0.71 ±0.06 0.71 ±0.07 0.64 ±0.06 0.58 ±0.01 
GLN 0.13 ±0.02 0.13 ±0.02 O.13±O.OI 0.73±0.07 0.70 ±0.05 0.79±0.09 0.67±0.05 0.61 ±0.26 
Values are means ± SEM for 7 subjects. Heart rate was not recorded at rest. In all conditions, V02• %V021R11Xt RER, CHO Ox. and Fat Ox during exercise was significantly different to rest values (P < 0.05); 
.p < 0.05 vs 15 min exercise; cp < 0.05 vs GLN condition at same time point 
Table 6.5 Plasma amino acid and ammonia concentrations during the experimental period in the CON, 
OKG & GLN conditions 
REST EXERCISE 
Condition Basal fuex IOmin Exh 
NH, CON 23± I 23±4 32 ±7 ISO±3S" 
OKG 28±4 22±S 42±6 123±24" 
GLN 2l±3 2H4 28±4 ISO± 18" 
Valine CON 2IH 17 212 ± 13 200 ± IS 228 ± 13 
OKG 236 ±21 223±20 226±!4 216±22 
GLN 237± l3 219±!4 216 ± 13 226 ± 11 
Isoleucine CON 7l±8 70±6 68±6 7H6 
OKG 80±7 77±6 78±S 7S±7 
GLN 8H7 7S±7 74 ±7 76±S 
Leucine CON 128± 13 127± 11 121 ± 11 l3S±9 
OKG 144±!3 137± 12 140±7 l33± 14 
GLN 14S± 10 I3UII 130±9 136±8 
Tyrosine CON SH7 S6±7 S3±S 7S± 13'~ 
OKG 61 ±7 7S±7~ 74 ± IOII.C 69±8 
GLN 5H8 51 ±7 49 ±7 65±6' 
Phenylalanine CON 46±S 50±S 46 ±7 64 ± 6··: 
OKG 5S±6 56±8 S6±S 59±9 
GLN 54±5 49±6 50±S 64±8' 
Tryptophan CON 38±6 37±6 41 ±6 4S±8 
OKG 45±7 48±5 44±7 45±9 
GLN 45±7 39±7 44±7 51 ± 10 
Lysine CON 147± 14 148±20 125±18 161 ± 12 
OKG 165 ± 10 18H23 197± 10 14H 20 
GLN 16H l3 IS7± 15 159 ± 17 151 ± 14 
Methionine CON 31 ±3 3H2 31 ± 3 44 ± 3·· 
OKG 38±3 44 ± 7" 46 ± 7·,a,~ 4HS 
GLN 36±3 3S±3 36±3 4H2 
Threonine CON 121 ±6 126±6 119±S 13l±7 
OKG 126±9 l3H8 126 ±7 128± 11 
GLN l33±7 l33±4 126±7 147± 17 
Glycine CON 240± 18 261±30 2S4 ±23 285±29 
OKG 265±20 271 ± 18 271 ± 17 275±25 
GLN 276±23 24U 12 241 ±20 2S9 ± 37 
Histidine CON 72±!2 63± 10 59± 10 77±8 
OKG 94±12 85±8 91 ±7 8H 12 
GLN 88± 10 90±9 90± 13 78±8 
Aspartate CON 2H2 23±2 24± I 28±2" 
OKG 20±2 20± I 23±2 2H2' 
GLN 2U2 30±2".a.b 26 ± 3'" 26±2" 
Asparagine CON 4H2 43±2 42±2 4H2 
OKG 4HI2 45±2 42 ± 1 43±3 
GLN 4HI 43±1 41 ±2 4l±2 
Serine CON 129±6 127± 10 12S±7 l33±7 
OKG l37±6 12l±4 121 ±4 l3H8 
GLN l35±8 l35±4 131 ± 5 14l±9 
Arginine CON 95±8 10S±8 107 ±6'·· 112 ±6·· 
OKG 98±4 IIH6" 119±5" 107±4' 
GLN 97±6 IIS± 8" 116±6" IlO±S·· 
Values are means ± SEM for 7 subjects, expressed in pmolll. NH3, ammonia * P < 0.05 vs. Basal, .. P < 0.01 vs. 
Basal, :P < 0.05 vs. \0 min ex, 'P < 0.05 vs. CON condition at same time point, bp < 0.05 vs. OKG condition at 
same time point, e P < 0.05 vs. GLN condition at same time point. 
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Table 6.6 Summed plasma amino acid concentrations during the experimental period in the CON, 
OKG & GLN conditions 
REST EXERCISE 
Condition Basal Preex 10min Exh 
Tryp:BCAA CON 0.10±0.02 0.09±0.02 0.11 ±0.02 0.11 ±0.03 
OKG 0.11 ±0.02 0.12±0.02 O.lO±0.02 0.11 ±0.02 
GLN 0.1O±0.02 0.10±0.02 0.11 ±0.02 0.12 ± 0.03 
n-mAA CON 585 ±35 618 ± 54 575 ±40 685 ±36' 
OKG 648 ±39 687 ± 51 696±30" 646 ±46 
GLN 662 ±38 615 ±2I 6\3 ±30 663 ±32 
BCAA CON 410 ±37 409 ±30 389 ±32 438 ±27 
OKG 461 ±40 438 ±37 445 ±26 422 ±43 
GLN 464 ±29 425 ±31 420 ±28 438 ±23 
AAA CON 138 ± 14 142 ± 13 140 ± 14 184± \3" 
OKG 161 ± \3 179± 16" 174± 19" 173 ±22 
GLN 153 ± 11 139 ± 10 144 ± 10 180 ± 17' 
EAA CON 737 ±59 738 ± 51 690 ±59 824 ±35 
OKG 838 ±56 849 ±67 864 ±25 786 ±75 
GLN 838 ±38 797 ±43 796 ±46 834 ±32 
Tot. AA CON 2358± 120 2431 ± 112b,< 2474 ± 109b,< 3056 ± 121"1 
OKG 2584 ± 154 2931± 170' 3133 ± 101" 3163±230" 
GLN 2636 +98 2908 ± 123 2881 ± 124 3100 ± 50" 
Values are means ± SEM for 7 subjects, expressed in "molJl. nom AA, sum of non-metabolised amino acids (Thr, 
Met, Phe, Lys, Gly & Tyr); BCAA, sum of branched-chain amino acids (Lell, Iso, VaI); MA, sum of aromatic 
amino acids (Try, Tyr & Phe); EAA, sum of essential amino acids (His, Iso, Lell, Lys, Met, Phe, Thr, Try, & VaI); 
Tot. AA, sum of all amino acids . 
• p < 0.05 vs. Basal, .. P < 0.01 vs. Basal, ~p < 0.05 vs. \0 min ex, 'p < 0.05 vs. CON condition at same time point, 
bp < 0.05 vs. OKG condition at same time point, 'P< 0.05 vs. GLN condition at same time point. 
Sum of non -essential amino acids (NEAA, Ala, Arg. Asp, Aso, GIll, Gin ,Gly, Ser, & Tyr) are shown in Fig. 6. \0 
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Table 6.7 Content of amino acids in hwnan skeletal muscle at rest and during exercise after ingestion of the CON, OKG or GLN solution 
CON OKG GLN 
Preex 10 min Exh Pre ex 10min Exh Pre ex 10 min Exh 
Glutamine 30.1 ± 1.8 
Glutamate 18.3 ± 0.9 
31.7± 1.6 33.2± 1.8' 29.6±0.4 
19.1±1.0 
33.1 ± 1.6* 35.6 ± 1.9* 38.4± I.1t 31.2± 1.3' 34.2 ± 1.6' 
7.5 ± 0.6' 7.4 ± 0.7* 7.7±0.S' 7.1 ±0.6* 18.0 ± 1.3 7.3 ± 0.6* 7.6± 0.5* 
Values are means ± SEM for 7 subjects, expressed in mmollkg dry muscle. Exh, exhaustion. *p < 0.05 vs. Pre ex, tP < 0.05 vs. 
CON and OKG treatment 
Table 6.8 Content ofTCAI in hwnan skeletal muscle at rest and during exercise after ingestion of the CON, OKG or GLN solution 
CON OKG GLN 
Pre ex IOmin Exh Pre ex 10 min Exh Preex 10 min 
Citrate 0.59 ± 0.06 0.78 ± 0.06 0.79±0.1O 0.57±0.07 0.87±0.08 0.88 ±0.06 0.51 ± 0.07 0.90±0.01 
Malate 0.25±0.OS 1.61 ± 0.23 1.09 ±0.24 0.24±0.03 1.6HO.20 1.24± 0.35 0.24±0.04 2.12±0.22 
Fumarate O.OHO.OI 0.19 ± 0.03 0.14±0.04 O.OHO.OI 0.17±0.03 0.14±0.04 0.04 ± 0.04 0.26±0.OS 
Succinate 0.25 ± 0.04 1.16±0.13 1.14±0.23 0.24±0.03 1.17±0.12 1.24 ± 0.36 0.23 ± 0.06 1.6HO.36 
Values are means ± SEM for 7 subjects, expressed in rnrnollkg dry muscle. Exh, exhaustion; TCAI, tricarboxylic acid cycle 
intermediates. For all intermediates, there was a main effect (P < 0.05) for time, such that 10 min and Exh > Pre ex. *p < 0.05 vs. 
10 min. 
Table 6.9 Metabolite content in hwnan skeletal muscle at rest and during exercise after ingestion of the CON, OKG or GLN solution 
CON OKG GLN 
Pre ex 10min Exh Preex 10 min Exh Preex 10 min 
ATP 26.5± 1.0 27.1 ±2.4 27.4 ± 1.9 26.4 ± 1.0 26.5± 1.4 26.4± 1.4 25.0±0.9 24.8 ± 1.0 
PCr 89.5±2.9 65.S±5.1* 63.0± 8.7* 93.6 ± 1.7 76.6 ±7.6' 64.8 ± 11.2' 88.2±3.7 69.4 ± 5.5* 
Creatine 41.1 ± 1.8 60.5±S.9* 74.1 ± 13.1' 40.6±2.6 62.3 ± 8.2 79.7± 12.7* 3S.S±4.2 S9.H7.1 
Lactate 2.2±0.1 6.7± 1.7 9.1 ± 3.5* 2.1± 0.1 6.0 ± 1.0 9.4± 3.5* 1.9±0.1 7.1 ± 1.8 
Pyruvate 0.37±0.06 0.51 ± 0.05 0.62±0.08' 0.31 ± 0.06 0.42±0.09 0.47±0.09 0.32±0.07 0.60 ± 0.07* 
Values are means ± SEM for 7 subjects, expressed in mmollkg dry muscle. Exh, exhaustion; ATP, adenosine triphosphate; PCr, 
phosphocreatine. * P < 0.05 vs. Pre ex. 
Exh 
0.87±0.08 
1.29 ± 0.25' 
0.IHO.03 
l.lH 0.23 
Exh 
25.6 ± 1.3 
59.6 ± 7.7' 
73.2± 9.S' 
8.1±3.0* 
0.61 ± 0.14* 
Fig. 6.3 Blood lactate concentration during the experimental period in the CON, OKG and GLN 
conditions. Values are means ± SEM for 7 subjects. 
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Fig. 6.4 Blood glucose concentration during the experimental period in the CON, OKG and GLN 
conditions. Values are means ± SEM for 7 subjects. 
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Fig. 6.S Serum insulin concentration during the experimental period in the CON, OKG and GLN 
conditioos. Values are means ± SEM for 7 subjects. 
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Fig. 6.6 Serum NEFA concentration during the experimental period in the CON, OKG and GLN 
conditioos. Values are means ± SEM for 7 subjects. 
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Fig. 6.7 Plasma glutamine concentration dtning the experimental period in the CON, OKG and GLN 
conditions. Values are means ± SEM for 7 subjects . 
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Fig. 6.8 Plasma glutamate concentration during the experimental period in the CON, OKG and GLN 
conditions. Values are means ± SEM for 7 subjects. 
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Fig. 6.9 Plasma ornithine concentration during the experimental period in the CON, OKG and GLN 
conditions. Values are means ± SEM for 7 subjects. 
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Fig.6.10 Plasma alanine concentration during the experimental period in the CON, OKG and GLN 
conditions. Values are means ± SEM for 7 subjects . 
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Fig. 6.11 Sum of non-essential amino acids during the experimental period in the CON, OKG and GLN 
conditions. Values are means ± SEM for 7 subjects. 
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Fig. 6.12 Sum of aromatic amino acids during the experimental period in the CON, OKG and GLN 
conditions. Values are means ± SEM for 7 subjects. 
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Fig. 6.13 Total muscle content of the 4 measured tricarboxylic acid cycle intermediates 
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6.4 DISCUSSION 
The main fmdings from the present investigation were that the consumption of 
glutamine I h prior to exercise markedly increased the total content of the TCAl in 
human skeletal muscle after 10 min of moderate intensity cycling exercise. However, 
despite this further increase in the TCAl pool size, no sparing of PCr or reduction in 
muscle lactate accumulation was observed during this initial period of exercise. Taken 
together, these fmdings suggest that since the rate of mitochondrial respiration is 
reflected by the extent of phosphocreatine breakdown, at the onset of exercise (Hultman 
et al. 1967b), oxidative energy production does not appear to be limited by the size of 
the TCAl pool. Secondly, no difference was observed in the total content of the TCAl 
at exhaustion or in cycle time to exhaustion between conditions suggesting that the size 
of the TCAl pool is not an important factor in the aetiology of fatigue during this type 
of exercise. 
In the present study, our aim was to increase the TCAl pool size through nutritional 
intervention. Glutamine ingestion resulted in an amplification of TCAl pool expansion 
during the fIrst 10 min of exercise, however the decline in PCr content and 
accumulation in muscle lactate content were similar in all conditions. Glutamine is 
readily taken up into skeletal muscle via the high capacity, sodium-dependent system 
Nm (Ahmed et al. 1993), resulting in the elevated muscle glutamine content in the GLN 
condition relative to the CON and OKG conditions 1 h after consuming the 
supplements. 
There are several pathways by which a-ketoglutarate may derive from glutamine and 
hence increase the total content of the TCAl. Glutamine that enters skeletal muscle can 
be deaminated to form glutamate and then a-ketoglutarate through the action of 
glutaminase (glutaminase I) and glutamate dehydrogenase, respectively. Alternatively, 
glutamine may be deaminated to form a-ketoglutaramate and then a-ketoglutarate 
through the action of glutamine transaminase (glutaminase 11) and ro-amidase, 
respectively. The enzymes responsible for the conversion of glutamine to a-
ketoglutarate have all been shown to be present in skeletal muscle (Wu et al. 1991; 
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Rennie et al. 1992). In the present study, glutamine ingestion resulted in an increase in 
both plasma and muscle glutamine concentration. 
Despite the greater elevation in the TCAl pool size at 10 min of exercise after glutamine 
ingestion, compared to the OKG or CON conditions, it appears that ATP production via 
oxidative phosphorylation was not enhanced, since neither PCr depletion or muscle 
lactate accumulation was different between conditions. This finding would appear to 
suggest that TCAl pool size does not limit oxidative energy production at the onset of 
exercise. Indeed, it has been suggested that the availability of acetyl units (Constantin-
Teodosiu et al. 1999; Gibala and Saltin, 1999a; Howlett et al. 1999; Constantin-
Teodosiu et al. 1999) or some other factor such as muscle oxygenation may limit the 
extent of oxidative energy production at the start of exercise. 
It is noteworthy, however, that after pharmacological activation of the PDC with 
dichloroacetate (DCA), a decrease was observed in PCr utilisation at 2 min of moderate 
intensity exercise (Howlett et al. 1999). It is possible therefore that taking a muscle 
biopsy at 10 min of exercise resulted in an equilibration between conditions in 
phosphocreatine utilisation, whereas an earlier sampling point may have resulted in a 
difference in PCr utilisation between conditions. Furthermore, although the TCA cycle 
ostensibly refers to the mitochondrial matrix, most of the TCAl and the enzymes that 
catalyse anaplerotic reactions are present in both cytosolic and mitochondrial 
compartments. At present, analytical techniques allow content and activity to be 
measured only in whole muscle homogenate. It is conceivable that the mitochondrial 
content may not be reflected by whole muscle homogenate and that differences may 
exist between skeletal muscle fibre types. 
At exhaustion, the total content of the TCAl was decreased from that at 10 min of 
exercise in all conditions. The greatest decrease was observed in the GLN condition, so 
that TCAl content was not different between conditions at exhaustion. In addition, no 
difference was observed in cycle time to exhaustion between the three conditions. Very 
few studies have examined the total content of the TCAl during moderate intensity 
exercise to exhaustion in humans (Sahlin et al. 1990; Spencer et al. 1991 c; Gibala et al. 
1997b). The present study is in agreement with previous fmdings (Gibala et al. 1997b), 
demonstrating a decrease in the TCAl pool size at exhaustion, relative to the expansion 
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in the pool observed during the initial minutes of exercise. These findings could be 
interpreted to suggest that, as no difference was observed in TCAI content at exhaustion 
between conditions, the TCAI content may decrease to a limiting value at which fatigue 
occurs. 
Although no difference was observed in cycle time to exhaustion between the three 
conditions, there was a tendency for increased exercise capacity in the GLN condition 
(P = 0.063 vs. OKG). It would have been interesting to measure the total content of the 
TCAI in the GLN condition at the exhaustion time point in the other conditions, 
however due to the double-blind design employed this was not feasible in the present 
study. It is feasible that at this time point the total content of the TCAI in the GLN 
condition may be elevated above the other conditions, and it is only at exhaustion that 
total content of the TCAI are similar (Fig. 6.13). In this respect, it is conceivable that a 
critical level in the total content of the TCAI may exist during prolonged moderate 
exercise, and a decrease below this level may play a part in the aetiology of fatigue. 
This may explain why, at exhaustion, no difference was observed between conditions in 
the total content of the TCAI. Only two studies have measured the total content ofthe 
TCAI at exhaustion during prolonged moderate exercise (Sahlin et al. 1990; Gibala et 
al. 1997b), and a reduction in the total content of the TCAI was observed at exhaustion 
in both studies. 
In the present study, glutamine was provided as a single bolus prior to exercise, thus an 
elevation of plasma and muscle glutamine content was not observed beyond 10 min of 
exercise, hence the TCAI pool size decreased rapidly (from 4.90 ± 0.61 mmol/k:g dry wt 
at 10 min exercise to 3.41 ± 0.53 mmol/k:g dry wt at exhaustion [net decrease CON: 
0.58 ± 0.59; OKG: 0.30 ± 0.59; GLN: 1.49 ± 0.74 mmol/k:g dry wt). It would be 
interesting to supplement glutamine throughout exercise to determine whether the 
elevation in TCAI pool size could be maintained during exercise and examine the effect 
upon exercise capacity. 
However, an alternative explanation arises if the relationship between the TCAI and 
endurance capacity is examined in detail. There is a large degree of intra- and inter-
subject variation, failing to demonstrate any relationship between TCAI content (at 10 
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min exercise) and fatigue during prolonged exercise (Fig. 6.14). This would appear to 
imply that there is no relationship between TCAl content and fatigue, implying that 
TCAl pool size is not an important factor in the aetiology of fatigue. It appears that the 
aetiology of fatigue during prolonged moderate intensity exercise is multi-factorial, with 
factors such as the supply of acetyl units to the TCA cycle or increases in the products 
of ATP hydrolysis (i.e. ADP, AMP or Pi) being of greater importance than the TCAl 
pool size. 
It is acknowledged that the measurements of substrate-leve1 phosphorylation in the 
present study (i.e. PCr degradation and muscle lactate accumulation) provide only 
indirect measurements of the rate of TCA cycle flux and oxidative energy production. 
However, it was beyond the scope ofthe study to obtain more direct measurements of 
TCA cycle flux, which would have required arterio-venous O2 difference 
measurements. Furthermore, the technique of nuclear magnetic resonance (NMR) has 
also shown potential in determining TCA cycle activity (Cohen and Bergman, 1997; 
Jeffrey et al. 1999; Jucker et al. 1998; Robitaille et al. 1993) which was also beyond 
the scope of the present study. 
Previous studies using DCA to pharmacologically increase the active fraction of PDC, 
have demonstrated an increase in intramuscular acetyl-CoA and acety1carnitine 
(Constantin-Teodosiu et al. 1999; Howlett et al. 1999) with a concomitant reduction in 
the TCAl pool size at rest, due to a diversion of pyruvate away from anaplerosis 
(Constantin-Teodosiu et al. 1999; Gibala and Saltin, 1999a). At the onset of exercise 
the TCAl pool size was not different, however an enlarged pool of acetyl units was 
readily available, allowing oxidative metabolism to be enhanced leading to a sparing of 
both phosphocreatine and glycogen and a reduction in muscle lactate accumulation 
(Timmons et al. 1996). The lesser reliance upon substrate level phosphorylation during 
this initial period of exercise was possibly due to an increased flux through PDC at the 
onset of exercise (Howlett et al. 1999) or an accumulation of acetyl groups prior to 
exercise, 'priming' the TCA cycle with readily available 'fuel' (Constantin-Teodosiu et 
al. 1999). In terms of oxidative energy delivery, these fmdings have prompted the 
notion that the delivery of acetyl units to the TCA cycle is of greater importance than an 
increase in the total content of the TCAl. In the present study, two strategies were 
employed to examine the relationship between TCAI pool size and oxidative energy 
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metabolism. Firstly, to feed carbon, derived from either glutamine or OKG 
supplements, into the TCA cycle at the level of a-ketoglutarate. Secondly, to deplete 
the muscle glycogen stores in order to reduce the availability of pyruvate for anaplerotic 
reactions, so that the influx of a-ketoglutarate into the TeA cycle could be more readily 
observed. It was hypothesised that this nutritional intervention, as opposed to 
pharmacological intervention (DCA), would allow the TCAI pool size to be 
manipulated without altering acetyl unit availability. Therefore, it was hoped that these 
strategies would allow oxidative energy production to be examined in the presence of an 
increased TCAI pool size, but with similar acetyl unit availability. 
Previously, it has been suggested that anaplerosis is dependent upon pyruvate 
availability (Constantin-Teodosiu et al. 1999). We therefore employed a bout of 
exercise followed by a low-carbohydrate diet on the day prior to the experiment to 
ensure that intramuscular and hepatic glycogen content was reduced prior to exercise. 
Glycogenolysis and hence the rate of pyruvate formation is reduced in the glycogen-
depleted state. The aim of this strategy was to reduce pyruvate related anaplerosis thus 
allowing the effect of the nutritional intervention on alternative anaplerotic pathways to 
be observed more readily. Although muscle glycogen content was not measured in the 
present study, the bout of glycogen depleting exercise employed has previously been 
shown by our group to reduce muscle glycogen content to 13 mmol glycosyl U/kg wet 
weight (-55 mmol glycosyl U/kg dry weight) (Bowtell et al. 1999). It is likely 
therefore that, in combination with the low-carbohydrate diet, muscle glycogen stores 
were substantially reduced. The diet and exercise regimen were replicated for each trial 
and the metabolic response during the glycogen-depleting exercise bout was identical 
between trials confirming that the physiological status of each subject was similar prior 
to each trial. 
It has been reported that approximately 50% of an enterally delivered dose of glutamine 
is sequestered on first pass through the splanchnic bed (Matthews et al. 1993; Hankard 
et al. 1995). However, in the present study, the oral provision of glutamine was able to 
increase plasma glutamine at the peak concentration by 51 %, demonstrating that a 
substantial portion of the oral load escaped utilisation by the gut mucosal cells and 
uptake by the kidneys and liver. Due to this increase in systemic glutamine 
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concentration, glutamine will be readily available to be taken up into skeletal muscle via 
the high capacity, sodium-dependent system Nm• In skeletal muscle, glutamine can 
undergo a series of reactions to form a-ketoglutarate that can enter the TCA cycle. In 
addition, plasma ornithine concentration increased by 345% 1 hour after consumption of 
. the OKG solution, suggesting that at least the omithine component of the oral dose of 
OKG also escaped utilisation by the splanchnic bed. 
The increase in the TCAl pool size was concomitant with a decrease in intramuscular 
glutamate content in all conditions, presumably asserting the prime importance of 
glutamate as an anaplerotic precursor via the alanine aminotransferase, glutamate 
dehydrogenase or ro-arnidase reaction in the process of anaplerosis. Furthermore, the 
ingestion of glutamine, prior to exercise, enhanced the expansion of the TCAl at 10 rnin 
of exercise (Fig. 1). Intramuscular glutamine and plasma glutamine concentrations 
decreased in the GLN condition in addition to the decrease in muscle glutamine content 
during the initial 10 rnin of exercise, presumably accounting for the larger expansion in 
the TCAl pool. These factors suggest that carbon derived from glutamine was able to 
enter the TCA cycle, presumably at the level of a-ketoglutarate, and was rapidly 
converted into other TCAl, namely succinate, malate and fumarate, during the initial 
period of exercise. 
Gibala et al. (Gibala et al. 1997b) demonstrated that the sum of citrate, succinate, 
malate, and fumarate accounts for ~85% of the total TCAl, both at rest and during 
exercise in humans, thus we are confident that our data represents an accurate 
quantitative and qualitative index of the total TCAl pool. a-ketoglutarate content was 
not measured in the present study, however, previous studies have not observed an 
increase in this TCAl during the initial minutes of moderate exercise (Gibala et al. 
1997a; Gibala et al. 1997b; Graham and Saltin, 1989). This phenomenon has been 
linked to the equilibrium between a-ketoglutarate and glutamate via the glutamate 
dehydrogenase reaction, thus a-ketoglutarate content may be influenced by the decrease 
in glutamate content during the initial minutes of exercise (Gibala et al. 1997b; Sahlin 
et al. 1990; van Hall et al. 1999; Sahlin et al. 1990; van Hall et al. 1999). (Gibala et 
al. 1998) A disproportionate increase in the content of succinate, malate and fumarate 
has been observed during exercise in the present and previous studies (Constantin-
194 
• 
Teodosiu et al. 1999; Gibala et al. 1998). It has been demonstrated that an increase in 
a-ketoglutarate content causes a rapid activation of the a-ketoglutarate dehydrogenase 
complex (Bunik et al. 1991), therefore, a-ketoglutarate derived from exogenous 
glutamine is likely to be rapidly converted to intermediates situated in the 'second span' 
of the TCA cycle. In particular, there appears to be a greater increase in the content of 
malate in comparison with the rest if the TCAI at 10 min of exercise in the present 
study. The malate dehydrogenase reaction (L-MDH; oxaloacetate + NADH + W ~ 
malate + NAD1, one possible pathway for malate formation, appears to favour malate 
formation as the Km for oxaloacetate is reported to be 10 times lower than for malate 
(Bergmeyer, 1974). If this is the case, a reduction in oxaloacetate content may limit 
TCA cycle flux by reducing the availability of substrate for citrate formation, despite an 
adequate supply of acetyl-CoA. 
In addition to the increase in intramuscular glutamine content after GLN 
supplementation, an increase was observed in plasma glutamate concentration 1 h after 
GLN supplementation. It is likely that glutamine-glutamate cycling in the splanchnic 
bed resulted in the higher plasma glutamate level (Curthoys and Watford, 1995; Haisch 
et a1. 2000). Plasma glutamate concentration decreased at 10 min of exercise, 
suggesting that glutamate was taken up into skeletal muscle and fed into the alanine 
aminotransferase reaction (glutamate + pyruvate ~ a-ketoglutarate + alanine) to 
increase the total TCAI pool size, which has been observed in previous studies (Gibala 
et al. 1997b; Sahlin et al. 1990), particularly in the glycogen depleted state (van Hall et 
al. 1999). Indeed, it has been reported that resting skeletal muscle is able to act as a 
sink for excess circulating glutamate (Graham et al. 2000), and given the central role 
that glutamate holds in amino acid metabolism is thus able to modulate human skeletal 
muscle metabolism. However, it has been reported (Rennie, 1996a) that the glutamate 
transporter in skeletal muscle (System XA.G) has a low capacity (80 nmol'g-l.min-1). The 
kinetics of this transporter do not appear to adequately explain the vast concentration 
difference that is maintained between the muscle and blood (muscle > blood) 
(Bergstrom et al. 1974), nor the uptake of glutamate from the blood into the muscle 
despite this gradient. Furthermore, it has been reported that under conditions in which 
glutamine concentrations full, the capacity of this transporter is elevated (Low et al. 
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1994). More work is required in this area to fully understand the kinetics of glutamate 
transport. 
Despite increasing the intramuscular glutamine pool after glutamine ingestion, there 
appears to be some discrepancy in the increase that one may expect to observe in the 
expansion of the TCAl pool An -7 mmol/kg dw decrease was observed in 
intramuscular glutamine content in the GLN condition, in addition to an -11 mmol/kg 
dw decrease in the intramuscular glutamate pool during exercise. If all 
glutamine/glutamate carbon were exclusively channelled into expansion of the TCA 
cycle intermediate pool, then the extent of the TCAl expansion would have been -4-
fold higher. Furthermore, during the CON and OKG conditions the net decline of 
glutamine and glutamate pools (-9 mrnol/kg dw), still far exceeds the expansion 
observed in the TCAl pool (-3 mmol/kg dw). 
It is possible to speculate on the potential pathways by which the apparent 'excess' 
glutamine/glutamate carbon may be disposed. During the GLN condition, it is feasible 
that the elevated intramuscular glutamine pool drives its own deamination to form 
glutamate catalysed by glutaminase. However, this is not a simple substrate driven 
mechanism related to the Km of glutaminase (4.65 mM in cultured rat skeletal muscle 
cells; Smith et al 1984), since exercise must be taken into consideration. There are two 
possible explanations: fIrst, the decline in glutamate precedes that of glutamine and 
'pulls' the conversion of glutamine to glutamate due to the elevated glutamine content 
and the resultant shift in the reaction equilibrium. Secondly, there is an exercise-
induced activation of glutaminase. The former is the most likely explanation since the 
conversion of glutamine to glutamate does appear to occur in the other two conditions 
and there is negligible evidence to suggest that glutaminase is activated during exercise. 
However, the processes that account for the large decline in intramuscular glutamate 
content at the start of exercise are more difficult to determine. Certainly, the alanine 
aminotransferase reaction is an important factor in to this decrease (glutamate + 
pyruvate ..... a-ketoglutarate + alanine) (Gibala et al. 1997a). It is thought that at the 
start of exercise the reaction is driven by the excess pyruvate present due to the rapid 
stimulation of glycolysis and delayed activation of pyruvate dehydrogenase complex. 
Certainly plasma alanine concentration was higher during the GLN than the CON 
condition indicating increased alanine synthesis, if one assumes that splanchnic uptake 
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of alanine was not different between conditions. Furthermore, as the intracellular 
compartmentation of the glutamate is yet to be determined, it is feasible that 
mitochondrial glutamate is more extensively depleted thus limiting the aminotransferase 
reactions, since these take place largely in the mitochondria. In addition, there is also 
evidence of glutamate dehydrogenase activity (glutamate + NAD+ --+ a-ketoglutarate + 
NH3 + NADH) in human skeletal muscle (Wibom et al. 1992; Starritt et al. 1999) 
which may contribute to the reduction in the glutamate pool at the onset of moderate 
intensity exercise. 
Glutamate is also a key amino group donor in many other reactions. There are two 
possibilities by which the smaller than 'expected' increase in the TCAl pool might be 
explained. Firstly, drainage of TCAl to take part in the plethora of other reactions in 
which the TCAl are involved. Secondly, glutamate and a-ketoglutarate participate in 
other reactions with no net production of a-ketoglutarate e.g. transamination. The 
production of aspartate via the aspartate aminotransferase (EC 2.6.1.1) reaction, which 
is present in human skeletal muscle (Schantz and Henriksson, 1987; Lindena et al. 
1986), is an example of the former, with oxaloacetate acting as the amino group 
(oxaloacetate + glutamate ~ aspartate + a-ketoglutarate). The drainage of oxaloacetate 
(OAA) is balanced by the production of a-ketoglutarate, hence a decrease in glutamate 
occurs with no net production ofTCAl. Certainly in the present study, plasma aspartate 
was elevated during exercise and to a greater extent in the GLN condition and hence 
this pathway may provide a partial explanation for the 'disappearance' of glutamate 
carbon. 
Furthermore, the synthesis of glutamine in exercising skeletal muscle is another 
pathway by which glutamate carbon may be 'lost' from the muscle. Glutamine efflux 
from skeletal muscle increases significantly from resting levels (3 Jlmol.min·1.kg ww·1) 
during moderate intensity exercise (-70 Jlmol.min·1.kg ww·1) (Gibala et al. 1998). 
However, it is unlikely that glutamine synthesis occurred to any great extent during the 
GLN condition since it has been demonstrated that exogenous glutamine suppresses de 
novo glutamine production (Hankard et al. 1995). 
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The elevation in plasma aspartate in the present study following glutamine ingestion is 
similar to that seen with monosodium glutamate supplementation (Graham et al. 2000; 
Stegink et al. 1987), presumably produced via the aspartate aminotransferase reaction 
(oxaloacetate + glutamate # aspartate + a-ketoglutarate). It is interesting to note 
however, that although plasma glutamate concentration was elevated in the present 
study, intramuscular glutamate concentration was not, whereas both plasma and 
intramuscular glutamate concentration were elevated by monosodium glutamate 
ingestion (Graham et al. 2000). It is feasible that this may be due to differences in the 
intracellular compartmentation of the glutamate carbon in the two studies. Monosodium 
glutamate will be taken up slowly into the muscle cytosol via the System X~G 
transporter. However, glutamine is rapidly taken up by the system Nm transporter and 
then converted to glutamate within the mitochondria since glutaminase is exclusively 
mitochondrial, as are the majority of aminotransferase enzymes. Cytosolic glutamate is 
therefore less available and to some extent accumulates, since mitochondrial glutamate 
uptake is slow. However, mitochondrial glutamate is rapidly utilised in a multitude of 
reactions and hence does not accumulate. 
Ingestion of OKG did not enhance TCAl expansion at the onset of exercise either 
directly via entry of a-ketoglutarate into the TCA cycle or indirectly via the elevation of 
the muscle glutamate or glutamine pool. In fact, the ingestion of OKG elicited 
intramuscular responses that to some extent mirrored the response observed in the 
control condition. It is possible therefore that despite successfully increasing plasma 
ornithine concentration and presumably also plasma a-ketoglutarate concentration 
(Cynober et al. 1990), the substrate was not effectively taken up by the skeletal muscle. 
The splanchnic bed may have sequestered a large portion of the OKG given by the oral 
route (particularly the a-ketoglutarate component), as reported previously in starved rats 
(Ziegler et al. 1992), which may have resulted in the amount of a-ketoglutarate 
entering the skeletal muscle being too low to affect metabolism. 
It is unclear however, whether the a-ketoglutarate component ofOKG would follow the 
same time course, since a-ketoglutarate and ornithine interact resulting in a different 
metabolic pattern to that observed when subjects receive ornithine (as hydrochloride) or 
a-ketoglutarate (as a calcium salt) individually (Cynober et al. 1990). Indeed, previous 
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studies in bum-injured rats have shown that OKG counteracts the trauma-induced 
decrease of the intramuscular glutamine pool after 48 11, when administered enterally in 
three boluses daily (5 g.kg·1 day; Vaubourdolle et al. 1991). This suggests that OKG 
may elicit anabolic effects over a greater time course than in the present study. 
Furthermore, the majority of studies have investigated the effect of OKG 
supplementation in hypercatabolic states, employing animal models or human subjects. 
When the muscle glutamine pool is reduced it has been shown that the administration of 
OKG to humans post-surgery effectively restores the muscle glutamine pool 
(Wernerman et al. 1990), presumably due to OKG acting as a precursor to glutamine 
(Cynober, 1999). However, in the present study, at rest, no increase was observed in 
muscle glutamine content in the OKG condition compared to the CON condition. The 
effect of OKG upon muscle glutamine may therefore only be evident when the muscle 
glutamine pool is previously depleted, which was not the case in the present study. 
Theoretically, providing the substrate a-ketoglutarate would be the most direct way of 
attempting to introduce carbon into the TCA cycle in human skeletal muscle. However, 
in the present study, the oral provision of OKG did not increase the content of the 
TCAI. There are two possible explanations for the absence of any effect of OKG upon 
the TCAl and glutamine pool size. First, the ingested a-ketoglutarate component was 
sequestered by the splanchnic bed, as suggested previously. Secondly the transport of 
a-ketoglutarate into skeletal muscle is not efficient enough to increase a-ketoglutarate 
content. Given that the infusion of a-ketoglutarate has been shown to increase the 
intramuscular a-ketoglutarate content (Roth et al. 1991), it is more likely that the oral 
delivery ofOKG resulted in the uptake of the a-ketoglutarate moiety by the splanchnic 
bed, which would substantially reduce the amount of a-ketoglutarate available to enter 
the muscle. This is supported by the fact that when OKG is given parenterally, 
effectively avoiding the effect of'frrst pass' sequestration of the a-ketoglutarate moiety 
by the splanchnic bed observed when provided enterally (Ziegler et al. 1992), it is 
equally as effective as a-ketoglutarate or glutamine in restoring the muscle glutamine 
pool (Vinnars et al. 1990). However, in the study by Vinnars et al. (1990) the two 
groups (OKG and a-ketoglutarate) were not identical in terrns of a-ketoglutarate intake, 
precluding any frrm conclusion. 
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It has previously been demonstrated that OKG and glutamine exert their metabolic 
influence in different target tissues (Ziegler et al. 1992). OKG was shown to interact 
most in the splanchnic region, predominantly in the liver, demonstrated by an increase 
in OKG metabolites (proline, arginine, glutamate). Furthermore, the higher blood 
glucose levels during exercise in the present study provide further support for the notion 
that the splanchnic bed sequestered the OKG load during the OKG condition. This 
suggests an increased metabolism of gluconeogenic amino acids, in particular proline, 
which although not measured in the present study, has been shown to increase rapidly in 
response to an OKG load (Cynober et al. 1990). 
The concentrations of both tyrosine and phenylalanine have previously been used as an 
indicator of muscle protein breakdown (Blomstrand and Saltin, 1999), with an increase 
in their appearance representing and increase in muscle protein breakdown, based upon 
the fact that phenylalanine has no significant role other than as a component of proteins 
and a precursor to tyrosine. An increase in plasma phenylalanine concentration was 
observed at exhaustion in all conditions, therefore suggesting an increase in muscle 
protein breakdown. The increase in plasma tyrosine concentration, and parallel increase 
in the sum ofthe aromatic amino acids and non-metabolised amino acids, in response to 
the ingestion of OKG is difficult to explain. No concomitant increase was observed in 
plasma phenylalanine concentration after OKG ingestion in the present study suggesting 
that muscle protein degradation was not increased. Indeed, it has been reported that 
plasma phenylalanine concentration is actually reduced after OKG ingestion (Cynober 
et al. 1984). Therefore the mechanism for this increase in tyrosine concentration in the 
present study remains to be elucidated. On the basis of these fmdings it is impossible to 
determine the effect of OKG upon protein turnover. Although, the increase in tyrosine 
concentration would seem to suggest a catabolic rather than anabolic influence. 
In the glycogen depleted state it has been suggested that branched chain amino acid 
(BCAA) oxidation is increased, resulting in a reduction in a-ketoglutarate content, due 
to a-ketoglutarate acting as an amino group recipient in the BCAA aminotransferase 
reaction (Wagemnakers et al. 1991). It would therefore be expected to observe a 
decrease in plasma BCAA concentration during exercise as they are taken up by skeletal 
muscle for oxidation. However, no change in the sum of the plasma BCAA was 
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observed over time in any condition. One explanation may be that the increase in 
BCAA oxidation was matched, and somewhat masked by an increase in proteolysis, 
which is supported by the increase in plasma phenylalanine concentration at exhaustion 
in both the CON and GLN conditions. 
The increase in plasma arginine concentration at 10 min of exercise in the OKG 
condition is most likely due to the elevated ornithine concentration, since ornithine is 
the precursor to arginine in the urea cycle. Furthermore, although not statistically 
different to the other conditions, there was a tendency for the increase in blood lactate 
concentration to be greater during exercise after OKG ingestion. This may also infer an 
increased metabolism in the splanchnic bed, principally in the liver, which would be in 
agreement with previous results suggesting that orally provided OKG is primarily 
trapped in splanchnic areas (Ziegler et al. 1992). 
The increase in plasma alanine concentration at exhaustion in all conditions was 
somewhat surprising, although the increase observed at 10 min of exercise is commonly 
seen (Gibala et al. 1997a). Alanine is produced in skeletal muscle intra-
mitochondrially primarily through the transamination of pyruvate (alanine 
aminotransferase reaction (AAT): glutamate + pyruvate Ba-ketoglutarate + alanine) 
(Chang and Goldberg, 1978b; Spydevold, 1976), and plasma alanine is derived 
primarily from the export of this alanine from the skeletal muscle (Consoli et al. 1990). 
In addition, alanine may be synthesised in muscle from the amino groups of other amino 
acids, derived through proteolysis (Felig and Wahren, 1971; Garber et al. I 976b). It is 
somewhat paradoxical to observe a peak in plasma alanine concentration at exhaustion, 
muscle glycogen levels would be low at this time, and thus muscle pyruvate availability 
reduced, leading to less formation of alanine. However, during the latter stages of 
prolonged submaximal exercise, particularly in the glycogen depleted. state as in the 
present study, BCAA transamination will be increased (Gibala et al. 1999b) giving rise 
to an increased number of amino groups which may be used for alanine synthesis (Felig 
and Wahren, 1971; Garber et al. 1976b). This may therefore partly explain the 
unexpected increase in plasma alanine concentration. 
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Inherently linked to the alanine concentration, it was also somewhat surprising to 
observe an increase in muscle pyruvate content at exhaustion, given the glycogen 
depleted state induced in the present study. This may be due to an increased recruitment 
of type 11 muscle fibres. It has previously been demonstrated during prolonged 
submaximal exercise that as muscle glycogen is depleted in type I fibres, there is an 
increase in the number of type 11 fibres recruited (Gollnick et al. 1973). It is therefore 
possible that the lowered glycogen levels led to an increase in the number of type 11 
fibres recruited and thus an increase in glyco lytic activity in these fibres leading to the 
increase in muscle pyruvate content during exercise. 
In conclusion, it has been demonstrated that in the low glycogen state, the provision of 
glutamine 1 h prior to exercise was able to increase the TeAl pool expansion after 10 
min of moderate intensity exercise. However, despite this further increase in the TeAl 
pool size, no sparing of phosphocreatine or reduction in muscle lactate accumulation 
was observed. This suggests that at the onset of exercise, oxidative energy production is 
not limited by the size of the TeAl pool, but some other factor, possibly muscle 
oxygenation or the availability of acetyl units to the TeA cycle may limit oxidative 
energy production during this period of exercise. Furthermore, no difference was 
observed in endurance capacity despite a greater elevation in the TeAl pool size after 
glutamine ingestion. However, TeAl pool size was not maintained following glutamine 
ingestion at exhaustion. Therefore, the data in the present study suggests a lack of a 
relationship between TeAl pool size and the fatigue process. 
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CHAPTER 7 
GENERAL DISCUSSION 
Introduction 
Amino acids are involved in a wide array of physiological processes, some common to 
all 20 amino acids and others restricted to particular amino acids. In general, all amino 
acids are involved in protein turnover. Further to this, the intermediary metabolism of 
amino acids, within and beyond skeletal muscle, is linked to a wide variety of metabolic 
functions. The intracellular functions include maintenance of adenine nucleotide 
concentrations, de novo synthesis of purines and pyrimidine bases, the transfer of 
reducing equivalents in the mitochondria, anaplerotic maintenance of intermediates of 
the TCA cycle, and extracellular functions which include the provision of fuel for cells 
of the immune system, acid-base regulation, gluconeogenesis and ureagenesis. The 
non-essential amino acid glutamine has a role in almost all of these processes and in this 
respect has been described as 'conditionally-essential' (Lacy and Wilmore, 1990) 
particularly due to its role in gluconeogenesis (Nurjhan et al. 1995), cell swelling in 
both the liver (Haussinger et al. 1990) and skeletal muscle (Low et al. 1996) and as an 
important respiratory fuel for the cells of the immune system (Ardawi and Newsholme, 
1983) and gut (Windmueller and Spaeth, 1974). 
The aim of all of the studies presented in this thesis was to investigate the role of 
amino acid metabolism during exercise and during recovery from exercise in humans. 
Amino acids were supplemented during recovery from exercise or prior to exercise 
providing a model to examine the interaction between amino acid metabolism and 
carbohydrate metabolism both at the whole-body level (Chapters 4 & 5) and at cellular 
level (Chapter 6). In the flfst two studies presented in this thesis, the oral consumption 
of glutamine during recovery from exhaustive exercise, whether ingested in 
combination with a glucose-polymer or not, appeared to facilitate a better maintenance 
of glucose levels during a subsequent cycle to exhaustion. Despite this, cycle time to 
exhaustion was not different between conditions. 
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Research findings 
The oral consumption of 0.3 g.kg-1 glutamine over a 4 h recovery period (-6 g 
glutamine in total) was able to increase plasma glutamine concentration by -30 % when 
consumed in combination with glucose-polymer, and by -60 % when glutamine only 
was consumed. Therefore, it appears that the addition of 1.7 g.kg-1 glucose-polymer 
solution diluted the increase in plasma glutamine concentration by approximately half. 
The increase in plasma glutamine concentration is similar to that observed when 0.3 
g.kg-1 glutamine and 1.7 g.kg-1 glucose-polymer were provided (Bowtell et al., 
unpublished findings)_ In the third study, it was demonstrated that the oral consumption 
of 0.125 g.kg-1 glutamine (-10 g glutamine) was able to increase plasma glutamine 
concentration by -50 %, with a corresponding increase muscle glutamine content (-30 
%) compared to the control condition. Based on the findings of the third study, it is 
conceivable that the increase in plasma glutamine concentration observed in both the 
fIrst and second studies of this thesis was sufficient to increase muscle glutamine 
concentration. By comparison, the intravenous infusion of glutamine after exhaustive 
exercise, which would be expected to increase plasma glutamine concentration to a 
greater extent than oral provision, was able to increase plasma glutamine concentration 
by -70 %, however muscle glutamine content increased by only -15% (Varnier et al. 
1995). The disparity in the increase in muscle glutamine content between the results of 
the third study and the work of Varnier et al. may be related to the extent that the 
intramuscular glutamine pool was depleted prior to glutamine administration. Indeed, 
basal muscle glutamine concentration was reduced to -30 mmol/kg dry muscle in the 
third study (based on the CON condition value 1 hour post ingestion), whereas basal 
muscle glutamine concentration in the study by Vamier et al. was -55 mmol/kg dry 
muscle, which suggests that skeletal muscle uptake of glutamine may be proportional to 
the size of the intramuscular glutamine pool following the exogenous provision of 
glutamine. 
It is evident from both the first and second studies that the plasma concentration of 
serine, asparagine, threonine and ornithine, in addition to alanine and glycine, were 
increased in response to alanine and glycine ingestion. This is most probably due to a 
saturation of the normal metabolic pathways, causing reactions to be shifted in the 
opposite direction, leading to the biosynthesis of these amino acids. In the second study 
(Chapter 5), when alanine and glycine were consumed without glucose-polymer, the 
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plasma concentration of glycine increased approximately 3-fold, and the peak in 
concentration occurred 45 min after consumption. In the first study (Chapter 4), when 
alanine and glycine were consumed with glucose-polymer, the increase in plasma 
glycine concentration was ofa similar order, but the peak in concentration occurred 150 
min after consumption. Therefore, there appears to some effect of the addition of the 
glucose-polymer to the solution. This effect is mirrored in the plasma serine response, 
which is expected as serine can be synthesised from glycine via the serine 
transhydroxymethylase reaction. This may infer that the supplementation of glucose-
polymer in addition to alanine and glycine reduces the rate of absorption in the gut or 
the uptake of glycine into the systemic circulation. 
The combined results of the studies presented in this thesis demonstrate that the 
ingestion of glutamine is able to increase the plasma concentration of both glutamate 
and aspartate, in addition to glutamine. Furthermore, the plasma concentrations of 
phenylalanine, tyrosine and methionine were decreased in response to glutamine 
ingestion. The reduction in the plasma concentrations of phenylalanine, tyrosine and 
methionine may be indicative of a reduction in skeletal muscle protein breakdown. An 
increase in the concentration of these amino acids that are not metabolised in skeletal 
muscle is suggestive of an increase in skeletal muscle protein breakdown as these amino 
acids are only used for protein synthesis (van Hall et aI. 1999; Blomstrand and Saltin, 
1999). Therefore, a decrease in their concentration would suggest a decrease in skeletal 
muscle protein breakdown. Indeed a reduction in skeletal muscle protein breakdown 
has previously been observed following glutamine administration (MacLennan et al. 
1988), with glutamine having a similar mode of action to that of insulin, inferring that 
glutamine does indeed have an anabolic affect. 
The increase in plasma glutamate concentration observed following glutamine 
supplementation is most likely due to the deamination of glutamine to glutamate via 
glutaminase in the liver. Indeed, a degree of glutamate-glutamine 'cycling' appears to 
have occurred between the splanchnic bed, in particular the liver, and skeletal muscle 
giving rise to the increased plasma glutamate concentration following glutamine 
supplementation. It is apparent that the increase in plasma glutamate concentration also 
had a 'knock-on' effect, increasing plasma aspartate concentration. This was most 
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probably due to an increase in flux through the aspartate aminotransferase reaction (EC 
2.6.1.1; glutamate + oxaloacetate + NAD+ ++ a-ketoglutarate + aspartate + NADH). 
In the fIrst study (Chapter 4), the plasma free tryptophan:BCAA ratio increased during 
recovery and at exhaustion in the second bout of exercise in the glucose-polymer and 
glutamine condition. However, a similar response was not observed in the second study 
(Chapter 5) when glutamine alone was supplemented during recovery from exercise. It 
is feasible that when both glucose-polymer and glutamine are ingested together a 
different and synergistic metabolic response is invoked. Indeed, the supplementation of 
both glucose-polymer and glutamine was able to suppress the plasma NEFA 
concentration during both the recovery period and the second bout of exercise to a 
greater extent than when glucose-polymer and alanine and glycine were supplemented. 
However, the supplementation of glutamine alone was unable to produce a similar 
response during the second study when compared to the supplementation of alanine and 
glycine. The reduction in plasma NEFA concentration following glucose-polymer and 
glutamine ingestion is most probably related to the ability of glutamine to increase 
insulin concentration or to suppress lipolysis (Cersosimo et al. 1986). According to the 
central fatigue hypothesis, the reduction in plasma FF A concentration would have 
allowed increased binding of tryptophan to albumin, thereby decreasing the plasma free 
tryptophan concentration. Contrary to this, in the fIrst study an increase in plasma free 
tryptophan concentration was observed during the second bout of exercise, which, in 
combination with the decrease in plasma BCAA concentration, increased the plasma 
free tryptophan:BCAA ratio. Therefore, the mechanism for this response is difficult to 
explain, although it appears to be related mostly to tryptophan biosynthesis. 
The anabolic effect of ingesting carbohydrate (glucose-polymer) post exercise was 
clearly demonstrated in the fIrst study. An increase was observed in both glucose and 
insulin concentrations in both the experimental conditions. The increase in insulin 
concentration following carbohydrate supplementation was such that the contribution 
from any amino acid was masked. However, when the results from the second study are 
considered, it is apparent that there is an increase in insulin concentration which is 
attributable to the ingestion of either alanine or glycine, or a combination of both 
(Kuhara et al. 1991). This would suggest that glutamine has less signillcant 
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insulinogenic properties than previously thought, in concurrence with recent fmdings 
demonstrating that other amino acids have greater insulinogenic properties than 
glutamine (van Loon et al. 2000). 
It is surprising, however, that no difference was observed in cycle time to exhaustion 
between the control conditions (placebo) and the experimental conditions (glucose-
polymer plus amino acids). Previous investigations by Blom et al. (Blom et al. 1987) 
and Ivy et al. (Ivy et al. 1988b) demonstrated that carbohydrate ingestion between 0.7 
and 1.5 g·kg- I body wt·h-I after exhaustive exercise provided adequate stimulus for 
maximal muscle glycogen restoration over a 4 h period. However, carbohydrate 
ingestion greater than 0.7 g·kg-I body wt·h- I did not appear to provide an enhanced 
benefit in the restoration ofmnscle glycogen (Blom et al. 1987; Ivy et al. I 988b). In 
the first study, 1.7 g·kg-I body wt carbohydrate was ingested over the 4 h recovery 
period, equating to approximately 0.43 g·kg-I body wt·h-I . This dose of glucose-
polymer solution may have not been sufficient to fully activate the enzyme glycogen 
synthase and achieve maximal muscle glycogen resynthesis during this time period. 
Even if the maximal rate of muscle glycogen resynthesis was achieved (--6-7 mmol·kg-I 
·h-I dry weight) by providing a greater glucose load, then over the 4 h recovery period 
there would have been at most an increase in muscle glycogen content of28 mmol·kg-I 
dry weight. Even with an increase in muscle glycogen content of this order, it is 
questionable whether this would equate to an increase in endurance capacity in a 
subsequent bout of exercise. 
However, one would intuitively expect that cycle time to exhaustion to be greater after 
the ingestion of a glucose-polymer solution during the recovery period after exercise. 
Theoretically, this would have promoted a greater resynthesis of both liver and skeletal 
muscle glycogen, thus providing a greater supply of energy for the second bout of 
exercise. However, it is possible that a trade off between the supplementation of 
glucose-polymer and the suppression of fat oxidation during exercise may have 
occurred. Certainly, carbohydrate oxidation was greater in the period following the 
ingestion of the glucose-polymer and glutamine solution compared to the control 
conditions. Furthermore, the hypothesised increase in both muscle and liver glycogen 
storage following glucose-polymer and glutamine supplementation during the recovery 
period would be expected to increase carbohydrate oxidation in the second bout of 
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exercise, thus increasing the rate of depletion of carbohydrate stores and placing a lesser 
demand upon filt as a fuel source. This may have partly accounted for the failure to 
observe a difference between conditions in exercise capacity. 
The addition of a glucose-polymer solution to the amino acids in the first study made it 
difficult to delineate the effects of the ingestion of amino acids. However, some clear 
differences were observed between the experimental conditions and the control 
conditions that were attributable only to the ingestion of the amino acids. Furthermore, 
differences were observed between the two experimental conditions, suggesting that the 
individual amino acids or a combination of the amino acid and the glucose-polymer 
elicited an altered metabolic response. When the findings ofthe first (Chapter 4) and 
second (Chapter 5) studies are combined, it is clear that the ingestion of glutamine 
during recovery from exhaustive exercise is able to modulate glucose metabolism in a· 
subsequent bout of exercise. In both the first and second studies of this thesis (Chapters 
4 & 5), systemic glucose concentration in the second bout of exercise was either 
increased or maintained after glutamine supplementation, conversely a decrease was 
observed in systemic glucose concentration in the comparative condition. This fmding 
is suggestive that glutamine may hold glucogenic or glycogenic properties, possibly 
through an increase in liver glycogen content or by acting as a gluconeogenic precursor, 
the former being more likely given previous findings (Mouterde et al. 1992; Bowtell et 
al. 1999). Despite this suggested increase in liver glycogen storage, no difference in 
cycle time to exhaustion was observed in either study. This is surprising since it has 
been demonstrated that fatigue during prolonged cycling exercise was delayed 
following an increase in systemic glucose concentration (Coyle et al. 1983). 
Furthermore, it has been reported that a greater rate of glucose utilisation occurs during 
prolonged cycling exercise compared to prolonged running exercise (Derman et al. 
1996), most probably related to the observation that glucose uptake by a given muscle 
group is inversely related to the total amount of muscle that is exercising (i.e. greater 
glucose utilisation due to a smaller active muscle mass) (Richter et al. 1988). 
Therefore, during prolonged cycling exercise, systemic glucose concentration may 
affect the aetiology offatigue. 
Although systemic glucose concentration was maintained during the second bout of 
exercise following both glucose-polymer & glutamine and glutamine supplementation 
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in both the first and second studies respectively (Chapters 4 & 5), it is feasible that 
hypoglycaemia may have played a minor role in the aetiology of fatigue in this bout of 
exercise. Felig et al. (1982) have demonstrated that during cycling exercise to 
exhaustion at 60-65% V02max, symptoms of hypoglycaemia are exhibited. Although, a 
higher intensity of exercise was utilised in the present studies, which may place a 
greater reliance upon blood borne fuel sources such as glucose, in neither study did 
systemic glucose at exhaustion reach clinically defined hypoglycaemic levels « 2.5 
mM), suggesting that hypoglycaemia may not have been the primary cause of fatigue. 
Indeed, Felig et al. were able to demonstrate that cycling exercise could be continued 
even in the presence of symptoms of hypoglycaemia. Therefore, the failure to observe a 
difference in cycle time to exhaustion between conditions in the first and second studies, 
may in part be related to the fact that cycle time to exhaustion (endurance capacity) may 
not be a sensitive enough tool to detect differences between conditions, as discussed in 
Chapter 4. There is also the possibility that the recovery period (4 h) was too short for 
the purported anabolic effects of glutamine to influence endurance capacity. 
In light of recent evidence suggesting that the addition of glutamine to a glucose 
solution is unable to further increase skeletal muscle glycogen synthesis or increase the 
activation of skeletal muscle glycogen synthase compared to glucose alone 
(Wagemnakers et al. 1997; van Hall et al. 2000a), it would appear that the proven 
ergogenic effect of carbohydrate supplementation post exercise in skeletal muscle is not 
further enhanced by the addition of glutamine (van Hall et al. 2000b). However, Blom 
et at. (1987) have demonstrated that increasing the amount of glucose provided post 
exercise from 0.7 to 1.4 g.kg-l body wt·h· l does not cause a further increase in the rate 
of skeletal muscle glycogen synthesis. It is feasible therefore, that the glucose dose (0.8 
g.kg-l body wt) provided by van Hall et al_ (2000b) may have been great enough to 
maximally stimulate skeletal muscle glycogen synthase. Thus, any activation of 
glycogen synthase by glutamine would not be observed, if glutamine-stimulated 
glycogen synthesis were mediated via glycogen synthase activation and glycogen 
synthesis would not be increased. 
The effect that the supplementation of glutamine alone may have on both hepatic and 
skeletal muscle glycogen synthase has not been examined in vivo in humans. 
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Furthermore, the extent to which glycogen synthase is activated by glutamine, both in 
the liver and skeletal muscle, may be determined by glycogen concentration. Indeed, 
the administration of glutamine alone post exercise has been shown to increase muscle 
glycogen content (Varnier et al. 1995). The effect observed, in absolute terms, was 
rather modest and responsible for no more than 2 mmol·kg·[ wet weight of glycogen per 
hour. Nevertheless, an increase was observed in muscle glycogen content following the 
provision of glutamine, which cannot be merely attributed to a gluconeogenic effect as 
the total amount of carbon provided as alanine and glycine, in the comparator condition, 
was equivalent to that in glutamine. Therefore, it appears that a reduction in glycogen 
content, may provide the stimulus for the activation of glycogen synthase following the 
administration of glutamine. It is feasible that the same response could be invoked in 
the liver following glutamine supplementation, if liver glycogen content has been 
reduced through a previous bout of exercise. Indeed, in rats whose liver glycogen 
content has been reduced through starvation, glutamine has been shown to be a good 
substrate for liver glycogen synthesis (Mouterde et al. 1992). Therefore, the provision 
of glutamine, a glycogenic substrate, may prove a suitable alternative source of carbon 
for glycogen synthesis in the glycogen depleted state in both the liver and skeletal 
muscle, if the availability of common glycogenic substrates is reduced. 
It would have been interesting ifWagenmakers et al. (1997) or van Hall et al. (2000b) 
had included a glutamine only condition to determine the extent that glutamine itself 
may increase skeletal muscle glycogen content. Recent research has indicated that the 
addition of glutamine to glucose-polymer supplementation is unable to further increase 
skeletal muscle glycogen synthesis compared to glucose-polymer alone (Bowtell et al. 
1999). However, in this study, whole-body carbohydrate storage was increased 
following glutamine and glucose-polymer supplementation, with the most feasible site 
of the increased storage being the liver. Therefore, it is plausible that the ingestion of 
glutamine and glucose-polymer post exercise may produce a synergistic effect, an effect 
not observed when either glutamine or glucose-polymer are consumed individually. 
Further to this, it is an intriguing possibility that the production of glucosamine, 
following the consumption of glucose-polymer and glutamine, may increase liver 
glycogen content by increasing the availability of glucose to the liver, via a reduction in 
skeletal muscle glucose uptake due to an impairment ofGLUT-4 translocation (Baron et 
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al. 1995). The results from the studies presented in this thesis provide some evidence 
to suggest that the supplementation of glutamine is able modulate metabolism in the 
liver. In particular, the elevated glucose levels during the second bout of exercise after 
glutamine supplementation may be indicative of increased hepatic glucose output, 
which in turn may be indicative of an increase in liver glycogen storage during the 
recovery period. However, given the complexity in measuring liver metabolism in vivo, 
it is difficult to determine whether the effect is glucogenic or glycogenic. 
To date, liver glycogen content has never been assessed in vivo in humans following the 
consumption of either glucose-polymer and glutamine or glutamine. Until such data is 
obtained, which would involve MRSINMR techniques or liver biopsies, the exact 
mechanism for the increase in systemic glucose concentration, observed in these studies 
following glutamine supplementation, will remain unresolved. 
It is evident from the results of the third study (Chapter 6) that the supplementation of 
glutamine is able to alter skeletal muscle metabolism at a cellular level. The 
consumption of glutamine 1 h prior to exercise, in glycogen-depleted subjects, resulted 
in a further increase in the total concentration of the TCAI (i.e. promoting anaplerosis) 
after 10 min of submaximal exercise. For glutamine to interact with the TCA cycle, the 
catabolism of glutamine must have occurred. Although, no tracer technique was 
implemented to track the carbon skeleton of glutamine, the most logical and feasible 
route by which glutamine can enter the TCA cycle is by the two-step conversion to a-
ketoglutarate. Glutamine that enters skeletal muscle can be deaminated to form 
glutamate and then a-ketoglutarate through the action of glutaminase (glutaminase I) 
and glutamate dehydrogenase or alanine aminotransferase, respectively. Alternatively, 
glutamine may be deaminated to form a-ketoglutaramate and then a-ketoglutarate 
through the action of glutamine transaminase (glutaminase 11) and ro-amidase, 
respectively. It is noteworthy that the activity of either form of glutaminase (I or 11) in 
human skeletal muscle has not been quantified, although there is some tenuous evidence 
that glutaminase I is present in both in rat (Ottaway, 1969; de Almeida et al. 1989) and 
human skeletal muscle (Swierczynski et al. 1993). The pathway by which glutamine 
degradation occurs is unclear. However, glutamine degradation is not inhibited by the 
presence of the glutaminase inhibitor 6-diazo-5-oxo-L-norleucine (DON) in rat skeletal 
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muscle (Wu et al. 1991), suggesting that the glutamine transaminase and ro-amidase 
pathway is most feasible in skeletal muscle, although it is conceivable that a species 
difference may exist. However, future research should attempt to determine the activity 
of both isoforms of glutaminase in human skeletal muscle so that the pathway of 
glutamine degradation may be resolved. 
Despite effectively promoting anaplerosis at 10 min of submaximal exercise, following 
the ingestion of glutamine 1 h prior to exercise, the decrease in phosphocreatine and 
increase in muscle lactate content was similar in all conditions at 10 min exercise. 
This would appear to suggest that the enhanced increase in the TCAl observed during 
exercise was not important for oxidative energy delivery. Furthermore, despite 
increasing the total concentration of the TCAl at 10 min of exercise, no difference was 
observed at exhaustion, with cycle time to exhaustion no different between conditions. 
This suggests that the total concentration of the TCAl may not be important in the 
aetiology offatigue during submaxirnaJ exercise. 
Implications for athletes 
The implications for athletes from results of the presented studies are related to the 
anabolic benefit that may be gained from the supplementation of glutamine. Athletes 
involved in endurance activities have primarily used glutamine as a post exercise 
'ergogenic aid' to ensure optimal functioning of the immune system. Evidence from the 
studies presented in this thesis, would suggest that supplementation of glutamine during 
recovery from exercise or prior to exercise is able to modulate both whole body and 
cellular level metabolism. In particular, the provision of glutamine in the dose and 
pattern described in the studies reported in this thesis demonstrates that glutamine can 
invoke an anabolic enviromnent in humans potentially allowing a more rapid recovery 
post exercise. However the proven anabolic effect of glucose-polymer supplementation 
must not be overlooked. The provision of glucose-polymer alone post exercise has been 
demonstrated to increase both liver and skeletal muscle glycogen resynthesis (Casey et 
al. 2000) and reduce skeletal muscle protein breakdown (Roy et al. 1997). For this 
reason, the consumption of glutamine post exercise is most probably best combined 
with glucose-polymer to achieve the maximal beneficial effect. 
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Future work 
In light of the fmdings from the third study (Chapter 6), it would be interesting to 
further examine the role of the TCAI in the aetiology of fatigue. One possible way to 
study this would be to supplement glutamine during exercise in an attempt to increase 
the TCAI pool size in skeletal muscle, and take multiple biopsies whilst exercising to 
exhaustion. This would allow a better understanding of the role of the intermediates in 
the fatigue process, in addition to determining whether or not a critical level in the total 
content of the TCAI exists. Furthermore, it would also be intriguing to examine the 
effect of infusing dichloroacetate (DCA), to increase the supply of acetyl units to the 
TCA cycle, whilst providing a supply of either glutamine or pyruvate, both of which 
have proved capable of increasing the total content of the TCAI (Gibala and Saltin, 
2000). This may provide an optimal environment for oxidative metabolism, which may 
reduce the lag in the onset of oxidative metabolism at the onset of moderate intensity 
exercise, with a lesser reliance on substrate level phosphorylation and which may also 
extend endurance capacity during submaximal exercise. 
The studies in this thesis have been able to demonstrate that exercise is able to alter 
amino acid metabolism in humans and that the supplementation of amino acids during 
recovery from exercise can modulate exercise metabolism during a subsequent bout of 
exercise. Furthermore, it has been shown that amino acids in muscle do indeed occupy 
a central role in metabolism during exercise acting as precursors for the synthesis of 
TCA cycle intermediates. However, the physiological significance of increasing the 
TCA cycle intermediates may not be as important to TCA cycle flux and oxidative 
energy metabolism during exercise as previously thought. 
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APPENDIX A 
PLASMA GLUCOSE 
Principle 
Plasma glucose concentration was determined using an automated analyser (Cobas Mira 
Plus, Roche Diagnostic Systems, Basal, Switzerland) employing a enzymatic 
colorimetric method using a commercially available kit (Boehringer Mannheim GmbH, 
No. 166391). The GOD-PAP method for glucose determination was used in this kit. 
In the presence of peioxidase, the hydrogen peroxide formed affects the oxidative 
coupling of hydroxybenzoic acid and 4-aminoantipyrine to form a red-coloured 
quinoneimine derivative. The colour intensity is directly related to the glucose 
concentration and is measured photometrically at 500 nm. 
GOD 
POD 
2 H202 + 4-aminophenazone + phenol 
4-(p-benzoquinone-mono-imino)phenazone + 4 H20 
GOD ~ glucose oxidase; POD ~ perioxidase 
Reagents 
Reagent 
Assay solution Phenol 
4-aminophenazone 
Enzymes 
Reagents 
Method 
GOD 
POD 
Water 
Concentration/other details Storage conditions 
11.0 mmol.r1 
0.77 mmol.r1 
18 U/ml 
1.1 Ulml 
+4 - 8°C 
+4 - 8°C 
+4 - 8°C 
+4 - 8°C 
Room temp 
A calibration curve is run using a calibrator and appropriate quality controls (CFAS: 
calibrator for automated systems and Control Serum Precinorm N & U; all Boehringer 
Mannheim). Samples, standards and controls are pipetted in excess into cuvettes and 
loaded into the analyser. The analyser adds 300 J.ll of the assay solution containing both 
reagents and enzymes to 4 III of sample, standard or control at 37°C. The absorbance of 
the cuvettes is then measured at 500 nm and the colour intensity is directly related to the 
glucose concentration relative to the calibration curve. 
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APPENDIXB 
BLOOD LACTATE 
Principle 
Blood lactate concentration was detennined manually using a fluorometric method 
(Maughan, 1982). The principle is based on a change in the oxidative state ofNAD+, 
with the buffer containing and excess NAD+ and of a high pH to ensure the reaction 
proceeds from left to right. A 20 III sample was deproteinsised in 200 III 2.5 % 
perchloric acid. 
LDH n+ Lactate + NAD+ .... (f-----)~ Pyruvate + NADH + 1"1 
LDH = lactate dehydrogenase; NAD = nicotinamide adenine dinucleotide; NADH = 
reduced nicotinamide adenine dinucleotide 
Reagents 
Reagent Concentration/other details Storage conditions 
Bnffer (1.1 moI.r!) Hydrazine sulphate 6.5 g Room temp 
(PH 9.0-9.5) Hydrazine hydrate 24.26ml Room temp 
EDTA 1.0 g Room temp 
Diluent HCI 0.07 mon! Room temp 
Cofactor NAD 5.0 mmol.r! +4 - SOC 
Enzymes Lactate dehydrogenase (Boehringer 106984) +4 - SOC 
Reagents Water Room temp 
Method 
1. Prepare hydrazine buffer by adding 6.5 g hydrazine sulphate, 24.26 m1 hydrazine 
hydrate and 1.0 g EDTA to a volumetric flask and make up to 500 m1 with distilled 
water. Check pH with pH meter (PH 9.0-9.5). 
2. Prepare lactate diluent by adding 70 m1 of I M HCI to a volumetric flask, make up 
to 1.0 L with distilled water. 
3. Prepare buffer mixture by adding 10 III LDH and 2.0 mg of NAD per 1.0 m1 of 
buffer mixture (e.g. for 10 samples; 10 x 200 III = 2.0 m1: 2.0 m1 hydrazine buffer, 
20 III LDH and 4.0 mg NAD) 
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4. Pipette 200 ~I of buffer mixture and 20 ~I of standard, control (2.2 mM) or sample 
into Pyrex glass test tubes (75 x 10 mm). Samples should be defrosted thoroughly, 
mixed with Whirlimix and centrifuged for 3 min prior to use. 
5. Prepare standard curve using standards of the following concentration: 0, 1.25, 2.5, 
5.0, 10.0 (mmol.l'I). 
6. Mix solution in tubes thoroughly using a Whirlimix taking care not to displace any 
of the contents. Cover appropriately to prevent contamination. 
7. Incubate for 30 min at room temperature. 
8. Add 1.0 ml of lactate diluent to each tube to end reaction. 
9. Read fluorescence (FI) of tubes using a fluorometer (Locarte Model LF 8-9, 
Locarte, London, UK). 
10. Calculations: 
The inverse relationship between fluorescence and lactate concentration of the 
lactate standards was determined using a software program by fitting a linear 
trendline (Microsoft Excel; see Figure B,1). Concentration of the lactate in the 
samples was then calculated from the equation for the relationship. 
Figure B.t Example standard curve for lactate. 
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Example calculation: 
Lactate (mmol rl) = Fl x 0.0902 - 0.0711 
Fl = fluorescence of sample at the end of step 9. 
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APPENDIXC 
SERUM AND PLASMA NON-ESTERIFIED 
FATTY ACIDS (NEFA) 
Plasma and serum NEFA concentration was determined colorimetrically using a 
commercially available kit (Wako ACS-ACOD Method). NEFA when treated with 
acyl-CoA synthetase (ACS) in the presence of adenosine triphoshophate (ATP), 
magnesium cations and CoA, form the thiol esters of CoA known as acyl-CoA as well 
as the by products adenosine monophopshate (AMP) and pyrophopshate (PPi). The 
acyl-CoA is oxidaised by adding aceyl-CoA oxidase (ACOD) to produce hydrogen 
peroxide which in the presence of added peroxidase (POD) allows the oxidative 
condensation of 3-methyl-N-ethyl-N-(~-hydroxyethyl)-aniline (MEHA) with 4-
aminoabtipyrine to form a purple coloured adduct with an absorption maximum of 550 
nm. Therefore the amount ofNEFA in the sample can be determined from the optical 
density measured at 550 nm. 
ACS 
NEFA + ATP + CoA ) Acyl-CoA + AMP + PPi 
Acyl-CoA + 02 ACOD ) 2,3-trans-Enoyl-CoA + H202 
Reagents 
Reagent Concentration/other details Storage conditions 
Assay solution Phosphate buffer! (PH 6.9) 0.05 moH! +4 - scC 
Magnesium chloride! 3.0 mmol.r! +4 - scC 
MEHA2 1.2 mmol.r! +4 - scC 
CoA3 7 mg/vial +4 - scC 
ATp3 30 mg/vial +4 - scC 
4-aminoantipyrine3 3 mg/vial +4 - scC 
Enzymes ACS3 3 V/vial +4 - scC 
A003 (ascorbate oxidase) 30 V/vial +4 - SOC 
ACOO4 132 V/vial +4 - scC 
POO4 150 V/vial +4 - scC 
Reagents Water Room temp 
1 = contained in solvent A; 2 = contained in solvent B; 3 = contained in reagent A; 3 = contained in 
reagentB 
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Method 
This assay is run using an automated analyser (Cobas Mira Plus, Roche Diagnostic 
Systems, Basal, Switzerland). Both plasma and serum NEF A concentration can be 
determined. To create the reagents required for the assay 10 rn1 of solvent A is added to 
reagent A and 7 rn1 of solvent B is added to reagent B. 
A calibration curve is run using the standard provided with the kit and an appropriate 
quality control. Samples, standards and controls are pipetted in excess into cuvettes and 
loaded into the analyser. The analyser adds 120 J.1l of reagent A to 6 J.1l of sample, 
standard or control and incubates at 37°C for 10 min. The analyser then adds 85 III of 
reagent B to the sample, standard or control and incubates for a further 10 min at 3rC. 
The optical density of the cuvettes is then measured at 550 nm. The NEF A 
concentration corresponding to the measured absorbance can be determined directly 
from the previously run calibration curve. 
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APPENDIXD 
PLASMA AMMONIA (NB3) 
Principle 
Plasma ammonia (NH3) concentration was determined using a commercially available 
kit (Sigma I 71-UV). The principle is based on the reductive amination of a-
ketoglutarate, using glutamate dehydrogenase and reduced nicotinamide adenine 
dinucleotide phosphate. The decrease in absorbance at 340 nm due to oxidation of 
NADPH is proportional to the plasma ammonia concentration. The procedure is 
standardised by means of the millimolar absorptivity ofNADPH, which is 6.22 at 340 
nm. The reductive amination of a-ketoglutarate to form glutamate catalysed by GDH is 
coupled with the oxidation ofNADPH to NADP on a molar equivalent basis. 
GDH 
a-ketoglutarate + NH3 + NADPH ----~) Glutamate + NADP 
GDH = glutamate dehydrogenase; NADPH = reduced nicotinamide adenine dinucleotide phosphate 
Reagents 
Reagent Concentration/other details Storage conditions 
Assay solution 2-oxoglutarate 3.4 mmoU1 +4 - goC 
NADPH 0.23 mmoU1 +4 - goC 
Enzymes Glutamate dehydrogenase 1200 Vlml (Sigma 170-4) +4 - goC 
Phosphate buffer pH 7.4 +4 - goC 
Glycerol 50%w/v +4 - goC 
Reagents Water Room temp 
Method 
1. Label cuvettes for blank, standards and samples all in duplicate. 
2. Pipette 500 Jll of assay solution into all cuvettes. To blank cuvette add 150 Jll water, 
to standard cuvette add 50 Jll of standard (29.4 JlM, 118 JlM and 294 JlM) and 100 
Jll of water, to sample cuvettes add 150 Jll of plasma sample. 
3. Cover cuvettes with Parafilm@ and mix by gentle inversion. 
4. Allow cuvette to equilibrate for approximately 3 min at room temperature. 
5. Set zero on spectrophotometer using blank cuvette. 
6. Read initial absorbance (AI) of each cuvette versus blank at 340 nm. 
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7. Add 5 III ofGDH to each cuvette. Mix by gentle inversion and wait approximately 
5 min for reaction to complete. 
8. Set zero on spectrophotometer using blank cuvette. 
9. Read fmal absorbance (A2) of each cuvette versus blank at 340 nm. 
10. Calculation: 
Plasma ammonia (Ilmol.-1) = 
«AI-A2) x 35.8) x 58.8 
Al = absorbance of sample and blank at the end of step 6. 
A2 = absorbance of sample and blank at the end of step 9. 
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APPENDIXE 
SERUM INSULIN (RADIOIMMUNOASSAy) 
Principle 
1251 labeled insulin competes for a fixed time with insulin in the sample for sites on 
insulin-specific antibody. Because the antibody is immobilised on the wall of a 
polypropylene tube, decanting the supernatant suffices to terminate the competition and 
to isolate the antibody-bound fraction of the radiolabeled insulin. Counting the tube in a 
gamma counter then yields a value, which converts using a calibration curve to a 
measure of the insulin in the sample. 
Method 
1. Label four uncoated tubes for total count (TOT) and non-specific binding (NSB). 
2. Label seven Insulin Ab-coated tubes in duplicate for calibrators of standard 
(calibration) curve (see table below). 
Calibrator Approximate j!IU/ml 
A(MB) 0 
B 5 
C 15 
D 50 
E 100 
F 200 
G 400 
MB = maximwn binding 
3. Pipette 200 J.1l of the zero calibrator A into the NSB and A tubes, and 200 J.1l of each 
remaining calibrator, control and sample into the labelled prepared tubes. Three 
different concentrations of control were used every 15 samples during each run. 
4. Add 1.0 ml of 1251 Insulin to every tube and vortex taking care not to displace any of 
the contents. 
5. Incubate for 18-24 h at room temperature (IS-28°C) with the tubes covered 
appropriately (e.g. silver foil). 
6. Decant thoroughly all contents of tubes, except for TOT tubes. 
7. Count for one minute in a gamma counter (Cobra 11, Packard Instruments) 
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8. Insulin concentration of each sample was calculated using computer software 
(Cobra II, Packard Instruments) fitting an auto-spline curve to the calibration data, 
plotting concentration against percentage of [251 Insulin bound. 
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APPENDIXF 
MUSCLE ADENOSINE TRIPHOSPHATE (ATP) 
AND PHOPSHOCREATINE (pCr) 
The content of ATP and PCr can be measured by the production ofNADPH at 340 nm 
when sufficient NADP, glucose, ADP and glucose-6-phosphate dehydrogenase (G-6-
PDH) are included in the assays, so that the reaction is limited by the availability of 
ATPand PCr. 
CPK 
PCr + ADP ----~)o Cr + ATP 
HI( 
ATP + Glucose -----~)o ADP + G-6-P 
G-6·PDH 
G-6-P + NADP+ -----)o~ 6-P-Gluconolactone + NADPH + if 
ADP ~ adenosine diphosphate; Cr ~ creatine; CPK ~ creatine phosphokinase; HI( ~ hexokinase; G-6-P ~ g1ucose-6-
phosphate; G-6-PDH ~ g1ucose-6-phosphate dehydrogenase; NADP ~ nicotinamide adenine dinucleotide phosphate 
Reagents 
Reagent Concentration/other details Storage conditions 
Bnffer Triethanolamine (TEA) (18.6 g·mr!) +4- 8°C 
(pH 7.5-7.6) Magnesium acetate (2.2 g·mr!) Room temp 
EDTA (0.1 g·mr!) Room temp 
Cofactor NADP (20.9 mg·mr!) +4 - 8°C 
Enzymes G-6-PDH (Boehringer 127035) +4 - 8°C 
Hexokinase (Boehringer 127 175) +4- SOC 
Creatine phosphokinase (Sigma C-3755) -20°C 
Reagents Dithiothreitol (DTT) (7.S mg·mr!) +4 - SOC 
Glucose (22.5 mg·mr!) Room temp 
ADP (5.1 mg·mr!) -20°C 
Water Room temp 
Working standards were prepared prior to analysis and stored at -20°C (ATP: 1.51 
mmolll; PCr: 2.11 mmolll). 
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Method 
1. Make up the reagent mixture, vortex and store at room temperature. 
2. Dilute the following enzymes: 
Hexokinase (HK). Dilute 1 part enzyme to 1 part water. Use 3 III per cuvette. 
Vortex gently and keep on ice. 
Creatine phosphokinase (CPK). Dissolve IS mg·mr! in O.S% NaHC03 + O.OS% 
Bovine Serum Albumin (BSA). Dilute 2 parts enzyme to 1 part water. Use 3 111 per 
cuvette. Vortex gently and keep on ice. 
3. Pipette 3S0 III of the reagent mix into each cuvette. Samples are run in batches of 
10 + 1 blank. 
4. Add 40 III of water for the blank, 20 III of ATP standard and 20 III ofPCr standard, 
or 40 III sample. The muscle samples should be defrosted quickly in hot water, then 
vortexed and spun down (22,000 x g, 3 min) before use. 
5. Set the spectrophotometer to read samples at 340 run, from 0.0-1.1 units absorbance. 
6. Read initial absorbance (AI) at 30 sec intervals. 
7. Add 3 III of HK to each cuvette, agitate to mix. Incubate for 15 min at room 
temperature. Read intermediate absorbance at 30 sec intervals. 
8. Add 3 III of CPK to each cuvette, agitate to mix. Incubate for 30 min at room 
temperature. Read final absorbance (A2) at 30 sec intervals. 
9. Calculations: 
(1) ATP (mmol kg·! dm) = 
«393 x (A2-BI2) - 390 x (AI-Bll »/6.22 x 40} x EF x 1.25 
(2) PCr (mmol kg·! dm) = 
«396 x (A2-BI2) - 393 x (AI-Bll »/6.22 x 40) x EF x 1.25 
ATP: Al and Bll = absorbance of sample and blank at the end of step 6. 
A2 and BI2 = absorbance of sample and blank at the end of step 7. 
PCr: Al and Bll = absorbance of sample and blank at the end of step 7. 
A2 and B12 = absorbance of sample and blank at the end of step 8. 
6.22 = molar extinction coefficient ofNADPH at 340 nm (units are cm2·llmor!). 
40 = sample volume (Ill) 
EF = extraction factor (known volume of PCA added to muscle powder during 
extraction procedure/weight of sample in mg). 
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APPENDIXG 
MUSCLE CREATINE (Cr) 
Principle 
The content of Cr can be measured by the utilisation of NADH at 340 nm when 
sufficient NADH, PEP and ATP is included in the assay. 
CPK 
Cr + ATP ----~) PCr + ADP 
ADP + PEP 
PK 
_____ ~) ADP + Pyruvate 
LDH 
Pyruvate + NADH ----.) Lactate + NAD+ 
Cr ~ creatine; A TP ~ adenosine triphosphate; ADP ~ adenosine diphosphate; CPK = creatine phosphokinase; PEP = 
phosphoenolpyruvate; PK = pyruvate kinase; G-6-P = glucose-6-phosphate; LDH = lactate dehydrogenase; NADH = 
reduced nicotinamide adenine dinucleotide; NAD+ = nicotinamide adenine dinucleotide 
Reagents 
Reagent Concentration/other details Storage conditions 
Buffer Glycine (2.4 g 100·mr!) +4 - 8°C 
(pH 9.0-9.1) Magnesium acetate (0.4 g 100·mr!) Room temp 
Cofactor NADH (9.0 mg·mr!) +4 - 8°C 
Enzymes Creatine phosphokinase (Sigma C-3755) -20°C 
Lactate dehydrogenase (Boehringer 107034) +4 - 8°C 
Pyruvate kinase (Boehringer 128155) +4 - 8°C 
Reagents KCI (15 g 100·mr!) +4 - 8°C 
ATP (15.4 mg·mr!) 
-20°C 
PEP (11.6 mg·ml-!) 
-20°C 
Water Room temp 
Working standards were prepared prior to analysis and stored at -20°C (Cr: 3.34 
mmoVl). 
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Method 
1. Make up the reagent mixture, vortex and store at room temperature. 
2. Prepare the CPK enzyme, by dissolving 15 mg ml·1 in 0.5% NaHC03 + 0.05% 
Bovine Serum Albumin (BSA). Use 10 l-llper cuvette. Vortex and keep on ice. 
3. Pipette 450ul of the reagent mix into each cuvette. Samples are run in batches of 10 
+ 1 blank. 
4. Add 30 III of water for the blank, 30 l-ll of standard or 30 III of extract. The muscle 
samples should be defrosted quickly in hot water, then vortexed and spun down 
(22,000 x g, 3 min) before use. Mix well. 
5. Set the spectrophotometer to read samples at 340 run, from 0.0-1.1 units absorbance. 
6. Read initial absorbance (AI) at 30 sec intervals. 
7. Add 10 III ofCPK to each cuvette, agitate to mix. Incubate for 20 minutes at room 
temperature. 
8. Read fmal absorbance (A2) at 30 sec intervals. 
9. Calculation: 
Cr (mmol kg·1 dm) = 
(-1) x «490 x (A2-B12)-480 x (AI-Bll)) x (EF x 1.25))/(6.22 x 30) 
Al and Bll = absorbance of sample and blank at the end of step 6. 
A2 and Bl2 = absorbance of sample and blank at the end of step 8. 
6.22 = molar extinction coefficient ofNADH at 340nm (units are cm2·l-lmorl). 
30 = sample volume (l-ll) 
EF = extraction factor (known volume of PCA added to muscle powder during 
extraction procedure/weight of sample in mg). 
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APPENDIXH 
MUSCLE LACTATE 
Principle 
Lactate was determined indirectly from changes in the absorbance of NADH, using a 
fluorometric assay. Calculation of lactate concentration was from an NADH standard 
curve, which was run in parallel with the samples. 
LDH 
Lactate + NAD+ + W ----~) Pyruvate + NADH 
LDH = lactate dehydrogenase; NAD+ = nicotinamide adenine dinucleotide; NADH = reduced nicotinamide adenine 
dinucleotide 
Reagents 
Reagent 
Buffer 2-amino-2-methyl-l-
(pH 10.0) propranolol 
Cofactor NAD+ 
Enzymes Lactate debydrogenase 
Reagents Hydrazine 
Water 
Concentration/otber details 
1 M (9.5 ml or 8.9 g of powder 
in 100 mr!) 
100 mM (70.0 mg·mr!) 
(Boehringer 106 984) 
1 M (Dilute Sml of 20M stock 
solution to 100 ml) 
Storage conditions 
+4 - 8°C 
+4 - 8°C 
+4 - 8°C 
Room temp 
Room temp 
N.B.The assay is carried out at pH 10.0. At this pH beefheart lactate dehydrogenase is more stable than 
the skeletal enzyme. 
Method 
I. Prepare lactate standards: 
Make up sodium lactate stock solution 500 /lM (6.0 mg sodium lactate/lOO ml 
water). Store at -20°C. 
2. Prepare 2-arnino-2-methyl-l-propranolol buffer 1 M pH 8.0. Set pH 10.0 with HCL 
6 M. Store at -20°C. 
3. Prepare the enzyme: 
Dilute lactate dehydrogenase (beef heart) to 550 U/ml from stock 1250 U/ml, with 
Tris buffer 20 mM, pH 8.0 containing 0.02% albumin. Store on ice. 
4. Make up the reagent mixture, vortex and store at room temperature. 
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5. Prepare the lactate standards by adding the following volumes of sodium lactate 
stock solution (500 1lM) to the reagent buffer in cuvettes. Mix well and leave for 5 
min at room temperature. 
Sodium lactate (500 1lM) stock (Ill) 1 3 5 10 15 20 
Reagent buffer (Ill) 525 525 525 525 525 525 
Water (Ill) 74 72 70 65 60 55 
[Lactate JIlM 0.83 2.48 4.13 8.26 12.40 16.53 
6. Pipette 525 III of reagent buffer, 65 III water and 10 III sample into each cuvette. 
The muscle samples should be defrosted quickly in hot water, then vortexed and 
spun down (22,000 x g, 3 min) before use. Samples are run in batches of 10 + 1 
blank. Mix well. 
7. Leave for 5 min at room temperature. 
8. Read initial fluorescence (Fl) at 30 sec intervals (Excitation 340 nmlEmission 460 
nm; Hitachi F2000, fluorescence spectrophotometer). 
9. Add 5 III of LDH each cuvette, agitate to mix and incubate for 30 min at room 
temperature. 
10. Read final fluorescence (F2) at 30 sec intervals. 
11. Calculations: 
The inverse relationship between fluorescence and lactate concentration was 
determined using a software program by fitting a second order polynomial trendIine 
(Microsoft Excel; see Figure H.1). Concentration of lactate was then calculated 
from the (second degree) equation for the relationship. 
Figure H.t Example standard curve for lactate. 
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Example calculation: 
Lactate (mmol kg-! dm) = 
(-0.053 + 0.007 x «F2-Fl)-(B12-Bll)) + 0.00002 x «F2-Fl)-(B12-Bll)) x «F2-
Fl)-(B12-Bll)) x EF x 1.25 x 605)/10000 
Fl and Bll = fluorescence of sample and blank at the end of step 8. 
F2 and B12 = fluorescence of sample and blank at the end of step 10. 
605 = total cuvette volume (Ill). 
EF = extraction factor (known volume of peA added to muscle powder during 
extraction procedure/weight of sample in mg). 
271 
APPENDIX I 
MUSCLE PYRUVATE 
Principle 
Pyruvate concentration was determined indirectly from changes in NADH using a 
fluorometric assay. NADH oxidation by compounds other than pyruvate is minimised 
at pH 6.8-7.0, therefore a phosphate buffer is used. However, phosphate accelerates the 
destruction ofNADH, therefore a blank, standard and sample must be run in parallel. 
LDH 
Pyruvate + NADH ----~) Lactate + NAD+ + W 
LDH = lactate dehydrogenase; NAD+ = nicotinamide adenine dinucleotide; NADH = reduced nicotinamide adenine 
dinucleotide 
Reagents 
Reagent Concentration Storage conditions 
Buffer K,HPO. 1 M (17.4 g·IOOmr') +4 - 8°C 
(pH 7.5-7.6) NaH,PO.·2H,O 1 M (15.6 g·IOO mr') +4 - 8°C 
Cofactor NADH 5 M (20.9 mg·mr') +4 - 8°C 
Enzymes Lactate dehydrogenase (Boehringer 106984) +4 - 8°C 
Reagents Water Room temp 
Method 
1. Prepare pyruvate standards: 
Make up pyruvate stock solution lOO mM (11.0 mg pyruvate/m! water). Store at -
20°C. Dilute the pyruvate standard to 20 IlM prior to use. 
2. Prepare phosphate buffers (K2HP04 and NaH,P04·2H20). 
3. Prepare the NADH solution: 
Carbonate buffer (lOO mM; pH 10.6); dissolve 0.85 g Na2C03 and 0.17 g NaHC03 
in 100 ml water. Dissolve NADH 3.5 mg/ml in carbonate buffer. 
4. Prepare the enzyme: 
Dilute lactate dehydrogenase stock (beef heart) (50 mg/IQ m! or 5 mg/ml or 250 
V/m! or 1250 V/m!) to 0.4 mg/ml with Tris buffer 20 mM, pH 8.0 containing 0.02% 
albumin (0.24 g·1 00 mr! Tris with 2.0 mg albumin). 
5. Prepare the pyruvate standards by adding the following volumes of pyruvate stock 
solution (20 1lM) to the reagent buffer in cuvettes. Mix well. 
272 
2 4 8 12 15 20 25 40 
600 600 600 600 600 600 600 600 
Pyruvate (20 ~M) stock (~l) 
Reagent buffer (~l) 
[Pyruvate 1 ~M 0.066 0.132 0.263 0.391 0.487 0.644 0.798 1.247 
6. Make up the reagent mixture, containing phosphate buffers, and titrate with NADH 
solution until the initial fluorescence is -700-800 units. Store at room temperature. 
7. Pipette 600 ~l of reagent buffer in each cuvette. Samples are run in batches of 10 + 
I blank. 
8. Add 20 ~l of water for the blank or 20 ~l of sample. The muscle samples should be 
defrosted quickly in hot water, then vortexed and spun down (22,000 x g, 3 min) 
before use. Mix well. 
9. Read initial fluorescence (Fl) at 30 sec intervals (Excitation 340 nmlEmission 460 
nm; Hitachi F2000, fluorescence spectrophotometer). 
10. Add 1.5 ~l ofLDH to each cuvette, agitate to mix and incubate for 10 min at room 
temperature. 
11. Read fmal fluorescence (F2) at 30 sec intervals. 
12. Calculations: 
The relationship between fluorescence and pyruvate concentration was determined 
using a software program by fitting a linear trendline (Microsoft Excel; see Figure 
1.1). Concentration of pyruvate was then calculated using the slope from the 
equation of the relationship. 
Figure 1.1 Example standard curve for pyruvate. 
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1.2 1.4 
Example calculation: 
Pyruvate (mmol kgol dm) = 
««F2-Fl )-(B12-Bll »/950992) x EF x 1-25 x 31-075)/1 000 
Fl and BB = fluorescence of sample and blank at the end of step 9. 
F2 and B12 = fluorescence of sample and blank at the end of step 1 I-
31-075 = dilution factor (total cuvette volume (621.5 Ill)/sample volume (20 Ill». 
EF = extraction factor (known volume of peA added to muscle powder during 
extraction procedure/weight of sample in mg). 
274 
APPENDIXJ 
MUSCLE CITRATE 
Principle 
Citrate concentration was detennined indirectly from changes in NADH using a 
fluorometric assay. 
CL 
Citrate ----~) Oxaloacetate + H20 
TT+ MDH + Oxaloacetate + NADH + n ___ ~) Malate + NAD 
MDH ~ Malate dehydrogenase; CL ~ citrate lyase; NAD+ ~ nicotinamide adenine dinucleotide; NADH ~ reduced 
nicotinamide adenine dinucleotide 
Reagents 
Reagent 
ButTer Tris Base 
(pH S.O) EDTA 
MgCh*6H2O 
Stabilising ButTer Triethanolamine 
(pH 7.4) MgCh*H2O 
(NHohSO. 
Cofactor NADH 
Enzymes Citrate Lyase 
Malate Dehydrogenase 
Reagents Water 
Method 
1. Prepare citrate buffer: 
Concentration Storage conditions 
45 mM (0.55 g·IOO mr') +4 - SOC 
0.1 mM (3.7 mg·IOO mr') 
2.5 mM 
45 mM (0.23 g·25 mr') 
0.3 mM (1.5 mg·25 mr') 
0.5 mM (1.65 g·25 mr') 
10mg·mr' 
(Boehringer 374 074) 
(Boehringer 127256) 
+4 - SOC 
+4 - SOC 
+4 - SOC 
Room temp 
Add 0.55 g Tris Base, 3.7 mg EDTA and 51 rng MgCh*6H20 to 100 rnl water. Set 
to pH 8.0 with HC!. 
2. Prepare stabilising buffer: 
Add 0.23 g Triethanolamine, 1.5 mg MgCh*H20 and 1.65 g (NH4)2S04 to 25 rnl 
water. Set to pH 7.4 with NH.OH. Stable for 24 h. 
3. Prepare citrate standard: 
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Make up citrate stock solution (2 mM). Store at -20°C. Dilute the citrate standard 
to I 00 ~M prior to use. 
4. Prepare the NADH solution: /' 
Carbonate buffer (100 mM; pH 10.6); dissolve 0.85 g Na2C03 and 0.17 g NaHC03 
in 100 ml water. Dissolve NADH 10 mg/ml in carbonate buffer. 
5. Prepare the enzyme: 
Dilute 1 mg citrate lyase (CL) liophilysate 200JlI stabilising buffer. Dilute 5 times 
with citrate buffer (without NADH) just prior to use. 
6. Prepare the citrate standards by adding the following volumes of citrate diluted 
stock solution (100 JlM) to the reagent buffer in cuvettes. Mix well. 
Citrate (100 JlM) stock (JlI) 20 20 20 20 20 20 20 20 
Water (JlI) 1980 980 480 313.3 230 180 146.7 113.3 
[Citrate 1 JlM 1 2 4 6 8 10 12 15 
13. Make up the reagent mixture: To 100 m1 citrate buffer, add 5 JlI of undiluted malate 
dehydrogenase (MOH) and 75 ~I ofNADH solution. Store at room temperature. 
14. Pipette 500 JlI of reagent buffer in each cuvette. Samples are run in batches of 10 + 
1 blank. 
IS. To each cuvette add 75 JlI of water for the blank, 75 JlI of standard mixture or 75 JlI 
of sample. The muscle samples should be defrosted quickly in hot water, then 
vortexed and spun down (22,000 x g, 3 min) before use. Mix well. 
16. Read initial fluorescence (Fl) at 30 sec intervals (Excitation 340 nmlEmission 460 
nm; Hitachi F2000, fluorescence spectrophotometer). 
17. Add 10.0 JlI of CL to each cuvette, agitate to mix and incubate for 15 min at room 
temperature. 
18. Read final fluorescence (F2) at 30 sec intervals. 
19. Calculations: 
The relationship between fluorescence and citrate concentration was determined 
using a software program by fitting a linear trendline (Microsoft Excel; see Figure 
J.l). Concentration of citrate was then calculated using the slope from the equation 
of the relationship. 
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Figure J.t Example standard curve for citrate. 
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Example calculation: 
Citrate (mmol kg-! dm) = 
««F2-Fl)-(B12-Bll))/1O.274) x EF x 1.25)/1000 
12 14 
Fl and Bll = fluorescence of sample and blank at the end of step 16. 
F2 and B12 = fluorescence of sample and blank at the end of step 18. 
16 
EF = extraction factor (known volume of PCA added to muscle powder during 
extraction procedure/weight of sample in mg). 
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APPENDIXK 
MUSCLE SUCCINATE 
Principle 
Succinate concentration was determined indirectly from changes in NADH using a 
fluorometric assay. 
ss 
Succinyl CoA + Pi + GDP ----). Succinate + GTP + CoA 
ss = Succinyl CoA synthetase; NAD+ = nicotinamide adenine dinucleotide; NADH = reduced nicotinamide adenine 
dinucleotide 
Reagents 
ButTers 
(pH 7.4) 
NADHbutTer 
(pH S.2) 
Cofactor 
Enzymes 
Reagents 
Method 
Reagent 
Triethanolamine * HCI 
EDTA 
MgCh*6H2O 
Triethanolamine 
K2C03 
NADH 
CoASH 
GTP 
PEP 
Lactate Dehydrogenase 
Pyruvate kinase 
Succinyl-CoA synthetase 
Water 
1. Prepare TEA buffer: 
Concentration Storage conditions 
50 mM (0.93 g. 100 mr!) +4 - SOC 
5 mM (0.19 g. 100 mr!) 
10 mM (0.2 g·1 00 mr!) Room temp 
0.1 M(1 g·100mr!) +4 - SOC 
2.3 M (-S g) 
2.4 mM (2.4 mg·mr!) +4 - SOC 
11 mM (8.45 mg·mr!) +4- SOC 
21 mM (11.3 mg·mr!) +4 - SOC 
110 mM (51.21 mg·mr!) 
(Boehringer 106 9S4) +4- SOC 
(Boehringer 12S 155) +4 - SOC 
(Boehringer 161 543) +4 - SOC 
Room temp 
Add 0.93 g Triethanolamine, 0.19 g EDTA and 0.2 g MgCh*6H20 to 100 m1 water. 
Set to pH 7.4 with 1 M KOH. 
2. Prepare TEAlK2C03 buffer: 
Add 1 g Triethanolamine to 100 m1 water and titrate with K2C03 until pH 8.2. 
3. Prepare succinate standard: 
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Make up succinate stock solution 10 mM (I1.S mg succinic acid/ml water), adjust 
pH to 7.0 with 1 M KOH. Store at -20°C. Dilute the succinate standard to 50 IlM 
prior to use (50 III of 10 IlM stock with 9,950 III water). 
4. Prepare the NADH solution: 
Dissolve NADH 2 mg/m! in TEAlK2C03 buffer. 
5. Prepare the enzymes: 
Lactate dehydrogenase (5 mg/ml), recommended 4.2 Ilg/m! in cuvette. Pyruvate 
kinase (10 mg/ml) recommended 4.21lg/m! in cuvette. Succinyl-CoA synthatase (5 
mg/ml), recommended 90 mU/ml in cuvette. 
6. Prepare the succinate standards by adding the following volumes of diluted 
succinate stock solution (10 mM diluted to 50 IlM) to the reagent buffer in cuvettes. 
Mix well. 
Succinate (50 IlM) stock (Ill) 2 
Water (Ill) 73 
Reagent (Ill) 
[Succinate] IlM 
500 
1.33 
3 5 
72 70 
500 500 
2.00 3.33 
S 
67 
500 
5.33 
10 15 
65 60 
500 500 
6.66 10.00 
20 
55 
500 
13.33 
30 
45 
500 
20.00 
7. Make up the reagent mixture (For 1 sample): Add 1 m! TEA buffer, 10 III CoASH, 
10 III GTP, 10 III PEP, 1 III lactate dehydrogenase (undiluted) and 0.5 III pyruvate 
kinase (undiluted). Titrate with NADH solution until initial fluorescence is -SOO 
units. 
NB. The pyruvate contained within PEP and the samples causes erroneously high values. To 
overcome this, the reagent mixture is titrated with NADH to provide a high initial fluorescence, 
taking care not to reduce sensitivity. The reagent mixture containing PEP and NADH should be left 
for 15 min in the dark in order for the pyruvate contained within PEP to be reduced to lactate. Prior 
to use the fluorescence of the reagent mixture should be checked. Pipetted samples should be left for 
at least 10 min to allow pyruvate contained in samples to be reduced to lactate. 
S. Pipette 500 III of reagent buffer in each cuvette. Samples are run in batches of 10 + 
1 blank. 
9. To each cuvette add 75'lll of water for the blank, 75 III of standard mixture or 75 III 
of sample. The muscle samples should be defrosted quickly in hot water, then 
vortexed and spun down (22,000 x g, 3 min) before use. Mix well. 
10. Read initial fluorescence (Fl) at 30 sec intervals (Excitation 340 nmlEmission 460 
nm; Hitachi F2000, fluorescence spectrophotometer). 
11. Add 2.5 III of succinyl-CoA synthatase to each cuvette, agitate to mix and incubate 
for 30 min at room temperature. 
12. Read fmal fluorescence (F2) at 30 sec intervals. 
13. Calculations: 
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The relationship between fluorescence and succinate concentration was determined 
using a software program by fitting a linear trend line (Microsoft Excel; see Figure 
K.I). Concentration of succinate was then calculated using the slope from the 
equation of the relationship. 
Figure K.1 Example standard curve for succinate. 
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Example calculation: 
Succinate (mmol kg"l dm) = 
((((F2-Fl)-(BI2-BIl»/11.91) x EF x 1.25)/1000 
20 
Fl and BIl = fluorescence of sample and blank at the end of step 10. 
F2 and BI2 = fluorescence of sample and blank at the end of step 12. 
25 
EF = extraction factor (known volume of PCA added to muscle powder during 
extraction procedure/weight of sample in mg). 
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APPENDIXL 
MUSCLE MALATE AND FUMARATE 
Principle 
Both malate and fumarate concentration was determined indirectly from changes in 
NADH using a fluorometric assay. 
FM 
Fumarate + H20 Malate 
Malate + NAD+ __ MD_H_~) Oxaloacetate + NADH + W 
FM ~ Fumarase; MDH ~ Malate dehydrogenase; NAD+ ~ nicotinamide adenine dinucleotide; NADH ~ reduced 
nicotinamide adenine dinucleotide 
Reagents 
Reagent Concentration Storage conditions 
ButTer Hydrazine 1.0 M _20°C 
(pH 9.0) EDTA 0.1 M (3.7 g'l 00 mrl) +4 - 8°C 
Acetylpyridin~adenine 0.1 M (70 mg·mrl) -20°C 
dinucleotide (AP AD) 
Stabilising ButTer Tris 0.02 M (0.24 g·100 mrl) -20°C 
(pH 8.0) 
Enzymes Malate Dehydrogenase (Boehringer 127256) +4 - 8°C 
Fumarase (Sigma-FI757) +4 - 8°C 
Reagents Water Room temp 
Method 
1. Prepare malate and fumarate buffer: 
Add 0.55 g Tris Base, 3.7 mg EDTA and 51 mg MgCh*6H20 to 100 rnl water. Set 
to pH 8.0 with HC!. 
2. Prepare stabilising buffer: 
Tris buffer 0.02 M containing 0.02% albumin (0.24 g·100 rnl- l Tris with 2.0 mg 
albumin). Set to pH 8.0 with 1 M HCl. 
3. Prepare malate and fumarate standards: 
Make up L-malate stock solution 100 mM (19.97 mg malic acidfrnl water). Store at 
-20°C. Dilute the malate standard to 50 J.lM prior to use (5 J.ll of 100 mM stock to 
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10 mI water). Make up fumarate stock solution 100 mM (16.0 mg fumaric acid/ml 
water). Store at -20°C. Dilute the fumarate standard to 50 ).IM prior to use (5 ).11 of 
100 mM stock to 10 mI water). 
4. Prepare the enzymes: 
Dilute malate dehydrogenase stock (5 mg/mI) 5 times with stabilising buffer (Tris 
buffer 0.02 M, pH 8.0, containing 0.02% albumin) until fmal concentration is I mg 
proteinlmI. Dilute fumarase stock (2500 U) with stabilising buffer (Tris buffer 0.02 
M, pH 8.0, containing 0.02% albumin) until final concentration is I mg proteinlmI. 
5. Prepare the malate and finnarate standards by adding the following volumes of 
diluted malate and fumarate stock solution (100 mM diluted to 50 ).IM) to the 
reagent buffer in cuvettes. Mix well. 
Malate (50 ).IM) ().II) 2 4 6 8 10 15 20 25 
Fumarate (50 ).IM) ().II) 2 4 6 8 10 15 20 25 
Water ().II) 71 67 63 59 55 45 35 25 
Reagent ().II) 500 500 500 500 500 500 500 500 
[Malate] ).IM 0.173 0.345 0.518 0.691 0.864 1.295 1.727 2.159 
[Fumarate] ).IM 0.172 0.343 0.515 0.686 0.858 1.286 1.715 2.144 
6. Make up the reagent mixture: To 100 mI water, add 10 mI ofhydrazine 1.0 M, pH 
9.0 (5 ml hydrazine hydrate -20 M), 0.2 ml EDTA 0.1 M and 0.06 mI AP AD 0.1 M. 
Store at room temperature. 
7. Pipette 500 ).11 of reagent buffer in each cuvette. Samples are run in batches of 10 + 
1 blank. 
8. To each cuvette add 75 ).11 of water for the blank, 75 ).11 of standard mixture or 75 ).11 
of sample. The muscle samples should be defrosted quickly in hot water, then 
vortexed and spun down (22,000 x g, 3 min) before use. Mix well. 
9. Read initial fluorescence (F1) at 30 sec intervals (Excitation 340 nmlEmission 460 
nrn; Hitachi F2000, fluorescence spectrophotometer). 
10. Add 4 ).11 of malate dehydrogenase to each cuvette, agitate to mix and incubate for 
25 min at room temperature. 
11. Read intermediate fluorescence (F2) at 30 sec intervals. 
12. Add 4 ).11 of fumarase to each cuvette, agitate to mix and incubate for 25 min at 
room temperature. 
13. Read final fluorescence (F3) at 30 sec intervals. 
14. Calculations: 
The relationship between fluorescence and malate and fumarate concentration was 
determined using a software program by fitting a linear trendline (Microsoft Excel; 
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see Figures L.l and L.2). Concentration of malate and fumarate was then calculated 
using the slope from the equation of the relationship. 
Figure L.t Example standard curve for malate. 
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Example calculation: 
Malate (mmol kg· l dm) = 
««F2-Fl)-(BI2-BI1»/28.722) x EF x 1.25 x (579175»/1000 
Fl and BI1 = fluorescence of sample and blank at the end of step 9. 
F2 and BI2 = fluorescence of sample and blank at the end of step 11. 
EF = extraction factor (known volume of PCA added to muscle powder during 
extraction procedure/weight of sample in mg). 
579 = total volume in cuvette 
75 = volume of sample added 
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Figure L.2 Example standard curve for fumarate. 
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Example calculation: 
Fumarate (mmol kg'! dm) = 
««F2-FI)-(B12-Bll))/21.086) x EF x 1.25 x (583/75))/1000 
2 
FI and Bll = fluorescence of sample and blank at the end of step 11. 
F2 and B12 = fluorescence of sample and blank at the end of step 13. 
2.5 
EF = extraction factor (known volume of peA added to muscle powder during 
extraction procedure/weight of sample in mg). 
583 = total volume in cuvette 
75 = volume of sample added 
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APPENDIX M 
MUSCLE GLUTAMINE AND GLUTAMATE 
Principle 
Both glutamine and glutamate concentration was determined indirectly from changes in 
NADH using a fluorometric assay. The assay is performed in two steps; firstly the 
glutamine contained in the sample is converted to glutamate (1), in the second step 
glutamate concentration is determined by converting glutamate to 2-oxoglutarate (2) 
with a concomitant measurable change in NADH. 
Glutaminase 
Glutamate + ~ + (1) Glutamine + H20 
GDH 
(2) Glutamate + NAD+ + H20 ----')~ 2-oxoglutarate + NH3 + NADH 
GDH = glutamate dehydrogenase; NAD+ = nicotinamide adenine dinucleotide; NADH = reduced nicotinamide 
adenine dinucleotide 
The equilibrium of reaction (2) favours glutamate formation. To overcome the 
unfavourable kinetics a high concentration of NAD+ and low concentration of W is 
used. ADP is used to activate glutamate dehydrogenase and to decrease its reactivity 
with other amino acids. 
Reagents 
Reagent Concentration Storage conditions 
Glutamine ButTer Sodium acetate lS.44 g'1000 mrl Room temp 
(pH 5.0) 0.2 M Glacial acetic acid 3.74 ml·1000 mrl Room temp 
Glutamate ButTer Hydrazine sulphate 1.3 g'l 00 mrl Room temp 
(pH 9.0) 1.1 M Hydrazine hydrate 5.0g·100mr1 Room temp 
EDTA(Na2) 0.2 g'100 mrl Room temp 
Cofactors ADP 100 mM (S.O g·100 mrl) -20cC 
NAD 50 mM (33.0 mg·1 mrl) +4 - sce 
Enzymes Glutaminase (Sigma-GSSSO) +4 - gcC 
Glutamate dehydrogenase (Boehringer 127 710) +4 - gcC 
Reagents Water Room temp 
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Method 
1. Prepare glutamine buffer: 
Add 18.44 g sodium acetate, 3.74 ml glacial acetic acid to 1000 ml water. Check 
pH 5.0 with pH meter. 
2. Prepare glutamate buffer: 
Add 1.3 g hydrazine sulphate, 5.0 g hydrazine hydrate and 0.2 g EDTANa2 to 100 
ml water. Check pH 9.0 with pH meter. 
3. Prepare glutamine and glutamate standards: 
Make up L-glutamine stock solution 100 mM (14.61 mg L-glutamine/ml water). 
Store at -20°C. Dilute the glutamine standard to 900 )lM prior to use (90 )ll of 100 
mM stock in 10 ml water). Make up glutamate stock solution 100 mM (16.92 mg 
L-glutamic acid/ml water). Store at -20°C. Dilute the glutamate standard to 155 
)lM prior to use (15.5 )ll of 100 mM stock in 10 ml water). 
4. Prepare the enzymes: 
Dissolve 25 U of glutaminase powder in 2.5 ml in 0.1 M acetate buffer (stable for 
several months). Use glutamate dehydrogenase undiluted (10 mg/ml in glycerol). 
5. Prepare the glutamine and glutamate standards by adding the following volumes of 
diluted glutamine stock solution (100 mM diluted to 900 )lM) and glutamate stock 
solution (100 mM diluted to 155 )lM) to the reagent buffer in cuvettes. Mix well. 
(1) For glutamine standards: 
Glutamine (900 )lM) ()ll) 5 10 15 20 25 30 35 40 
Water ()ll) 45 40 35 30 25 20 15 10 
Reagent ()ll) 555 555 555 555 555 555 555 555 
[Glutamine] )lM 90 180 270 360 450 540 630 720 
(2) For glutamate standards: 
Glutamate (155 )lM) ()ll) 2 4 6 8 10 12 15 20 
Water ()ll) 18 16 14 12 10 8 5 0 
Reagent ()ll) 565 565 565 565 565 565 565 565 
[Glutamate] )lM 15.5 31.0 46.5 62.0 77.5 93.0 116.3 155.0 
A separate set of standards is required for each step of the assay; the glutamine is 
converted to glutamate in the fIrst step and then assayed for glutamate concentration 
along with the glutamate standards in the second step of the assay. 
6. For glutamine assay: To a flip-top eppendorf add 100 )ll of acetate buffer, 5 )ll of 
glutaminase and 450 )ll of water. Add 50 )ll of water for the blank, 50 )ll of 
standard mixture for the glutamine assay or 40 )ll of sample. The muscle samples 
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should be defrosted quickly in hot water, then vortexed and spun down (22,000 x g, 
3 min) before use. Mix well 
7. Incubate for 1 h at 37°C. 
8. For glutamate assay: To each cuvette add 550 /-11 of hydrazine buffer, 10 /-11 ofNAD 
solution and 5 /-11 of ADP solution. Add 20 /-11 of water for the blank or 20 /-11 of 
standard mixture for the glutamate assay. For the samples, add either 20 /-11 of 
hydrolysed sample (from the first step of the assay) or 20 /-11 of untreated sample. 
The muscle samples should be defrosted quickly in hot water, then vortexed and 
spun down (22,000 x g, 3 min) before use. Mix well. 
9. Read initial fluorescence (Fl) at 30 sec intervals (Excitation 340 nmlEmission 460 
nm; Hitachi F2000, fluorescence spectrophotometer). 
10. Add 5 /-11 of glutamate dehydrogenase to each cuvette (from both the first step and 
second step of the assay), agitate to mix and incubate for 25 min at room 
temperature. 
11. Read fmal fluorescence (F2) at 30 sec intervals. 
12. Calculations: 
The relationship between fluorescence and glutamine and glutamate concentration 
was determined using a software program by fitting a linear trend line (Microsoft 
Excel; see Figures M.l and M.2). Concentration of glutamine and glutamate was 
then calculated using the slope from the equation of the relationship. 
Figure M.I Example standard curve for glutamine. 
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Example calculation: 
Glutamine (mmol kg· l dm) = 
«(F2-FI)-(B12-BII)) x EF x 1-25)/(0.686 x 1000)) 
FI and BII = fluorescence of sample and blank at the end of step 9. 
F2 and B12 = fluorescence of sample and blank at the end of step 11. 
EF = extraction factor (known volume of PCA added to muscle powder during 
extraction procedure/weight of sample in mg). 
N.B. To calculate fmal glutamine concentration, subtract the calculated glutamate 
concentration from the calculated glutamine concentration. 
Figure M.2 Example standard curve for glutamate. 
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Glutamate (mmol kg·l dm) = 
«(F2-FI)-(B12-BII)) x EF x 1.25)/(2.9644 x 1000)) 
140 
FI and BII = fluorescence of sample and blank at the end of step 9. 
F2 and B12 = fluorescence of sample and blank at the end of step 11. 
160 180 
EF = extraction factor (known volume of PCA added to muscle powder during 
extraction procedure/weight of sample in mg). 
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Abstract 
The purpose of the present work was to compare the whole blood and plasma glucose 
and lactate concentrations obtained by different commonly used automated and manual 
analytical methods to determine whether results are quantitatively and qualitatively 
similar. Measurements of blood glucose and lactate concentration were made using a 
Yellow Springs Instruments (YSI) automated analyser and manual methods, and plasma 
glucose and lactate concentration using two automated analysers; the YSI analyser and 
the Cobas Mira Plus analyser. A high level of agreement was observed between all 
comparisons (Mean difference; blood glucose: -0·04 ± 0·15 mmollL; blood lactate: 0·01 
± 0·05 mmollL; plasma lactate: 0·01 ± 0·15 mmollL), except plasma glucose 
concentration measured on the YSI analyser and the Cobas Mira Plus analyser (0·47 ± 
0·16 mmollL; 10% difference). The present work suggests that it cannot be assumed 
that glucose and lactate concentrations can be quantitatively compared when different 
analytical methods have been used. 
Keywords: Level of agreement, glucose oxidase,.exercise, manual and automated 
methods. 
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Introduction 
A variety of methods have been employed for the determination of glucose and lactate 
concentrations both within the clinical and research setting. An accurate and precise 
method for the measurement of these metabolites is desirable, in each of these settings. 
Furthermore, it would be desirable that different methods of determination display a 
high level of agreement, so that data from different laboratories are comparable. 
Blood glucose concentration declines immediately after the sample has been collected, 
with a concomitant increase in blood lactate concentration, due to the action of 
glycolytic enzymes within both erythrocytes and leukocytes. When a delay is expected 
between sample collection and analysis, pre-treatment of the blood sample is required, 
e.g. deproteinisation in perchloric acid to prevent glycolysis. This time consuming pre-
treatment of samples and relatively lengthy manual assays for lactate and glucose 
concentration makes the automated analysis of fresh samples an attractive alternative. 
Furthermore, the rapid and accurate determination of both glucose and lactate 
concentrations is vita~ particularly in the clinical environment. 
Automated analysers such as the Yellow Springs Instruments glucose and lactate 
analyser allow the analysis of fresh blood or plasma samples without any pre-treatment 
of the sample. Manual methods of analysis generally require the deproteinisation and 
storage of the sample, with the glucose or lactate concentration being determined at a 
later date. This results in a longer analysis period. Alternatively, plasma can be 
analysed using an automated analyser (e.g. Cobas Mira Plus), which will reduce 
analysis time compared to performing the analysis manually. The latter methods 
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involve a longer delay before the glucose and lactate concentration data are available, 
thus limiting their suitability in the clinical setting. 
Different methods of analysis for both glucose and lactate will not necessarily produce 
quantitatively the same results (Genter and Ipp, 1994). However, direct comparisons of 
results between studies are often made without consideration of any systematic 
difference in the analytical methods. Published studies that have compared different 
methods of analysis have, in general, applied unsuitable statistical analysis (i.e. 
correlation or regression) to assess the agreement between methods (Chua and Tan, 
1978). A more appropriate statistical analysis of different methods has been suggested 
(Bland and Altman, 1986). 
The purpose of the present work was to compare glucose and lactate data derived by 
different analytical methods in both plasma and blood. Measurements of blood glucose 
concentration were made using a Yellow Springs Instruments automated analyser and a 
colorimetric manual method. Plasma glucose concentration was measured using two 
automated analysers: the Yellow Springs Instruments analyser and the Cobas Mira Plus 
analyser. Comparisons of blood lactate concentration were made between the Yellow 
Springs Instruments analyser and a manual fluorometric method, and plasma lactate 
concentration using the Yellow Springs Instruments analyser and the Cobas Mira Plus 
analyser. 
Method 
Samples (n = 168) were obtained from healthy subjects completing a standard short-
term exercise and recovery protocol (7 h protocol incorporating periods of rest and 
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exercise; Fallowfield et al. 1995). Samples were taken from normal postabsorptive 
subjects through an indwelling forearm venous cannula throughout the experimental 
period. After an overnight fast, subjects completed approximately 90 min of cycling 
exercise at 70 % of their maximal oxygen uptake (V02max). After 30 min, subject 
completed 3 x 50 s efforts at twice the workload, followed by a further 45 min at the 
original intensity. After this initial exercise bout subjects recovered passively for 4 h. 
Subjects then performed a second bout of exercise which entailed cycling to exhaustion 
at 70 % VOzmax• The experimental protocol was approved by the Ethical Committee of 
Loughborough University. 
The concentration of glucose in whole blood was determined using both a Yellow 
Springs Instruments automated analyser (YSI) (Model 2300 STAT Plus, YSI, Ohio, 
USA) and a manual technique using a commercially available kit (GOD-Perid; 
Boehringer Mannheim, GmbH) employing an enzymatic (glucose oxidase) colorimetric 
method. The concentration of glucose in plasma was determined using the YSI analyser 
and another automated analyser (Cobas Mira Plus, Roche Diagnostic Systems, Basel, 
Switzerland) using a commercially available kit (GOD-PAP; Boehringer Mannheim, 
GmbH) employing an enzymatic (glucose oxidase) colorimetric method (see Table 1). 
The concentration oflactate in whole blood was determined using both the YSI analyser 
and a manual technique employing an enzymatic fluorometric method (Maughan, 
1982). The concentration of lactate in plasma was determined using the YSI analyser 
and the Cobas Mira Plus analyser using a commercially available kit (Boehringer 
Mannheim, GmbH) employing an enzymatic method (see Table 1). 
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Table 1. Comparison of analytical methods employed for the determination of glucose 
and lactate concentration. 
Analytical methods compared 
Blood glucose YSI analyser Manual spectrophotometric 
Blood lactate YSI analyser Manual flurometric 
Plasma glucose Cobas Mira Plus analyser YSI analyser 
Plasma lactate Cobas Mira Plus analyser YSI analyser 
Principles of Analysis 
The conversion of glucose to gluconate and hydrogen peroxide, in a reaction catalysed 
by the enzyme glucose oxidase (EC 1.1.3.4), constitutes the basis for several widely 
used methods of glucose determination in either whole blood or plasma. The increase 
in gluconate and hydrogen peroxide being proportional to the concentration of glucose 
in the sample being analysed. 
Glucose oxidase 
Both the manual and automated (Cobas Mira Plus) methods rely on the 
spectrophotometric determination of glucose. 
Automated determination of plasma glucose concentration (Cobas Mira Plus) 
A 4 ml aliquot was collected into a plastic tube containing ethylenediamine-tetra-acetic 
acid (EDTA) (Sarstedt, Leicester, UK) and was promptly centrifuged (6000 g, 15 min). 
After centrifugation, all samples were immediately stored at -20°C in untreated 
Eppendorf tubes. After a mean storage time of approximately 5 weeks, the plasma 
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samples were analysed for glucose concentration using the Cobas Mira Plus analyser. 
Plasma treated with EDT A has been shown not to interfere with any subsequent glucose 
analysis. 
Plasma samples can be analysed using the Cobas Mira Plus (GOD-PAP method) since 
deproteinisation is not required. The presence of peroxidase, phenol and 4-
aminophenazone in the reaction mixture results in the conversion of the hydrogen 
peroxide produced by the glucose oxidase reaction, to water and 4 --(p-benzoquinone-
mono-imino )phenazone. The intensity of the resultant change in colour is measured 
spectrophotometrically at 500 nm, and is directly proportional to the glucose 
concentration. 
Manual determination o/blood glucose concentration 
A 20 III sample of whole blood was deproteinised in 200 III of perchloric acid to halt 
glycolysis and immediately centrifuged (12,000 g, 4 min). After centrifugation, all 
samples were stored at -20°C. Due to the relative instability of glucose, the supernatant 
was analysed firstly for blood glucose concentration (manual method) and then, after re-
freezing, blood lactate concentration (manual method). 
For the manual method of blood glucose analysis (GOD-Perid method), peroxidase and 
ABTS (di-ammonium 2,2' -azino-bis(3-ethylbenzothiazo line-6-sulfonate) are 
introduced into the reaction mixture, resulting in the conversion of hydrogen peroxide to 
water and a coloured complex .. The intensity of the resultant colour change measured 
on a spectrophotometer at 610 nm (Cecil Instruments Model 393 Series 2, Cambridge, 
UK) is directly proportional to the glucose concentration. 
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Manual determination of blood lactate concentration 
The method for the fluorometric determination of blood lactate concentration was based 
upon that of Maughan (1982). The addition of lactate dehydrogenase (EC 1.1.1.27) to 
the reaction mixture (PH 9.0) containing excess NAD+ results in the production of 
reduced NAD+ (NADH) causing a change in fluorescence, measured using a fluorimeter 
(Locarte Model LF 8-9; Locarte, London, UK). 
+ LDH T'+ 
L-Lactate + NAD ..co(====)~ Pyruvate + NADH + n 
Automated determination of both plasma and blood glucose and lactate concentration 
(Yellow Springs Instruments analyser) 
Al ml aliquot was collected into an Eppendorftube for whole blood lactate and glucose 
analysis using the YSI analyser. After analysis of whole blood and within 1 minute of 
collection, this aliquot was centrifuged and the subsequent plasma sample was then 
presented to the YSI analyser for lactate and glucose analysis. 
The YSI analyser measured total (i.e. intracellular and extracellular using a cell-lysing 
agent) concentration of glucose and lactate in whole blood or plasma. Upon injection of 
the test sample (25 Ill) into the chamber, the determination of either glucose and lactate 
concentration depends on the following principle: 
Oxidase enzyme 
(1) Substrate + O2 ) H202 + oxidised products 
The test substrate (glucose or lactate) is rapidly oxidised upon contact with the 
respective membrane (separate membranes for glucose and lactate) holding an 
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immobilised oxidase enzyme, producing hydrogen peroxide (H20 2). The H20 2 
produced is oxidised at a platinum anode producing electrons: 
(2) ----)~ 02 + 2W + 2e" 
A dynamic equilibrium is achieved when the rate of H202 production and the rate at 
which the H202 leaves the immobilised enzyme are constant. The electron flow is 
linearly proportional to the H20 2 concentration, and therefore to the glucose or lactate 
concentration of the test sample. The current generated is equated to the metabolite 
concentration by the use of internal standards, provided by the manufacturer. 
Standards and Quality Controls 
All assays using commercially available kits followed the manufacturers instructions for 
analysis. All buffers, standards and control sera were freshly prepared prior to analysis. 
The standards used during the manual blood lactate assay ranged from 0 mmollL to 10 
mmollL, with a quality control of 2·2 mmollL. The standard used in the manual blood 
glucose assay was provided by the manufacturer (0·505 mmollL) and a deproteinised 
serum based quality control was used (Precinorm U, Boehringer Mannheim, GmBH; 
Assigned value: 5·71 mmollL; Range: 4·86 - 6·57 mmollL). 
The YSI analyser was checked and calibrated daily according to manufacturers 
instructions using aqueous standards obtained from the manufacturer. An internal 
aqueous standard was used to calibrate the analyser (Lactate: 5 mmoVL; Glucose: 10 
mmollL), in addition to external aqueous standards to check linearity (Lactate: 30 
mmollL; Glucose: 50 mmollL). A serum based quality control (Control Serum N, 
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Boehringer Mannheim, GmBH; Assigned values: Lactate: 1·27 mmollL; Glucose: 4·44 
mmollL) was also used to check the analyser. 
A variety of serum based quality controls were used to check the Cobas Mira Plus 
analyser (CFAS [calibrator for automated systems], Precinorm U, Precipath U; 
Boehringer Mannheim, GmBH and Control Serum N, Control Serum P; Roche 
Diagnostics; Range: Lactate: 1·14 - 5·04 mmoVL; Glucose: 3·94 - 16·0 mmollL). 
Between-assay means and coefficient of variations (CV) were determined for each 
analytical method: 
4·26 mmollL, CV 1·3 %, glucose - YSI analyser (serum based QC) 
1·30 mmollL, CV 2·2 %, lactate - YSI analyser (serum based QC) 
4·57 mmollL, CV 2·8 %, plasma glucose - Cobas Mira Plus analyser 
4·64 mmollL, CV 2·0 %, plasma lactate- Cobas Mira Plus analyser 
2·22 mmollL, CV 2·2 %, blood lactate - manual method 
5·54 mmollL, CV 1·3 %, blood glucose - manual method 
Statistical methods 
Agreement between methods was assessed using the method recommended by Bland 
and Altman (1986). In order to apply this method, differences in time over the 
experimental period were ignored. A two-way analysis of variance (ANOV A) for 
repeated measurements (time x method) was used to determine if any quantitative 
differences existed between methods. The interaction between time and method effects 
of the two-way ANOVA was used to examine whether there were qualitative 
differences between two given methods of analysis. A Pearson Product Moment 
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correlation was used to examine the relationship between methods. The 0·05 level was 
used for statistical significance, values are presented as means ± SO. 
Results 
Glucose analysis - Plasma 
A mean difference (-10 %) of 0·47 ± 0·16 mmollL (95 % confidence interval 0·11 -
0·82 mmollL) was observed in plasma glucose concentrations measured using the two 
automated analysers (Cobas Mira Plus analyser and the YSI analyser) (Fig. 1). This 
difference between methods was significant (P < 0.0001) (Fig. 2), but, there was no 
interaction between method of analysis and time effects. Despite this difference 
between the two methods, a significant positive correlation was observed (r = 0·9952, P 
< 0·01). 
Glucose analysis - Blood 
There was no significant difference between the blood glucose concentration measured 
on the YSI analyser and by the manual method (-0·04 ± 0·15 mmollL, 95 % confidence 
interval-0·38 - 0·30 mmollL, -1 % difference). A significant positive correlation (r = 
0·9872, P < 0·01) was observed between the two methods. 
Lactate analysis - Plasma 
The mean difference (Fig. 3) between the measurements for plasma lactate 
concentration made using the two automated analysers (YSI analyser and Cobas Mira 
Plus analyser) was 0·01 ± 0·15 mmollL (95 % confidence interval"'{)·32 - 0·33 mmollL, 
-0·6 % difference). No difference was observed between the two methods of analysis 
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using a two-way ANOV A (Fig. 4). A significant positive correlation was found 
between the measurements of plasma lactate (r = 0·9967, P < 0·01). 
Lactate analysis - Blood 
When comparing the measurements of blood lactate made on the YSI analyser and 
those made using the manual method, a mean difference of 0·01 ± 0·05 mmoIIL (95 % 
confidence interval-O·09 - 0·12 mm01lL) (-1·3 % difference) was observed between 
the two methods, which was not statistically significant. Furthermore, a significant 
positive correlation was found between the measurements of blood lactate (r = 0·9998, 
P<O·OI). 
Glucose and Lactate analysis - Plasma vs Blood 
Plasma glucose concentrations were consistently -14 % (0·58 ± O·JO mmoIIL, P < 
0·001) higher than blood glucose concentration, both measured on the YSI analyser. A 
significant positive correlation (r = 0·9919, P < 0·01) was observed between the two 
measurements. 
Plasma lactate concentrations were approximately 38 % (0·54 ± 0·47 mm01lL, P < 0·05) 
higher than blood lactate concentrations, both measured using the YSI analyser. 
However, a significant positive correlation was observed between plasma and blood 
lactate (r = 0·9994, P < 0·01). 
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Discussion 
The use of the enzymatic fluorometric method to determine blood lactate concentrations 
has previously been shown to be both reliable and accurate (Maughan, 1982). Despite 
employing different principles of determination, the results from the present work 
demonstrate that the Yellow Springs analyser using inunobiIised enzyme technology is 
able to produce consistently similar measurements of blood lactate to that of the 
conventional manual method. Indeed, this fmding is in accordance with previous 
research suggesting that the use of haemolysed blood samples with the YSI analyser, as 
in the present work, produces comparable lactate results with those obtained in 
deproteinised whole blood (Foxdal et al. 1992). 
Of greatest interest with the present work is the disparity between the two automated 
analysers (the YSI analyser and the Cobas Mira Plus analyser) measurements of plasma 
glucose concentration. The plasma glucose concentration values from the Cobas Mira 
Plus are consistently -10 % higher than the YSI analyser data. It has previously been 
reported that plasma glucose concentrations measured using YSI glucose analyser 
(Model 23AM) were lower than other glucose oxidase methods of plasma glucose 
concentration determination (Unwin et al. 1995). These authors suggested that the use 
of an aqueous calibrant with the YSI may not have been appropriate when plasma 
samples were presented, and may have resulted in lower plasma glucose measurements. 
Indeed, with the present work, when using an aqueous internal calibrator, the YSI 
analyser tended to return lower values for the serum based control. These values were 
approximately 3.6 % lower than the assigned value (Assigned value: 4.44 mmoIIL; 
Mean YSI value: 4.28 mmoIIL) for the quality control, but were stilI within the assigned 
range (4.00 - 4.88 mmoIlL). It should be noted that the underlying difference in the 
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calibration of the two automated analysers is that a serum based calibrator was used 
with Cobas Mira Plus (CFAS), whereas the YSI analyser used aqueous standards. It is 
conceivable that this difference in calibration may have led to the difference observed in 
the plasma glucose concentrations between the two analysers. 
The lack of an accepted 'gold standard' measurement of plasma glucose concentration 
makes any comparison between the two measurements difficult. The close agreement 
between the YSI analyser and the manual methods for both blood glucose and blood 
lactate measurement corroborates the use of these methods. The lack of agreement 
between the two methods for plasma glucose determination would suggest that the 
method employed by the Cobas Mira Plus may have produced elevated values for 
plasma glucose concentration. However, one cannot merely attribute the difference in 
measurement to the Cobas Mira Plus analyser itself as a close agreement was observed 
between the YSI analyser and Cobas Mira Plus analyser in the determination of plasma 
lactate concentration. 
Several confounding factors exist, that may explain the observed difference between the 
two measurements of plasma glucose concentration. In the case of the YSI analyser, 
fresh samples were presented to the analyser, whereas stored samples (5 weeks at-20°C) 
were presented to the Cobas Mira Plus analyser. During the process of sample 
collection, it is possible that there may have been a delay in spinning the samples, 
furthermore, no glycolytic inhibitor (e.g. fluoride) was used in the tubes at any point in 
the process. These factors may have served to reduce the glucose concentration in the 
plasma sample presented to the Cobas Mira Plus analyser. In addition, the freezing 
process itself has been shown to decrease plasma glucose concentration in the sample, 
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with a linear relationship being observed between storage duration and the decrease the 
plasma glucose concentration (Giampietro et al. 1980). However, it has been 
demonstrated that the decrease in plasma glucose concentration due to freezing, is no 
greater after one month than one day, and is not prevented by the addition of fluoride to 
the samples (Clark et al. 1990). 
However, the present data shows approximately 10 % higher values for the Cobas Mira 
Plus analyser than the YSI analyser. Therefore the disparity observed between the two 
methods may in fact be an underestimation of the true difference. Further support for 
the notion that the difference is related to the analytical method employed rather than 
differences in sample collection and storage, is supplied by the quality control data. The 
glucose concentration in the freshly prepared control sera was consistently 8 % higher 
when measured using the Cobas Mira Plus rather than the YSI analyser. 
The plasma glucose concentrations measured by the Cobas Mira Plus were consistently 
10 % higher than the YSI analyser throughout the experimental period. Indeed there 
was no interaction effect (method of analysis x time) was demonstrated using a two-way 
analysis of variance (Fig. 2), confirming that the data was qualitatively identical, 
although the plasma glucose concentrations were quantitatively different. 
It is evident from the present work that the use of correlation as a technique for 
assessing agreement between two methods is inappropriate. This is highlighted by the 
fact that, in spite of a lack of agreement using the Bland and Altman method between 
the Cobas and YSI methods for analysing plasma glucose, a correlation coefficient of> 
0.99 was demonstrated. The correlation coefficient is able to detect qualitative 
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differences, but in the present context was unable to detect quantitative differences 
between methods. This suggests that reliance upon such statistical techniques is 
inadequate. Bland and Altman (1986) have proposed more appropriate statistical 
techniques when making comparisons. 
In agreement with previous findings (Holtkamp et al. 1975), plasma glucose 
concentrations were consistently 14 % higher than blood glucose concentrations. The 
difference between plasma and blood concentrations remained constant for the range of 
glucose values observed in the present work, suggesting that the proportion of glucose 
transported in plasma and erythrocytes remains consistent through the physiological 
range of glucose concentration. 
Haemoglobin, the main constituent of erythrocytes, has a negative charge and thus 
attracts a greater number of If" ions than plasma. This results in a strong ionic 
difference between plasma and erythrocytes, also known as the Donnan equilibrium. 
Lactate is a strong anion, and therefore the greater accumulation of lactate in plasma 
than in erythrocytes counteracts the ionic difference between plasma and erythrocytes. 
In the present study, lactate concentrations were 38 % (0.58 ( 0.10 mmollL) higher in 
plasma than in blood throughout the experimental period. Previously, plasma lactate 
concentrations were reported to be approximately 40 % higher than blood lactate 
concentrations (Foxdal et al. 1990), indicating an unequal distribution of lactate 
between plasma and erythrocytes, most probably due to the Donnan equilibrium (Harris 
et al. 1989). 
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The levels of agreement between different methods of analysis employed in the present 
work are generally good, indicating both accuracy and precision. This statement holds 
true for all comparisons except for the comparison of plasma glucose measured on the 
YSI analyser and the Cobas Mira Plus analyser. The reason for the disparity between 
the two methods of plasma glucose determination remains umesolved. However, it is 
evident that one cannot assume data derived using different analytical techniques to be 
quantitatively comparable. 
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Figure Legends 
Fig 1. 
Bland-Altman plot of plasma glucose concentration measured by the YSI analyser and 
Cobas Mira Plus analyser. The difference between each pair of measurements is plotted 
against their mean (n = 168). Dotted line indicates the mean difference between the two 
methods (0.47 mmoIlL). 
Fig 2. 
Plasma glucose concentrations measured by YSI analyser and Cobas Mira Plus 
analyser. Shaded blocks represent exercise periods at 70% V02max• 
Fig 3. 
Bland-Altman plot of plasma lactate concentration measured by the YSI analyser and 
Cobas Mira Plus analyser. The difference between each pair of measurements is plotted 
against their mean (n = 168). Dotted line indicates the mean difference between the two 
methods (0.01 mmollL). 
Fig 4. 
Plasma lactate concentrations measured by YSI analyser and Cobas Mira Plus analyser. 
Shaded blocks represent exercise periods at 70% V02max• 
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